<SEC-DOCUMENT>0001193125-16-577773.txt : 20160504
<SEC-HEADER>0001193125-16-577773.hdr.sgml : 20160504
<ACCEPTANCE-DATETIME>20160504164634
ACCESSION NUMBER:		0001193125-16-577773
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20160331
FILED AS OF DATE:		20160504
DATE AS OF CHANGE:		20160504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALNYLAM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001178670
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770602661
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36407
		FILM NUMBER:		161620100

	BUSINESS ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 551-8200

	MAIL ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALNYLAM PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20020724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d166732d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended March&nbsp;31, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-36407 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ALNYLAM
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>77-0602661</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>300 Third Street,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02142</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(617) 551-8200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At April&nbsp;29, 2016, the registrant had 85,560,535 shares of Common Stock, $0.01 par value per share, outstanding. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PAGE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>PART I. FINANCIAL INFORMATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&nbsp;1. FINANCIAL STATEMENTS (Unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_1">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2016 AND DECEMBER 31, 2015
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_2">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED
MARCH 31, 2016 AND 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_3">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH
 31, 2016 AND 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_4">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_5">ITEM&nbsp;
2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_6">ITEM&nbsp;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_7">ITEM&nbsp;4. CONTROLS AND PROCEDURES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><A HREF="#tx166732_8">PART II. OTHER INFORMATION</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_9">ITEM&nbsp;1. LEGAL PROCEEDINGS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_10">ITEM&nbsp;1A. RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_11">ITEM&nbsp;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_12">ITEM&nbsp;6. EXHIBITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx166732_13">SIGNATURES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALNYLAM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx166732_1"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">748,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in equity securities of Regulus Therapeutics Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Billed and unbilled collaboration receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,316,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,386,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.01 par value per share, 5,000,000 shares authorized and no shares issued and
outstanding at March&nbsp;31, 2016 and December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value per share, 125,000,000 shares authorized; 85,463,258 shares issued
and outstanding at March&nbsp;31, 2016; 85,090,968 shares issued and outstanding at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,546,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,506,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,011</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,349,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,246,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,189,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,264,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,316,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,386,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALNYLAM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx166732_2"></A>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net revenues from collaborators</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used to compute basic and diluted net loss per common
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized (loss) gain on marketable securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification adjustment for realized gain on marketable securities included in net
loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(116,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(1) Non-cash stock-based compensation expenses included in operating expenses are as follows:</P></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALNYLAM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx166732_3"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charge for 401(k) company stock match</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on sale of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from intraperiod tax allocation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Billed and unbilled collaboration receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,432</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(164,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(507,617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit for manufacturing facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(341,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options and other types of equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock to Sanofi Genzyme</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for repurchase of common stock for employee tax withholding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">306,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALNYLAM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx166732_4"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared in
accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the
results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements
for the year ended December&nbsp;31, 2015, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission, or SEC, on February&nbsp;12, 2016. The year-end condensed consolidated balance sheet data
was derived from our audited financial statements, but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim
period or for a full fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our
wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Common Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding. We compute diluted
net loss per common share by dividing net loss by the weighted-average number of common shares and dilutive potential common share equivalents then outstanding. Potential common shares consist of shares issuable upon the exercise of stock options
(using the treasury stock method), and unvested restricted stock awards. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth for the periods presented the potential common shares (prior to consideration of the treasury stock
method) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive, in thousands: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2015, we sold an aggregate of 5,447,368 shares of our common stock through an underwritten public offering at a price to the public
of $95.00 per share. As a result of the offering, which included the full exercise of the underwriters&#146; option to purchase additional shares, we received aggregate net proceeds of $496.4 million, after deducting underwriting discounts and
commissions and other offering expenses of $21.1 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. In general, fair values determined by Level&nbsp;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level&nbsp;2 inputs utilize data
points that are observable, such as quoted prices (adjusted), interest rates and yield curves. Fair values determined by Level&nbsp;3 inputs utilize unobservable data points for the asset or liability, and include situations where there is little,
if any, market activity for the asset or liability. The fair value hierarchy level is determined by the lowest level of significant input. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investments in Marketable Securities and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We invest our excess cash balances in short-term and long-term marketable debt and equity securities. We classify our investments in marketable
debt securities as either held-to-maturity or available-for-sale based on facts and circumstances present at the time we purchased the securities. At each balance sheet date presented, we classified all of our investments in debt and equity
securities as available-for-sale. We report available-for-sale investments at fair value at each balance sheet date and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss),
a component of stockholders&#146; equity. At March&nbsp;31, 2016, the balance in our accumulated other comprehensive loss was composed solely of activity related to our available-for-sale marketable securities, including our investment in equity
securities of Regulus Therapeutics Inc., or Regulus. Realized gains and losses are determined using the specific identification method and are included in other income (expense). We recognized $5.2 million of realized gains from sales of our Regulus
available-for-sale securities as other income on our condensed consolidated statements of comprehensive loss during the three months ended March&nbsp;31, 2016. If any adjustment to fair value reflects a decline in the value of the investment, we
consider all available evidence to evaluate the extent to which the decline is &#147;other than temporary,&#148; including our intention to sell and, if so, mark the investment to market through a charge to our condensed consolidated statements of
comprehensive income (loss). We did not record any impairment charges related to our fixed income marketable securities during the three months ended March&nbsp;31, 2016 or 2015. Our marketable securities are classified as cash equivalents if the
original maturity, from the date of purchase, is 90&nbsp;days or less, and as marketable securities if the original maturity, from the date of purchase, is in excess of 90&nbsp;days. Our cash equivalents are composed of commercial paper, corporate
notes, U.S. government-sponsored enterprise securities and money market funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We account for our investment in Regulus as an
available-for-sale marketable security.&nbsp;Intraperiod tax allocation rules require us to allocate our provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in
which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, we must allocate the tax provision to the other categories of earnings. We then record a
related tax benefit in continuing operations. Upon sales of our available-for-sale marketable securities, we apply the aggregate portfolio approach to recognize the related tax provision or benefit into income (loss) from continuing operations. As a
result, the disproportionate tax effect remains in accumulated other comprehensive income (loss) as long as we maintain an investment portfolio. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsequent Events </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We did not have
any material recognized subsequent events. However, we did have the following nonrecognized subsequent events, which are more fully described in Note 5: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On April&nbsp;4, 2016, we completed our purchase of land in Norton, Massachusetts for the construction of our new drug substance manufacturing facility. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On April&nbsp;29, 2016, we and Alnylam U.S., Inc., our wholly-owned subsidiary, entered into credit agreements with Bank of America N.A., or BOA, and Wells Fargo Bank, National Association, or Wells, related to the
build out of our new drug substance manufacturing facility. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board, or FASB, issued a new revenue recognition standard which amends revenue recognition
principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred
to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and
annual periods. In August 2015, the FASB deferred the effective date of the new revenue standard from January&nbsp;1, 2017 to January&nbsp;1, 2018. In March 2016, the FASB issued amendments to clarify the implementation guidance on principal versus
agent considerations. In April 2016, the FASB issued amendments to clarify the guidance on accounting for licenses of intellectual property and identifying performance obligations. Early adoption is permitted any time after the original effective
date, which for us is January&nbsp;1, 2017. The standard allows for adoption using a full retrospective method or a modified retrospective method. We are currently evaluating the timing, method of adoption and the expected impact that the standard
could have on our condensed consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2016, the FASB issued new guidance on
recognition and measurement of financial assets and financial liabilities. The new guidance will impact the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for
financial instruments. All equity investments in unconsolidated entities (other than those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounted for under the equity method of accounting) will generally be measured at fair value with changes in fair value recognized through earnings. There will no longer be an available-for-sale
classification (changes in fair value reported in other comprehensive income (loss)) for equity securities with readily determinable fair values. In addition, the FASB clarified the need for a valuation allowance on deferred tax assets resulting
from unrealized losses on available-for-sale debt securities. In general, the new guidance will require modified retrospective application to all outstanding instruments, with a cumulative effect adjustment recorded to opening retained earnings.
This guidance will be effective for us on January&nbsp;1, 2018. We are currently evaluating the expected impact that the standard could have on our condensed consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued a new leasing standard that requires that all lessees recognize the assets and liabilities that arise from
leases on the condensed consolidated balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January&nbsp;1, 2019. Early adoption is permitted. We are currently
evaluating the expected impact that this standard may have on our condensed consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
March 2016, the FASB issued guidance that will update the accounting for certain aspects of share-based payments to employees, including the income tax consequences, classification of awards as either equity or liabilities and classification on the
condensed consolidated statement of cash flows. The new standard will be effective for us on January&nbsp;1, 2017. Early adoption is permitted. We are currently evaluating the expected impact that this standard may have on our condensed consolidated
financial statements and related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT AGREEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our total consolidated net revenues from collaborators, for the periods indicated, in thousands: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi Genzyme</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Medicines Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monsanto</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenues from collaborators</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Alliances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sanofi Genzyme Collaboration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2014, we entered into a global, strategic collaboration with Sanofi Genzyme, the specialty care global business unit of Sanofi, or
Sanofi Genzyme, to discover, develop and commercialize RNAi therapeutics as Genetic Medicines to treat orphan diseases. The 2014 Sanofi Genzyme collaboration superseded and replaced the previous collaboration between us and Sanofi Genzyme entered
into in October 2012 to develop and commercialize RNAi therapeutics targeting transthyretin, or TTR, for the treatment of TTR-mediated amyloidosis, or ATTR amyloidosis, including patisiran and revusiran, in Japan and the Asia-Pacific region. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2012 Sanofi Genzyme Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the 2012 Sanofi Genzyme agreement, Sanofi Genzyme paid us an upfront cash payment of $22.5 million. We were also entitled to receive
certain milestone payments under the 2012 Sanofi Genzyme agreement. In the fourth quarter of 2013, we earned a milestone of $7.0 million based upon the completion of a successful patisiran Phase 2 clinical trial and a milestone of $4.0 million based
upon the initiation of the Phase 3 clinical trial for patisiran. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the 2012 Sanofi Genzyme agreement, the parties agreed to
collaborate in the development and commercialization of licensed products, with Sanofi Genzyme assuming primary responsibility in the Sanofi Genzyme territory, which included Japan and the Asia-Pacific region, and us retaining primary responsibility
in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We determined that the
deliverables under the 2012 Sanofi Genzyme agreement included the license, a joint steering committee and any additional TTR-specific RNAi therapeutic compounds that comprised the ALN-TTR program. We also determined that, pursuant to the accounting
guidance governing revenue recognition on multiple element arrangements, the license and undelivered joint steering committee and any additional TTR-specific RNAi therapeutic compounds did not have standalone value due to the specialized nature of
the services to be provided by us. In addition, while Sanofi Genzyme had the ability to grant sublicenses, it could not sublicense all or substantially all of its rights under the 2012 Sanofi Genzyme agreement. The uniqueness of our services and the
limited sublicense right were indicators that standalone value was not present in the arrangement. Therefore the deliverables were not separable and, accordingly, the license and undelivered services were treated as a single unit of accounting. We
were unable to reasonably estimate the period of performance under the 2012 Sanofi Genzyme agreement, as we were unable to estimate the timeline of our deliverables related to the deliverable for any additional TTR-specific RNAi therapeutic
compounds. Through December&nbsp;31, 2013, we had deferred all revenue, or $33.5 million, under the 2012 Sanofi Genzyme agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2014 Sanofi Genzyme Collaboration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2014, we entered into the 2014 Sanofi Genzyme collaboration. As noted above, the 2014 Sanofi Genzyme collaboration superseded and
replaced the 2012 Sanofi Genzyme agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2014 Sanofi Genzyme collaboration is structured as an exclusive relationship for the
worldwide development and commercialization of RNAi therapeutics in the field of Genetic Medicines, which includes our current and future Genetic Medicine programs that reach Human Proof-of-Principle Study Completion (as defined in the Sanofi
Genzyme master agreement), or Human POP, by the end of 2019, subject to extension to the end of 2021 in various circumstances. We will retain product rights in North America and Western Europe, referred to as the Alnylam Territory, while Sanofi
Genzyme will obtain exclusive rights to develop and commercialize collaboration products in the rest of the world, referred to as the Sanofi Genzyme Territory, together with certain broader co-development/co-promote or worldwide rights for certain
products. Sanofi Genzyme&#146;s rights, described in detail below, are structured as an opt-in that is triggered upon achievement of Human POP. We maintain development control for all programs prior to Sanofi Genzyme&#146;s opt-in and maintain
development and commercialization control after Sanofi Genzyme&#146;s opt-in for all programs in the Alnylam Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Specifically, in
addition to its regional rights for our current and future Genetic Medicine programs in the Sanofi Genzyme Territory, Sanofi Genzyme has the right to either (i)&nbsp;co-develop and co-promote fitusiran for the treatment of hemophilia and other rare
bleeding disorders in the Alnylam Territory, with us maintaining development and commercialization control, or (ii)&nbsp;obtain a global license to ALN-AS1 for the treatment of hepatic porphyrias. Sanofi Genzyme may exercise this selection right
upon the completion of Human POP for both the fitusiran and ALN-AS1 programs. Finally, Sanofi Genzyme has the right for a global license to a single, future Genetic Medicine program that was not one of our defined Genetic Medicine programs as of the
effective date of the 2014 Sanofi Genzyme collaboration. We will retain global rights to any RNAi therapeutic Genetic Medicine program that does not reach Human POP by the end of 2019, subject to certain limited exceptions. We retain full rights to
all current and future RNAi therapeutic programs outside of the field of Genetic Medicines, including the right to form new collaborations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the 2014 Sanofi Genzyme collaboration, Sanofi Genzyme&#146;s specific license rights and the programs into which Sanofi Genzyme has
opted include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Regional license terms and programs &#151; Upon opt-in, we will retain product rights in the Alnylam Territory, while Sanofi Genzyme will obtain exclusive rights to develop and commercialize the product in the Sanofi
Genzyme Territory. Sanofi Genzyme can elect this license for any of our current and future Genetic Medicine programs that complete Human POP by the end of 2019, subject to limited extension. Development costs for products once Sanofi Genzyme
exercises an option will be shared between Sanofi Genzyme and us, with Sanofi Genzyme responsible for twenty percent of the global development costs. Upon the effective date of the 2014 Sanofi Genzyme collaboration, Sanofi Genzyme expanded the scope
of its regional license and collaboration for patisiran, an investigational RNAi therapeutic currently in a Phase 3 clinical trial, which was originally established under the 2012 Sanofi Genzyme agreement. In September 2015, Sanofi Genzyme elected
to opt into our fitusiran clinical development program for the treatment of hemophilia and other rare bleeding disorders under the regional license terms. As described above, Sanofi Genzyme retains its future opt-in right to co-develop and
co-promote fitusiran in the Alnylam Territory pursuant to the co-development/co-promote license terms described below. Cost-sharing for the fitusiran program began in January 2016. Sanofi Genzyme will be required to make payments totaling up to
$50.0 million upon the achievement of certain patisiran development milestones. We could potentially earn the next patisiran milestone payment, ranging between $5.0 million and $20.0 million based on the geographic region, upon the achievement of
specified events in connection with a regulatory filing or approval. In addition, Sanofi Genzyme will be required to make payments totaling up to $75.0 million per product other than patisiran, including fitusiran, consisting of up to $55.0 million
in development milestones and $20.0 million in commercial milestones. We could potentially earn the first fitusiran milestone payment of $25.0 million based upon the initiation of the first global Phase 3 clinical trial for fitusiran. Sanofi Genzyme
will also be required to pay tiered double-digit royalties up to twenty percent for each regional product based on annual net sales, if any, of such regional product by Sanofi Genzyme, its affiliates and sublicensees. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Co-development/co-promote license terms and programs &#151; Upon opt-in, we will retain product rights in the
Alnylam Territory, while Sanofi Genzyme will obtain exclusive rights to develop and commercialize the product in the Sanofi Genzyme Territory, and will co-promote the product in the Alnylam Territory. Upon the effective date of the 2014 Sanofi
Genzyme collaboration, Sanofi Genzyme expanded its regional rights for revusiran, an investigational RNAi therapeutic currently in a Phase 3 clinical trial, which were originally granted under the 2012 Sanofi Genzyme agreement, to include a
co-development/co-promote license and collaboration. As noted above, Sanofi Genzyme also has the right to elect a co-development/co-promote license and collaboration for fitusiran, if it does not elect a global license and collaboration for ALN-AS1.
Development costs for co-development/co-promote products, once Sanofi Genzyme exercises an option, will be shared between Sanofi Genzyme and us, with Sanofi Genzyme responsible for fifty percent of the global development costs. Sanofi Genzyme will
be required to make payments totaling up to $75.0 million in development milestones for revusiran and, if selected, fitusiran. In December 2014, we earned a development milestone payment of $25.0 million based upon the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
initiation of the first global Phase 3 clinical trial for revusiran. We could potentially earn the next revusiran milestone payment, ranging between $5.0 million and $25.0 million based on the
geographic region, upon the achievement of specified events in connection with regulatory approval. Sanofi Genzyme will also be required to pay tiered double-digit royalties up to twenty percent for each co-development/co-promote product based on
annual net sales, if any, in the Sanofi Genzyme Territory for such co-development/co-promote product by Sanofi Genzyme, its affiliates and sublicensees. The parties will share profits equally and we expect to book product sales in the Alnylam
Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Global license terms and programs &#151; Upon opt-in, Sanofi Genzyme will obtain a worldwide license to develop and commercialize the product. Sanofi Genzyme can elect a global license for ALN-AS1, if it does not elect
a co-development/co-promote license for fitusiran, as described above. Sanofi Genzyme will also have one right to a global license through 2019, subject to limited extension, for a future Genetic Medicine program that was not one of our defined
Genetic Medicine programs as of the effective date of the 2014 Sanofi Genzyme collaboration. Sanofi Genzyme shall be responsible for one hundred percent of global development costs. Sanofi Genzyme will be required to make payments totaling up to
$200.0 million per global product, including up to $60.0 million in development milestones and $140.0 million in commercial milestones. Sanofi Genzyme will also be required to pay tiered double-digit royalties up to twenty percent for each global
product based on annual net sales, if any, of each global product by Sanofi Genzyme, its affiliates and sublicensees. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due
to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any additional milestone payments or any royalty payments from Sanofi Genzyme under the 2014 Sanofi
Genzyme collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the master agreement, the parties will collaborate in the development of option products, with us leading
development for all programs prior to Sanofi Genzyme&#146;s opt-in and also leading development and commercialization for all programs in the Alnylam Territory after Sanofi Genzyme&#146;s opt-in. If Sanofi Genzyme does not exercise its option to
license rights to a particular program, we will retain the exclusive right to develop and commercialize such program throughout the world, including the right to sublicense to third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2014 Sanofi Genzyme collaboration is governed by an alliance joint steering committee that is comprised of an equal number of
representatives from each party. There are additional committees to manage various aspects of each regional, co-developed/co-promoted and global program. We and Sanofi Genzyme intend to enter into supply agreements to provide for supply of
collaboration products to Sanofi Genzyme for clinical studies, and, at Sanofi Genzyme&#146;s request, commercial sales. Sanofi Genzyme also has certain rights to manufacture collaboration products. Additionally, Sanofi Genzyme has certain limited
opt-out rights, as specified in the master agreement, upon which products revert fully back to us with no further obligations to Sanofi Genzyme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The master agreement (including the license terms appended thereto) contains certain termination provisions, including for material breach by
the other party. Unless terminated earlier pursuant to its terms, the master agreement will terminate upon the last to expire of any of the option periods under the master agreement or the license terms appended thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the closing of the equity transaction in February 2014, we sold to Sanofi Genzyme 8,766,338 shares of our common stock and Sanofi Genzyme
paid $700.0 million in aggregate cash consideration to us. As a condition to the closing of the equity transaction, Sanofi Genzyme entered into an investor agreement with us. Under the investor agreement, until the earlier of the fifth anniversary
of the expiration or earlier termination of the 2014 Sanofi Genzyme collaboration and the date on which Sanofi Genzyme and its affiliates cease to beneficially own at least 5% of our outstanding common stock, Sanofi Genzyme and its affiliates are
bound by certain &#147;standstill&#148; provisions. The standstill provisions include agreements not to acquire more than 30% of our outstanding common stock, call stockholder meetings, nominate directors other than those approved by our board of
directors, subject to certain limited exceptions, or propose or support a proposal to acquire us. Further, Sanofi Genzyme has agreed to vote, and cause its affiliates to vote, all shares of our voting securities they are entitled to vote, up to a
maximum of 20% of our outstanding common stock, in a manner either as recommended by our board of directors or proportionally with the votes cast by our other stockholders, except with respect to certain change of control transactions or our
liquidation or dissolution. Until Sanofi Genzyme owns less than 7.5% of our outstanding common stock, subject to Sanofi Genzyme&#146;s limited right to maintain its ownership percentage as described below, if we issue common stock or securities
convertible into or exercisable for common stock to a third party that holds at least 30% of our outstanding common stock or, in connection with a collaboration or license transaction, to a third party that will initially hold at least the
percentage of our outstanding common stock represented by the shares purchased by Sanofi Genzyme at the closing of the equity transaction, we will offer Sanofi Genzyme an opportunity to amend the standstill and voting provisions in the investor
agreement to be consistent with the terms provided to such third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the investor agreement, Sanofi Genzyme has also agreed not
to dispose of any shares of common stock beneficially owned by it immediately after the closing of the stock purchase until the earlier of (i)&nbsp;December&nbsp;31, 2019 (subject to extension by up to two years if Sanofi Genzyme&#146;s option to
select additional compounds under the master agreement is extended beyond December&nbsp;31, 2019) and (ii)&nbsp;six months after the expiration or earlier valid termination of the collaboration, in each case subject to earlier termination in the
event certain clinical activities under the collaboration fail to occur. Following the expiration of this lock-up period, Sanofi Genzyme will be permitted to sell such shares of common stock subject to certain limitations, including volume and
manner of sale restrictions. Notwithstanding the foregoing, following the two-year anniversary of the closing of the stock purchase, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the event that the market price per share of our common stock is at least 100% higher than the market price per share of our common stock at closing of the stock purchase (in each case based upon
a ten-day trailing average), Sanofi Genzyme may sell up to 25% of its initial shares, subject to certain restrictions on post-lock-up period dispositions as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the investor agreement, following the lock-up period, Sanofi Genzyme will have three demand rights to require us to conduct a registered
underwritten public offering with respect to the shares of common stock beneficially owned by Sanofi Genzyme immediately after the closing of the stock purchase, subject to certain conditions. In addition, following the lock-up period, subject to
certain conditions, Sanofi Genzyme will be entitled to participate in registered underwritten public offerings by us if other selling stockholders are included in the registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The investor agreement provides that, until Sanofi Genzyme owns less than 7.5% of our outstanding common stock, subject to Sanofi
Genzyme&#146;s limited right to maintain its ownership percentage as described herein, in connection with new issuances of common stock, subject to certain exceptions, Sanofi Genzyme will be entitled to a right of first offer to participate
proportionally to maintain its then-current ownership percentage of our common stock. If Sanofi Genzyme is not entitled to a right of first offer with respect to a new issuance, Sanofi Genzyme will have the opportunity, on a post-transaction basis,
to purchase additional shares sufficient to maintain its pre-transaction ownership percentage of our common stock (subject to the same 7.5% ownership threshold). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Finally, in the event Sanofi Genzyme and its affiliates acquire at least 20% or more of our outstanding common stock, Sanofi Genzyme will be
entitled to appoint one individual to our board of directors. Sanofi Genzyme will also be entitled to certain information rights, including with respect to financial information in the event Sanofi Genzyme or its affiliates require such information
for its own financial reporting purposes. The rights and restrictions under the investor agreement are subject to termination upon the occurrence of certain events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded the issuance of 8,766,338 shares of our common stock under the stock purchase agreement using the price of our common stock on the
date the shares were issued to Sanofi Genzyme. Based on the common stock price of $85.72, the fair value of the shares issued was $751.5 million, which was $51.5 million in excess of the proceeds received from Sanofi Genzyme for the issuance of our
common stock. This $51.5 million is being amortized on a straight-line basis over the performance period, which is currently approximately six years as described below. In addition, due to intraperiod tax allocation rules, upon closing of the equity
transaction we recorded a benefit from income taxes of $15.2 million due to the Sanofi Genzyme equity purchase being recorded in additional paid-in capital, net of tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with the investor agreement, as a result of our issuance of shares in connection with our acquisition of Sirna Therapeutics,
Inc., in March 2014, Sanofi Genzyme exercised its right to purchase an additional 344,448 shares of our common stock for $23.0 million. In addition, in January 2015, in connection with our public offering, Sanofi Genzyme exercised its right to
purchase directly from us, in concurrent private placements, 744,566 shares of common stock at the public offering price resulting in $70.7 million in proceeds to us. The sales of common stock to Sanofi Genzyme were not registered as part of the
public offering, though they were consummated simultaneously with the public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sanofi Genzyme also has the right at the beginning
of each year to purchase a number of shares of our common stock based on the number of shares we issued during the previous year for compensation-related purposes. Sanofi Genzyme exercised this right to purchase directly from us 196,251 shares of
our common stock on January&nbsp;22, 2015 for $18.3 million and 205,030 shares of our common stock on February&nbsp;1, 2016 for $14.3 million. The sales of these shares to Sanofi Genzyme were consummated as private placements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In each instance, the purchase by Sanofi Genzyme described above allowed Sanofi Genzyme to maintain its ownership level of our common stock of
approximately 12%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We determined that the deliverables
for the programs on which Sanofi Genzyme was collaborating with us upon initiation of the 2014 collaboration included the licenses to our patisiran and revusiran clinical programs, which licenses were delivered to Sanofi Genzyme upon the closing
date of the transaction, and the associated development activities, joint steering committee participation and information exchange for these clinical programs. We also determined that, pursuant to the accounting guidance governing revenue
recognition on multiple element arrangements, the license and associated undelivered development activities, joint steering committee participation and information exchange activities did not have standalone value due to the specialized nature of
the services to be provided by us. In addition, while Sanofi Genzyme has the ability to grant sublicenses, it cannot sublicense all or substantially all of its rights under the 2014 Sanofi Genzyme collaboration. The uniqueness of our services and
the limited sublicense rights are indicators that standalone value is not present in the arrangement. Therefore the deliverables are not separable and, accordingly, the license and undelivered services were treated as a single unit of accounting.
When multiple deliverables are accounted for as a single unit of accounting, we base our revenue recognition model on the final deliverable. Under the 2014 Sanofi Genzyme collaboration, the last deliverables for patisiran and revusiran are expected
to be completed within approximately six years from the closing date of the transaction and the last deliverables for fitusiran are expected to be completed within approximately five years from the date Sanofi Genzyme elected to opt into our
fitusiran clinical development program under the regional license terms. We determined that the total cash received from Sanofi Genzyme under the now superseded 2012 Sanofi Genzyme agreement reflects consideration for certain of the performance
obligations for ALN-TTR programs included in the 2014 Sanofi Genzyme collaboration. Therefore we are recognizing the $33.5 million of deferred revenue under the 2012 Sanofi Genzyme agreement on a straight-line basis over the period of performance of
the ALN-TTR programs, which, as noted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
above, is currently approximately six years. In addition, during the fourth quarter of 2014, we recognized as revenue a portion of the $25.0 million milestone payment earned in December 2014
equal to the percentage of the performance period completed when the milestone was earned. During the year ended December&nbsp;31, 2015, we also recognized as revenue a portion of the expense reimbursement of $33.9 million due to us under the terms
of the 2014 Sanofi Genzyme collaboration equal to the percentage of the performance period completed to date. During the three months ended March&nbsp;31, 2016, we also recognized as revenue a portion of the expense reimbursement of $8.8 million due
to us under the terms of the 2014 Sanofi Genzyme collaboration equal to the percentage of the performance period completed to date. As future consideration is achieved, including any milestones or reimbursement for development activities, we will
recognize as revenue a portion of these payments equal to the percentage of the performance period completed when the milestone or activities have been satisfied, multiplied by the amount of the payment. We will recognize the remaining portion of
consideration received over the remaining performance period on a straight-line basis. At March&nbsp;31, 2016, deferred revenue under the 2014 Sanofi Genzyme collaboration was $34.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We determined that the opt-in rights that Sanofi Genzyme has for future Genetic Medicine programs represent separate and additional
deliverables that Sanofi Genzyme may receive from us in future periods. Upon each opt-in by Sanofi Genzyme, we have determined that each program and the related activities will represent a single unit of accounting and, consistent with our
accounting policies, we will base our revenue recognition period on the final deliverable associated with each future opt-in. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. FAIR VALUE
MEASUREMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables present information about our assets that are measured at fair value on a recurring basis at
March&nbsp;31, 2016 and December&nbsp;31, 2015, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value, in thousands: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At&nbsp;March&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted</B><br><B>Prices in</B><br><B>Active</B><br><B>Markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities (fixed income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government-sponsored enterprise securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities (Regulus equity holdings)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash (money market funds)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,210,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">229,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">981,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At</B><br><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted</B><br><B>Prices in</B><br><B>Active</B><br><B>Markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government-sponsored enterprise securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities (fixed income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">904,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">904,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Municipal debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government-sponsored enterprise securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities (Regulus equity holdings)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash (money market funds)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,320,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,118,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2016, there were no transfers between Level 1 and Level 2
financial assets. The carrying amounts reflected in our condensed consolidated balance sheets for cash, billed and unbilled collaboration receivables, other current assets, accounts payable and accrued expenses approximate fair value due to their
short-term maturities. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. MARKETABLE SECURITIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables summarize the fair value, accumulated other comprehensive income (loss) and intraperiod tax allocation
regarding our investment in Regulus available-for-sale marketable securities at March&nbsp;31, 2016 and 2015, and for the activity recorded for the three months ended March&nbsp;31, 2016 and 2015, in thousands: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At</B><br><B>December&nbsp;31,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sales&nbsp;of&nbsp;Regulus</B><br><B>Shares</B><br><B>During Three</B><br><B>Months Ended</B><br><B>March&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Activity</B><br><B>During Three</B><br><B>Months Ended</B><br><B>March&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance at</B><br><B>March&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss), before tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in equity securities of Regulus, as reported</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss), before tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intraperiod tax allocation recorded as a benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss), net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At</B><br><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sales&nbsp;of&nbsp;Regulus</B><br><B>Shares</B><br><B>During Three</B><br><B>Months&nbsp;Ended</B><br><B>March&nbsp;31,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Activity<BR>During Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance at</B><br><B>March&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss), before tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in equity securities of Regulus, as reported</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss), before tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intraperiod tax allocation recorded as a benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intraperiod tax allocation recorded as an accrued liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss), net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We obtain fair value measurement data for our marketable securities from independent pricing services. We
perform validation procedures to ensure the reasonableness of this data. This includes meeting with the independent pricing services to understand the methods and data sources used. Additionally, we perform our own review of prices received from the
independent pricing services by comparing these prices to other sources and confirming those securities are trading in active markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables summarize our marketable securities, other than our holdings in Regulus noted above, at March&nbsp;31, 2016 and
December&nbsp;31, 2015, in thousands: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At March&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government-sponsored enterprise securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">977,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">977,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">907,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">904,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Municipal debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government-sponsored enterprise securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,102,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We classify our debt security investments based on their contractual maturity dates. The following table
summarizes our available-for-sale debt securities by contractual maturity, at March&nbsp;31, 2016, in thousands: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At March&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less than one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">748,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">748,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater than one year but less than two years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">977,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">977,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. COMMITMENTS AND CONTINGENCIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing Facility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;10, 2016, we entered into an agreement with 20 Commerce LLC to purchase 12 acres of undeveloped land in Norton, Massachusetts
for approximately $8.0 million in cash payable for the land and related acquisition costs. We completed the purchase and closed this transaction on April&nbsp;4, 2016. We intend to construct a manufacturing facility at this site for drug substance,
including siRNAs and siRNA conjugates, for clinical and commercial use. As of March&nbsp;31, 2016, the cash payable for the land and related acquisition costs was put in escrow and recorded in prepaid expenses and other current assets on our
condensed consolidated balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Credit Facility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;29, 2016, we entered into (i) a Credit Agreement, or the BOA Credit Agreement, with Alnylam U.S., Inc., as the borrower, us, as a
guarantor, and BOA, as the lender and (ii)&nbsp;a Credit Agreement, or the Wells Credit Agreement, together with the BOA Credit Agreement, the Credit Agreements, by and among Alnylam U.S., Inc., as the borrower, us, as a guarantor, and Wells, as the
lender. The Credit Agreements were entered into in connection with the planned build out of our new drug substance manufacturing facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The BOA Credit Agreement provides for a $120 million term loan facility, and matures on April&nbsp;29, 2021. The Wells Credit Agreement
provides for a $30 million term loan facility, and matures on April&nbsp;29, 2021. The proceeds of the borrowing under each of the BOA Credit Agreement and the Wells Credit Agreement are to be used for working capital and general corporate purposes.
Interest on borrowings under the Credit Agreements will be calculated based on LIBOR plus 0.45 percent, except in the event of default. The borrower may prepay loans under each of the BOA Credit Agreement and the Wells Credit Agreement at any time,
without premium or penalty, subject to certain notice requirements and LIBOR breakage costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The obligations of the borrower under each
Credit Agreement are guaranteed by us. The obligations of Alnylam U.S., Inc. and us under each Credit Agreement are secured by cash collateral in an amount equal to, at any given time, at least 100% of the principal amount of all term loans
outstanding under such Credit Agreement at such time. Each of the lenders and the borrower have agreed to consider the appropriateness of a change in the type of approved collateral on a periodic basis throughout the term of the Credit Agreements;
provided that any such change to the type of such approved collateral shall be made only upon each of the lender&#146;s and the borrower&#146;s consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each Credit Agreement contains limited representations and warranties and limited affirmative and negative covenants. Each Credit Agreement
also contains certain customary events of default, including nonpayment of principal or interest, material inaccuracy of representations, failure to comply with covenants, cross-defaults to certain other indebtedness, invalidity of any loan document
relating to such Credit Agreement, judgments having a material adverse effect, insolvency events and change of control. If an event of default occurs and is continuing under either Credit Agreement, the entire outstanding balance under such Credit
Agreement may become immediately due and payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Several of the lenders under each of the Credit Agreements, as well as their
affiliates, have various relationships with us and our subsidiaries involving the provision of financial services, such as investment banking, commercial banking, advisory, cash management, custody and corporate credit card services for which they
receive customary fees and may do so in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>University of Utah Litigation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;22, 2011, The University of Utah, or Utah, filed a civil complaint in the United States District Court for the District of
Massachusetts, or the MA District Court, against us, Max Planck Gesellschaft Zur Foerderung Der Wissenschaften e.V. and Max Planck Innovation GmbH, the Whitehead Institute for Biomedical Research, the Massachusetts Institute of Technology and the
University of Massachusetts, claiming a professor at Utah is the sole inventor or, in the alternative, a joint inventor, of the Tuschl patents. Utah was seeking changes to the inventorship of the Tuschl patents, unspecified damages and other relief.
After several years of court proceedings and discovery, on September&nbsp;28, 2015, the MA District Court granted both of our motions for summary judgment, finding that there was no collaboration between Dr.&nbsp;Bass and Dr.&nbsp;Tuschl, which is a
pre-requisite for co-inventorship, and dismissing Utah&#146;s state law damages claims as well. On October&nbsp;28, 2015, Utah filed a notice of appeal to the United States Court of Appeals for the Federal Circuit, or the CAFC. On December&nbsp;18,
2015, the CAFC entered an order dismissing Utah&#146;s appeal following a joint motion filed by us and Utah seeking dismissal of the appeal with prejudice. This disposed of Utah&#146;s inventorship claims and its state law claims for damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2015, we filed a motion with the MA District Court seeking reimbursement of costs and fees associated with defending this
action in the amount of approximately $8.0 million. On November&nbsp;30, 2015, the MA District Court denied our motion and on December&nbsp;15, 2015, we filed a notice of appeal of this ruling with the CAFC. On February&nbsp;16, 2016, we filed our
appeal brief with the CAFC. Utah filed a response on April&nbsp;11, 2016 and our reply is due May&nbsp;9, 2016. While we believe a fee award is merited in this case, such awards are not customary and are made at the discretion of the court. We
anticipate a ruling on our appeal by the end of the third quarter of 2016, however, the timing will be determined by the CAFC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dicerna Litigation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2015, we filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc., or Dicerna, in the Superior
Court of Middlesex County, Massachusetts, seeking to stop misappropriation by Dicerna of our confidential, proprietary and trade secret information related to the RNAi assets we purchased from Merck Sharp &amp; Dohme Corp., including certain GalNAc
conjugate technology. In addition to permanent injunctive relief, we are also seeking monetary damages from Dicerna. On July&nbsp;10, 2015, Dicerna filed its answer to our complaint, in which it denied our claims, along with initial discovery
requests, to which we responded in a timely fashion. On July&nbsp;27, 2015, Dicerna filed a motion seeking removal of the case to the Business Litigation Session of the Superior Court of Suffolk County, which we opposed. On August&nbsp;31, 2015, the
Court denied Dicerna&#146;s motion. We and Dicerna agreed to a protective order, which was entered by the Court on November&nbsp;12, 2015. Discovery is ongoing and we expect discovery to close September&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we believe we have meritorious claims in this matter, litigation is subject to inherent uncertainty and a court could ultimately rule
against us. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our accounting policy for accrual of legal costs is to recognize such expenses as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx166732_5"></A>ITEM&nbsp;2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties.
The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended. Without limiting the foregoing, the words &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;target,&#148; &#147;goal&#148; and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these words. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us up to, and including, the date of this document, and we expressly disclaim any
obligation to update any such forward-looking statements to reflect events or circumstances that arise after the date hereof. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of
certain important factors, including those set forth in this Item&nbsp;2 &#151; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; as well as under Part&nbsp;II, Item&nbsp;1A &#151; &#147;Risk
Factors&#148; and elsewhere in this Quarterly Report on Form 10-Q. You should carefully review those factors and also carefully review the risks outlined in other documents that we file from time to time with the Securities and Exchange Commission,
or SEC.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a
biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases
are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. We believe that drugs that work through RNAi have the potential to
become a broad new class of innovative medicines, and that this potential new drug class is similar to the opportunity created with other major biological discoveries such as recombinant DNA and monoclonal antibodies. Using our intellectual property
and expertise, we are developing what we believe to be a reproducible and modular platform to develop RNAi therapeutics for a variety of human diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development strategy is focused primarily on use of our proprietary N-acetylgalactosamine, or GalNAc-conjugate strategy for
delivery of small interfering RNAs, or &#147;siRNAs&#148; &#151; the molecules that mediate RNAi &#151; toward genetically validated, liver-expressed genes involved in the cause or pathway of human diseases. We are also focused on clinical
indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Specifically, our pipeline of investigational RNAi therapeutics is focused in three Strategic Therapeutic Areas, or &#147;STArs:&#148; Genetic
Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Diseases, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular
and metabolic diseases, such as dyslipidemia, non-alcoholic steatohepatitis, type 2 diabetes, hypertension and other major diseases; and Hepatic Infectious Diseases, with a pipeline of RNAi therapeutics designed to address the major global health
challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. We continue to make progress towards our <I>Alnylam 2020</I> guidance, launched in January 2015, for the advancement and commercialization of
RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, we expect to achieve a company profile with three marketed products and ten RNAi therapeutic clinical programs, including four in late stages of
development, across our three STArs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our expertise in RNAi therapeutics and broad intellectual property estate we have formed
alliances with leading pharmaceutical and life sciences companies, including Ionis Pharmaceuticals, Inc., or Ionis (formerly Isis Pharmaceuticals, Inc.), Novartis Pharma AG (which assigned its rights and obligations to Arrowhead Pharmaceuticals,
Inc., or Arrowhead (formerly Arrowhead Research Corporation), in early 2015), or Novartis/Arrowhead, F. Hoffmann-La&nbsp;Roche Ltd (which assigned its rights and obligations to Arrowhead in 2011), or Roche/Arrowhead, Takeda Pharmaceutical Company
Limited, or Takeda, Kyowa Hakko Kirin Co., Ltd., Cubist Pharmaceuticals, Inc., or Cubist (now a wholly-owned subsidiary of Merck&nbsp;&amp; Co., Inc.), Monsanto Company, or Monsanto, Sanofi Genzyme, the specialty care global business unit of Sanofi,
or Sanofi Genzyme, and The Medicines Company, or MDCO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred significant losses since we commenced operations in 2002 and
expect such losses to continue for the foreseeable future. At March&nbsp;31, 2016, we had an accumulated deficit of $1.35 billion. Historically, we have generated losses principally from costs associated with research and development activities,
acquiring, filing and expanding intellectual property rights and general administrative costs. As a result of planned expenditures for research and development activities relating to our drug development programs, clinical trial and manufacturing
costs, the establishment of late-stage clinical and commercial capabilities, continued management and growth of our patent portfolio, collaborations and general corporate activities, we expect to incur additional operating losses for the foreseeable
future. We also anticipate that our operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we currently have programs focused on a number of therapeutic areas, we are unable to predict when, if ever, we will successfully
develop or be able to commence sales of any product. To date, a substantial portion of our total net revenues has been derived from collaboration revenues from strategic alliances with Roche/Arrowhead, Takeda, Cubist, Novartis/Arrowhead, Monsanto,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sanofi Genzyme and MDCO. We expect our sources of potential funding for the next several years to be derived primarily from existing and new strategic alliances, which may include license and
other fees, funded research and development and milestone payments, and proceeds from the sale of equity or debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recent
Developments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Sanofi Genzyme Stock Purchase</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under our investor agreement with Sanofi Genzyme, Sanofi Genzyme has the right at the beginning of each year to purchase a number of shares of
our common stock based on the number of shares we issued during the previous year for compensation-related purposes. Sanofi Genzyme exercised this right to purchase directly from us 205,030 shares of our common stock on February&nbsp;1, 2016 for
$14.3 million. The sale of these shares to Sanofi Genzyme was consummated as a private placement. This purchase by Sanofi Genzyme allowed Sanofi Genzyme to maintain its ownership level of our common stock of approximately 12%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Land Purchase</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
February 2016, we entered into an agreement with 20 Commerce LLC to purchase 12 acres of undeveloped land in Norton, Massachusetts for an aggregate of approximately $8.0 million in cash payable for the land and related acquisition costs. We
completed the purchase and closed this transaction on April&nbsp;4, 2016. We intend to construct a manufacturing facility at this site for drug substance, including siRNAs and siRNA conjugates, for clinical and commercial use. We expect to incur
approximately $100.0&nbsp;million in expenditures related to our planned capital investment in this manufacturing facility during 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Credit Agreements</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
April 2016, our subsidiary, Alnylam U.S., Inc., entered into credit agreements with Bank of America N.A., or BOA, and Wells Fargo Bank, National Association, or Wells, for which we are the guarantor, related to the build out of our new drug
substance manufacturing facility, that together provide for a $150.0 million term loan facility, and mature in April 2021. Interest on the borrowings will be calculated based on LIBOR plus 0.45 percent. The obligations under the credit agreements
are secured by cash collateral in an amount equal to, at any given time, at least 100 percent of the principal amount of all term loans outstanding under the credit agreements at such time. See Note&nbsp;5 to our condensed consolidated financial
statements included in Item&nbsp;1, &#147;Financial Statements (Unaudited),&#148; of this quarterly report on Form&nbsp;10-Q for a description of these credit agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our inception, we have focused on drug discovery and development programs. Research and development expenses represent a substantial
percentage of our total operating expenses. In early 2015, we launched our guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, we expect to achieve a
company profile with three marketed products and ten RNAi therapeutic clinical programs, including four in late stages of development, across our three STArs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our broad pipeline of investigational RNAi therapeutics is focused in three STArs: Genetic
Medicines; Cardio-Metabolic Diseases; and Hepatic Infectious Diseases. The following is a summary of our product development programs in each of our STArs as of April&nbsp;29, 2016, that identifies those programs in which we have achieved human
proof of concept by demonstrating target gene knockdown and/or additional evidence of activity in clinical studies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g166732img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the first quarter of 2016 and recent period, we reported the following updates from our
clinical-stage programs: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Genetic Medicine STAr: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We advanced investigational RNAi therapeutic programs for the treatment of transthyrethin (TTR)-mediated amyloidosis, or ATTR amyloidosis. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We completed enrollment in our APOLLO Phase 3 clinical trial with patisiran for the treatment of hereditary TTR-mediated amyloidosis with polyneuropathy, or hATTR-PN, also known as familial amyloidotic polyneuropathy,
or FAP. The study was substantially over enrolled with 225 patients. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to report data from the APOLLO clinical trial in mid-2017, and, assuming positive results, we expect to submit a new drug application, or NDA, and a marketing authorization application, for patisiran by the
end of 2017 and launch in 2018. </TD></TR></TABLE> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We announced complete 18-month data from our ongoing Phase 2 open-label extension, or OLE, study with patisiran. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We continued enrollment in our ENDEAVOUR Phase 3 clinical trial of revusiran for the treatment of hereditary TTR-mediated amyloidosis with cardiomyopathy, or hATTR-CM, also known as familial amyloidotic cardiomyopathy,
or FAC. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We announced that we expect to complete ENDEAVOUR enrollment in late 2016 and report results in mid-2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We filed a clinical trial application, or CTA, for ALN-TTRsc02, an ESC-GalNAc-siRNA conjugate targeting TTR for the treatment of ATTR amyloidosis, which is expected to enable a once-quarterly subcutaneous dosing
regimen. Assuming a positive Phase 1 study, we plan to initiate a Phase 3 clinical trial in 2017. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We advanced fitusiran (ALN-AT3) for the treatment of hemophilia and rare bleeding disorders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We initiated dosing of hemophilia patients with inhibitors in Part D of our ongoing Phase 1 clinical trial evaluating a once-monthly subcutaneous dose regimen of fitusiran. Both patients with hemophilia A with
inhibitors and hemophilia B with inhibitors have now been dosed with fitusiran. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We continued dosing patients in our ongoing Phase 1 OLE study, where once-monthly doses of fitusiran are being administered to patients with moderate or severe hemophilia A or B with or without inhibitors.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We announced that we are on track to initiate two Phase 3 clinical trials: the first in mid-2016 in hemophilia A and B patients with inhibitors; and, the second in late 2016 in moderate or severe hemophilia A and B
patients without inhibitors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We initiated discussions with global regulatory authorities to confirm specific Phase 3 trial designs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We advanced ALN-CC5 for the treatment of complement-mediated diseases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We reported that we have achieved preliminary evidence for clinical activity in a small number of paroxysmal nocturnal hemoglobinuria, or PNH, patients enrolled in Part C of our ongoing Phase 1/2 clinical trial, and we
believe that based on LDH data, the optimal development path for ALN-CC5 in PNH is for eculizumab poor responders and for eculizumab sparing. We plan to present initial data from a small cohort of PNH patients in the ongoing Phase 1/2 study in June
2016. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We now plan to transition toward a new Phase 2 study in PNH patients focused on that development plan, which is expected to start by the end of 2016. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We also reported that we expect to initiate studies of ALN-CC5 as a monotherapy and/or in combination with anti-C5 monoclonal antibodies in additional complement-mediated disease indications, such as atypical hemolytic
uremic syndrome and myasthenia gravis, starting in early 2017. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We advanced ALN-AS1 for the treatment of acute hepatic porphyrias. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We transitioned to Part C in our ongoing Phase 1 study where ALN-AS1 is being evaluated in porphyria patients with recurrent attacks and plan to initiate a Phase 3 trial in 2017, if the Phase 1 study results are
positive. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We advanced ALN-AAT for the treatment of alpha-1 antitrypsin deficiency-associated liver disease in a Phase 1 clinical trial. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We advanced ALN-GO1 for the treatment of primary hyperoxaluria type 1, or PH1. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We initiated a Phase 1/2 clinical trial that is being conducted initially in normal healthy volunteers, and, then, will be conducted in patients with PH1. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We received orphan drug designations for ALN-GO1 from the European Medicines Agency and the U.S. Food and Drug Administration, or FDA. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cardio-Metabolic Disease STAr: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MDCO continued enrollment in its Phase 2 ORION-1 trial for ALN-PCSsc for the treatment of atherosclerotic cardiovascular disease. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Hepatic Infectious Disease STAr: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We filed and obtained approval for a CTA for ALN-HBV, an investigational RNAi therapeutic targeting the hepatitis B virus, or HBV, genome for the treatment of HBV infection and we are on track to start a Phase 1 study
in mid-2016. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is a risk that any drug
discovery or development program may not produce revenue for a variety of reasons, including the possibility that we will not be able to adequately demonstrate the safety and effectiveness of the product candidate. Moreover, there are uncertainties
specific to any new field of drug discovery, including RNAi. The successful development of any product candidate we develop is highly uncertain. Due to the numerous risks associated with developing drugs, we cannot reasonably estimate or know the
nature, timing and estimated costs of the efforts necessary to complete the development of, or the period, if any, in which material net cash inflows will commence from, any potential product candidate. These risks include the uncertainty of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to discover new product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to progress product candidates into pre-clinical and clinical trials; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress and cost of our pre-clinical trials and other research and development activities, including those related to developing safe and effective ways of delivering siRNAs into cells and tissues;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress and cost of any clinical trials we commence; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trial results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms, timing and success of any collaboration, licensing and other arrangements that we may establish or any development and commercialization activities by any collaborator under such arrangements;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing and success of regulatory filings and approvals or potential changes in regulations that govern our industry or the way in which they are interpreted or enforced; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sufficient sales, marketing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sufficient manufacturing capabilities and securing clinical and commercial supplies for any product candidates and products that we may develop and ultimately commercialize;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limits on our ability to research, develop or manufacture our product candidates as a result of contractual obligations to third parties or intellectual property held by third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing technological and market developments. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any failure to complete any
stage of the development of any potential products in a timely manner could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our
projects on schedule, or at all, and the potential consequences of failing to do so, are set forth in Part&nbsp;II, Item&nbsp;1A below under the heading &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Strategic Alliances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business strategy is to develop and commercialize a broad pipeline of RNAi therapeutic products directed towards our three STArs. As part
of this strategy, we have entered into, and expect to enter into additional, collaboration and licensing agreements as a means of obtaining resources, capabilities and funding to advance our investigational RNAi therapeutic programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our collaboration strategy is to form alliances that create significant value for ourselves and our collaborators in the advancement of RNAi
therapeutics as a new class of innovative medicines. Specifically, with respect to our Genetic Medicine pipeline, we formed a broad strategic alliance with Sanofi Genzyme in 2014 pursuant to which we retain development and commercial rights for our
current and future Genetic Medicine products in North America and Western Europe, and Sanofi Genzyme will develop and commercialize our current and future Genetic Medicine products principally in territories outside of North America and Western
Europe, subject to certain broader rights. With respect to our Cardio-Metabolic and Hepatic Infectious Disease pipelines, we intend to seek future strategic alliances for these programs, while retaining significant product development and
commercialization rights in the United States and European Union, or EU. We currently have a global alliance with MDCO for the development and commercialization of our ALN-PCSsc program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also seek to form or advance new ventures and opportunities in areas outside our primary focus on RNAi therapeutics. In 2007, we and Ionis
formed Regulus Therapeutics Inc., or Regulus, to capitalize on our technology and intellectual property in the field of microRNA therapeutics. Currently, we own approximately 9% of Regulus&#146; outstanding common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into license agreements with Ionis, Max Planck Innovation GmbH (formerly known as Garching Innovation GmbH), or Max Planck
Innovation, Cancer Research Technology Limited, or CRT, and Whitehead Institute for Biomedical Research, or Whitehead, as well as a number of other entities, to obtain rights to intellectual property in the field of RNAi. In addition, because
delivery of RNAi therapeutics has historically been an important objective of our research activities, we have also evaluated potential collaboration and licensing arrangements with other companies and academic institutions to gain access to
delivery technologies. For example, we entered into agreements with Arbutus Biopharma Corporation, or ABC (formerly Tekmira Pharmaceuticals Corporation), Protiva Biotherapeutics, Inc., a wholly owned subsidiary of ABC, and together with ABC,
referred to as Arbutus, The University of British Columbia and Acuitas Therapeutics Inc. (formerly AlCana Technologies, Inc.), among others, related to various lipid nanoparticle, or LNP, delivery technologies. Finally, we have sought, and may seek
in the future, funding for the development of our proprietary RNAi therapeutics pipeline from the government and foundations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The strength of our intellectual property portfolio relating to the development and commercialization of siRNAs as therapeutics is essential to
our business strategy. We own or license issued patents and pending patent applications in the United States and in key markets around the world claiming fundamental features of siRNAs and RNAi therapeutics as well as those claiming crucial chemical
modifications and promising delivery technologies. Specifically, we have a portfolio of patents, patent applications and other intellectual property covering: fundamental aspects of the structure and uses of siRNAs, including their use as
therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic and other uses; siRNAs directed to specific targets as treatments for particular diseases;&nbsp;delivery technologies, such as
in the fields of carbohydrate conjugates and cationic liposomes; and all aspects of our specific development candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that
no other company possesses a portfolio of such broad and exclusive rights to the patents and patent applications required for the commercialization of RNAi therapeutics. Our intellectual property estate for RNAi therapeutics includes over 2,000
active cases and over 1,100 granted or issued patents, of which over 400 are issued or granted in the United States, the EU, including by the European Patent Office, or EPO, and Japan. We continue to seek to grow our portfolio through the creation
of new technology in this field. In addition, we are very active in our evaluation of third-party technologies. To that end, in January 2014, we acquired the RNAi assets of Sirna Therapeutics, Inc., or Sirna, including an extensive patent estate,
from Merck Sharp &amp; Dohme Corp., or Merck. The granted patents, applications and know-how obtained through this acquisition further strengthened the breadth and depth of our intellectual property portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend
against challenges that have arisen or may arise in this area. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been no significant changes to our critical accounting policies since the beginning of this fiscal year. Our critical accounting
policies are described in the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, which we filed with the SEC on
February&nbsp;12, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following data summarizes the results of our operations for the periods indicated, in thousands: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues from collaborators</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net revenues from collaborators </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We generate revenues through research and development collaborations. The following table summarizes our total consolidated net revenues from
collaborators, for the periods indicated, in thousands: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi Genzyme</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Medicines Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monsanto</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenues from collaborators</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net revenues from collaborators decreased during the three months ended March&nbsp;31, 2016 as compared to the
three months ended March&nbsp;31, 2015 due primarily to the completion of our performance obligations under the Monsanto agreement in February 2015 and the completion of our revenue amortization under the Takeda agreement in May 2015, partially
offset by services performed in connection with our performance obligations under our agreement with Sanofi Genzyme. In addition, net revenues from other collaborators decreased due to the achievement of certain non-recurring milestones from other
sources during the three months ended March&nbsp;31, 2015. We expect net revenues from collaborators to increase during the remainder of 2016 due to expected increases in expense reimbursement and an expected milestone payment under our agreement
with Sanofi Genzyme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had $70.9 million of deferred revenue at March&nbsp;31, 2016, which consists primarily of payments we have
received from collaborators, primarily Sanofi Genzyme, MDCO, Kyowa Hakko Kirin and Monsanto, but have not yet recognized pursuant to our revenue recognition policies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the foreseeable future, we expect our revenues to be derived primarily from our alliances
with Sanofi Genzyme, MDCO and other strategic alliances, as well as new collaborations and licensing activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our operating expenses for the periods indicated, in thousands and as a percentage of total
operating expenses, together with the changes, in thousands and percentages: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Months</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>% of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Operating</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Months</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>% of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Operating</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase&nbsp;(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development</I></B>. The following table summarizes the components of our research and
development expenses for the periods indicated, in thousands and as a percentage of total research and development expenses, together with the changes, in thousands and percentages: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Months</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>% of<BR>Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Months</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>% of<BR>Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase&nbsp;(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Category</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Category</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research and development</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical trial and manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab supplies and materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased during the three months ended March&nbsp;31, 2016 as compared to
the three months ended March&nbsp;31, 2015 due primarily to additional expenses for clinical trial and manufacturing and external services resulting from the significant advancement of our Genetic Medicine pipeline. In addition, compensation and
related expenses and non-cash stock-based compensation expenses increased during the three months ended March&nbsp;31, 2016 as compared to the three months ended March&nbsp;31, 2015 due primarily to a significant increase in headcount during the
period as we expand and advance our development pipeline, as well as the vesting of certain performance-based stock option awards during the first quarter of 2016 upon completion of enrollment in our patisiran Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to continue to devote a substantial portion of our resources to research and development expenses, including for the advancement of
our Genetic Medicine, Cardio-Metabolic Disease and Hepatic Infectious Disease STArs, to support our goal of three marketed products and ten programs in clinical development, including four late stage programs, by 2020. We expect that on a quarterly
basis research and development expenses will increase from the first quarter of 2016 as we continue to develop our pipeline and advance our product candidates into clinical trials, but that such expenses will be variable on a quarterly basis
depending on the timing of manufacturing batches, clinical trial enrollment and non-cash stock-based compensation expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A significant
portion of our research and development costs are not tracked by project as they benefit multiple projects or our technology platform. However, certain of our collaboration agreements contain cost-sharing arrangements pursuant to which certain costs
incurred under the project are reimbursed. Costs reimbursed under the agreements typically include certain direct external costs and a negotiated full-time equivalent labor rate for the actual time worked on the project. As a result, although a
significant portion of our research and development expenses are not tracked on a project-by-project basis, we do track direct external costs attributable to, and the actual time our employees worked on, our collaborations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative.</I></B> The following table summarizes the components of our
general and administrative expenses for the periods indicated, in thousands and as a percentage of total general and administrative expenses, together with the changes, in thousands and percentages: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Months</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>% of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Months</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>% of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase&nbsp;(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Category</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Category</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>General and administrative</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total general and administrative expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased during the three months ended March&nbsp;31, 2016 as compared to
the three months ended March&nbsp;31, 2015 due primarily to an increase in non-cash stock-based compensation expense due to an increase in headcount, as well as the vesting of certain performance-based stock option awards during the first quarter of
2016 upon completion of enrollment in our patisiran Phase 3 clinical trial. For the remainder of 2016, we expect that on a quarterly basis general and administrative expenses will remain relatively consistent with the first quarter of 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table summarizes our cash flow activities for the periods indicated, in thousands: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(341,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">306,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since we commenced operations in 2002, we have generated significant losses. At March&nbsp;31, 2016, we had an
accumulated deficit of $1.35 billion. At March&nbsp;31, 2016, we had cash, cash equivalents and fixed income marketable securities of $1.21 billion, compared to cash, cash equivalents and fixed income marketable securities of $1.28&nbsp;billion at
December&nbsp;31, 2015, in each case excluding our investment in equity securities of Regulus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2015, we sold an aggregate of
5,447,368 shares of our common stock through an underwritten public offering at a price to the public of $95.00 per share. As a result of the offering, which included the full exercise of the underwriters&#146; option to purchase additional shares,
we received aggregate net proceeds of $496.4 million, after deducting underwriting discounts and commissions and other offering expenses of $21.1 million. We have used and intend to continue to use these proceeds for general corporate purposes,
focused on achieving our <I>Alnylam 2020</I> profile with three marketed products and ten RNAi therapeutic clinical programs, including four in late stages of development, across our three STArs, by the end of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sanofi Genzyme has certain rights to purchase additional shares from us under our investor agreement. In January 2015, in connection with our
public offering described above, Sanofi Genzyme exercised its right to purchase directly from us, in concurrent private placements, 744,566 shares of common stock, resulting in proceeds to us of $70.7 million. Sanofi Genzyme has the right at the
beginning of each year to purchase a number of shares of our common stock based on the number of shares we issued during the previous year for compensation-related purposes. Sanofi Genzyme exercised this right to purchase directly from us 196,251
shares of our common stock on January&nbsp;22, 2015 for $18.3 million and 205,030 shares of our common stock on February&nbsp;1, 2016 for $14.3 million. This purchase allowed Sanofi Genzyme to maintain its ownership level of our outstanding common
stock of approximately 12%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We invest primarily in money market funds, U.S.&nbsp;government-sponsored enterprise securities,
U.S. treasury securities, high-grade corporate notes and commercial paper. Corporate notes also include foreign bonds denominated in U.S. dollars. Our investment objectives are, primarily, to assure liquidity and preservation of capital and,
secondarily, to obtain investment income. All of our investments in debt securities are recorded at fair value and are available-for-sale. Fair value is determined based on quoted market prices and models using observable data inputs. We have not
recorded any impairment charges to our fixed income marketable securities during the three months ended March&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have required significant amounts of cash to fund our operating activities as a result of net losses since our inception. Cash used in
operating activities is adjusted for non-cash items to reconcile net loss to net cash provided by or used in operating activities. These non-cash adjustments have historically included stock-based compensation, in-process research and development,
intraperiod tax allocation, and depreciation and amortization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that we will require significant amounts of cash to fund our
operating activities for the foreseeable future as we continue to execute on our <I>Alnylam 2020</I> guidance through the advancement of our research and development initiatives. The actual amount of overall expenditures will depend on numerous
factors, including the timing of expenses, the timing and terms of collaboration agreements or other strategic transactions, if any, and the timing and progress of our research, development and commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The increase in net cash used in operating activities for the three months ended March&nbsp;31, 2016 compared to the three months ended
March&nbsp;31, 2015 was due primarily to our net loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31, 2016 and 2015, net cash provided by or used in investing activities was due primarily to activity
related to our fixed income marketable securities in accordance with management of our liquidity needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing activities
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31, 2016, net cash of $16.1 million provided by financing activities was due primarily to
proceeds of $14.3 million received from our issuance of common stock to Sanofi Genzyme in February 2016. For the three months ended March&nbsp;31, 2015, net cash of $599.0 million provided by financing activities was due primarily to proceeds of
$496.4 million received from our January 2015 underwritten public offering, proceeds of $89.0 million received from our issuances of common stock to Sanofi Genzyme in January 2015, as well as proceeds of $13.6 million from the issuance of common
stock in connection with stock option exercises. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Capital Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not know when, if ever, we will successfully develop or be able to commence sales of any product. Therefore, we anticipate that we will
continue to generate significant losses for the foreseeable future as a result of planned expenditures for research and development activities relating to our drug development programs, including clinical trial and manufacturing costs, the
establishment of late-stage clinical and commercial capabilities, continued management and growth of our patent portfolio, collaborations and general corporate activities. In addition, we expect to expand our manufacturing capabilities, including
through construction of a drug substance manufacturing facility in Norton, Massachusetts. We expect to incur approximately $100.0&nbsp;million in expenditures related to our planned capital investment in this manufacturing facility during 2016. In
April 2016, our subsidiary, Alnylam U.S., Inc., entered into credit agreements with BOA and Wells, for which we are the guarantor, related to the build out of our new drug substance manufacturing facility, that together provide for a $150.0 million
term loan facility, and mature in April 2021. Interest on the borrowings will be calculated based on LIBOR plus 0.45 percent. The obligations under the credit agreements are secured by cash collateral in an amount equal to, at any given time, at
least 100 percent of the principal amount of all term loans outstanding under the credit agreements at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our current
operating plan, we believe that our existing cash, cash equivalents and fixed income marketable securities, together with the cash we expect to generate under our current alliances, will be sufficient to enable us to achieve our <I>Alnylam 2020</I>
guidance. For reasons discussed below, we may require significant additional funds earlier than we currently expect in order to develop, conduct clinical trials for and commercialize any product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the future, we may seek additional funding through additional collaborative arrangements and public or private financings. Additional
funding may not be available to us on acceptable terms or at all. In addition, the terms of any additional financing may further adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing
equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities, further dilution to our existing stockholders will result. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights
superior to those of existing stockholders. If we are unable to obtain funding on a timely basis, we may be required to significantly delay or curtail one or more of our research or development programs. We also could be required to seek funds
through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we are able to raise additional funds in a timely manner, our future capital requirements may vary from what we expect and will depend
on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop relatively standard procedures for selecting and modifying siRNA product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our progress in demonstrating that siRNAs can be active as drugs and achieve desired clinical effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress in our research and development programs, as well as what may be required by regulatory bodies to advance these programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the resources, time and costs required to successfully initiate and complete our pre-clinical and clinical trials, obtain regulatory approvals, prepare for commercialization of our product candidates and obtain and
maintain licenses to third-party intellectual property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish, maintain and operate our own manufacturing facilities in a timely and cost effective manner; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture, or contract with third parties for the manufacture of, our product candidates for clinical testing and commercial sale; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress in the research and development programs of Regulus;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales and royalties, if any, from our potential products. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual
Obligations and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The disclosure of our contractual obligations and commitments is set forth under the heading
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Contractual Obligations&#148; in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015. We recently entered into credit
agreements, related to the build out of our new drug substance manufacturing facility, that provide for a $150.0 million term loan facility, and mature in April 2021. See Note&nbsp;5 to our condensed consolidated financial statements included in
Item&nbsp;1, &#147;Financial Statements (Unaudited),&#148; of this quarterly report on Form&nbsp;10-Q for a description of these credit agreements. As a result, we expect our contractual obligations through 2021 will increase from the amounts
previously disclosed in our 2015 Annual Report on Form 10-K due to the interest on borrowings under the credit agreements which will be calculated based on LIBOR plus 0.45 percent, as well as the principal payments due in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See
Note 1 to our condensed consolidated financial statements included in Item&nbsp;1, &#147;Financial Statements (Unaudited),&#148; of this quarterly report on Form 10-Q for a description of recent accounting pronouncements applicable to our business.
</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx166732_6"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of our investment
portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. Our fixed income
marketable securities consist primarily of U.S.&nbsp;government-sponsored enterprise securities, U.S. treasury securities, high-grade corporate notes, certificates of deposit and commercial paper. Corporate notes also include foreign bonds
denominated in U.S. dollars. All of our investments in debt securities are classified as available-for-sale and are recorded at fair value. Our available-for-sale investments in debt securities are sensitive to changes in interest rates and changes
in the credit ratings of the issuers. Interest rate changes would result in a change in the net fair value of these financial instruments due to the difference between the market interest rate and the market interest rate at the date of purchase of
the financial instrument. If market interest rates were to increase immediately and uniformly by 50&nbsp;basis points, or one-half of a percentage point, from levels at March&nbsp;31, 2016, the net fair value of our interest-sensitive financial
instruments would have resulted in a hypothetical decline of $2.6 million. We currently do not seek to hedge this exposure to fluctuations in interest rates. A downgrade in the credit rating of an issuer of a debt security or further deterioration
of the credit markets could result in a decline in the fair value of the debt instruments. Our investment guidelines prohibit investment in auction rate securities and we do not believe we have any direct exposure to losses relating from
mortgage-based securities or derivatives related thereto such as credit-default swaps. Historically, foreign currency fluctuations have not been material. We did not record any impairment charges to our fixed income marketable securities during the
three months ended March&nbsp;31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="tx166732_7"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management, with the participation of our chief executive
officer (principal executive officer) and vice president of finance and treasurer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of March&nbsp;31, 2016. The term &#147;disclosure controls and
procedures,&#148; as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to
be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#146;s rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#146;s
management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated,
can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls
and procedures as of March&nbsp;31, 2016, our chief executive officer and vice president of finance and treasurer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No change in our internal control over financial reporting (as defined in Rules&nbsp;13a&#150;15(f) and 15d&#150;15(f) under the Exchange Act)
occurred during the three months ended March&nbsp;31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx166732_8"></A>PART II. OTHER INFORMATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx166732_9"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LEGAL PROCEEDINGS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>University of Utah Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;22, 2011, The University of Utah, or Utah, filed a civil complaint in the United States District Court for the District of
Massachusetts, or the MA District Court, against us, Max Planck Gesellschaft Zur Foerderung Der Wissenschaften e.V. and Max Planck Innovation, together, Max Planck, Whitehead, the Massachusetts Institute of Technology, or MIT, and the University of
Massachusetts, or UMass, claiming a professor at Utah is the sole inventor or, in the alternative, a joint inventor, of the Tuschl patents. Utah was seeking changes to the inventorship of the Tuschl patents, unspecified damages and other relief.
After several years of court proceedings and discovery, on September&nbsp;28, 2015, the MA District Court granted both of our motions for summary judgment, finding that there was no collaboration between Dr.&nbsp;Bass and Dr.&nbsp;Tuschl, which is a
pre-requisite for co-inventorship, and dismissing Utah&#146;s state law damages claims as well. On October&nbsp;28, 2015, Utah filed a notice of appeal to the United States Court of Appeals for the Federal Circuit, or the CAFC. On December&nbsp;18,
2015, the CAFC entered an order dismissing Utah&#146;s appeal following a joint motion filed by us and Utah seeking dismissal of the appeal with prejudice. This disposed of Utah&#146;s inventorship claims and its state law claims for damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2015, we filed a motion with the MA District Court seeking reimbursement of costs and fees associated with defending this
action in the amount of approximately $8.0 million. On November&nbsp;30, 2015, the MA District Court denied our motion and on December&nbsp;15, 2015, we filed a notice of appeal of this ruling with the CAFC. On February&nbsp;16, 2016, we filed our
appeal brief with the CAFC. Utah filed a response on April&nbsp;11, 2016 and our reply is due May&nbsp;9, 2016. While we believe a fee award is merited in this case, such awards are not customary and are made at the discretion of the court. We
anticipate a ruling on our appeal by the end of the third quarter of 2016, however, the timing will be determined by the CAFC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dicerna Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2015, we filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc., or Dicerna, in the Superior
Court of Middlesex County, Massachusetts, seeking to stop misappropriation by Dicerna of our confidential, proprietary and trade secret information related to the RNAi assets we purchased from Merck, including certain GalNAc conjugate technology. In
addition to permanent injunctive relief, we are also seeking monetary damages from Dicerna. On July&nbsp;10, 2015, Dicerna filed its answer to our complaint, in which it denied our claims, along with initial discovery requests, to which we responded
in a timely fashion. On July&nbsp;27, 2015, Dicerna filed a motion seeking removal of the case to the Business Litigation Session of the Superior Court of Suffolk County, which we opposed. On August&nbsp;31, 2015, the Court denied Dicerna&#146;s
motion. We and Dicerna agreed to a protective order, which was entered by the Court on November&nbsp;12, 2015. Discovery is ongoing and we expect discovery to close September&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we believe we have meritorious claims in this matter, litigation is subject to inherent uncertainty and a court could ultimately rule
against us. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;<A NAME="tx166732_10"></A>1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RISK FACTORS</B>&nbsp;<B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Our business is subject to numerous risks. We caution you
that the following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in filings with the SEC, press releases, communications with
investors and oral statements. All statements other than statements relating to historical matters should be considered forward-looking statements. When used in this report, the words &#147;believe,&#148; &#147;expect,&#148; &#147;plan,&#148;
&#147;anticipate,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;may,&#148; &#147;could,&#148; &#147;should,&#148; &#147;intend,&#148; &#147;will,&#148; &#147;target,&#148; &#147;goal&#148; and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these words. Any or all of our forward-looking statements in this quarterly report on Form&nbsp;10-Q and in any other public statements we make may turn out to be wrong.
They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in the discussion below will be important in determining future results. Consequently, no forward-looking statement
can be guaranteed. Actual future results may vary materially from those anticipated in forward-looking statements. We explicitly disclaim any obligation to update any forward-looking statements to reflect events or circumstances that arise after the
date hereof. You are advised, however, to consult any further disclosure we make in our reports filed with the SEC.</I> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related
to Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Being a Clinical Stage Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because we are in clinical development, there is limited information about our ability to successfully overcome many of the risks and
uncertainties encountered by companies in the biopharmaceutical industry. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a company in clinical development, we have limited
experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to
execute our business plan, we will need to successfully: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">execute product development activities using unproven technologies related to both RNAi and to the delivery of siRNAs to the relevant tissues and cells; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build and maintain a strong intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gain regulatory acceptance for the development and commercialization of our product candidates and market success for any products we commercialize; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and maintain successful strategic alliances; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, commercialize products, raise capital, expand our
business or continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The approach we are taking to discover and develop novel RNAi therapeutics is unproven and may
never lead to marketable products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have concentrated our efforts and therapeutic product research on RNAi technology and our
future success depends on the successful development of this technology and products based on it. Neither we nor any other company has received regulatory approval to market therapeutics utilizing siRNAs, the class of molecule we are trying to
develop into drugs. The scientific discoveries that form the basis for our efforts to discover and develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs based on these discoveries is both
preliminary and limited. Skepticism as to the feasibility of developing RNAi therapeutics has been expressed in scientific literature. For example, there are potential challenges to achieving safe RNAi therapeutics based on the so-called off-target
effects and activation of the interferon response. In addition, decisions by other companies with respect to their RNAi development efforts or their adoption of different or related technologies may increase skepticism in the marketplace regarding
the potential for RNAi therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Relatively few product candidates based on these discoveries have ever been tested in humans. siRNAs
may not naturally possess the inherent properties typically required of drugs, such as the ability to be stable in the body, or the ability to enter cells within relevant tissues in order to exert their effects. We currently have only limited data
to suggest that we can introduce these properties into siRNAs. We have spent and expect to continue to spend large amounts of money trying to develop siRNAs that possess the properties typically required of drugs, and we may never succeed in doing
so. In addition, these compounds may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory studies, and they may interact with human biological systems in unforeseen, ineffective or harmful ways. As a
result, we may never succeed in developing a marketable product, we may not become profitable and the value of our common stock will decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, our focus solely on RNAi technology for developing drugs, as opposed to multiple, more proven technologies for drug development,
increases the risks associated with the ownership of our common stock. If we are not successful in developing a product candidate using RNAi technology, we may be required to change the scope and direction of our product development activities. In
that case, we may not be able to identify and implement successfully an alternative product development strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Results and Need for Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have a history of losses and may never become and remain consistently profitable. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have experienced significant operating losses since our inception. At March&nbsp;31, 2016, we had an accumulated deficit of $1.35 billion.
To date, we have not developed any products nor generated any revenues from the sale of products. Further, we do not expect to generate any product revenues for at least the next several years. We expect to continue to incur annual net operating
losses over the next several years and will require substantial resources over the next several years as we expand our efforts to discover, develop and commercialize RNAi therapeutics. We anticipate that the majority of any revenues we generate over
the next several years will be from alliances with pharmaceutical and biotechnology companies, but cannot be certain that we will be able to maintain our existing alliances or secure and maintain new alliances, or meet the obligations or achieve any
milestones that we may be required to meet or achieve to receive payments. We anticipate that revenues derived from such sources will not be sufficient to make us consistently profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that to become and remain consistently profitable, we must succeed in discovering, developing and commercializing novel drugs with
significant market potential. This will require us to be successful in a range of challenging activities, including pre-clinical testing and clinical trial stages of development, obtaining regulatory approval for these novel drugs and manufacturing,
marketing and selling them. We may never succeed in these activities, and may never generate revenues that are significant enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability
on a quarterly or annual basis. If we cannot become and remain consistently profitable, the market price of our common stock could decline. In addition, we may be unable to raise capital, expand our business, develop additional product candidates or
continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional funds to complete our research and development activities and if
additional funds are not available, we may need to critically limit, significantly scale back or cease our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
used substantial funds to develop our RNAi technologies and will require substantial funds to conduct further research and development, including pre-clinical testing and clinical trials of our product candidates, and to manufacture and market any
products that are approved for commercial sale. Because we cannot be certain of the length of time or activities associated with successful development of our product candidates, we are unable to estimate the actual funds we will require to develop
and commercialize them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future capital requirements and the period for which we expect our existing resources to support our
operations may vary from what we expect. We have based our expectations on a number of factors, many of which are difficult to predict or are outside of our control, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop relatively standard procedures for selecting and modifying siRNA product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our progress in demonstrating that siRNAs can be active as drugs and achieve desired clinical effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress in our research and development programs, as well as what may be required by regulatory bodies to advance these programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the resources, time and costs required to initiate and complete our pre-clinical and clinical studies, obtain regulatory approvals, prepare for the commercialization of our product candidates, and obtain and maintain
licenses to third-party intellectual property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish, maintain and operate our own manufacturing facilities in a timely and cost effective manner; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture, or contract with third parties for the manufacture of, our product candidates for clinical testing and commercial sale; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress in the research and development programs of Regulus; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales and royalties, if any, from our potential products. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
our estimates and predictions relating to these factors are incorrect, we may need to modify our operating plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if our estimates
are correct, we will be required to seek additional funding in the future and intend to do so through either collaborative arrangements, public or private equity offerings or debt financings, or a combination of one or more of these funding sources.
Additional funds may not be available to us on acceptable terms or at all. In April 2016, our subsidiary, Alnylam U.S., Inc., entered into credit agreements with BOA and Wells, for which we are the guarantor, related to the build out of our new drug
substance manufacturing facility, that together provide for a $150.0 million term loan facility, and mature in April 2021. Interest on the borrowings will be calculated based on LIBOR plus 0.45 percent. During an event of default under either credit
agreement, the obligations under such credit agreement will bear interest at a rate per annum equal to the interest rate then in effect plus two percent. The obligations under the credit agreements are secured by cash
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collateral in an amount equal to, at any given time, at least 100 percent of the principal amount of all term loans outstanding under the credit agreements at such time. The credit agreements
include restrictive covenants that could limit our flexibility in conducting future business activities and further limit our ability to change the nature of our business and, in the event of insolvency, the lenders would be paid before holders of
equity securities received any distribution of corporate assets. If an event of default occurs, the interest rate would increase and the lenders would be entitled to take various actions, including the acceleration of amounts due under the loan. Our
ability to satisfy our obligations under the credit agreements and meet our debt service obligations will depend upon our future performance, which will be subject to financial, business and other factors affecting our operations, many of which are
beyond our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For
example, if we raise additional funds by issuing equity securities, further dilution to our existing stockholders will result. In addition, as a condition to providing additional funding to us, future investors may demand, and may be granted, rights
superior to those of existing stockholders. Moreover, our investor agreement with Sanofi Genzyme provides Sanofi Genzyme with the right, subject to certain exceptions, generally to maintain its ownership position in us until Sanofi Genzyme owns less
than 7.5% of our outstanding common stock, subject to certain additional limited rights of Sanofi Genzyme to maintain its ownership percentage. In accordance with the investor agreement, as a result of our issuance of shares in connection with our
acquisition of Sirna in March 2014, Sanofi Genzyme exercised its right to purchase an additional 344,448 shares of our common stock. In January 2015, Sanofi Genzyme also exercised its right to purchase 196,251 shares based on its 2014
compensation-related right and its right to purchase 744,566 shares in connection with our public offering. In February 2016, Genzyme purchased an additional 205,030 shares based on its 2015 compensation-related right. These purchases allowed Sanofi
Genzyme to maintain its ownership level of approximately 12% of our outstanding common stock. While the exercise of these rights by Sanofi Genzyme has provided us with an additional $126.3&nbsp;million in cash to date, and while any exercise of
these rights by Sanofi Genzyme in the future will provide us with further additional cash, these exercises have caused, and any future exercise of these rights by Sanofi Genzyme will also cause further, dilution to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis, we may be required to significantly delay or curtail one or more of our research or
development programs or undergo future reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to
some of our technologies, product candidates or products that we would otherwise pursue on our own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If the estimates we make, or
the assumptions on which we rely, in preparing our condensed consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our projections and accruals. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by
us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our
estimates, or the assumptions underlying them, will be correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The investment of our cash, cash equivalents and fixed income
marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At March&nbsp;31,
2016, we had $1.21 billion in cash, cash equivalents and fixed income marketable securities, excluding our investment in equity securities of Regulus. We historically have invested these amounts in high&#150;grade corporate notes, commercial paper,
securities issued or sponsored by the U.S. government and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. Corporate notes also include foreign bonds denominated in U.S. dollars.
These investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our condensed
consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect
on our results of operations, liquidity and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to execute our business strategy if we are unable to enter into alliances with other companies that can provide
business and scientific capabilities and funds for the development and commercialization of our product candidates. If we are unsuccessful in forming or maintaining these alliances on terms favorable to us, our business may not succeed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently have any capability for sales or
distribution and have early capability for marketing and market access, and limited capacity for drug development due to our growing pipeline of RNAi therapeutic opportunities. Accordingly, we have entered into alliances with other companies and
collaborators that we believe can provide such capabilities in certain territories, and we intend to enter into additional such alliances in the future. Our collaboration strategy is to form alliances that create significant value for ourselves and
our collaborators in the advancement of RNAi therapeutics as a new class of innovative medicines. Specifically, with respect to our Genetic Medicine pipeline, we formed a broad strategic alliance with Sanofi Genzyme in 2014 pursuant to which we
retain development and commercial rights for our current and future Genetic Medicine products in North America and Western Europe, and Sanofi Genzyme will develop and commercialize our current and future Genetic Medicine products principally in
territories outside of North America and Western Europe, subject to certain broader rights. With respect to our Cardio-Metabolic and Hepatic Infectious Disease pipelines, we intend to seek future strategic alliances for these programs, while
retaining significant product development and commercialization rights in the United States and EU. We currently have a global alliance with MDCO to advance our ALN-PCS program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In such alliances, we expect our current, and may expect our future, collaborators to provide
substantial capabilities in clinical development, regulatory affairs, and/or marketing, sales and distribution. Under certain of our alliances, we also may expect our collaborators to develop, market and/or sell certain of our product candidates. We
may have limited or no control over the development, sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. For example, we will rely entirely
on (i)&nbsp;Sanofi Genzyme for the development and commercialization of patisiran, revusiran, fitusiran and potentially other of our Genetic Medicine programs in territories outside of North America and Western Europe under the 2014 Sanofi Genzyme
collaboration, and (ii)&nbsp;MDCO for all future development and commercialization of ALN-PCSsc worldwide. If Sanofi Genzyme and/or MDCO are not successful in their commercialization efforts, our future revenues from RNAi therapeutics for these
indications may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be successful in entering into such alliances on terms favorable to us due to various
factors, including our ability to successfully demonstrate proof of concept for our technology in humans, our ability to demonstrate the safety and efficacy of our specific drug candidates, our ability to manufacture or have third parties
manufacture RNAi therapeutics, the strength of our intellectual property and/or concerns around challenges to our intellectual property. Even if we do succeed in securing any such alliances, we may not be able to maintain them if, for example,
development or approval of a product candidate is delayed, challenges are raised as to the validity or scope of our intellectual property or sales of an approved drug are lower than we expected. In the case of the Monsanto agreement, if we cease to
own or otherwise exclusively control certain licensed patent rights in the agriculture field, resulting in the loss of exclusivity with respect to Monsanto&#146;s rights to such patent rights, and such loss of exclusivity has a material adverse
effect on the licensed products (as defined in the agreement), we would be required to pay Monsanto up to $5.0&nbsp;million in liquidated damages, and Monsanto&#146;s royalty obligations to us would be reduced or, under certain circumstances,
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, any delay in entering into collaboration agreements would likely either delay the development and
commercialization of certain of our product candidates and reduce their competitiveness even if they reach the market, or prevent the development of certain product candidates. Any such delay related to our collaborations could adversely affect our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For certain product candidates that we may develop, we have formed collaborations to fund all or part of the costs of drug
development and commercialization, such as our collaborations with Sanofi Genzyme and MDCO. We may not, however, be able to enter into additional collaborations for certain other programs, and the terms of any collaboration agreement we do secure
may not be favorable to us. If we are not successful in our efforts to enter into future collaboration arrangements with respect to one or more of our product candidates, we may not have sufficient funds to develop that or other product candidates
internally, or to bring our product candidates to market. If we do not have sufficient funds to develop and bring our product candidates to market, we will not be able to generate revenues from these product candidates, and this will substantially
harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If any collaborator terminates or fails to perform its obligations under agreements with us, the development and
commercialization of our product candidates could be delayed or terminated. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our dependence on collaborators for capabilities and
funding means that our business could be adversely affected if any collaborator terminates its collaboration agreement with us or fails to perform its obligations under that agreement. Our current or future collaborations, if any, may not be
scientifically or commercially successful. Disputes may arise in the future with respect to the ownership of rights to technology or products developed with collaborators, which could have an adverse effect on our ability to develop and
commercialize any affected product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current collaborations allow, and we expect that any future collaborations will allow,
either party to terminate the collaboration for a material breach by the other party. In addition, our collaborators may have additional termination rights for convenience under certain circumstances. For example, our agreement with MDCO relating to
the development and commercialization of ALN-PCSsc worldwide may be terminated by MDCO at any time upon four months&#146; prior written notice. If we were to lose a commercialization collaborator, we would have to attract a new collaborator or
develop internal sales, distribution and marketing capabilities, which would require us to invest significant amounts of financial and management resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if we have a dispute with a collaborator over the ownership of technology or other matters, or if a collaborator terminates its
collaboration with us, for breach or otherwise, or determines not to pursue the research and development of RNAi therapeutics, it could delay our development of product candidates, result in the need for additional company resources to develop
product candidates, require us to expend time and resources to develop sales and marketing capabilities outside of the United States and EU, make it more difficult for us to attract new collaborators and could adversely affect how we are perceived
in the business and financial communities. For example, in March 2011, Arbutus (formerly Tekmira) filed a civil complaint against us claiming, among other things, misappropriation of its confidential and proprietary information and trade secrets. As
a result of the litigation, which was settled in November 2012, we were required to expend resources and management attention that would otherwise have been engaged in other activities. In addition, in August 2013, we initiated binding arbitration
proceedings to resolve a disagreement with Arbutus regarding the achievement by Arbutus of a $5.0&nbsp;million milestone payment under our cross-license agreement relating to the manufacture of ALN-VSP clinical trial material for use in China. The
Arbutus arbitration hearing was held in May 2015. On March&nbsp;9, 2016, the arbitration panel ruled in our favor and as a result, no milestone payment is due to Arbutus at this time. The grounds on which Arbutus may appeal this ruling are limited
and Arbutus has until June&nbsp;8, 2016 to file any such appeal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, a collaborator, or in the event of a change in control of a collaborator or the
assignment of a collaboration agreement to a third party, the successor entity or assignee, could determine that it is in its interests to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue alternative technologies or develop alternative products, either on its own or jointly with others, that may be competitive with the products on which it is collaborating with us or which could affect its
commitment to the collaboration with us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue higher-priority programs or change the focus of its development programs, which could affect the collaborator&#146;s commitment to us; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if it has marketing rights, choose to devote fewer resources to the marketing of our product candidates, if any are approved for marketing, than it does for product candidates developed without us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any of these occur, the development and commercialization of one or more product candidates could be delayed, curtailed or terminated
because we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, our development plans may be
adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely on independent clinical investigators, contract research organizations and other third-party service
providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We have contracted, and we plan to continue to contract with, certain third parties to provide certain services, including site selection, enrollment,
monitoring and data management services. Although we depend heavily on these parties, we do not control them and therefore, we cannot be assured that these third parties will adequately perform all of their contractual obligations to us. If our
third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third party to adhere to our protocols or regulatory
requirements or if such third parties otherwise fail to meet deadlines, our development plans may be delayed or terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have
limited manufacturing experience and resources and we must incur significant costs to develop this expertise and/or rely on third parties to manufacture our products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have limited manufacturing experience. In order to develop our product candidates, apply for regulatory approvals and commercialize our
products, if approved, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Historically, our internal manufacturing capabilities were limited to small-scale production of material for use in
<I>in vitro</I> and <I>in vivo</I> experiments that is not required to be produced under current good manufacturing practices, or cGMP, standards. During 2012, we developed cGMP capabilities and processes for the manufacture of patisiran for
late-stage clinical trial use and commercial supply. In addition, in April 2016, we completed our purchase of a parcel of land in Norton, Massachusetts, where we intend to construct a cGMP manufacturing facility for drug substance, including siRNAs
and siRNA conjugates, for clinical and commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may manufacture limited quantities of clinical trial materials ourselves, but
otherwise we currently rely on third parties to manufacture the drug substance and finished product we will require for any clinical trials that we initiate and to support the commercial launch of our first several products. There are a limited
number of manufacturers that supply synthetic siRNAs. We currently rely on a limited number of contract manufacturers for our supply of synthetic siRNAs. For example, in July 2015, we amended our manufacturing agreement with Agilent Technologies,
Inc., or Agilent, to provide for Agilent to supply, subject to any conflicting obligations under our third-party agreements, a specified percentage of the active pharmaceutical ingredients required for certain of our products in clinical
development, as well as other products the parties may agree upon in the future. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our contract manufacturers, including Agilent, to meet our delivery time
requirements or provide adequate amounts of material to meet our needs. Included in these risks are potential synthesis and purification failures and/or contamination during the manufacturing process, which could result in unusable product and cause
delays in our manufacturing timelines and ultimately delay our clinical trials, as well as additional expense to us. To fulfill our siRNA requirements, we may need to secure alternative suppliers of synthetic siRNAs and such alternative suppliers
are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. As noted above, in order to ensure long-term supply capabilities for our RNAi therapeutics, we intend to
develop our own capabilities to manufacture drug substance, including siRNAs and siRNA conjugates, for clinical and commercial use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the manufacture of the synthetic siRNAs, we may
have additional manufacturing requirements related to the technology required to deliver the siRNA to the relevant cell or tissue type, such as LNPs or conjugates. In some cases, the delivery technology we utilize is highly specialized or
proprietary, and for technical and legal reasons, we may have access to only one or a limited number of potential manufacturers for such delivery technology. In addition, the scale-up of our delivery technologies could be very difficult. We also
have very limited experience in such scale-up and manufacturing, requiring us to depend on a limited number of third parties, who might not be able to deliver in a timely manner, or at all. Failure by manufacturers to properly manufacture our
delivery technology and/or formulate our siRNAs for delivery could result in unusable product. Furthermore, competition for supply from our manufacturers from other companies, a breach by such manufacturers of their contractual obligations or a
dispute with such manufacturers would cause delays in our discovery and development efforts, as well as additional expense to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Given the limited number of suppliers for our delivery technology and drug substance, we have
developed cGMP capabilities and processes for the manufacture of patisiran formulated bulk drug product for late-stage clinical use and early commercial supply. During 2015, we scaled our cGMP manufacturing capacity for patisiran and believe we
should have adequate resources to supply our commercial needs. In addition, as noted above, we intend to develop our own capabilities to manufacture drug substance, including siRNAs and siRNA conjugates, for clinical and commercial use. In
developing these manufacturing capabilities by building our own manufacturing facilities, we have incurred substantial expenditures, and expect to incur significant additional expenditures in the future. In addition, the construction and
qualification of our drug substance facility is expected to take several years to complete and there are many risks inherent in the construction of a new facility that could result in delays and additional costs. Also, we have had to, and will
likely need to continue to, hire and train qualified employees to staff our facilities. We do not currently have a second source of supply for patisiran formulated bulk drug product. If we are unable to manufacture sufficient quantities of material
or if we encounter problems with our facilities in the future, we may also need to secure alternative suppliers of patisiran formulated bulk drug product and drug substance, and such alternative suppliers may not be available, or we may be unable to
enter into agreements with them on reasonable terms and in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacturing process for any products that we may
develop is subject to the FDA and foreign regulatory authority approval process and we will need to meet, and will need to contract with manufacturers who can meet, all applicable FDA and foreign regulatory authority requirements on an ongoing
basis. In addition, if we receive the necessary regulatory approval for any product candidate, we also expect to rely on third parties, including our commercial collaborators, to produce materials required for commercial supply. We may experience
difficulty in obtaining adequate manufacturing capacity for our needs. If we are unable to obtain or maintain contract manufacturing for these product candidates, or to do so on commercially reasonable terms, we may not be able to successfully
develop and commercialize our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that we have existing, or enter into future, manufacturing arrangements with third
parties, we depend, and will depend in the future, on these third parties, including Agilent, to perform their obligations in a timely manner and consistent with contractual and regulatory requirements, including those related to quality control and
quality assurance. The failure of Agilent or any other third-party manufacturer to perform its obligations as expected, or, to the extent we manufacture all or a portion of our product candidates ourselves, our failure to execute on our
manufacturing requirements, could adversely affect our business in a number of ways, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our current or future collaborators may not be able to initiate or continue clinical trials of product candidates that are under development; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our current or future collaborators may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may lose the cooperation of our collaborators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our facilities and those of our third party manufacturers, and our products could be the subject of inspections by regulatory authorities that could have a negative outcome and result in delays in supply;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to cease distribution or recall some or all batches of our products or take action to recover clinical trial material from clinical trial sites; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ultimately, we may not be able to meet commercial demands for our products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any
third-party manufacturer with whom we contract, including Agilent, fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a
different third-party manufacturer, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some
cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring
such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities
and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product
according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a
timely manner or within budget. Furthermore, a manufacturer may possess technology related to the manufacture of our product candidate that such manufacturer owns independently. This would increase our reliance on such manufacturer or require us to
obtain a license from such manufacturer in order to have another third party manufacture our products or product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have no sales or distribution experience and only early capabilities for marketing and
market access, and expect to invest significant financial and management resources to establish these capabilities and to establish capabilities in the EU. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have no sales or distribution experience and only early capabilities for marketing and market access. We currently expect to rely heavily
on third parties to launch and market certain of our product candidates in certain geographies, if approved. However, we intend to commercialize the majority of our products on our own in the United States and EU, and accordingly, we will need to
develop internal sales, distribution and marketing capabilities as part of our core product strategy in the United States and the EU, which will require significant financial and management resources. For our Genetic Medicine programs where we will
perform sales, marketing and distribution functions ourselves in North America and Western Europe, and for future Cardio-Metabolic and Hepatic Infectious Disease products we successfully develop where we intend to retain significant product
development and commercialization rights in the United States and EU, we could face a number of additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to establish our capabilities and infrastructure in the EU in a timely manner; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to attract and build a significant marketing or sales force; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of establishing a marketing or sales force may not be justifiable in light of the revenues generated by any particular product; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our direct sales and marketing efforts may not be successful. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to develop our
own sales, marketing and distribution capabilities in the United States and the EU, we will not be able to successfully commercialize our Genetic Medicine pipeline or our future Cardio-Metabolic and Hepatic Infectious Disease pipelines in our sales
territories without reliance on third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Credit and financial market conditions may exacerbate certain risks affecting our
business from time to time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to tightening of global credit, there may be a disruption or delay in the performance of our
third-party contractors, suppliers or collaborators. We rely on third parties for several important aspects of our business, including significant portions of our manufacturing needs, development of product candidates and conduct of clinical trials.
If such third parties are unable to satisfy their commitments to us, our business could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to secure
additional financing in addition to the credit agreements with BOA and Wells and to satisfy our financial obligations under indebtedness outstanding from time to time will depend upon our future operating performance, which is subject to then
prevailing general economic and credit market conditions, including interest rate levels and the availability of credit generally, and financial, business and other factors, many of which are beyond our control. In light of periodic uncertainty in
the capital and credit markets, there can be no assurance that sufficient financing will be available on desirable or even any terms to fund investments, acquisitions, stock repurchases, dividends, debt refinancing or extraordinary actions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Managing Our Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to attract and retain qualified key management and scientists, development and commercial staff, consultants and
advisors, our ability to implement our business plan may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are highly dependent upon our senior
management and our scientific, clinical and medical staff. The loss of the service of any of the members of our senior management, including Dr.&nbsp;John Maraganore, our Chief Executive Officer, may significantly delay or prevent the achievement of
product development and other business objectives. Our employment agreements with our key personnel are terminable without notice. We do not carry key person life insurance on any of our employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have grown our workforce significantly over the past year and anticipate continuing to add a significant number of additional employees as
we focus on achieving our <I>Alnylam 2020</I> profile. We face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities, governmental entities and other research institutions, many of which
have substantially greater resources with which to reward qualified individuals than we do. We may be unable to attract and retain suitably qualified individuals in order to support our growing research, development and commercialization efforts and
initiatives, and our failure to do so could have an adverse effect on our ability to implement our future business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may
have difficulty expanding our operations successfully as we evolve from a U.S.-based company primarily involved in discovery, pre-clinical testing and clinical development into a global company that develops and commercializes multiple drugs.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that as we increase the number of
product candidates we are developing we will also need to expand our operations in the United States and establish operations in the EU. As noted above, we have grown our workforce significantly over the past year and anticipate continuing to add a
significant number of additional employees, including employees in the EU, as we focus on achieving our <I>Alnylam 2020</I> profile. This expected growth is placing a strain on our administrative and operational infrastructure, and we will need to
develop additional and/or new infrastructure and capabilities to support our growth and obtain additional space to conduct our operations in the United States and the EU. If we are unable to develop such additional infrastructure or obtain
sufficient space to accommodate our growth in a timely manner and on commercially reasonable terms, our business could be negatively impacted. As product candidates we develop enter and advance through clinical trials, we will need to expand our
development, regulatory, manufacturing, marketing and sales capabilities in the United States and the EU or contract with other organizations to provide these capabilities for us. In addition, as our operations expand due to our development
progress, we expect that we will need to manage additional relationships with various collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational,
financial and management controls and systems, reporting systems and infrastructure, and policies and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may
discover deficiencies in existing systems and controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations could suffer in the event of system failures. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of pre-clinical trial data or data
from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. To the extent that any disruption or security breach were to result
in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Industry </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidates we develop may
fail in development or be delayed to a point where they do not become commercially viable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval
for the commercial distribution of our product candidates, we must conduct, at our own expense, extensive nonclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. Nonclinical and clinical
testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome, and the historical failure rate for product candidates is high. We currently have multiple programs in clinical development,
including two programs in Phase&nbsp;3 clinical trials, as well as several earlier stage clinical programs. However, we may not be able to further advance these or any other product candidate through clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we enter into clinical trials, the results from nonclinical testing or early clinical trials of a product candidate may not predict the
results that will be obtained in subsequent subjects or in subsequent human clinical trials of that product candidate or any other product candidate. For example, during 2015, we announced updated results from our Phase&nbsp;1 clinical trial of
fitusiran, including initial clinical data on a small number of people with hemophilia. Although the initial clinical data from this trial are encouraging, the data are preliminary in nature, based on a limited number of people with hemophilia, and
the fitusiran Phase&nbsp;1 study is not complete. These data, or other positive data, may not continue for these people with hemophilia or occur for any future patients in this study, and may not be repeated or observed in any future studies. There
can be no assurance that this study will ultimately be successful or support further clinical advancement of this product candidate. In addition, in April 2016, we reported that based on preliminary data in our ALN-CC5 Phase 1/2 clinical trial that
we expect to present at an upcoming medical meeting, we now plan to pursue a more focused development path in PNH where ALN-CC5 would be being evaluated in eculizumab poor responders and for eculizumab sparing. There is a high failure rate for drugs
proceeding through clinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks
in our clinical development could have a material adverse effect on our business and operating results. Moreover, patisiran, revusiran, fitusiran and our other product candidates each employ novel delivery technologies that have yet to be
extensively evaluated in human clinical trials and proven safe and effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we, the FDA or other applicable regulatory
authorities, or an institutional review board, or IRB, or similar foreign review board or committee, may suspend clinical trials of a product candidate at any time for various reasons, including if we or they believe the healthy volunteer subjects
or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a product candidate on healthy volunteer subjects or patients in a clinical trial could result in the FDA or
foreign regulatory authorities suspending or terminating the trial and refusing to approve a particular product candidate for any or all indications of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering
from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the age and condition of the patients, the
stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. For example, we may
experience difficulty enrolling our clinical trials, including, but not limited to, our clinical trials for fitusiran, due to the availability of existing approved treatments, as well as other investigational treatments in development. Delays or
difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments, can result in increased costs, longer development times or termination of a
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although our investigational RNAi therapeutics have been generally well tolerated in our clinical trials to date, new
safety findings may emerge. For example, in our ALN-VSP clinical trial, one patient with advanced pancreatic neuroendocrine cancer with extensive involvement of the liver developed hepatic failure five days following the second dose of ALN-VSP and
subsequently died; this was deemed possibly related to the study drug. In our patisiran Phase 2 OLE study in FAP patients, based on complete 18-month data reported from 27 FAP patients as of the data cutoff on February&nbsp;23, 2016, the most common
drug-related or possibly drug-related adverse events, or AEs, were flushing and infusion-related reactions, which were all mild in severity and did not result in any discontinuations. There were eight reports of serious adverse events, or SAEs, in
five patients, all of which were unrelated to study </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug, including one discontinuation for gastroesophageal cancer at approximately 20 months in a patient who subsequently died. After the data cut-off date, an additional unrelated SAE of
myocardial infarction was reported in a 79 year-old patient who subsequently died after having completed the full 24 months of treatment. The most common AE in our revusiran Phase 2 study was injection site reactions, or ISRs. The next most common
adverse event in our Phase 2 study of revusiran was a low incidence of transient mild liver function test changes that, in all cases, resolved without discontinuing therapy. During 2015, we reported initial data from our revusiran Phase 2 OLE study
for 18 patients who had reached the six-month endpoint as of the data transfer date of October&nbsp;12, 2015. SAEs were observed in eight patients, including one death due to infiltrative cardiomyopathy; none of these SAEs were deemed to be related
to the study drug. The majority of the AEs were mild or moderate in severity; ISRs were reported in 11 patients. In August 2015, we reported that three patients had discontinued from the revusiran Phase 2 OLE study due to recurrent localized
reactions at the injection site or a diffuse rash; no further discontinuations due to ISRs had occurred as of October&nbsp;12, 2015. The occurrence of AEs can result in the suspension or termination of clinical trials of a product candidate by us or
the FDA or a foreign regulatory authority, or refusal to approve a particular product candidate for any or all indications of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials also require the review, oversight and approval of IRBs, which continually review clinical investigations and protect the
rights and welfare of human subjects. Inability to obtain or delay in obtaining IRB approval can prevent or delay the initiation and completion of clinical trials, and the FDA or foreign regulatory authorities may decide not to consider any data or
information derived from a clinical investigation not subject to initial and continuing IRB review and approval in support of a marketing application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product candidates that we develop may encounter problems during clinical trials that will cause us, an IRB or regulatory authorities to
delay, suspend or terminate these trials, or that will delay or confound the analysis of data from these trials. If we experience any such problems, we may not have the financial resources to continue development of the product candidate that is
affected, or development of any of our other product candidates. We may also lose, or be unable to enter into, collaborative arrangements for the affected product candidate and for other product candidates we are developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as
a result of, nonclinical testing and the clinical trial process that could delay or prevent regulatory approval or our ability to commercialize our product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our nonclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical testing or clinical trials, or we may abandon
projects that we expect to be promising; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in filing investigational new drug, or IND, applications or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs in order to commence a clinical trial
at a prospective trial site, or their suspension or termination of a clinical trial once commenced; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions imposed on us by an IRB, or the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">problems in engaging IRBs to oversee clinical trials or problems in obtaining or maintaining IRB approval of trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in enrolling patients and volunteers into clinical trials, and variability in the number and types of patients and volunteers available for clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">high drop-out rates for patients and volunteers in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inadequate supply or quality of product candidate materials or other materials necessary for the conduct of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater than anticipated clinical trial costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">poor or disappointing effectiveness of our product candidates during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or records of any clinical or nonclinical investigation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </TD></TR></TABLE>
<P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our
technology in particular; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying interpretations of data by the FDA and similar foreign regulatory agencies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if
we successfully complete clinical trials of our product candidates, any given product candidate may not prove to be a safe and effective treatment for the disease for which it was being tested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to obtain United States or foreign regulatory approval and, as a result,
unable to commercialize our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product candidates are subject to extensive governmental regulations relating
to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous nonclinical
testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory
requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling
them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including
approval by the FDA. The time required to obtain FDA and other regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product
candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from nonclinical and clinical activities is subject to
confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or
administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations,
guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because the drugs we are developing may
represent a new class of drug, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these drugs. The lack of policies, practices or guidelines may hinder or slow review by the
FDA of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our product
candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we
develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent years, there has been increased public and political pressure on the FDA with respect to the
approval process for new drugs, and the FDA&#146;s standards, especially regarding drug safety, appear to have become more stringent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any
delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a
product may be subject to limitations on the approved uses for which we may market the product or the labeling or other restrictions. In addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy, or REMS, plan as part
of an NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training,
limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. In the EU, we could be required to adopt a similar plan, known as a risk management plan, and our products could be subject to
specific risk minimization measures, such as restrictions on prescription and supply, the conduct of post-marketing safety or efficacy studies, or the distribution of patient and/or prescriber educational materials. In either instance, these
limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also
subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among
countries and includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not ensure approval by regulatory
authorities outside the United States and vice versa. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing
regulatory oversight. If we fail to comply with continuing U.S. and foreign requirements, our approvals could be limited or withdrawn, we could be subject to other penalties, and our business would be seriously harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following any initial regulatory approval of any drugs we may develop, we will also be subject to continuing regulatory oversight, including
the review of adverse drug experiences and clinical results that are reported after our drug products are made commercially available. This would include results from any post-marketing tests or surveillance to monitor the safety and efficacy of the
drug product required as a condition of approval or agreed to by us. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved uses for which the product may be marketed. Other ongoing
regulatory requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with cGMP requirements and good clinical practices requirements
for any clinical trials that we conduct post-approval. In addition, we are conducting, and intend to continue to conduct, clinical trials for our product candidates, and we intend to seek approval to market our product candidates, in jurisdictions
outside of the United States, and therefore will be subject to, and must comply with, regulatory requirements in those jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate serious safety risks related to the use of
a drug and to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacturer and manufacturing facilities we use to make our product candidates, including our Cambridge facility, our future Norton
facility and Agilent and other third-party manufacturers, will also be subject to periodic review and inspection by the FDA and other regulatory agencies. To date, our Cambridge manufacturing facility has not been subject to an inspection by any
regulatory authority. The discovery of any new or previously unknown problems with us or our third-party manufacturers, or our or their manufacturing processes or facilities, may result in restrictions on the drug or manufacturer or facility,
including withdrawal of the drug from the market. We have developed cGMP capabilities and processes for the manufacture of patisiran for Phase&nbsp;3 clinical and commercial use. In addition, in April 2016, we completed our purchase of a parcel of
land in Norton, Massachusetts, where we intend to construct a cGMP manufacturing facility for drug substance, including siRNAs and siRNA conjugates, for clinical and commercial use. We may not have the ability or capacity to manufacture material at
a broader commercial scale in the future. We may manufacture clinical trial materials or we may contract a third party to manufacture these materials for us. Reliance on third-party manufacturers entails risks to which we would not be subject if we
manufactured products ourselves, including reliance on the third-party manufacturer for regulatory compliance. Our product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we or our collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United
States or foreign jurisdictions in which we may seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA or foreign regulatory authorities to approve pending
applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal
prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our
product candidates upon their commercial introduction, which will prevent us from becoming profitable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The product candidates
that we are developing are based upon new technologies or therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors and consumers, may not accept a product intended to improve therapeutic results
based on RNAi technology. As a result, it may be more difficult for us to convince the medical community and third-party payors to accept and use our product, or to provide favorable reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other factors that we believe will materially affect market acceptance of our product candidates include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety and efficacy of our product candidates, as demonstrated in clinical trials and as compared with alternative treatments, if any; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of patients to accept potentially new routes of administration or new or different therapeutic approaches and mechanisms of action; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of our physician education programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of adequate government and third-party payor reimbursement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the pricing of our products, particularly as compared to alternative treatments; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative effective treatments for the diseases that product candidates we develop are intended to treat and the relative risks, benefits and costs of those treatments. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our estimates regarding the potential market size may be materially different from what we currently expect at the time we
commence commercialization, which could result in significant changes in our business plan and may have a material adverse effect on our results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or our collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be
subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a manufacturer of pharmaceuticals, we are subject to federal, state, and comparable foreign healthcare laws and regulations pertaining to
fraud and abuse and patients&#146; rights. These laws and regulations include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an
individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. federal false claims law, which prohibits, among other things, individuals or entities from knowingly presenting or causing to be presented, claims for payment by government-funded programs such as Medicare or
Medicaid that are false or fraudulent, and which may apply to us by virtue of statements and representations made to customers or third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. federal Health Insurance Portability and Accountability Act and Health Information Technology for Economic and Clinical Health Act, which impose requirements relating to the privacy, security, and transmission
of individually identifiable health information; and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. federal Open Payments requirements were implemented by The Centers for Medicare and Medicaid Services, or CMS, pursuant to the Patient Protection and Affordable Care Act, also referred to as the PPACA or the
Affordable Care Act. Under the National Physician Payment Transparency Program, manufacturers of medical devices, biological products and drugs covered by Medicare, Medicaid and Children&#146;s Health Insurance Programs report all transfers of
value, including consulting fees, travel reimbursements, research grants, and other payments or gifts with values over $10 made to physicians and teaching hospitals; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state and foreign laws comparable to each of the above federal laws, including in the EU laws prohibiting giving healthcare professionals any gift or benefit in kind as an inducement to prescribe our products, national
transparency laws requiring the public disclosure of payments made to healthcare professionals and institutions, and data privacy laws, in addition to foreign, anti-kickback and false claims laws applicable to commercial insurers and other
non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to government reimbursement programs, patient data privacy and security. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal
penalties, criminal prosecution, monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government contracting, healthcare reimbursement or other
government programs, including Medicare and Medicaid, or the imposition of a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services, any of which could adversely affect our financial
results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause
us to incur significant legal expenses and could divert our management&#146;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may
be costly to us in terms of money, time and resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we or our collaborators, manufacturers or service providers fail to comply with
applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and could harm our reputation and lead to reduced acceptance
of our products by the market. These enforcement actions include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse regulatory inspection findings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on, or prohibitions against, marketing our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on, or prohibitions against, importation or exportation of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of review or refusal to approve pending applications or supplements to approved applications; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exclusion from participation in government-funded healthcare programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exclusion from eligibility for the award of government contracts for our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of product approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, federal, state or foreign laws or regulations are subject to change, and while we, our collaborators, manufacturers and/or service
providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or the legal structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform
initiatives, thereby harming our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The regulations that govern marketing approvals, pricing and reimbursement for new
drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some
foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. We are actively monitoring these regulations as several of our programs move into late stages of
development, however, a number of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a product
in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country and potentially in other
countries due to reference pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any products successfully also will depend in part on the extent to
which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if we succeed in bringing one or more products to the market,
these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Increasingly, the third-party payors who reimburse patients or healthcare
providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. If the
price we are able to charge for any products we develop, or the reimbursement provided for such products, is inadequate in light of our development and other costs, or if reimbursement is denied, our return on investment could be adversely affected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently expect that some of the drugs we develop may need to be administered under the supervision of a physician or other
healthcare professional on an outpatient basis. Under currently applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under the Medicare Part B program if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">they are incident to a physician&#146;s services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">they have been approved by the FDA and meet other requirements of the statute. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There may be significant delays in obtaining coverage for
newly-approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or foreign regulatory authorities. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or
at a rate that covers our costs, including research, development, manufacture, sale and distribution or that covers a particular provider&#146;s cost of acquiring the drug. Interim payments for new drugs, if applicable, may also not be sufficient to
cover our costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or
imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from
countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and
adequate reimbursement rates from both government-funded and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed
to commercialize products, and our overall financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the efforts of governments and third-party payors to contain or reduce the cost
of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. A number of legislative and regulatory
changes in the healthcare system in the United States and other major healthcare markets have been proposed in recent years, and such efforts have expanded substantially in recent years. These developments have included prescription drug benefit
legislation that was enacted in 2003 and took effect in January 2006, healthcare reform legislation enacted by certain states, and major healthcare reform legislation that was passed by Congress and enacted into law in the United States in 2010.
These developments could, directly or indirectly, affect our ability to sell our products, if approved, at a favorable price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
particular, in March 2010, the PPACA was signed into law. This legislation changed the system of healthcare insurance and benefits intended to broaden coverage and control costs. The law also contains provisions that affect companies in the
pharmaceutical industry and other healthcare related industries by imposing additional costs and changes to business practices. Provisions affecting pharmaceutical companies include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mandatory rebates for drugs sold into the Medicaid program were increased, and the rebate requirement was extended to drugs used in risk-based Medicaid managed care plans. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The 340B Drug Pricing Program under the Public Health Service Act was extended to require mandatory discounts for drug products sold to certain critical access hospitals, cancer hospitals and other covered entities.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pharmaceutical companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part&nbsp;D coverage gap, commonly referred to as the &#147;Donut Hole.&#148; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pharmaceutical companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#146;s market share of prior year total sales of branded products to certain federal
healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal health program pharmaceutical market, we
do not expect this annual assessment to have a material impact on our financial condition. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The law provides that approval of an application for a follow-on biologic product may not become effective until 12 years after the date on which the reference innovator biologic product was first licensed by the FDA,
with a possible six-month extension for pediatric products. After this exclusivity ends, it will be easier for generic manufacturers to enter the market, which is likely to reduce the pricing for such products and could affect our profitability.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The full effects of the U.S. healthcare reform legislation cannot be known until the law is fully implemented through
regulations or guidance issued by the CMS and other federal and state healthcare agencies. The financial impact of the U.S. healthcare reform legislation over the next few years will depend on a number of factors, including, but not limited, to the
policies reflected in implementing regulations and guidance, and changes in sales volumes for products affected by the new system of rebates, discounts and fees. This legislation may also have a positive impact on our future net sales, if any, by
increasing the aggregate number of persons with healthcare coverage in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, we cannot predict what healthcare
reform initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the United States to increase pressure on drug pricing. Such reforms could have an
adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal
spending. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Budget Control Act of 2011, the failure of Congress to enact deficit reduction measures of at least
$1.2&nbsp;trillion for the years 2013 through 2021 triggered automatic cuts to most federal programs. These cuts included aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, starting in 2013. Under the American
Taxpayer Relief Act of 2012, which was enacted on January&nbsp;1, 2013, the imposition of these automatic cuts was delayed until March&nbsp;1, 2013. As required by law, President Obama issued a sequestration order on March&nbsp;1, 2013. Certain of
these automatic cuts have been implemented resulting in reductions in Medicare payments to physicians, hospitals, and other healthcare providers, among other things. The full impact on our business of these automatic cuts is uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If other federal spending is reduced, any budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or National
Institutes of Health to continue to function. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research and
development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>There is a substantial risk of product liability claims in our business. If we are unable
to obtain sufficient insurance, a product liability claim against us could adversely affect our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business exposes us
to significant potential product liability risks that are inherent in the development, testing, manufacturing and marketing of human therapeutic products. Product liability claims could delay or prevent completion of our clinical development
programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our
products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased
demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#146;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We
currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide
sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us
against losses caused by product liability claims that could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not comply
with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
research, development and manufacturing involves the use of hazardous materials, chemicals and various radioactive compounds. We maintain quantities of various flammable and toxic chemicals in our facilities in Cambridge that are required for our
research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing,
handling and disposing these materials in our Cambridge facilities comply with the relevant guidelines of the City of Cambridge, the Commonwealth of Massachusetts and the Occupational Safety and Health Administration of the U.S. Department of Labor.
Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If
an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure
to blood-borne pathogens and the handling of biohazardous materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover
us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. Additional federal, state and local laws and regulations affecting our operations may be
adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Patents, Licenses and Trade Secrets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain and enforce patent protection for our discoveries, our ability to develop and commercialize our product
candidates will be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends, in part, on our ability to protect proprietary methods and technologies that we
develop under the patent and other intellectual property laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold proprietary rights to
some patents required for us to commercialize our proposed products. Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November&nbsp;29, 2000, or applications filed after such date
which will not be filed in foreign countries, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority
over those applications. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity. Further, we may be required to obtain licenses under third-party patents to market our proposed products or
conduct our research and development or other activities. If licenses are not available to us on acceptable terms, we may not be able to market the affected products or conduct the desired activities. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our strategy depends on our ability to rapidly identify and seek
patent protection for our discoveries. In addition, we may rely on third-party collaborators to file patent applications relating to proprietary technology that we develop jointly during certain collaborations. The process of obtaining patent
protection is expensive and time-consuming. If our present or future collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected.
Despite our efforts and the efforts of our collaborators to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. While issued patents are presumed valid, this does not
guarantee that the patent will survive a validity challenge or be held enforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable or circumvented by parties attempting to design around
our intellectual property. Moreover, third parties or the United States Patent and Trademark Office, or USPTO, may commence interference proceedings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation or circumvention of, our patents or patent applications, would be costly, would require
significant time and attention of our management and could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our pending patent
applications may not result in issued patents. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its
foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and
foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic discussions in the Congress of the United States and in international
jurisdictions about modifying various aspects of patent law. For example, the America Invents Act included a number of changes to the patent laws of the United States. If any of the enacted changes do not provide adequate protection for discoveries,
including our ability to pursue infringers of our patents for substantial damages, our business could be adversely affected. One major provision of the America Invents Act, which took effect in March 2013, changed United States patent practice from
a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer have the ability to provide proof that we were in possession of the invention prior to the competitor&#146;s
filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any
patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected
by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain or enforce the patents
underlying such licenses, our competitive position and business prospects may be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a party to a number of licenses
that give us rights to third-party intellectual property that is necessary or useful for our business. In particular, we have obtained licenses from, among others, CRT, Ionis (formerly Isis), MIT, Whitehead, Max Planck Innovation and Arbutus. We
also intend to enter into additional licenses to third-party intellectual property in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success will depend in part on the
ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent
applications to which we are licensed. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents,
or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our
competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our
collaboration agreements or result in termination of an agreement by one or more of our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other companies or
organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RNAi is a relatively new scientific field, the commercial exploitation of which has resulted in many different patents and patent applications
from organizations and individuals seeking to obtain patent protection in the field. We have obtained grants and issuances of RNAi patents and have licensed many of these patents from third parties on an exclusive basis. The issued patents and
pending patent applications in the United States and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of RNAi
therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Specifically, we have a portfolio of patents, patent applications and other intellectual property covering: fundamental
aspects of the structure and uses of siRNAs, including their use as therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic and other uses; siRNAs directed to specific targets as
treatments for particular diseases; delivery technologies, such as in the fields of carbohydrate conjugates and cationic liposomes; and all aspects of our specific development candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As the field of RNAi therapeutics is maturing, patent
applications are being fully processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. It is likely that there will be significant
litigation and other proceedings, such as interference, reexamination and opposition proceedings, as well as <I>inter partes</I> and post-grant review proceedings introduced by provisions of the America Invents Act, which became available to third
party challengers on September&nbsp;16, 2012, in various patent offices relating to patent rights in the RNAi field. For example, various third parties have initiated oppositions to patents in our McSwiggen, Kreutzer-Limmer and Tuschl&nbsp;II series
in the EPO and in other jurisdictions. We expect that additional oppositions will be filed in the EPO and elsewhere, and other challenges will be raised relating to other patents and patent applications in our portfolio. In many cases, the
possibility of appeal exists for either us or our opponents, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may
adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are
not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require
significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete in the field of RNAi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need to apply to our
siRNA therapeutic candidates. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for siRNA drugs we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to
which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market products or perform research and development or other activities covered by these patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs
and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third parties may sue us for infringing their patent rights. Likewise, we may need to resort to litigation to enforce a patent issued or
licensed to us or to determine the scope and validity of proprietary rights of others or protect our proprietary information and trade secrets. For example, during the second quarter of 2015, we filed a trade secret misappropriation lawsuit against
Dicerna to protect our rights in the RNAi assets we purchased from Merck. A third party may also claim that we have improperly obtained or used its confidential or proprietary information. For example, in March 2011, Arbutus (formerly Tekmira) filed
a civil complaint against us alleging, among other things, misappropriation of the plaintiffs&#146; confidential and proprietary information and trade secrets. In November 2012, we settled this litigation and restructured our contractual
relationship with Arbutus. In connection with this restructuring, we incurred a $65.0&nbsp;million charge to operating expenses during the quarter ended December&nbsp;31, 2012. In addition, during the pendency of the litigation, we incurred
significant costs, and the defense of this litigation diverted the attention of our management and other resources that would otherwise have been engaged in other activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, third parties may challenge the inventorship of our patents or licensed patents. For example, in March 2011, Utah filed a
complaint in the MA District Court, against us, Max Planck, Whitehead, MIT and UMass, claiming that a professor of Utah is the sole inventor, or in the alternative, a joint inventor of certain of our in-licensed patents. Utah was seeking correction
of inventorship of the Tuschl patents, unspecified damages and other relief. After several years of court proceedings and discovery, in September 2015, the MA District Court granted our motions for summary judgment, finding that there was no
collaboration between Dr.&nbsp;Bass and Dr.&nbsp;Tuschl, which is a pre-requisite for co-inventorship, and dismissing Utah&#146;s state law damages claims as well. On October&nbsp;28, 2015, Utah filed a notice of appeal from this ruling to the CAFC.
On December&nbsp;18, 2015, the CAFC entered an order dismissing Utah&#146;s appeal following a joint motion filed by us and Utah seeking dismissal of the appeal with prejudice. This disposed of Utah&#146;s inventorship claims and its state law
claims for damages. On October&nbsp;14, 2015, we filed a motion with the MA District Court seeking reimbursement of costs and fees associated with defending this action in the amount of approximately $8.0 million. On November&nbsp;30, 2015, the MA
District Court denied our motion and on December&nbsp;15, 2015 we filed a notice of appeal of this ruling with the CAFC. On February&nbsp;16, 2016, we filed our appeal brief with the CAFC. Utah filed a response on April&nbsp;11, 2016 and our reply
is due May&nbsp;9, 2016. While we believe a fee award is merited in this case, such awards are not customary and are made at the discretion of the court. We anticipate a ruling on our appeal by the end of the third quarter of 2016, however, the
timing will be determined by the CAFC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in connection with certain license and collaboration agreements, we have agreed to
indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual
property rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#146;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can
because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could delay our research and development efforts and limit our ability to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any parties successfully claim that our creation or use of proprietary technologies infringes upon or otherwise violates their intellectual
property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties&#146; patent rights. In addition to any damages we might have to pay, a court could require us to
stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors
may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to
generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our
intellectual property may be offset by amounts paid by our collaborators to third parties who have competing or superior intellectual property positions in the relevant fields, which could result in significant reductions in our revenues from
products developed through collaborations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under any licenses or related agreements, we may
be required to pay damages and could lose license or other rights that are necessary for developing and protecting our RNAi technology and any related product candidates that we develop, or we could lose certain rights to grant sublicenses.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization,
funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we
may be required to pay damages and the licensor may have the right to terminate the license or render the license non-exclusive, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed
technology or enable a competitor to gain access to the licensed technology. For example, in 2013, Arbutus (formerly Tekmira) notified us that it believed it had achieved a $5.0&nbsp;million milestone payment under our cross-license agreement
relating to the manufacture of ALN-VSP clinical trial material for use in China. We notified Arbutus that we did not believe that the milestone has been achieved under the terms of the cross-license agreement. In August 2013, we initiated binding
arbitration proceedings seeking a declaratory judgment that Arbutus had not yet met the conditions of the milestone and was not entitled to payment at the time. The Arbutus arbitration hearing was held in May 2015. On March&nbsp;9, 2016, the
arbitration panel ruled in our favor and as a result, no milestone payment is due to Arbutus at this time. The grounds on which Arbutus may appeal this ruling are limited and Arbutus has until June&nbsp;8, 2016 to file any such appeal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to
claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#146;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we will be required to pay on sales of future
products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we
successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements
with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to
protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not
effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary
information, and in such cases we could not assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain
trade secret protection could adversely affect our competitive business position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods
and new technologies, we may be unable to commercialize successfully any drugs that we develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The pharmaceutical market is
intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the
same diseases that we are targeting or expect to target. Many of our competitors have: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates that are based on previously tested or accepted technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">products that have been approved or are in late stages of development; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborative arrangements in our target markets with leading companies and research institutions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the
conditions for which we may develop drugs. We also expect to face competition from new drugs that enter the market. We believe a significant number of drugs are currently under development, and may become commercially available in the future, for
the treatment of conditions for which we may try to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop. For example, we are developing patisiran for the
treatment of hATTR-PN. We have completed enrollment in our ongoing Phase 3 clinical trial and expect to report data from the Phase 3 clinical trial in 2017. We are aware of other approved products used to treat this disease, including tafamadis,
marketed by Pfizer, as well as product candidates in various stages of clinical development, including an investigational drug being developed for which Ionis has completed enrollment in an ongoing Phase 3 clinical trial. Patisiran may not compete
favorably with these products and product candidates, and even if approved, it may not achieve commercial success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we successfully develop product candidates, and obtain approval for them, we will face
competition based on many different factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety and effectiveness of our products relative to alternative therapies, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and scope of regulatory approvals for these products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability and cost of manufacturing, marketing and sales capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reimbursement coverage; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patent position. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our competitors may develop or commercialize products with significant
advantages over any products we develop based on any of the factors listed above or on other factors. Our competitors may therefore be more successful in commercializing their products than we are, which could adversely affect our competitive
position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our product candidates. Such competitors could also recruit our employees,
which could negatively impact our level of expertise and the ability to execute on our business plan. Furthermore, we also face competition from existing and new treatment methods that reduce or eliminate the need for drugs, such as the use of
advanced medical devices. The development of new medical devices or other treatment methods for the diseases we are targeting could make our product candidates noncompetitive, obsolete or uneconomical. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We face competition from other companies that are working to develop novel drugs and technology platforms using technology similar to
ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the competition we face from competing drugs in general, we also face competition from other companies working to develop novel
drugs using technology that competes more directly with our own. We are aware of multiple companies that are working in the field of RNAi. In addition, we granted licenses or options for licenses to Ionis (formerly Isis), Benitec Ltd., Arrowhead and
its subsidiary, Calando Pharmaceuticals, Inc., Arbutus, Quark, Sylentis S.A. and others under which these companies may independently develop RNAi therapeutics against a limited number of targets. Any of these companies may develop its RNAi
technology more rapidly and more effectively than us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, as a result of agreements that we have entered into, Arrowhead, as the
assignee of Roche, and Takeda have obtained non-exclusive licenses, and Arrowhead, as the assignee of Novartis, has obtained specific exclusive licenses for 30 gene targets, to certain aspects of our technology that give them the right to compete
with us in certain circumstances. We also compete with companies working to develop antisense-based drugs. Like RNAi therapeutics, antisense drugs target messenger RNAs, or mRNAs, in order to suppress the activity of specific genes. Ionis (formerly
Isis) is currently marketing an antisense drug and has several antisense product candidates in clinical trials, including one for the treatment of ATTR amyloidosis. The development of antisense drugs is more advanced than that of RNAi therapeutics,
and antisense technology may become the preferred technology for drugs that target mRNAs to silence specific genes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to
competition with respect to RNAi and with respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver siRNAs to the relevant cell and tissue types. Safe and effective means to deliver
siRNAs to the relevant cell and tissue types may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely affected. In addition, substantial resources are being expended by third parties
in the effort to discover and develop a safe and effective means of delivering siRNAs into the relevant cell and tissue types, both in academic laboratories and in the corporate sector. Some of our competitors have substantially greater resources
than we do, and if our competitors are able to negotiate exclusive access to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our stock price fluctuates, purchasers of our common stock could incur substantial losses. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The market price of our common stock has fluctuated significantly and may continue to fluctuate significantly in response to factors that are
beyond our control. The stock market in general has from time to time experienced extreme price and volume fluctuations, and the biotechnology in particular has very recently experienced extreme price and volume fluctuations. The market prices of
securities of pharmaceutical and biotechnology companies have been extremely volatile, and have experienced fluctuations that often have been unrelated or disproportionate to the clinical development progress or operating performance of these
companies. These broad market and sector fluctuations have resulted and could in the future result in extreme fluctuations in the price of our common stock, which could cause purchasers of our common stock to incur substantial losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may incur significant costs from class action litigation due to stock volatility.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our
development efforts or the development efforts of our collaborators and/or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of pharmaceutical and
biotechnology companies. When the market price of a stock has been volatile as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our
stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sales of additional shares of our common stock, including by us or our directors and officers, could cause the price of our common stock
to decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of substantial amounts of our common stock in the public market, or the availability of such shares for sale,
by us or others, including the issuance of common stock upon exercise of outstanding options, could adversely affect the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sanofi Genzyme&#146;s ownership of our common stock could delay or prevent a change in corporate control. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sanofi Genzyme currently holds approximately 12% of our outstanding common stock and has the right to increase its ownership up to 30%, as
well as the right to maintain its ownership percentage through the term of our collaboration, subject to certain limitations. This concentration of ownership may harm the market price of our common stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delaying, deferring or preventing a change in control of our company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impeding a merger, consolidation, takeover or other business combination involving our company; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our
stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Provisions
in our certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt
by our stockholders to replace current members of our management team. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a classified board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a prohibition on actions by our stockholders by written consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on the removal of directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General
Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our
outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx166732_11"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under our investor
agreement with Sanofi Genzyme, Sanofi Genzyme has the right at the beginning of each year to purchase a number of shares of our common stock based on the number of shares we issued during the previous year for compensation-related purposes. Sanofi
Genzyme exercised this right to purchase directly from us 205,030 shares of our common stock on February&nbsp;1, 2016 for $14.3 million. The sale of these shares to Sanofi Genzyme was consummated as a private placement. This purchase by Sanofi
Genzyme allowed Sanofi Genzyme to maintain its ownership level of our common stock of approximately 12%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This sale did not involve a
public offering and is therefore exempt from registration under Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx166732_12"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXHIBITS. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2016 Annual Incentive Program.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated 2009 Stock Incentive Plan, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Purchase and Sale Agreement entered into as of February 10, 2016 by and between 20 Commerce LLC and the Registrant, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of principal executive officer pursuant to Rule&nbsp;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of principal financial officer pursuant to Rule&nbsp;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of principal executive officer pursuant to Rule&nbsp;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States
Code.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of principal financial officer pursuant to Rule&nbsp;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States
Code.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The following materials from the Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii)
the Condensed Consolidated Statements of Comprehensive Loss, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx166732_13"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ALNYLAM PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Maraganore</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John M. Maraganore, Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael P. Mason</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael P. Mason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Finance and Treasurer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d166732dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alnylam Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 Annual Incentive Program </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary
Description </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the Compensation Committee of the Board of Directors (the &#147;Board&#148;) of Alnylam Pharmaceuticals, Inc.
(&#147;Alnylam&#148;) approved the 2016 Annual Incentive Program (the &#147;Bonus Plan&#148;) to incent and reward all regular employees of Alnylam or any of its affiliates (subject to applicable local laws) (collectively, the &#147;Company&#148;),
based upon their performance relative to pre-established 2016 corporate and individual goals and objectives, and retain company employees by establishing an important element of the Company&#146;s total rewards package consistent with the
Company&#146;s compensation philosophy and operating strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Eligibility </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All regular employees, who are employed by the Company both on or before October&nbsp;1, 2016 and on December&nbsp;31, 2016 (collectively, &#147;Plan
Participants&#148;), are eligible to receive an annual cash bonus (a &#147;Bonus Award&#148;) based upon achievement of individual and/or corporate goals and objectives for 2016. The Compensation Committee may, in its discretion, include employees
who join the Company or one of its affiliates after October&nbsp;1, 2016 as Plan Participants. Bonus Awards for Plan Participants who have been employed with the Company or one of its affiliates for less than one year as of December&nbsp;31, 2016
may be pro-rated by the Compensation Committee, in its discretion. In addition, Bonus Awards for Plan Participants who have been on an approved leave of absence for in excess of twelve consecutive weeks during calendar 2016 may be pro-rated by the
Compensation Committee, in its discretion (subject to applicable local laws). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate goals for 2016 were proposed by the Company&#146;s executive officers and approved by the Board. Bonus Awards for the Company&#146;s executive
officers will be based entirely upon achievement of the corporate goals. Individual objectives for all other Plan Participants were approved by the employees&#146; direct supervisor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Bonus Plan, each Plan Participant has
an established target award, as set forth in the table below, representing a percentage of the Plan Participant&#146;s annual base salary at year-end (a &#147;Target Award&#148;). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016 Annual Incentive Program Target
Awards</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:36.80pt; font-size:8pt; font-family:Times New Roman"><B>Title/Level</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Award</B><br><B>(%&nbsp;of&nbsp;Base&nbsp;Salary)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">65%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">30%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">25%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Associate Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Professionals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Regular Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7.5%</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bonus Awards under the Bonus Plan, if any, will be determined by first establishing a bonus pool (the &#147;Bonus
Pool&#148;). The Bonus Pool will be calculated by (1)&nbsp;aggregating each Plan Participant&#146;s Target Award and then (2)&nbsp;multiplying that sum by a modifier established by the Compensation Committee that is based on the Company&#146;s
performance as measured against the 2016 corporate goals (the &#147;Corporate Performance Level&#148;). The Corporate Performance Level for 2016 will range from 0% to 130%; provided, however, that the Corporate Performance Level can only exceed 100%
upon the achievement of specified clinical development goals and further provided that, if the Corporate Performance Level for 2016 falls below a threshold of 50%, no Bonus Awards will be paid under the Bonus Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bonus Pool will then be allocated among the Plan Participants based upon a consideration of each Plan Participant&#146;s title/level and salary (as
reflected by their Target Award percentage) and (i)&nbsp;with respect to Plan Participants who are executive officers, the Corporate Performance Level, and (ii)&nbsp;with respect to all other Plan Participants, their 2016 year-end performance
ratings, which shall be determined by their performance against their individual objectives for 2016, overall job performance and support of the Company&#146;s core values. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee retains the discretion under the Bonus Plan to adjust upward or downward any Bonus Award and/or the Bonus Pool as it deems
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2016, the Compensation Committee plans to evaluate the Company&#146;s performance against the established corporate goals,
establish the Bonus Pool, if any, available under the Bonus Plan and approve the individual Bonus Awards for each executive officer and each other employee at the level of Senior Vice President or higher. The Company&#146;s management will evaluate
the individual performance and contributions of the other Plan Participants, and determine the amount of the Bonus Awards to be granted from the Bonus Pool to such other Plan Participants. This determination is expected to be made on or before
December&nbsp;31, 2016 and any Bonus Awards granted to Plan Participants under the Bonus Plan are expected to be made in cash and to be paid in January 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Administration; Amendment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bonus Plan is administered
by the Compensation Committee. The Compensation Committee has full power and authority to interpret and make all decisions regarding the Bonus Plan, and its decisions and interpretations are final and binding on all Plan Participants. The
Compensation Committee or the full Board may amend the Bonus Plan in any manner at any time without the consent of any Plan Participant. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d166732dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALNYLAM PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDED AND RESTATED </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>2009 STOCK INCENTIVE PLAN </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(including amendment through March&nbsp;2, 2016) </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Purpose</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this Amended and Restated 2009 Stock Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148; or the &#147;<B><I>Amended and Restated Plan</I></B>&#148;) of Alnylam Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), is to advance the interests of the Company&#146;s
stockholders by enhancing the Company&#146;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing such persons with equity ownership opportunities and <FONT
STYLE="white-space:nowrap">performance-based</FONT> incentives that are intended to better align the interests of such persons with those of the Company&#146;s stockholders. Except where the context otherwise requires, the term
&#147;<B><I>Company</I></B>&#148; shall include any of the Company&#146;s present or future parent or subsidiary corporations as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Internal Revenue Code of 1986, as amended, and any regulations
promulgated thereunder (the &#147;<B><I>Code</I></B>&#148;) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of
Directors of the Company (the &#147;<B><I>Board</I></B>&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><U>Eligibility</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s employees, officers and directors are eligible to
be granted options, stock appreciation rights (&#147;<B><I>SARs</I></B>&#148;), restricted stock, restricted stock units (&#147;<B><I>RSUs</I></B>&#148;) and other <FONT STYLE="white-space:nowrap">stock-based</FONT> awards (each, an
&#147;<B><I>Award</I></B>&#148;) under the Plan. Consultants and advisors to the Company (as such terms are defined and interpreted for purposes of <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> (or any successor form)) are also eligible to
be granted Awards. Each person who is granted an Award under the Plan is deemed a &#147;<B><I>Participant</I></B>.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>Administration and Delegation</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration by Board of Directors</U>. The Plan
will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and
interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem
expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&#146;s sole discretion and shall be final and binding on all persons having or claiming any
interest in the Plan or in any Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Appointment of Committees</U>. To the extent permitted by applicable law, the Board may
delegate any or all of its powers under the Plan to one&nbsp;or more committees or subcommittees of the Board (a &#147;<B><I>Committee</I></B>&#148;). All references in the Plan to the &#147;<B><I>Board</I></B>&#148; shall mean the Board or a
Committee of the Board or the officers referred to in Section&nbsp;3(c) to the extent that the Board&#146;s powers or authority under the Plan have been delegated to such Committee or officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delegation to Officers</U>. To the extent permitted by applicable law, the Board may
delegate to one&nbsp;or more officers of the Company the power to grant Options and other Awards that constitute rights under Delaware law (subject to any limitations under the Plan) to employees or officers of the Company or any of its present or
future subsidiary corporations and to exercise such other powers under the Plan as the Board may determine, provided that the Board shall fix the terms of the Awards to be granted by such officers (including the exercise price of the Awards, which
may include a formula by which the exercise price will be determined) and the maximum number of shares subject to such Awards that the officers may grant; provided further, however, that no officer shall be authorized to grant Awards to any
&#147;executive officer&#148; of the Company (as defined by <FONT STYLE="white-space:nowrap">Rule&nbsp;3b-7</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;)) or to any &#147;officer&#148; of
the Company (as defined by <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1</FONT> under the Exchange Act). The Board may not delegate authority under this Section&nbsp;3(c) to grant restricted stock, unless Delaware law then permits such
delegation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Awards to Non-employee Directors</U>. Discretionary Awards to directors who are not employees of the Company at the
time of grant (&#147;<B><I>Non-employee Directors</I></B>&#148;) will only be granted and administered by a Committee, all of the members of which are independent as defined by Section&nbsp;4200(a)(15) of the Nasdaq Marketplace Rules. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><U>Stock Available for Awards</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Number of Shares; Share Counting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Authorized Number of Shares</U>. Subject to adjustment under Section&nbsp;10, Awards may be made under the Plan for up to 11,700,000
shares of common stock, $0.01&nbsp;par value per share, of the Company (the &#147;<B><I>Common Stock</I></B>&#148;), any or all of which Awards may be in the form of Incentive Stock Options (as hereinafter defined). Shares issued under the Plan may
consist in whole or in part of authorized but unissued shares or treasury shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Fungible Share Pool</U>. Subject to adjustment
under Section&nbsp;10, any Award that is not a <FONT STYLE="white-space:nowrap">Full-Value</FONT> Award shall be counted against the share limits specified in Sections&nbsp;4(a)(1) and 4(b)(2) as one&nbsp;share for each share of Common Stock subject
to such Award and any Award that is a <FONT STYLE="white-space:nowrap">Full-Value</FONT> Award shall be counted against the share limits specified in Sections&nbsp;4(a)(1) and 4(b)(2) as 1.5 shares for each one&nbsp;share of Common Stock subject to
such <FONT STYLE="white-space:nowrap">Full-Value</FONT> Award. &#147;<B><I><FONT STYLE="white-space:nowrap">Full-Value</FONT> Award</I></B>&#148; means any Restricted Stock Award or Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Award
(each as defined below). To the extent a share that was subject to an Award that counted as one&nbsp;share is returned to the Plan pursuant to Section&nbsp;4(a)(3), each applicable share reserve will be credited with one&nbsp;share. To the extent
that a share that was subject to a <FONT STYLE="white-space:nowrap">Full-Value</FONT> Award that counted as 1.5 shares is returned to the Plan pursuant to Section&nbsp;4(a)(3), each applicable share reserve will be credited with 1.5 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) <U>Share Counting</U>. For purposes of counting the number of shares available for the grant of Awards under the Plan and under the <FONT
STYLE="white-space:nowrap">sub-limits</FONT> contained in Section&nbsp;4(b)(2), (i)&nbsp;all shares of Common Stock covered by independent SARs shall be counted against the number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares available for the grant of Awards; <I>provided</I>, <I>however</I>, that independent SARs that may be settled only in cash shall not be so counted; (ii)&nbsp;if any Award (A)&nbsp;expires
or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance
price pursuant to a contractual repurchase right) or (B)&nbsp;results in any Common Stock not being issued (including as a result of an independent SAR that was settleable either in cash or in stock actually being settled in cash), the unused Common
Stock covered by such Award shall again be available for the grant of Awards; <I>provided</I>, <I>however</I>, in the case of Incentive Stock Options (as hereinafter defined), the foregoing shall be subject to any limitations under the Code; and
provided further, in the case of independent SARs, that the full number of shares subject to any <FONT STYLE="white-space:nowrap">stock-settled</FONT> SAR shall be counted against the shares available under the Plan and against the sub-limits listed
in the first clause&nbsp;of this Section&nbsp;in proportion to the portion of the SAR actually exercised regardless of the number of shares actually used to settle such SAR upon exercise; (iii)&nbsp;shares of Common Stock delivered (by actual
delivery, attestation, or net exercise) to the Company by a Participant to (A)&nbsp;purchase shares of Common Stock upon the exercise of an Award or (B)&nbsp;satisfy tax withholding obligations (including shares retained from the Award creating the
tax obligation) shall not be added back to the number of shares available for the future grant of Awards; and (iv)&nbsp;shares of Common Stock repurchased by the Company on the open market using the proceeds from the exercise of an Award shall not
increase the number of shares available for future grant of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U><FONT STYLE="white-space:nowrap">Sub-limits</FONT></U>.
Subject to adjustment under Section&nbsp;10, the following <FONT STYLE="white-space:nowrap">sub-limits</FONT> on the number of shares subject to Awards shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Section&nbsp;162(m) <FONT STYLE="white-space:nowrap">Per-Participant</FONT> Limit</U>. The maximum number of shares of Common Stock
with respect to which Awards may be granted to any Participant under the Plan shall be 500,000&nbsp;per calendar&nbsp;year, except in the calendar&nbsp;year in which the Participant is hired by the Company, in which case the maximum number of shares
shall be 1,000,000. For purposes of the foregoing limit, the combination of an Option in tandem with a SAR (as each is hereafter defined) shall be treated as a single Award. The per Participant limit described in this Section&nbsp;4(b)(1) shall be
construed and applied consistently with Section&nbsp;162(m) of the Code or any successor provision thereto, and the regulations thereunder (&#147;<B><I>Section&nbsp;162</I></B><B>(</B><B><I>m</I></B><B>)</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Limits on Awards to Non-employee Directors</U>. The maximum number of shares with respect to which Awards may be granted, in the
aggregate, to Non-employee Directors shall be 10% of the maximum number of authorized shares set forth in Section&nbsp;4(a)(1). The maximum number of shares subject to Awards granted to an individual in connection with such individual&#146;s initial
appointment or election as a Non-employee Director shall be 50,000. The maximum number of shares subject to Awards granted to a Non-employee Director in any calendar year in connection with such individual&#146;s service on the Board (excluding for
this purpose any shares subject to Awards granted under the preceding sentence) shall be 22,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Substitute Awards</U>. In
connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant awards in substitution for any options, stock or
<FONT STYLE="white-space:nowrap">stock-based</FONT> awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in
Section&nbsp;4(a)(1) or any sub-limits contained in the Plan, except as may be required by reason of Section&nbsp;422 and related provisions of the Code. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><U>Stock Options</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Board may grant options to purchase Common Stock
(each, an &#147;<B><I>Option</I></B>&#148;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including
conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An Option that is not intended to be an Incentive Stock Option (as hereinafter defined) shall be designated a &#147;<B><I>Nonstatutory Stock
Option</I></B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Incentive Stock Options</U>. An Option that the Board intends to be an &#147;incentive stock option&#148; as
defined in Section&nbsp;422 of the Code (an &#147;<B><I>Incentive Stock Option</I></B>&#148;) shall only be granted to employees of Alnylam Pharmaceuticals, Inc., any of Alnylam Pharmaceuticals, Inc.&#146;s present or future parent or subsidiary
corporations as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently with
the requirements of Section&nbsp;422 of the Code. The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if
the Company converts an Incentive Stock Option to a Nonstatutory Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise Price</U>. The Board shall establish the
exercise price of each Option and specify the exercise price in the applicable option agreement. The exercise price shall be not less than 100% of the Fair Market Value (as defined below) on the date the Option is granted; provided that if the Board
approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date. &#147;<B><I>Fair Market Value</I></B>&#148; of a share of Common
Stock for purposes of the Plan will be determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) if the Common Stock trades on a national securities exchange, the
closing sale price (for the primary trading session) on the date of grant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) if the Common Stock does not trade on any such exchange,
the average of the closing bid and asked prices as reported by an authorized OTCBB market data vendor as listed on the OTCBB website (otcbb.com) on the date of grant; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) if the Common Stock is not publicly traded, the Board will determine the Fair Market Value for purposes of the Plan using any measure of
value it determines to be appropriate (including, as it considers appropriate, relying on appraisals) in a manner consistent with the valuation principles under Section&nbsp;409A of the Code, except as the Board or Committee may expressly determine
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For any date that is not a trading&nbsp;day, the Fair Market Value of a share of Common Stock for such date will be determined by using the
closing sale price or average of the bid and asked </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prices, as appropriate, for the immediately preceding trading&nbsp;day and with the timing in the formulas above adjusted accordingly. The Board can substitute a particular time of&nbsp;day or
other measure of &#147;closing sale price&#148; or &#147;bid and asked prices&#148; if appropriate because of exchange or market procedures or can, in its sole discretion, use weighted averages either on a daily basis or such longer period as
complies with Section&nbsp;409A of the Code. The Board has sole discretion to determine the Fair Market Value for purposes of this Plan, and all Awards are conditioned on the Participants&#146; agreement that the Board&#146;s determination is
conclusive and binding even though others might make a different determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Duration of Options</U>. Each Option shall be
exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement; <I>provided</I>, <I>however</I>, that no Option will be granted for a term in excess of 10&nbsp;years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise of Option</U>. Options may be exercised by delivery to the Company of a written notice of exercise signed by the proper person
or by any other form of notice (including electronic notice) approved by the Company, together with payment in full as specified in Section&nbsp;5(f) for the number of shares for which the Option is exercised. Shares of Common Stock subject to the
Option will be delivered by the Company as soon as practicable following exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Payment Upon Exercise</U>. Common Stock
purchased upon the exercise of an Option granted under the Plan shall be paid for as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) in cash or by check, payable to the
order of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) except as may otherwise be provided in the applicable option agreement, by (i)&nbsp;delivery of an irrevocable
and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii)&nbsp;delivery by the Participant to the Company of a copy of irrevocable
and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) to the extent provided for in the applicable option agreement or approved by the Board, in its sole discretion, by delivery (either by
actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (i)&nbsp;such method of payment is then permitted under applicable law, (ii)&nbsp;such Common Stock, if acquired directly
from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii)&nbsp;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other
similar requirements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(4) to the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in
its sole discretion, by delivery of a notice of &#147;net exercise&#148; to the Company, as a result of which the Participant would receive the number of shares of Common Stock underlying the Option so exercised reduced by the number of shares of
Common Stock equal to the aggregate exercise price of the Option divided by the Fair Market Value on the date of exercise; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(5) to the extent permitted by applicable law and provided for in the applicable Option agreement
or approved by the Board, in its sole discretion, by payment of such other lawful consideration as the Board may determine; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(6) by any
combination of the above permitted forms of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Limitation on Repricing</U>. Unless such action is approved by the
Company&#146;s stockholders: (1)&nbsp;no outstanding Option granted under the Plan may be amended to provide an exercise price per share that is lower than the <FONT STYLE="white-space:nowrap">then-current</FONT> exercise price per share of such
outstanding Option (other than adjustments pursuant to Section&nbsp;10) and (2)&nbsp;the Board may not cancel any outstanding option (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the
same or a different number of shares of Common Stock and having an exercise price per share lower than the <FONT STYLE="white-space:nowrap">then-current</FONT> exercise price per share of the cancelled option or effect repricing by cancellation in
exchange for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Minimum Vesting</U>. Options granted to employees shall not become fully exercisable prior to the first
anniversary of the date of grant. Notwithstanding the foregoing, (i)&nbsp;the Board may, in its discretion, either at the time of grant or at any time thereafter, impose a faster vesting schedule than the schedule prescribed by the preceding
sentence in the following extraordinary circumstances: death, disability or retirement of the Participant, or a merger, consolidation, sale, reorganization, recapitalization or change in control of the Company, and (ii)&nbsp;the vesting schedule
prescribed by the preceding sentence shall not apply to options granted to employees, in the aggregate, for up to 10% of the maximum number of authorized shares set forth in Section&nbsp;4(a)(1). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"><U>Director Options</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Board Discretion</U>. The Board retains the specific authority
to, from time to time, determine the number of shares subject to Options granted to Non-employee Directors under this Section&nbsp;6, subject to the aggregate and individual limitations on the number of shares issuable to Non-employee Directors
contained in Section&nbsp;4(b)(2). All Options granted to Non-employee Directors shall be Nonstatutory Stock Options. The Board also retains the specific authority to issue SARs, Restricted Stock Awards or Other
<FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards in lieu of Options, subject to the aggregate and individual limitations on the number of shares issuable to Non-employee Directors contained in Section&nbsp;4(b)(2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Terms of Director Options</U>. Options granted under this Section&nbsp;6 shall (i)&nbsp;have an exercise price equal to the Fair Market
Value on the date of grant, (ii)&nbsp;vest in full on the first anniversary of the date of grant provided that the individual is serving on the Board on such date (or, in the case of Options granted under Section&nbsp;6(a) to a newly elected or
appointed director, as to <FONT STYLE="white-space:nowrap">one-third</FONT> of the shares subject to the Option on each of the first, second and third anniversaries of the date of grant); provided that no additional vesting shall take place after
the Participant ceases to serve as a director and further provided that the Board may provide for accelerated vesting in the case of death, disability, change in control, attainment of mandatory retirement age or retirement, (iii)&nbsp;expire on the
earlier of 10&nbsp;years from the date of grant or three&nbsp;months following cessation of service on the Board, provided that such three&nbsp;month period shall be extended to five&nbsp;years following cessation of service on the Board for any
director with five&nbsp;or more&nbsp;years of continuous service on the Board, and (iv)&nbsp;contain such other terms and conditions as the Board shall determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"><U>Stock Appreciation Rights</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Board may grant Awards consisting of
SARs entitling the holder, upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market
Value of a share of Common Stock over the measurement price established pursuant to Section&nbsp;7(c). The date as of which such appreciation is determined shall be the exercise date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Grants</U>. SARs may be granted in tandem with, or independently of, Options granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Tandem Awards</U>. When SARs are expressly granted in tandem with Options, (i)&nbsp;the SAR will be exercisable only at such time or
times, and to the extent, that the related Option is exercisable (except to the extent designated by the Board in connection with a Reorganization Event and will be exercisable in accordance with the procedure required for exercise of the related
Option; (ii)&nbsp;the SAR will terminate and no longer be exercisable upon the termination or exercise of the related Option, except to the extent designated by the Board in connection with a Reorganization Event and except that a SAR granted with
respect to less than the full number of shares covered by an Option will not be reduced until the number of shares as to which the related Option has been exercised or has terminated exceeds the number of shares not covered by the SAR;
(iii)&nbsp;the Option will terminate and no longer be exercisable upon the exercise of the related SAR; and (iv)&nbsp;the SAR will be transferable only with the related Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Independent SARs</U>. A SAR not expressly granted in tandem with an Option will become exercisable at such time or times, and on such
conditions, as the Board may specify in the SAR Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Measurement Price</U>. The Board shall establish the measurement price of
each SAR and specify it in the applicable SAR agreement. The measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted; provided that if the Board approves the grant of a SAR with a measurement price to be
determined on a future date, the measurement price shall be not less than 100% of the Fair Market Value on such future date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Duration of SARs</U>. Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; <I>provided</I>, <I>however</I>, that no SAR will be granted with a term in
excess of 10&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise of SARs</U>. SARs may be exercised by delivery to the Company of a written notice of exercise
signed by the proper person or by any other form of notice (including electronic notice) approved by the Company, together with any other documents required by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Limitation on Repricing</U>. Unless such action is approved by the Company&#146;s stockholders: (1)&nbsp;no outstanding SAR granted
under the Plan may be amended to provide an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise price per share that is lower than the <FONT STYLE="white-space:nowrap">then-current</FONT> exercise price per share of such outstanding SAR (other than adjustments pursuant to
Section&nbsp;10) and (2)&nbsp;the Board may not cancel any outstanding SAR (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and
having an exercise price per share lower than the <FONT STYLE="white-space:nowrap">then-current</FONT> exercise price per share of the cancelled SAR or effect repricing by cancellation in exchange for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Minimum Vesting</U>. SARs granted to employees shall not become fully exercisable prior to the first anniversary of the date of grant.
Notwithstanding the foregoing, (i)&nbsp;the Board may, in its discretion, either at the time of grant or at any time thereafter, impose a faster vesting schedule than the schedule prescribed by the preceding sentence in the following extraordinary
circumstances: death, disability or retirement of the Participant, or a merger, consolidation, sale, reorganization, recapitalization or change in control of the Company, and (ii)&nbsp;the vesting schedule prescribed by the preceding sentence shall
not apply to SARs granted to employees, in the aggregate, for up to 10% of the maximum number of authorized shares set forth in Section&nbsp;4(a)(1). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"><U>Restricted Stock; Restricted Stock Units</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Board may grant Awards
entitling recipients to acquire shares of Common Stock (&#147;<B><I>Restricted Stock</I></B>&#148;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require
forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the
Board for such Award. Instead of granting Awards for Restricted Stock, the Board may grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at the time such Award vests (&#147;<B><I>Restricted Stock
Units</I></B>&#148;) (Restricted Stock and Restricted Stock Units are each referred to herein as a &#147;<B><I>Restricted Stock Award</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Terms and Conditions for All Restricted Stock Awards</U>. The Board shall determine the terms and conditions of a Restricted Stock
Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. Restricted Stock Awards that vest solely based on the passage of time shall be zero percent vested prior to the first anniversary of the date of
grant (or, in the case of Awards to Non-employee Directors, if earlier, the date of the first annual meeting held after the date of grant), no more than <FONT STYLE="white-space:nowrap">one-third</FONT> vested prior to the second anniversary of the
date of grant (or, in the case of Awards to Non-employee Directors, if earlier, the date of the second annual meeting held after the date of grant), and no more than <FONT STYLE="white-space:nowrap">two-thirds</FONT> vested prior to the third
anniversary of the date of grant (or, in the case of Awards to Non-employee Directors, if earlier, the date of the third annual meeting held after the date of grant). Restricted Stock Awards that do not vest solely based on the passage of time shall
not vest prior to the first anniversary of the date of grant (or, in the case of Awards to Non-employee Directors, if earlier, the date of the first annual meeting held after the date of grant). The two&nbsp;foregoing sentences shall not apply to
(1)&nbsp;Performance Awards granted pursuant to Section&nbsp;11(i) or (2)&nbsp;Restricted Stock Awards granted, in the aggregate, for up to 10% of the maximum number of authorized shares set forth in Section&nbsp;4(a)(1). Notwithstanding any other
provision of this Plan (other than Section&nbsp;11(i), if applicable), the Board may, in its discretion, either at the time a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Restricted Stock Award is made or at any time thereafter, waive its right to repurchase shares of Common Stock (or waive the forfeiture thereof) or remove or modify any part or all of the
restrictions applicable to the Restricted Stock Award, provided that the Board may only exercise such rights in the following extraordinary circumstances: death, disability or retirement of the Participant, or a merger, consolidation, sale,
reorganization, recapitalization, or change in control of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Additional Provisions Relating to Restricted Stock</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Dividends</U>. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to
such shares, unless otherwise provided by the Board; provided, however, that with respect to Restricted Stock with vesting that is tied to the attainment of performance conditions, cash dividends may accrue during the performance period but may not
be paid unless and until the performance conditions are attained. Unless otherwise provided by the Board, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock other than an
ordinary cash dividend, the shares, cash or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each dividend payment will be made no
later than the end of the calendar&nbsp;year in which the dividends are paid to shareholders of that class of stock or, if later, the 15th&nbsp;day of the third&nbsp;month following the date the dividends are paid to shareholders of that class of
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Stock Certificates</U>. The Company may require that any stock certificates issued in respect of shares of Restricted Stock
shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the
certificates no longer subject to such restrictions to the Participant or if the Participant has died, to the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant
in the event of the Participant&#146;s death (the &#147;<B><I>Designated Beneficiary</I></B>&#148;). In the absence of an effective designation by a Participant, &#147;<B><I>Designated Beneficiary</I></B>&#148; shall mean the Participant&#146;s
estate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Additional Provisions Relating to Restricted Stock Units</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Settlement</U>. Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock
Unit, the Participant shall be entitled to receive from the Company one&nbsp;share of Common Stock or an amount of cash equal to the Fair Market Value of one&nbsp;share of Common Stock, as provided in the applicable Award agreement. The Board may,
in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Voting Rights</U>. A Participant shall have no voting rights with respect to any Restricted Stock Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) <U>Dividend Equivalents</U>. To the extent provided by the Board, in its sole discretion, a grant of Restricted Stock Units may provide
Participants with the right to receive an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (&#147;<B><I>Dividend Equivalents</I></B>&#148;). Dividend
Equivalents may be paid currently or credited to an account for the Participants, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with
respect to which paid, as determined by the Board in its sole discretion, subject in each case to such terms and conditions as the Board shall establish, in each case to be set forth in the applicable Award agreement. Notwithstanding the foregoing,
with respect to Restricted Stock Units with vesting that is tied to the attainment of performance conditions, Dividend Equivalents may accrue during the performance period but may not be paid unless and until the performance conditions are attained.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"><U>Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>.
Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants (&#147;<B><I>Other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Stock-Based-Awards</FONT></FONT></I></B>&#148;), including without limitation Awards entitling recipients to receive shares of Common Stock to be delivered in the future. Such Other <FONT
STYLE="white-space:nowrap">Stock-Based</FONT> Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other <FONT
STYLE="white-space:nowrap">Stock-Based</FONT> Awards may be paid in shares of Common Stock or cash, as the Board shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Terms and Conditions</U>. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Award, including any purchase price applicable thereto. Other <FONT
STYLE="white-space:nowrap">Stock-Based</FONT> Awards that vest solely based on the passage of time shall be zero percent vested prior to the first anniversary of the date of grant (or, in the case of Awards to Non-employee Directors, if earlier, the
date of the first annual meeting held after the date of grant), no more than <FONT STYLE="white-space:nowrap">one-third</FONT> vested prior to the second anniversary of the date of grant (or, in the case of Awards to Non-employee Directors, if
earlier, the date of the second annual meeting held after the date of grant), and no more than <FONT STYLE="white-space:nowrap">two-thirds</FONT> vested prior to the third anniversary of the date of grant (or, in the case of Awards to Non-employee
Directors, if earlier, the date of the third annual meeting held after the date of grant). Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards that do not vest solely based on the passage of time shall not vest prior to the first
anniversary of the date of grant (or, in the case of Awards to Non-employee Directors, if earlier, the date of the first annual meeting held after the date of grant). The two&nbsp;foregoing sentences shall not apply to (1)&nbsp;Performance Awards
granted pursuant to Section&nbsp;11(i) or (2)&nbsp;Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards granted, in the aggregate, for up to 10% of the maximum number of authorized shares set forth in Section&nbsp;4(a)(1).
Notwithstanding any other provision of this Plan (other than Section&nbsp;11(i), if applicable), the Board may, in its discretion, either at the time an Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Award is made or at any time
thereafter, waive its right to repurchase shares of Common Stock (or waive the forfeiture thereof) or remove or modify any part or all of the restrictions applicable to the Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Award, provided
that the Board may only exercise such rights in the following extraordinary circumstances: death, disability or retirement of the Participant, or a merger, consolidation, sale, reorganization, recapitalization, or change in control of the Company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"><U>Adjustments for Changes in Common Stock and Certain Other Events</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Changes in
Capitalization</U>. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization
or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities available under the Plan, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">sub-limits,</FONT>
fungible pool and share counting rules set forth in Sections&nbsp;4(a) and 4(b), (iii)&nbsp;the minimum vesting provisions of Restricted Stock Awards and Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards set forth in
Sections&nbsp;5(h), 7(g), 8(b) and 9(b), (iv)&nbsp;the number and class of securities and exercise price per share of each outstanding Option and each Option issuable under Section&nbsp;6, (v)&nbsp;the <FONT STYLE="white-space:nowrap">share-</FONT>
and <FONT STYLE="white-space:nowrap">per-share</FONT> provisions and the measurement price of each SAR, (vi)&nbsp;the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and
(vii)&nbsp;the <FONT STYLE="white-space:nowrap">share-</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">per-share-related</FONT></FONT> provisions and the purchase price, if any, of each outstanding Other <FONT
STYLE="white-space:nowrap">Stock-Based</FONT> Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event
the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the
record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares
of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Reorganization Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Definition</U>. A &#147;<B><I>Reorganization Event</I></B>&#148; shall mean: (a)&nbsp;any merger or consolidation of the Company with or
into another entity where the stockholders of the Company immediately before the merger or consolidation would not, immediately after the merger or consolidation, beneficially own, directly or indirectly, shares representing a majority of the
outstanding voting shares of the resulting or successor entity (or its ultimate parent, if applicable), (b)&nbsp;any transfer or disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share
exchange or other transaction or (c)&nbsp;any liquidation or dissolution of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Consequences of a Reorganization Event on
Awards Other than Restricted Stock Awards</U>. In connection with a Reorganization Event, the Board may take any one&nbsp;or more of the following actions as to all or any (or any portion of) outstanding Awards other than Restricted Stock Awards on
such terms as the Board determines: (i)&nbsp;provide that Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii)&nbsp;upon written notice to a
Participant, provide that the Participant&#146;s unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant within a specified period following the date of such notice,
(iii)&nbsp;provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv)&nbsp;in the event of a
Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment for each share surrendered in the Reorganization Event (the &#147;<B><I>Acquisition Price</I></B>&#148;), make or provide for a cash payment to a Participant equal to the excess, if any,
of (A)&nbsp;the Acquisition Price times the number of shares of Common Stock subject to the Participant&#146;s Awards (to the extent the exercise price does not exceed the Acquisition Price) over (B)&nbsp;the aggregate exercise price of all such
outstanding Awards and any applicable tax withholdings, in exchange for the termination of such Awards, (v)&nbsp;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation
proceeds (if applicable, net of the exercise price thereof and any applicable tax withholdings) and (vi)&nbsp;any combination of the foregoing. In taking any of the actions permitted under this Section&nbsp;10(b), the Board shall not be obligated by
the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of
clause&nbsp;(i)&nbsp;above, an Option shall be considered assumed if, following consummation of the Reorganization Event, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the
consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the
consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration
received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the
consideration to be received upon the exercise of Options to consist solely of common stock of the acquiring or succeeding corporation (or an affiliate thereof) equivalent in value (as determined by the Board) to the per share consideration received
by holders of outstanding shares of Common Stock as a result of the Reorganization Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) <U>Consequences of a Reorganization Event
on Restricted Stock Awards</U>. Upon the occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company under each outstanding Restricted Stock Award shall inure to the
benefit of the Company&#146;s successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same
manner and to the same extent as they applied to the Common Stock subject to such Restricted Stock Award; <I>provided</I>, <I>however</I>, that the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the
instrument evidencing any Restricted Stock Award or any other agreement between a Participant and the Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company,
except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock Award or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock Awards then
outstanding shall automatically be deemed terminated or satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"><U>General Provisions Applicable to Awards</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability of Awards</U>. Awards
shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an
Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant; <I>provided</I>, <I>however</I>, that the Board may permit or provide in an Award for
the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if, with respect to
such proposed transferee, the Company would be eligible to use a <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> for the registration of the sale of the Common Stock subject to such Award under the Securities Act of 1933, as amended; provided,
further, that the Company shall not be required to recognize any such transfer until such time as the Participant and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance
satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documentation</U>. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each
Award may contain terms and conditions in addition to those set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Board Discretion</U>. Except as otherwise
provided by the Plan, each Award may be made alone&nbsp;or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Status</U>. The Board shall determine the effect on an Award of the disability, death, termination or other cessation of
employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#146;s legal representative, conservator, guardian
or Designated Beneficiary, may exercise rights under the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Withholding</U>. The Participant must satisfy all applicable
federal, state, and local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may decide to satisfy the
withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a
broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise or release from forfeiture of an Award or, if the Company so requires, at the same
time as is payment of the exercise price unless the Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by
actual delivery or attestation) of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; <I>provided</I>, <I>however</I>, except as otherwise provided by the Board, that the
total tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#146;s minimum statutory withholding obligations (based on minimum statutory withholding rates for
federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other
similar requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendment of Award</U>. Except as otherwise provided in Sections&nbsp;5(h), 7(g), 8(b) and 9(b) with respect
to the vesting of Restricted Stock Awards and Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards, Section&nbsp;11(i) with respect to Performance Awards or Section&nbsp;12(d) with respect to actions requiring shareholder approval, the
Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to
a Nonstatutory Stock Option. The Participant&#146;s consent to such action shall be required unless (i)&nbsp;the Board determines that the action, taking into account any related action, would not materially and adversely affect the
Participant&#146;s rights under the Plan or (ii)&nbsp;the change is permitted under Section&nbsp;10 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Conditions on Delivery
of Stock</U>. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or removed
to the satisfaction of the Company, (ii)&nbsp;in the opinion of the Company&#146;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any
applicable stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any
applicable laws, rules or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Acceleration</U>. Except as otherwise provided in Sections&nbsp;5(h), 7(g), 8(b), 9(b) and
11(i), the Board may at any time provide that any Award shall become immediately exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Performance Awards</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) <U>Grants</U>. Restricted Stock Awards and Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards under the Plan may be made
subject to the achievement of performance goals pursuant to this Section&nbsp;11(i) (&#147;<B><I>Performance Awards</I></B>&#148;), subject to the limit in Section&nbsp;4(b)(1) on shares covered by such grants. Subject to Section&nbsp;11(i)(4), no
Performance Awards shall vest prior to the first anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) <U>Committee</U>. Grants of Performance Awards to
any Covered Employee intended to qualify as <FONT STYLE="white-space:nowrap">&#147;performance-based</FONT> compensation&#148; under Section&nbsp;162(m) (&#147;<B><I><FONT STYLE="white-space:nowrap">Performance-Based</FONT>
Compensation</I></B>&#148;) shall be made only by a Committee (or subcommittee of a Committee) comprised solely of two&nbsp;or more directors eligible to serve on a committee making Awards qualifying as
<FONT STYLE="white-space:nowrap">&#147;performance-based</FONT> compensation&#148; under Section&nbsp;162(m). In the case of such Awards granted to Covered Employees, references to the Board or to a Committee shall be treated as referring to such
Committee or subcommittee. &#147;<B><I>Covered Employee</I></B>&#148; shall mean any person who is, or whom the Committee, in its discretion, determines may be, a &#147;covered employee&#148; under Section&nbsp;162(m)(3) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) <U>Performance Measures</U>. For any Award that is intended to qualify as <FONT
STYLE="white-space:nowrap">Performance-Based</FONT> Compensation, the Committee shall specify that the degree of granting and vesting shall be subject to the achievement of one&nbsp;or more objective performance measures established by the
Committee, which shall be based on the relative or absolute attainment of specified levels of one&nbsp;or any combination of the following: net income, earnings before or after discontinued operations, interest, taxes, depreciation and/or
amortization, operating profit before or after discontinued operations and/or taxes, sales, sales growth, earnings growth, cash flow or cash position, gross margins, stock price, market share, return on sales, assets, equity or investment,
improvement of financial ratings, achievement of balance sheet or income statement objectives, total shareholder return, market penetration goals, unit volume, geographic business expansion goals, drug discovery or other scientific goals, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or clinical goals, organizational goals, regulatory approvals, cost targets and goals relating to acquisitions, divestitures and/or strategic partnerships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) <U>Adjustments</U>. Notwithstanding any provision of the Plan, with respect to any Performance Award that is intended to qualify as <FONT
STYLE="white-space:nowrap">Performance-Based</FONT> Compensation, the Committee may adjust downwards, but not upwards, the cash or number of Shares payable pursuant to such Award, and the Committee may not waive the achievement of the applicable
performance measures except in the case of the death or disability of the Participant or a change in control of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5)
<U>Other</U>. The Committee shall have the power to impose such other restrictions on Performance Awards as it may deem necessary or appropriate to ensure that such Awards satisfy all requirements for
<FONT STYLE="white-space:nowrap">Performance-Based</FONT> Compensation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"><U>Miscellaneous</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Right To Employment or Other Status</U>. No person shall have
any claim or right to be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to
dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Rights As Stockholder</U>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have
any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Effective Date and Term of Amended and Restated Plan</U>. The Amended and Restated Plan shall become effective on the date the Amended
and Restated Plan is approved by the Company&#146;s stockholders (the &#147;<B><I>Effective Date</I></B>&#148;). No Awards shall be granted under the Amended and Restated Plan after the expiration of 10&nbsp;years from the Effective Date, but Awards
previously granted may extend beyond that date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment of Plan</U>. The Board may amend, suspend or terminate the Plan or any portion
thereof at any time provided that (i)&nbsp;to the extent required by Section&nbsp;162(m), no Award granted to a Participant that is intended to comply with Section&nbsp;162(m) after the date of such amendment shall become exercisable, realizable or
vested, as applicable to such Award, unless and until the Company&#146;s stockholders approve such amendment if required by Section&nbsp;162(m) (including the vote required under Section&nbsp;162(m)); (ii)&nbsp;no amendment that would require
stockholder approval under the rules of the NASDAQ Stock Market (&#147;NASDAQ&#148;) may be made effective unless and until the Company&#146;s stockholders approve such amendment; and (iii)&nbsp;if the NASDAQ amends its corporate governance rules so
that such rules no longer require stockholder approval of &#147;material amendments&#148; to equity compensation plans, then, from and after the effective date of such amendment to the NASDAQ rules, no amendment to the Plan (A)&nbsp;materially
increasing the number of shares authorized under the Plan (other than pursuant to Sections&nbsp;4(c) or 10), (B)&nbsp;expanding the types of Awards that may be granted under the Plan, or (C)&nbsp;materially expanding the class of participants
eligible to participate in the Plan shall be effective unless and until the Company&#146;s stockholders approve such amendment. In addition, if at any time the approval of the Company&#146;s stockholders is required as to any other modification or
amendment under Section&nbsp;422 of the Code or any successor provision with respect to Incentive Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any
amendment to the Plan adopted in accordance with this Section&nbsp;12(d) shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment
does not materially and adversely affect the rights of Participants under the Plan. Options may be granted that are conditioned upon stockholder approval of any amendment adding shares of Common Stock to the Plan, but no such conditioned Options may
be exercised until stockholder approval is obtained. If stockholder approval is not obtained, all such conditioned Option grants shall be cancelled and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Authorization of <FONT STYLE="white-space:nowrap">Sub-Plans</FONT></U>. The Board may from time to time establish one&nbsp;or more <FONT
STYLE="white-space:nowrap">sub-plans</FONT> under the Plan for purposes of satisfying applicable securities or tax laws of various jurisdictions. The Board shall establish such <FONT STYLE="white-space:nowrap">sub-plans</FONT> by adopting
supplements to the Plan containing (i)&nbsp;such limitations on the Board&#146;s discretion under the Plan as the Board deems necessary or desirable or (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan as the
Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to
provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Participants</U>. Awards may be granted to Participants who are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> citizens or residents employed outside the United States, or both, on such terms and
conditions different from those applicable to Awards to Participants employed in the United States as may, in the judgment of the Board, be necessary or desirable in order to recognize differences in local law or tax policy. The Board also may
impose conditions on the exercise or vesting of Awards in order to minimize the Board&#146;s obligation with respect to tax equalization for Participants on assignments outside their home country. The Board may approve such supplements to or
amendments, restatements or alternative versions of the Plan as it may consider necessary or appropriate for such purposes, without thereby affecting the terms of this Plan as in effect for any other purpose, and the Secretary or other appropriate
officer of the Company may certify any such document as having been approved and adopted in the same manner as this Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Compliance with Section&nbsp;409A of the Code</U>. Except as provided in individual Award
agreements initially or by amendment, if and to the extent any portion of any payment, compensation or other benefit provided to a Participant in connection with his or her employment termination is determined to constitute &#147;nonqualified
deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code and the Participant is a specified employee as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, as determined by the Company in accordance with its procedures, by
which determination the Participant (through accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the&nbsp;day that is six&nbsp;months plus one&nbsp;day after the
date of &#147;separation from service&#148; (as determined under Section&nbsp;409A of the Code) (the &#147;<B><I>New Payment Date</I></B>&#148;), except as Section&nbsp;409A of the Code may then permit. The aggregate of any payments that otherwise
would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their
original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions
of or payments, compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section&nbsp;409A of the Code but do not to satisfy the conditions of that section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Limitations on Liability</U>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other
employee, or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such individual be personally
liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as a director, officer, other employee, or agent of the Company. The Company will indemnify and hold harmless each director,
officer, other employee, or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys&#146; fees) or liability
(including any sum paid in settlement of a claim with the Board&#146;s approval) arising out of any act or omission to act concerning this Plan unless arising out of such person&#146;s own fraud or bad faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Governing Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the
laws of the State of Delaware, excluding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of such state that would require the application of the laws of a jurisdiction other than
such state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Clawback</U>. Grants made under this Plan shall be subject to the Company&#146;s clawback policies in effect from time
to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d166732dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PURCHASE AND SALE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS PURCHASE AND SALE AGREEMENT (as the same may be hereafter amended, modified, supplemented, renewed or restated from time to time, this
&#147;<B>Agreement</B>&#148;) is made and entered into as of this 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of February, 2016 (the &#147;<B>Effective Date</B>&#148;), by and between 20 COMMERCE LLC, a Delaware limited liability
company (&#147;<B>Seller</B>&#148;), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (&#147;<B>Purchaser</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>PURCHASE AND SALE OF
PROPERTY</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the terms and conditions stated in this Agreement, Seller hereby agrees to sell to Purchaser and Purchaser hereby agrees
to purchase from Seller all of the following described property (collectively, the &#147;<B>Property</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Land</U>.
Seller&#146;s fee simple interest in and to all of that certain tract of land situated in Norton, Bristol County, Massachusetts, as more particularly described on <U>Exhibit 1.1</U> attached hereto and incorporated herein by reference, together with
all of Seller&#146;s right, title and interest in and to the rights, privileges and easements appurtenant to such land (collectively, the &#147;<B>Land</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Permits</U>. All of Seller&#146;s right, title and interest in and to any transferable licenses, permits, registrations, use
agreements, orders, entitlements, privileges, guaranties and warranties, and governmental and all other approvals, including, without limitation, that certain Tax Increment Financing Agreement by and between the Town of Norton, Seller and Purchaser
dated November&nbsp;19, 2015, relating to any or all of the Land and the Project (collectively, the &#147;<B>Permits</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>PURCHASE PRICE AND
DEPOSIT; OTHER PURCHASER PAYMENTS</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Payment</U>. The aggregate purchase price (the &#147;<B>Purchase Price</B>&#148;) for the
Property shall be Seven Million One Hundred Thousand and No/100 Dollars ($7,100,000.00). The Purchase Price shall be payable by wire transfer of immediately available federal funds at the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Deposit</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2.1 Within one (1)&nbsp;business day following execution of this Agreement, Purchaser shall deposit Three Hundred Fifty-Five
Thousand and No/100 Dollars ($355,000.00) (together with any and all interest that may accrue thereon, the &#147;<B>Initial Deposit</B>&#148;) by wire transfer of immediately available federal funds, with Fidelity National Title Insurance Company
(the &#147;<B>Escrow Agent</B>&#148; or &#147;<B>Title Company</B>&#148;) to assure Purchaser&#146;s performance hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;6.2, the Initial Deposit shall be fully refundable to Purchaser by written notice to Seller any time
on or before the Due Diligence Deadline. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2.2 Prior to the expiration of the Due Diligence Deadline (as hereinafter
defined), Purchaser shall deposit an additional Three Hundred Fifty-Five Thousand and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
No/100 Dollars ($355,000.00) (together with any and all interest that may accrue thereon, the &#147;<B>Additional Deposit</B>&#148; and, together with the Initial Deposit, the
&#147;<B>Deposit</B>&#148;), by wire transfer of immediately available federal funds, with the Escrow Agent. Purchaser&#146;s failure timely to deposit any amount required pursuant to this <U>Section&nbsp;2.2</U> (time being of the essence) shall be
deemed a default under this Agreement entitling Seller immediately and without notice to terminate this Agreement. Notwithstanding the foregoing, it is expressly understood and agreed that, in the event Purchaser terminates this Agreement before the
Due Diligence Deadline, the Deposit shall be immediately refunded to Purchaser. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2.3 Escrow Agent shall place the Deposit
in an interest-bearing escrow account at a federally-insured commercial bank reasonably acceptable to both Seller and Purchaser. The Escrow Agent shall hold the Deposit in accordance with this Agreement. At Closing, the Escrow Agent shall deliver
the Deposit to Seller and credit the Deposit against the Purchase Price in accordance with this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2.4
Notwithstanding anything contained in this Agreement to the contrary, following the Due Diligence Deadline, the entire Deposit shall be conclusively deemed to have been earned by Seller and to be non-refundable to Purchaser in whole or in part under
any circumstances (including, without limitation, any prior or subsequent breach or default by Seller hereunder and any termination of this Agreement by Seller or Purchaser for any reason), except to the extent specifically provided in
<U>Section&nbsp;10.1</U> of this Agreement. Notwithstanding that the Deposit shall belong to Seller from and after the Due Diligence Deadline, Seller hereby authorizes and directs Escrow Agent to continue to hold the Deposit in escrow for
Seller&#146;s account until the earlier to occur of (i)&nbsp;the Closing, or (ii)&nbsp;a default by Purchaser hereunder, whereupon Escrow Agent shall immediately release the entire Deposit from escrow and deliver the same to Seller. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Site Work Costs</U>. The parties acknowledge that, prior to Closing, Seller shall incur certain site work costs and other beneficial
costs with respect to the Land, as set forth on <U>Exhibit 2.3</U> attached hereto (the &#147;<B>Site Work Costs</B>&#148;). At Closing, Purchaser shall reimburse Seller for all such Site Work Costs incurred by Seller as of the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Contractor Termination Fee</U>. The parties acknowledge that Seller currently has a contract with Polar Design Build, Inc. for
construction services on the Land. At Closing, Seller shall terminate such contract and Purchaser shall pay Nine Hundred Thousand and No/100 Dollars ($900,000.00) (the &#147;<B>Contractor Termination Fee</B>&#148;) to Seller to reimburse Seller for
the cost of such termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>TITLE AND SURVEY</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>State of Title to be Conveyed</U>. Title to the Property shall be conveyed to Purchaser at Closing in fee simple by Quitclaim Deed (the
&#147;<B>Deed</B>&#148;), free and clear of any and all liens, mortgages, deeds of trust, security interests and other encumbrances, except for: (i)&nbsp;the standard printed exclusions and exceptions from coverage contained in the ALTA form of
owner&#146;s title policy issued by the Title Company to Purchaser at Closing and those items identified on Schedule&nbsp;B-II of the Policy of Title Insurance No.&nbsp;27306-15-0132TN-FN (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<B>Existing Title Policy</B>&#148;), a copy of which Existing Title Policy is attached to <U>Exhibit&nbsp;3.1</U> attached hereto (except for any mortgages and mortgage related documents
noted in the Existing Title Policy, which Seller agrees to pay off with the sale proceeds at Closing); (ii)&nbsp;the lien of real estate taxes, water, sewer, vault and other public charges or assessments levied or assessed against the Property,
including any so-called payments in lieu of taxes, in each case which are a lien but not yet due and payable; (iii)&nbsp;any state of facts shown on the Survey (as hereinafter defined); (iv)&nbsp;the Amended and Restated First Amendment to Sewer Use
Agreement dated September&nbsp;28, 2015 and recorded with the Bristol County North Registry of Deeds (the &#147;<B>Registry</B>&#148;) in Book 22581, Page 254; and (v)&nbsp;Declaration Regarding Cost Sharing dated October&nbsp;13, 2015 and recorded
with the Registry in Book 22581, Page 290. The items referred to in clauses (i)&nbsp;through (v)&nbsp;above are hereinafter referred to, collectively, as the &#147;<B>Permitted Exceptions</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Title Policy and Survey</U>. Purchaser hereby acknowledges receipt of: (i)&nbsp;a copy of the Existing Title Policy, identifying no
exceptions to title other than the Permitted Exceptions; and (ii)&nbsp;a survey of the Land and the Improvements titled &#147;ALTA/ACSM Land Title Update Survey Plan of Land in Norton, MA,&#148; by Halnon Land Surveying, Inc., dated June&nbsp;6,
2015, revised August&nbsp;28, 2015 (the &#147;<B>Survey</B>&#148;), identifying no exceptions to title other than the Permitted Exceptions. Without limiting the foregoing, but subject to <U>Section&nbsp;3.4</U>, Seller shall have no liability to
Purchaser on account of any claims or defects or title or survey objections affecting the Property which are not shown on the Existing Title Policy, but existed as of the date thereof, it being understood and agreed that Purchaser&#146;s sole remedy
shall be to proceed against the Title Company with respect to such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Title Objections</U>. During the Due Diligence Period,
Purchaser may review the Existing Title Policy as part of its investigations hereunder and will have the right to obtain a new title commitment from the Title Company (the &#147;<B>Title Commitment</B>&#148;) and to negotiate with the Title Company
in order to cause the Title Company to modify the Title Commitment to reflect only those exceptions to title that are acceptable to Purchaser. If Purchaser does not terminate this Agreement pursuant to <U>Section&nbsp;6.2</U>, then the exceptions to
title disclosed in the Title Commitment as of the expiration of the Due Diligence Period, including any survey matters, will be deemed to be Permitted Exceptions. Seller will have no obligation to cure or remove any exceptions shown on the Existing
Title Policy or the Title Commitment other than any delinquent taxes or assessments and any monetary liens or any other encumbrances created by, through or under Seller. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Gap Exceptions</U>. In the event any matter which adversely affects title or Seller&#146;s ability to comply with the terms of this
Agreement with respect to title first arises and/or is placed of record after the Due Diligence Deadline (a &#147;<B>Gap Exception</B>&#148;) and such exception is not a Permitted Exception, Purchaser shall notify Seller in writing (&#147;<B>Gap
Exception Notice</B>&#148;) of Purchaser&#146;s objection to such Gap Exception on or before the earlier of (i)&nbsp;the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>)&nbsp;Business Day following the date Purchaser first learns of
such Gap Exception, and (ii)&nbsp;the Closing Date. If for any reason Purchaser fails to deliver a timely Gap Exception Notice, any Gap Exception that could have been the subject of a proper Gap Exception Notice shall for all purposes constitute a
Permitted Exception for purposes of this Agreement. Seller shall have the right, but not the obligation, to attempt to cure any Gap Exceptions, and Seller shall notify Purchaser in writing within seven (7)&nbsp;Business Days of Seller&#146;s receipt
of the Gap Exception </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notice as to which, if any, of the Gap Exceptions Seller has elected to attempt to cure and, to the extent Seller elects to cure any such Gap Exceptions, Seller shall use commercially reasonable
efforts to cure such Gap Exceptions. If Seller fails to timely deliver notice to Purchaser that Seller has elected to attempt to cure a Gap Exception, Seller shall be conclusively deemed to have elected not to cure such Gap Exception. If Seller
elects to or is required to attempt to cure or remove any such Gap Exceptions, Purchaser&#146;s and Seller&#146;s respective rights and obligations, and any corresponding extensions of the Closing Date, shall be governed by the provisions of
<U>Section&nbsp;3.3</U> and <U>Section&nbsp;8.3</U>. If at any time Purchaser elects to accept title to the Property subject to such Gap Exceptions, such Gap Exceptions shall be conclusively deemed to constitute &#147;Permitted Exceptions&#148; for
purposes of this Agreement. Notwithstanding anything contained in this Agreement to the contrary, nothing shall be deemed to impair or limit Seller&#146;s right to challenge whether any purported Gap Exception constitutes a proper Gap Exception for
purposes of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>PROPERTY INFORMATION</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Property Information</U>. Purchaser hereby acknowledges and agrees that Seller has delivered, or otherwise made available, as
appropriate, to Purchaser, for Purchaser&#146;s review, copies of the Existing Title Policy, the Survey and the other documents and/or materials specifically listed on <U>Exhibit 4.1</U> attached hereto (collectively, the &#147;<B>Property
Information</B>&#148;). Seller makes no representation or warranty whatsoever as to the completeness, truth or accuracy of the Property Information provided to Purchaser, except as otherwise expressly provided in this Agreement. In the event of the
expiration or termination of this Agreement for any reason whatsoever, Purchaser shall, within ten (10)&nbsp;days of Seller&#146;s request, deliver to Seller at no cost or expense to Seller other than Purchaser&#146;s actual out-of-pocket
third-party expenses incurred by Purchaser in connection with Purchaser&#146;s investigation of the Property, any and all due diligence materials and other information or documentation obtained by, or made available to Purchaser, on its own or from
or at the request of Seller in connection with its investigation of the Property (to the extent the providers of such materials, information and documentation allow Purchaser to provide Seller with the same and to the extent Seller advises Purchaser
of Seller&#146;s desire to obtain), and Purchaser&#146;s obligation in such regard shall survive any such expiration or termination. Notwithstanding the foregoing, it is expressly understood and agreed that Seller shall not be required to pay
Purchaser&#146;s actual out-of-pocket third-party expenses for materials, information and documentation that Seller advises Purchaser it does not require Purchaser to provide. Seller shall, at Purchaser&#146;s request and at Purchaser&#146;s sole
cost and expense, use commercially reasonable efforts to obtain a reliance letter addressed to Purchaser from the preparer of any report listed on <U>Exhibit 4.1</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>CONDITION OF THE PROPERTY</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Condition of the Property</U>. Subject to those certain Seller&#146;s representations and warranties expressly set forth in this Agreement, the Property shall be sold and conveyed strictly on an &#147;as is,&#148; &#147;where is&#148; and
&#147;with all defects&#148; basis, without representation, warranty or covenant, express, implied or statutory, of any kind whatsoever by Seller. Without limiting the generality of the foregoing, Purchaser acknowledges that neither Seller nor any
other person or party on behalf of Seller has made any representations, warranties or covenants as to the compliance of the Property with any Applicable Law, including, without limitation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Environmental Laws (as hereinafter defined) and those pertaining to construction, building and health codes, land use (or permits issued in connection therewith), zoning, Hazardous Substances (as
hereinafter defined) or other environmental matters. Purchaser shall confirm the aforesaid acknowledgments in writing as of the Closing Date by executing and delivering that certain Acknowledgment and Agreement attached hereto as <U>Exhibit 5.1</U>
and incorporated herein by reference (the &#147;<B>Purchaser&#146;s Acknowledgment and Agreement</B>&#148;). The provisions of this paragraph shall survive the Closing (as hereinafter defined) and the delivery of the Deed or any expiration or
termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Applicable Law</U>. For purposes of this Agreement: (i)&nbsp;the term &#147;<B>Applicable
Law</B>&#148; shall mean with respect to any matter referred to herein, all present and future laws applicable with respect thereto, including, without limitation, all applicable constitutional provisions, statutes, ordinances, codes, by-laws,
regulations, rulings, decisions, rules, orders, determinations and requirements of any Federal, state, county, local or other legislative, executive, judicial or other governmental body or authority; (ii)&nbsp;the term &#147;<B>Environmental
Laws</B>&#148; shall mean all federal, state and local Applicable Laws relating to pollution or protection of the environment or occupational safety and health, including but not limited to the Comprehensive Environmental Response, Compensation and
Liability Act (&#147;<B>CERCLA</B>&#148;), 42 U.S.C. 9601 et seq., the Resource Conservation and Recovery Act, 42 U.S.C. 6901 et seq., the Federal Water Pollution Control Act, 33 U.S.C. 1251 et seq., the Clean Air Act, 42 U.S.C. 7401 et seq. and the
Toxic Substances Control Act (&#147;<B>TSCA</B>&#148;), 15 U.S.C. 2601 et seq., and all analogous state Applicable Laws; and (iii)&nbsp;the term &#147;<B>Hazardous Substances</B>&#148; shall mean each and every element, compound, chemical mixture,
contaminant, pollutant material, waste or other substance which is defined, determined or identified as hazardous, flammable, harmful, corrosive or toxic under any Environmental Law or the release of which is prohibited or restricted under any
Environmental Law. Without limiting the generality of the foregoing, the term &#147;Hazardous Substances&#148; shall mean and include: &#147;hazardous substances&#148;, &#147;pollutants&#148; and &#147;contaminants&#148; as defined in CERCLA and the
Superfund Amendment and Reauthorization Act (&#147;<B>SARA</B>&#148;), each as amended, and regulations promulgated thereunder; and &#147;hazardous materials&#148; as defined in the Hazardous Materials Transportation Act, each as amended, and
regulations promulgated thereunder; &#147;chemical substance or mixture&#148; as defined in TSCA, as amended, and regulations promulgated thereunder; or any similar definitions found in any other Environmental Laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>PURCHASER&#146;S DUE DILIGENCE</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1
<U>Purchaser&#146;s Due Diligence</U>. During the period (the &#147;<B>Due Diligence Period</B>&#148;) commencing on the Effective Date and ending at 5:00 p.m. local Boston, Massachusetts time on the date that is thirty (30)&nbsp;days following the
Effective Date (the &#147;<B>Due Diligence Deadline</B>&#148;), Purchaser shall have the right to review Seller&#146;s title to the Property, as well as the right and non-exclusive license to enter the Property after prior notice for the purpose of
conducting such investigations, inspections, audits, analyses, surveys, tests, examinations, studies, and appraisals of the Property as Purchaser has deemed necessary or desirable, at Purchaser&#146;s sole cost and expense, to determine whether the
Property is suitable for Purchaser&#146;s purposes. Seller shall coordinate such inspections, as necessary, and shall have the right to be present at all inspections. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1.1 <U>Access</U>. Purchaser shall use due diligence to minimize interference with Seller&#146;s operations at the Property.
Notwithstanding anything in this Agreement to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
contrary, Purchaser shall not alter or disturb the Property in any manner and Purchaser shall not permit any mechanics&#146; liens to be filed against all or any part of the Property. Prior to
Purchaser or any contractor, consultant or other party acting by or on behalf of Purchaser entering the Property in the exercise of the access rights provided hereunder, Purchaser shall deliver to Seller, from a reputable company or companies
acceptable to Seller, certificates evidencing (i)&nbsp;a policy or policies of commercial general liability insurance with respect to the Property and the operations of Purchaser and such parties on or about the Property, including but not limited
to owned and non-owned automobile (vehicle) liability, personal injury, blanket contractual, broad form property damage and product/completed operations liability coverage for not less than Two Million and No/100 Dollars ($2,000,000.00) combined
single limit bodily injury, death and property damage liability per occurrence, or the current limit of liability carried, whichever is greater, and (ii)&nbsp;workers compensation insurance in an amount required by law, together with employers
liability, with a waiver of subrogation endorsement by the insurance carrier as respects Seller and such other parties designated by Seller, and naming Seller and such other parties designated by Seller as additional insureds. To the extent the
coverages evidenced by such certificates are based on claims made, the coverages evidenced by such certificates shall remain in effect for no less than six (6)&nbsp;months after the exercise by Purchaser or such other parties of any access rights
provided hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1.2 <U>Indemnity</U>. Purchaser hereby agrees to indemnify, defend, and hold harmless Seller and its
respective partners, members, affiliates, property managers, and their respective officers, directors, agents, employees and representatives (collectively, the &#147;<B>Indemnified Parties</B>&#148;) from and against any and all liens, claims, or
damages of any kind or nature, including any demands, actions or causes of action, assessments, losses, costs, expenses, liabilities, interest and penalties, and reasonable attorneys&#146; fees suffered, incurred, or sustained by any of the
Indemnified Parties caused by the entry on the Property by Purchaser, its agents or representatives or any other due diligence activities pursuant to this Agreement (&#147;<B>Claims</B>&#148;), except to the extent such Claims are caused by the
negligence or willful misconduct of any of the Indemnified Parties.. Purchaser will promptly restore the Property substantially to its condition before any damages that may have been caused by Purchaser or its agents or representatives in the
conduct of the review. Notwithstanding anything set forth herein to the contrary, the indemnification and restoration obligations of Purchaser in this Section shall survive Closing or the earlier termination, for any reason, of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Option to Terminate</U>. Purchaser shall have the right, for any reason or no reason, in its sole discretion, at or prior to the Due
Diligence Deadline, to terminate Purchaser&#146;s obligations hereunder, said right to be exercised by providing Seller with written notice (the &#147;<B>Due Diligence Termination Notice</B>&#148;) of Purchaser&#146;s election not to proceed with
the consummation of the transaction contemplated by this Agreement. Upon receipt by Seller of a proper Due Diligence Termination Notice as aforesaid, the respective obligations contained herein of Seller and Purchaser to sell and purchase (as
applicable) the Property shall forthwith terminate and be of no further force and effect, and, except as otherwise provided herein, Seller and Purchaser shall be released and discharged from all further obligation and liability under this Agreement,
except that Seller shall cause the Deposit to be promptly returned to Purchaser and except for any covenants and agreements of the parties which by the specific terms of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement are stated to survive any expiration or termination of this Agreement. In the event that a proper Due Diligence Termination Notice is not given to Seller at or prior to the Due
Diligence Deadline, then for all purposes of this Agreement, the condition of the Property and title thereto as of the Due Diligence Deadline shall conclusively be deemed acceptable to Purchaser. Purchaser confirms and agrees that, from and after
the Due Diligence Deadline, Purchaser shall have no right to terminate this Agreement for any cause or reason whatsoever, except as set forth in <U>Section&nbsp;10.1</U> hereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>REPRESENTATIONS AND WARRANTIES</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1
<U>Seller&#146;s Representations and Warranties</U>. Seller represents to Purchaser as of the Effective Date as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.1 <U>Organization</U>. Seller is duly formed, validly existing and in good standing under the laws of the State of
Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.2 <U>Authority/Consent</U>. Seller is the owner of the fee simple interest in the Property and possesses all
requisite power and authority, and has taken or will by Closing have taken all actions required by its organizational documents and applicable law to execute and deliver this Agreement and to consummate the transactions contemplated by this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.3 <U>Foreign Person</U>. Seller is not a &#147;foreign person,&#148; &#147;foreign trust&#148; or
&#147;foreign corporation&#148; within the meaning of the United States Foreign Investment in Real Property Tax Act of 1980 and the Internal Revenue Code of 1986, as subsequently amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.4 <U>No Violation of Agreements, Orders, Etc. </U>The execution and delivery of this Agreement by Seller and the
consummation by Seller of the transactions contemplated hereby will not (i)&nbsp;violate any judgment, order, injunction or decree to which Seller or the Property is subject, or (ii)&nbsp;conflict with, result in a breach of, or constitute a default
under the organizational documents of Seller or any lease, mortgage, loan agreement, covenant, or other agreement or instrument to which Seller is a party or by which Seller or the Property may be bound. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.5 <U>No Possessory Rights</U>. Except for any parties in possession pursuant to, and any rights of possession granted under
the Permitted Exceptions, there are no parties in possession of any part of the Property, and there are no other rights of possession concerning the Property which have been granted to any third party or parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.6 <U>No Third-Party Interests</U>. As of the date of this Agreement, Seller has not granted to any party any option,
contract or other agreement with respect to a purchase or sale of the Property or any portion thereof or any interest therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.7 <U>Violation of Applicable Law</U>. Seller has not received any written notice of any violation or noncompliance issued
pursuant to any Applicable Law, including, but not limited to Environmental Laws, with respect to the Property or any use or condition thereof, and to Seller&#146;s actual knowledge, no such violation exists. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.8 <U>Litigation</U>. There is no litigation, action, suit, hearing or
administrative proceeding pending or, to Seller&#146;s actual knowledge, threatened in writing against the Seller or the Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.9 <U>Condemnation</U>. There are no presently pending condemnation actions against the Property or any part thereof, and
the Seller has no actual knowledge of any written notice of any condemnation actions being contemplated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.l.10
<U>Bankruptcy</U>. No bankruptcy, insolvency, reorganization or similar action or proceeding, whether voluntary or involuntary, is pending, or, to Seller&#146;s knowledge, has been threatened in writing, against Seller. Seller is not insolvent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1.11 <U>OFAC</U>. Neither Seller, nor to Seller&#146;s actual knowledge, any of Seller&#146;s employees, officers or
directors, is a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of the Office of Foreign Asset Control of the Department of the Treasury (&#147;<B>OFAC</B>&#148;), (including those named on
OFAC&#146;s Specially Designated and Blocked Persons List) or under any similar statute, executive order (including the September&nbsp;24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to
Commit, or Support Terrorism) or other similar governmental action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Purchaser&#146;s Representations and Warranties</U>. Purchaser
represents to Seller as of the Effective Date as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2.1 <U>Organization</U>. Purchaser is duly formed, validly
existing and in good standing under the laws of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2.2 <U>Authority/Consent</U>. Purchaser possesses
all requisite power and authority, has taken all actions required by its organizational documents and applicable law, and has obtained all necessary consents, to execute and deliver this Agreement and to consummate the transactions contemplated in
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2.3 <U>OFAC</U>. Neither Purchaser, nor to Purchaser&#146;s actual knowledge, any of Purchaser&#146;s
employees, officers or directors, is a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of OFAC, (including those named on OFAC&#146;s Specially Designated and Blocked Persons List) or under
any similar statute, executive order (including the September&nbsp;24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism) or other similar governmental action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Knowledge of Seller</U>. References in this Agreement to the &#147;knowledge&#148; and/or &#147;actual knowledge&#148; of Seller, or
any words of similar import, shall refer only to the current actual (as opposed to implied or constructive) knowledge of Jeffrey O&#146;Neill, and shall not be construed, by imputation or otherwise, to refer to the knowledge of Seller or any parent,
subsidiary or affiliate of Seller or to any other officer, agent, manager, representative or employee of Seller or to impose upon Jeffrey O&#146;Neill any duty to investigate the matter to which such actual knowledge, or the absence thereof,
pertains. Notwithstanding anything to the contrary contained in this Agreement, Jeffrey O&#146;Neill shall not have any personal liability hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>CONDITIONS PRECEDENT TO CLOSING</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Conditions Precedent to Purchaser&#146;s Obligation to Close</U>. Purchaser&#146;s obligation to purchase the Property is subject to
satisfaction, on or before the Closing Date (as such date may be extended as expressly provided herein), of the following conditions, any of which may be waived in writing by Purchaser in Purchaser&#146;s sole and absolute discretion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1.1 <U>Covenants</U>. Seller shall have performed and observed, in all material respects, all covenants of Seller under this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1.2 <U>Delivery of Closing Documents</U>. Seller shall have delivered each of the Closing Documents (as
hereinafter defined) required to be delivered under <U>Section&nbsp;9.2.1</U> of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1.3 <U>Representations
and Warranties</U>. All representations and warranties of Seller set forth in this Agreement shall be true and correct in all material respects as if made on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1.4 <U>Title</U>. A final examination of the title to the Land by the Title Company shall disclose no title exceptions except
for the Permitted Exceptions and other matters approved or deemed approved by Purchaser in accordance with this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2
<U>Conditions Precedent to Seller&#146;s Obligation to Close</U>. Seller&#146;s obligation to sell the Property is subject to satisfaction, on or before the Closing Date (as such date may be extended as expressly provided herein), of the following
conditions, any of which may be waived in writing by Seller in Seller&#146;s sole and absolute discretion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2.1
<U>Covenants</U>. Purchaser shall have performed and observed, in all material respects, all covenants of Purchaser under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2.2 <U>Representations and Warranties</U>. All representations and warranties of Purchaser set forth in this Agreement shall
be true and correct in all material respects as if made on the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2.3 <U>Delivery of Closing Documents</U>.
Purchaser shall have delivered each of the Closing Documents required to be delivered under <U>Section&nbsp;9.3.1</U> of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2.4 <U>Delivery of the Development Agreement</U>. Purchaser shall have executed and delivered development management contract
with Condyne Construct, Inc. in the form attached hereto as <U>Exhibit 8.2.4</U> (the &#147;<B>Development Agreement</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3
<U>Failure of a Condition</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3.1 If any condition precedent to Purchaser&#146;s obligation to close the transactions
contemplated by this Agreement, as set forth in <U>Section&nbsp;8.1</U> of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Agreement, has not been satisfied on or before the Closing Date, then Purchaser shall give written notice to Seller of the condition or conditions that Purchaser asserts are not satisfied. If the
conditions specified in such notice are not satisfied within ten (10)&nbsp;Business Days after receipt of such notice (with the Closing Date automatically being extended to accommodate such ten (10)&nbsp;Business Day period, then Purchaser may
terminate this Agreement by written notice to Seller and Escrow Agent, whereupon neither party shall have any further rights or obligations hereunder (other than any obligations of either party that expressly survive termination) and the Deposit
shall be returned to Purchaser. Notwithstanding anything contained herein to the contrary, if any of the conditions precedent to Purchaser&#146;s obligation to close, as set forth in <U>Section&nbsp;8.1</U> of this Agreement, cannot reasonably be
satisfied within the ten (10)&nbsp;Business Day period specified above, but the same are reasonably susceptible of being cured and Seller is diligently proceeding to cure the same, Seller shall have the right to extend such period in which to
satisfy the unsatisfied condition for a period of up to thirty (30)&nbsp;additional days, by giving written notice thereof to the Purchaser and Escrow Agent within the initial ten (10)&nbsp;Business Day period referenced above. Purchaser shall have
the right to waive the unsatisfied condition or conditions by written notice to Seller and Escrow Agent given within five (5)&nbsp;Business Days after expiration of the applicable satisfaction period without satisfaction having occurred, in which
event the Closing Date shall be the date that is five (5)&nbsp;Business Days after Seller&#146;s receipt of Purchaser&#146;s waiver notice. If the Closing Date is extended pursuant to this paragraph, then the Closing Date shall be the date that is
the earlier to occur of five (5)&nbsp;Business Days after (a)&nbsp;the date that the unsatisfied condition has been satisfied, or (b)&nbsp;Seller&#146;s receipt of Purchaser&#146;s waiver notice. It is understood and agreed that the failure of any
condition set forth in <U>Section&nbsp;8.1</U> hereof that is not reasonably susceptible of being cured within the time allotted shall not constitute a default, breach of a covenant, or other failure to perform by Seller hereunder unless such failed
condition was caused by Seller&#146;s willful and intentional actions or omissions in violation of its covenants set forth in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3.2 If any condition precedent to Seller&#146;s obligation to close the transactions contemplated by this Agreement, as set
forth in <U>Section&nbsp;8.2</U> of this Agreement, has not been satisfied on or before the Closing Date, then Seller shall give written notice to Purchaser of the condition or conditions that Seller asserts are not satisfied. If the conditions
specified in such notice are not satisfied within ten (10)&nbsp;Business Days after receipt of such notice (with the Closing Date automatically being extended to accommodate such ten (10)&nbsp;Business Day period), then Seller may terminate this
Agreement by written notice to Purchaser and Escrow Agent, whereupon neither party shall have any further rights or obligations hereunder (other than any obligations of either party that expressly survive termination) and the Deposit shall be
returned to Purchaser (unless the applicable conditions are not satisfied due to a default by Purchaser under this Agreement, in which case the Deposit shall be paid to Seller). Seller shall have the right to waive the unsatisfied condition or
conditions by written notice to Purchaser and Escrow Agent given within five (5)&nbsp;Business Days after expiration of the applicable satisfaction period without satisfaction having occurred, in which event the Closing Date shall be the date that
is five (5)&nbsp;Business Days after Purchaser&#146;s receipt of Seller&#146;s waiver notice. If the Closing Date is extended pursuant to this paragraph, then the Closing Date shall be the date that is the earlier to occur of five (5)&nbsp;Business
Days after (a)&nbsp;the date that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the unsatisfied condition has been satisfied, or (b)&nbsp;Purchaser&#146;s receipt of Seller&#146;s waiver notice. Notwithstanding the foregoing or anything set forth herein to the contrary, in
no event shall the Closing Date be extended with respect to Purchaser&#146;s failure to fund into escrow the balance of the Purchase Price due at Closing as required under this Agreement, unless expressly agreed by Seller in writing in Seller&#146;s
sole and absolute discretion; it being expressly understood and agreed that the failure of Purchaser to fund into escrow the balance of the Purchase Price due at Closing shall constitute a default under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3.3 If the transaction contemplated by this Agreement closes, the parties shall be deemed to have waived any and all unmet or
unsatisfied conditions, other than any unmet or unsatisfied conditions arising out of a breach by either party of any of its representations and warranties hereunder of which the other party has no knowledge as of Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>CLOSING</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <U>Closing Date</U>. The
consummation of the transaction contemplated hereby (the &#147;<B>Closing</B>&#148;) will take place via an escrow closing conducted by the Title Company, on the date that is ten (10)&nbsp;Business Days following the Due Diligence Deadline, or such
earlier date as Seller and Purchaser may mutually agree upon in writing (the &#147;<B>Closing Date</B>&#148;), TIME BEING OF THE ESSENCE, subject to the provisions of <U>Section 8.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <U>Seller&#146;s Obligations at the Closing</U>. At the Closing, Seller will do, or cause to be done, the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1 <U>Closing Documents</U>. Seller shall deliver originals of the following documents (collectively, the &#147;<B>Seller
Closing Documents</B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.1 An executed and acknowledged Deed in the form attached hereto as <U>Exhibit
9.2.1.1</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.2 An executed Certificate of Non-Foreign Status in the form of <U>Exhibit&nbsp;9.2.1.2</U> hereto (the
&#147;<B>FIRPTA</B>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.3 An Assignment and Assumption Agreement with respect to the Permits, substantially in
the form attached hereto as <U>Exhibit 9.2.1.3</U> (the &#147;<B>Assignment and Assumption Agreement</B>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.4
An executed Settlement statement showing all of the payments, adjustments and prorations provided for in <U>Section&nbsp;9.5</U> and otherwise agreed upon by Seller and Purchaser (the &#147;<B>Settlement Statement</B>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.5 An executed certificate stating that each of Seller&#146;s representations and warranties contained in this Agreement
is true and correct in all material respects; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.6 Such evidence as may be reasonably and customarily required by the Title
Company with respect to the authority of the person(s) executing the documents required to be executed by Seller on behalf of Seller; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.7 An executed Development Agreement from Seller&#146;s affiliate, Condyne Construct, Inc.; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.8 A Certificate of Approval of Plans and Improvements, in recordable form, as required under the Protective Restrictions
listed in Exception 7 of the Existing Title Policy and as required under the Declaration of Restrictive Covenants listed in Exception 15 of the Existing Title Policy; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.9 A Certificate of Compliance or other close out documentation, in recordable form, from the Norton Conservation
Commission, to close out the Order of Conditions DEP File No.&nbsp;250-751 listed as Exception 24 of the Existing Title Policy for which the work was never completed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.10 An estoppel from Seller, in recordable form, representing there are no outstanding charges owed or default of which
Seller is aware related to the Sewer Use Agreement listed as Exception 12 of the Existing Title Policy; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.11 An
estoppel from the Agent (as defined in the Cost Sharing Declaration), in recordable form, representing all assessments payable by the Seller have been paid, or if such is not the case, stating the nature, amount, and due date of any unpaid
assessments, related to the Declaration Regarding Cost Sharing, dated October&nbsp;13, 2015 and recorded with the Bristol County North Registry of Deeds in Book 22581, Page 290 (the &#147;<B>Cost Sharing Agreement</B>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.1.12 An Owner&#146;s Affidavit in the form of Exhibit <U>9.2.1.12</U> attached hereto or in such other form reasonably
requested by the Title Company, in order to delete from an owner&#146;s policy of title insurance issued by the Title Company to Purchaser at Closing any exceptions for parties in possession and mechanics&#146; or materialmen&#146;s liens (the
&#147;<B>Owner&#146;s Affidavit</B>&#148;). Seller shall also deliver to the Title Company and Purchaser such evidence as may reasonably be required by the Title Company with respect to the authority of the person(s) executing the Deed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.2 <U>Original Property Information Documents</U>. Seller will deliver to Purchaser originals within Seller&#146;s
possession of all items comprising the Property Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.3 <U>Possession</U>. Seller will deliver possession of
the Property, free and clear of all tenants and occupants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2.4 <U>Costs</U>. Seller will pay all costs allocated to
Seller pursuant to <U>Section&nbsp;9.5</U> of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>Purchaser&#146;s Obligations at the Closing</U>. At the Closing, Purchaser will do, or
cause to be done, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.1 <U>Closing Documents</U>. At Closing, Purchaser shall deliver originals of the
following documents (the &#147;<B>Purchaser Closing Documents</B>&#148; and, together with the Seller Closing Documents, the &#147;<B>Closing Documents</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.1.1 An executed Assignment and Assumption Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.1.2 An executed Settlement Statement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.1.3 Such evidence as may be reasonably and customarily required by the Title Company with respect to the authority of the
person(s) executing the documents required to be executed by Purchaser on behalf of Purchaser; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.1.4 An executed
certificate stating that each of Purchaser&#146;s representations and warranties contained in this Agreement is true and correct in all material respects; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.1.5 an executed Development Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.2 <U>Payment of Consideration</U>. At Closing, Purchaser shall pay to Seller a amount equal to the sum of the Purchase
Price (subject to the credits, prorations and adjustments provided hereby), the Site Work Costs and the Contractor Termination Fee via wire transfer of immediately available federal funds to an account designated by Seller in a written notice to the
Escrow Agent delivered prior to the Closing Date, such notice to contain all information necessary for the Escrow Agent to effectuate such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3.3 <U>Costs</U>. Purchaser will pay all costs allocated to Purchaser pursuant to <U>Section&nbsp;9.5</U> of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>Escrow</U>. The delivery of the documents and the payment of the sums to be delivered and paid at the Closing shall be
accomplished through an escrow with the Escrow Agent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>Costs and Adjustments at Closing</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5.1 <U>Expenses</U>. Seller shall pay the Massachusetts deeds excise tax, the cost of recording any instruments required to
deliver clear title and one-half of any escrow fees of Escrow Agent. Purchaser shall pay all costs and fees for title examination, title insurance and other title company charges, any new survey of the Property or update to the Survey and all of
Purchaser&#146;s due diligence studies and investigations, the cost of recording the Deed, and one-half of any escrow fees of the Escrow Agent. Seller and Purchaser shall each pay their respective attorney&#146;s fees. Seller and Purchaser shall
each pay all other expenses, charges or costs for which sellers and purchasers, respectively, are customarily responsible in real estate transactions in Massachusetts. All other costs and expenses incident to this transaction and the Closing shall
be paid by the party incurring same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5.2 <U>Deposit and Option Payments</U>. The Deposit shall be credited again the
Purchase Price at Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5.3 <U>Insurance Policies</U>. Premiums on insurance policies will not be adjusted. As of the
Closing Date, Seller will terminate its insurance coverage and Purchaser will effect its own insurance coverage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5.4
<U>Other Income and Expenses</U>. All other income and ordinary operating expenses for or pertaining to the Property, including, but not limited to, public utility charges, maintenance, service charges, and license fees, will be prorated as of the
Apportionment Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5.5 <U>Post-Closing Adjustment</U>. In the absence of error or omission, all prorations, adjustments
and credits made and determined as herein provided shall be final as of the Closing Date, unless otherwise specified herein. If, subsequent to the Closing Date, an error or omission in the determination or computation of any of the prorations,
adjustments and credits shall be discovered, then, promptly upon discovery thereof, the parties hereto shall make the appropriate adjustments required to correct such error or omission. The provisions of this subsection shall survive the Closing and
the delivery of the Deed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5.6 <U>Seller Election Regarding Prorations</U>. Notwithstanding anything contained herein to
the contrary, at Seller&#146;s election, any one or more of the prorations that would otherwise be made by adjustment to the Purchase Price may instead be paid by Seller out of separate funds, without adjustment to the Purchase Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5.7 <U>Survival</U>. The provisions of this <U>Section&nbsp;9.5</U> shall survive Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>REMEDIES AND ADDITIONAL COVENANTS</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Seller Default</U>. If Seller refuses or fails to consummate the transactions contemplated by this Agreement for any reason other than
Purchaser&#146;s default or the permitted termination of this Agreement as herein expressly provided, Purchaser shall be entitled, as its sole remedy, either (a)&nbsp;to receive the return of the Deposit with interest, which return shall operate to
terminate this Agreement and release Seller from any and all liability hereunder, or (b)&nbsp;to enforce specific performance of Seller&#146;s obligation to execute the documents required to convey the Property to Purchaser, it being understood and
agreed that the remedy of specific performance shall not be available to enforce any other obligation of Seller hereunder. Purchaser expressly waives its rights to seek damages in the event of Seller&#146;s default hereunder. Purchaser shall be
deemed to have elected to terminate this Agreement and receive back the Deposit if Purchaser fails to file suit for specific performance against Seller in a court having jurisdiction in Suffolk County, Massachusetts, on or before thirty
(30)&nbsp;days following the date upon which Closing was to have occurred. In no event shall Seller or any Seller Party have any personal liability in connection with this Agreement or the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties of Seller as contained in this Agreement shall survive for a
period of nine (9)&nbsp;months from and after the Closing Date. If Purchaser becomes aware of any breach and/or violation of any of Seller&#146;s representations and warranties prior to Closing and Purchaser fails to give Seller notice thereof
and/or proceeds to Closing with such knowledge, Purchaser is deemed to have waived any such breach and/or violation. If Purchaser commences any action(s) to enforce any alleged breach and/or violation of any of the representations and/or warranties
of Seller as set forth in this Agreement of which Purchaser becomes aware after Closing, then Purchaser&#146;s sole remedy shall be to seek recovery of its actual damages (but not special, consequential, speculative, punitive or other damages, all
of which are waived by Purchaser), provided, in no event may the amount of such damages, in the aggregate (with respect to any and all such breaches and/or violations for all of the Property) exceed Two Hundred Thousand and No/100 Dollars
($200,000.00) (the &#147;<B>Cap</B>&#148;), unless such breach or violation is due to Seller&#146;s fraud or intentional misrepresentation. Notwithstanding the foregoing, Seller shall not have any liability for cure of Seller&#146;s breach and/or
violation of Seller&#146;s representations and warranties hereunder, whether before or after Closing, unless and until the aggregate amount of claims by Purchaser as a result of all breaches and violations of Seller exceeds Twenty-Five Thousand and
No/100 ($25,000.00) (the &#147;<B>Basket</B>&#148;), in which case Seller&#146;s liability shall be limited to amounts in excess of the Basket. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>Purchaser Default</U>. If Purchaser fails to consummate the transactions contemplated by this Agreement for any reason other than
Seller&#146;s default or the permitted termination of this Agreement as herein expressly provided, Seller shall have the right, as its sole and exclusive remedy, to terminate this Agreement and to receive and retain the Earnest Money hereunder as
liquidated damages. Seller and Purchaser acknowledge and agree that (a)&nbsp;the Earnest Money is a reasonable estimate of and bears a reasonable relationship to the damages that would be suffered and costs incurred by Seller as a result of having
withdrawn the Property from sale and the failure of the Closing to occur due to a default by Purchaser under this Agreement; (b)&nbsp;the actual damages suffered and costs incurred by Seller as a result of such withdrawal and failure to close due to
a default by Purchaser would be extremely difficult and impractical to determine; and (c)&nbsp;the Earnest Money constitutes valid liquidated damages for such default by Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Damages</U>. In no event shall Seller or Purchaser ever be liable under this Agreement for damages of any kind whatsoever (including,
without limitation, direct, incidental, consequential or punitive damages) for any breach or default or failure to perform by any of the same under this Agreement, except as specifically provided for herein; it being understood and agreed that
Purchaser&#146;s and Seller&#146;s sole and exclusive rights and remedies on account of any such breach, default or failure shall be limited as set forth in <U>Section&nbsp;10.1</U> and <U>Section&nbsp;10.2</U>, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>BROKERAGE COMMISSION</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1
<U>Brokers</U>. Purchaser warrants and represents to Seller and Seller represents and warrants to Purchaser that each has dealt with no broker or other person entitled to a broker&#146;s commission in connection with the negotiation or execution of
this Agreement or the consummation of the transaction contemplated hereby, other than Transwestern RBJ (for whose commission Seller shall be responsible pursuant to a separate agreement), and each agrees to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hold the other harmless and indemnify the other against all damages, claims, losses and liabilities, including legal fees, incurred by the other, arising out of or resulting from the failure of
its representation and warranty. Notwithstanding anything to the contrary contained in this Agreement, the indemnities set forth in this <U>Section&nbsp;11.1</U> shall survive the Closing or earlier termination of this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>NOTICES</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1 <U>Written Notice</U>.
All notices, demands and requests which may be given or which are required to be given by either party to the other party under this Agreement must be in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 <U>Method of Transmittal</U>. All notices, demands, requests or other communications required or permitted to be given hereunder must be
sent by (i)&nbsp;United States certified mail, postage fully prepaid, return receipt requested, (ii)&nbsp;hand delivery, (iii)&nbsp;Federal Express or a similar nationally recognized overnight courier service or (iv)&nbsp;e-mail with a confirmation
copy sent the same day by another method set forth in this Section. All such notices, demands, requests or other communications shall be deemed to have been given for all purposes of this Agreement upon the date of receipt or refusal, except that
whenever under this Agreement a notice is either received on a day which is not a Business Day or is required to be delivered on or before a specific day which is not a Business Day, the day of receipt or required delivery shall automatically be
extended to the next Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3 <U>Addresses</U>. The addresses for proper notice under this Agreement are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>As to Purchaser</U>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>As to Seller</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">c/o Condyne Capital Partners</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">100 Grandview Road, Suite 312</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Braintree, MA 02184</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Jeffrey O&#146;Neill</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">E-mail:
joneill@condyne.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WITH A COPY TO:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">WITH A COPY TO:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B></B>Goodwin Procter LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exchange
Place</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Alexander Randall, Esq.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">E-mail: arandall@goodwinprocter.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nutter, McClennen &amp; Fish, LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seaport
West</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">155 Seaport Boulevard</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110-2604</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Paul A. Ayoub, Esq.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E-mail: payoub@nutter.com</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">AND TO:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>As to Escrow Agent</U>:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity National Title Insurance Company</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">133 Federal Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Terence J. Nolan<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>E-mail: TNolan@fnf.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amstar Advisers, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1401 17th Street, 12<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denver, CO 80202</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Patricia Noble</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;Tricia.Noble@amstaradvisers.com</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Gabe Finke</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>E-mail:
gabe.finke@amstaradvisers.com</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Either party may from time to time by written notice to the other party designate a different address for notices
within the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>ASSIGNMENT</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 Purchaser may not assign this Agreement or its rights and obligations hereunder, without the prior express written consent of Seller,
which consent may be withheld and/or conditioned by Seller in its sole and absolute discretion; provided, however, that, Purchaser shall have the right to assign its interest in this Agreement and delegate its duties to an affiliate, so long as such
affiliate controls, is controlled by, or is under common control with Purchaser, and provided that (a)&nbsp;such affiliate shall assume, in writing (by execution of an assignment and assumption of this Agreement in form and substance reasonably
satisfactory to Seller), all of Purchaser&#146;s obligations under this Agreement and (b)&nbsp;Purchaser shall not be released of any obligations under this Agreement. If Purchaser so assigns this Agreement to an affiliate, Purchaser shall, at least
five (5)&nbsp;Business Days prior to the Closing Date, give the Seller written notice of such assignment, together with a copy of the assignment and assumption agreement executed by Purchaser and the assignee. Other than an assignment in connection
with financing, Seller may not assign this Agreement or its rights and obligations hereunder, without the prior express written consent of Purchaser, which consent may be withheld and/or conditioned by Purchaser in its sole and absolute discretion.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>CIVIL ENGINEERING CONTRACT</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1 The parties acknowledge that Purchaser has entered into a contract for civil engineering services with CEG Engineering, LLC, a copy of
which is attached hereto as <U>Exhibit 14.1</U>. Purchaser shall pay all fees and costs required to be paid pursuant to said agreement, in accordance with the terms thereof, regardless of whether the transaction contemplated by this Agreement shall
close. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>MISCELLANEOUS</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.1
<U>Entire Agreement</U>. This Agreement embodies the entire agreement between the parties and cannot be varied except by the written agreement of the parties and supersedes all prior agreements and undertakings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2 <U>Modifications</U>. This Agreement may not be modified except by the written agreement of the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.3 <U>Gender and Number</U>. Words of any gender used in this Agreement will be construed to include any other gender and words in the
singular number will be construed to include the plural, and vice versa, unless the context requires otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.4 <U>Captions</U>. The captions used in connection with the Articles, Sections and Subsections
of this Agreement are for convenience only and will not be deemed to expand or limit the meaning of the language of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.5
<U>Successors and Assigns</U>. Subject to the limitations set forth in <U>Section&nbsp;13.1</U> hereof, this Agreement will be binding upon and inure to the benefit of the parties hereto and their respective permitted legal representatives,
successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.6 <U>Controlling Law</U>. This Agreement will be construed under, governed by and enforced in accordance with
the laws of the jurisdiction where the Property is located. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.7 <U>Exhibits</U>. All exhibits, attachments, annexed instruments and
addenda referred to herein will be considered a part hereof for all purposes with the same force and effect as if set forth verbatim herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.8 <U>No Rule of Construction</U>. Seller and Purchaser have each been represented by counsel in the negotiations and preparation of this
Agreement; therefore, this Agreement will be deemed to be drafted by both Seller and Purchaser, and no rule of construction will be invoked respecting the authorship of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.9 <U>Severability</U>. In the event that any one or more of the provisions contained in this Agreement (except the provisions relating to
Seller&#146;s obligations to convey the Property and Purchaser&#146;s obligation to pay the Purchase Price, the invalidity of either of which shall cause this Agreement to be null and void) are held to be invalid, illegal, or unenforceable in any
respect, such invalidity, illegality, or unenforceability will not affect any other provisions hereof, and this Agreement shall be construed as if such invalid, illegal, or unenforceable provision had not been contained herein; provided, however,
that the parties hereto shall endeavor in good faith to rewrite the affected provision to make it (i)&nbsp;valid, and (ii)&nbsp;consistent with the intent of the original provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.10 <U>Time of Essence</U>. Time is important to both Seller and Purchaser in the performance of this Agreement, and both parties have
agreed that TIME IS OF THE ESSENCE with respect to any date set out in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.11 <U>Business Days</U>. &#147;<B>Business
Day</B>&#148; means any day on which business is generally transacted by banks in the Commonwealth of Massachusetts. If the final date of any period which is set out in any paragraph of this Agreement falls upon a day which is not a Business Day,
then, and in such event, the time of such period will be extended to the next Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.12 <U>No Memorandum</U>. Purchaser and
Seller agree not to record this Agreement or any memorandum hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.13 <U>Press Releases</U>. Subject to the provisions of
<U>Section&nbsp;16</U> hereof, prior to Closing, any release to the public of information with respect to the matters set forth in this Agreement will be made only in the form and pursuant to the timing approved by Purchaser and Seller and their
respective counsel. Notwithstanding anything to the contrary contained herein, Seller hereby agrees that Purchaser shall be allowed to make any necessary disclosures to comply with U.S. Securities and Exchange Commission and investor notification
requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.14 <U>Attorneys&#146; Fees and Costs</U>. In the event either party is required to resort to
litigation to enforce its rights under this Agreement, the prevailing party in such litigation will be entitled to collect from the other party all costs, expenses and attorneys&#146; fees incurred in connection with such action. Notwithstanding any
other provision of this Agreement, the provisions of this <U>Section&nbsp;15.14</U> shall survive the Closing or earlier termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.15 <U>Counterparts and Expiration of Offer</U>. This Agreement may be executed in multiple counterparts which shall together constitute a
single document. However, this Agreement shall not be effective unless and until all counterpart signatures have been obtained. Faxed or electronically scanned signatures shall have the same binding effect as original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.16 <U>Waiver of Jury Trial</U>. EACH PARTY HEREBY WAIVES TRIAL BY JURY IN ANY ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM BROUGHT BY EITHER
PARTY IN CONNECTION WITH ANY MATTER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT, THE RELATIONSHIP OF SELLER AND PURCHASER HEREUNDER, PURCHASER&#146;S OWNERSHIP OR USE OF THE PROPERTY, AND/OR ANY CLAIMS OF INJURY OR DAMAGE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.17 <U>Venue; Jurisdiction</U>. For the purposes of any suit, action or proceeding involving this Agreement, the parties hereby expressly
submit to the jurisdiction of all federal and state courts sitting in the Commonwealth of Massachusetts and consent that any order, process, notice of motion or other application to or by any such court or a judge thereof may be served within or
without such court&#146;s jurisdiction by registered mail or by personal service, provided that a reasonable time for appearance is allowed, and the parties agree that such courts shall have exclusive jurisdiction over any such suit, action or
proceeding commenced by either or both of said parties. In furtherance of such agreement, the parties agree upon the request of the other to discontinue (or agree to the discontinuance of) any such suit, action or proceeding pending in any other
jurisdiction. Each party hereby irrevocably waives any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement brought in any federal or state court sitting in
the Commonwealth of Massachusetts and hereby further irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. In recognition of the benefits of having any disputes
with respect to this Agreement resolved by an experienced and expert person, Seller and Purchaser hereby agree that any suit, action or proceeding, whether claim or counterclaim, brought or instituted by any party in connection with this Agreement
or any event, transaction or occurrence arising out of or in any way connected with this Agreement or the Property, or the dealings of the parties with respect thereto, shall be tried only by a court and not by a jury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.18 <U>No Third Party Beneficiary</U>. The provisions of this Agreement and of the documents to be executed and delivered at Closing are and
will be for the benefit of Seller and Purchaser only and are not for the benefit of any third party, and accordingly, no third party shall have the right to enforce the provisions of this Agreement or of the documents to be executed and delivered at
Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.19 <U>Title Standards</U>. Any title matter which is the subject of a title standard of the
Real Estate Bar Association of Massachusetts (or any successor organization thereto) at the time for delivery of the Deed hereunder shall be governed by said title standards to the extent applicable and not inconsistent with statutory or common law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.20 <U>No Personal Liability of Officers or Directors</U>. Purchaser and Seller acknowledge and agree that no officer, partner,
director, manager, member, trustee, beneficiary, equity owner, employee, or representative of Purchaser or Seller shall ever have any personal liability under this Agreement for any document executed in connection with the transactions contemplated
by this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <U>CONFIDENTIALITY</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.1 Prior to Closing and except as provided otherwise in this <U>Section&nbsp;16</U>, Purchaser and Seller, for the benefit of each other,
hereby agree that neither of them nor any of their directors, officers, employees, partners, members, agents, subsidiaries or affiliates will release or cause or permit to be released to the public any press notices, publicity (oral or written) or
advertising promotion relating to, or otherwise publicly announce or disclose or cause or permit to be publicly announced or disclosed, in any manner whatsoever, the terms, conditions or substance of this Agreement or the transactions contemplated
herein, without first obtaining the consent of the other party hereto, which shall not be unreasonably withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.2 It is understood
that the foregoing shall not preclude any party from discussing the substance or any relevant details of the transactions contemplated in this Agreement on a confidential basis with such party&#146;s attorneys, accountants, professional consultants,
financial advisors, rating agencies, or potential lenders, as the case may be, or prevent any party hereto from complying with applicable laws, including, without limitation, governmental regulatory, disclosure, tax and reporting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURES ON FOLLOWING PAGE] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Purchase and Sale Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7"><B><U>SELLER</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20 COMMERCE LLC,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware
limited liability company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Amstar/Condyne Commerce, LLC,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">a Delaware limited liability company,<BR>its sole Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Amstar-111, LLC,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">a Colorado limited liability company,<BR>its Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gabe Finke</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gabe Finke</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CEO Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7"><B><U>PURCHASER</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7">ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Mason</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Michael Mason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Vice President of Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule of Exhibits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 1.1 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Legal Description of the Land</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 2.3 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Site Work Costs</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 3.1 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Existing Title Policy</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 4.1 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Property Information</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 5.1 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Purchaser&#146;s Acknowledgement and Agreement</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 8.2.4 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Development Agreement</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 9.2.1.1 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Deed</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 9.2.1.2 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Certificate of Non-Foreign Status</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 9.2.1.3 -</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Assignment and Assumption Agreement</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 9.2.1.12 -</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Owner&#146;s Affidavit</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit 14.2 &#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Civil Engineering Contract</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14.1-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO PURCHASE AND SALE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This AMENDMENT TO PURCHASE AND SALE AGREEMENT (this &#147;<B><U>Amendment</U></B>&#148;) is made as of March&nbsp;25, 2016, by and between 20
COMMERCE LLC, a Delaware limited liability company (&#147;<B><U>Seller</U></B>&#148;) and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (&#147;<B><U>Purchaser</U></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Seller and
Purchaser entered into that certain Purchase and Sale Agreement dated as of February&nbsp;10, 2016 (the &#147;<B><U>Purchase Agreement</U></B>&#148;), for the purchase and sale of certain Property located in Norton, Massachusetts, as more fully
described in the Purchase Agreement. Capitalized terms used but not otherwise defined herein shall be defined as provided in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Purchaser and Seller desire to amend the Purchase Agreement as herein provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto do hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The parties hereby agree that the term &#147;<B><U>Closing
Date</U></B>&#148; as defined in Section&nbsp;9.1 of the Purchase Agreement shall be changed to March&nbsp;31, 2016, or such earlier date as Seller and Purchaser may mutually agree upon in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. By executing this Amendment, the parties acknowledge and agree that, except as expressly amended hereby, all other items and provisions of
the Purchase Agreement remain unchanged and continue to be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This Amendment may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document. Executed copies hereof may be delivered by facsimile, PDF or email, and upon receipt, shall be deemed originals and binding upon
the parties hereto. Without limiting or otherwise affecting the validity of executed copies hereof that have been delivered by facsimile, PDF or email, the parties shall use diligent efforts to deliver originals as promptly as possible after
execution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signatures on Following Pages] </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the day and year first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7"><B><U>SELLER</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7">20 COMMERCE LLC,<BR>a Delaware limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Amstar/Condyne Commerce, LLC,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">a Delaware limited liability company,<BR>its sole Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Amstar-111, LLC,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">a Colorado limited liability company,<BR>its Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rob Toomey</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Rob Toomey</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><STRIKE>Manager</STRIKE><STRIKE> </STRIKE>Authorized Representative</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signatures Continue on the Following Page] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page -
Amendment to Purchase and Sale] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>PURCHASER</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Mason</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Mason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Finance</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page -
Amendment to Purchase and Sale] </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d166732dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, John M. Maraganore,
Ph.D., certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Maraganore</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John M. Maraganore, Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d166732dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Michael P. Mason,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael P. Mason</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael P. Mason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Finance and Treasurer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d166732dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#147;Company&#148;) for the quarter ended
March&nbsp;31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, John M. Maraganore, Ph.D., Chief Executive Officer of the Company, hereby certifies, pursuant to Section&nbsp;1350
of Chapter 63 of Title 18, United States Code, that to his knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Maraganore</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John M. Maraganore, Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>d166732dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 32.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#147;Company&#148;) for the quarter ended
March&nbsp;31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Michael P. Mason, Vice President of Finance and Treasurer of the Company, hereby certifies, pursuant to
Section&nbsp;1350 of Chapter&nbsp;63 of Title 18, United States Code, that to his knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael P. Mason</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael P. Mason</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Finance and Treasurer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>alny-20160331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 5 -->
<!-- Creation date: 2016-05-04T17:43:12Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:alny="http://www.alnylam.com/20160331" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="alny-20160331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <alny:StandstillRangeOfOutstandingCommonStockAcquiredPercentage contextRef="eol_PE375375--1610-Q0004_STD_0_20140228_0_1115253x1107704_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1B82C79B-1BD5-4C41-A699-27A9E8F796F0_3001_2">0.05</alny:StandstillRangeOfOutstandingCommonStockAcquiredPercentage>
  <alny:StandstillRangeOfOutstandingCommonStockAcquiredPercentage contextRef="eol_PE375375--1610-Q0004_STD_0_20140228_0_1115253x1116460_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1B82C79B-1BD5-4C41-A699-27A9E8F796F0_4001_3">0.30</alny:StandstillRangeOfOutstandingCommonStockAcquiredPercentage>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE375375--1610-Q0004_STD_0_20140228_0_1251668x1317809" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5871536_0EA280CB-79AB-4D4E-AA9B-8A868F5704C8_2002_1">85.72</us-gaap:SharesIssuedPricePerShare>
  <alny:MaximumPercentageOfVotingPerCompanyRecommendation contextRef="eol_PE375375--1610-Q0004_STD_0_20140228_0_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1B82C79B-1BD5-4C41-A699-27A9E8F796F0_5001_4">0.20</alny:MaximumPercentageOfVotingPerCompanyRecommendation>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE375375--1610-Q0004_STD_0_20150131_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5871536_48A12113-F83C-4615-ADBA-39CA12AE838A_1001_1">95.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:AreaOfLand contextRef="eol_PE375375--1610-Q0004_STD_0_20160404_0_1106880x1108681_1107576x1323477" unitRef="acre" decimals="INF" id="id_5871536_958121E2-4467-42FE-BE1A-324AEC1194F1_2001_1">12</us-gaap:AreaOfLand>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE375375--1610-Q0004_STD_0_20160429_0" unitRef="shares" decimals="INF" id="id_5871536_29A7188E-9849-4A06-83E2-D9B2402DD54B_2_500005">85560535</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE375375--1610-Q0004_STD_0_20160429_0_1106880x1108681_1107053x1287013_1117020x1189687" unitRef="iso4217_USD" decimals="INF" id="id_5871536_0F0BDFF1-FD28-4543-A785-37D3B8BEAB7D_5001_3">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE375375--1610-Q0004_STD_0_20160429_0_1106880x1108681_1107053x1287013_1117020x1194715" unitRef="iso4217_USD" decimals="INF" id="id_5871536_0F0BDFF1-FD28-4543-A785-37D3B8BEAB7D_6001_0">120000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE375375--1610-Q0004_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1002_30">306580000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_0_20150331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1002_6">52728000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="eol_PE375375--1610-Q0004_STD_0_20150331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1002_1">87955000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
  <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome contextRef="eol_PE375375--1610-Q0004_STD_0_20150331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1002_4">33223000</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20150331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1002_2">99890000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <alny:CarryingValueInEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20150331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1002_0">11935000</alny:CarryingValueInEquitySecurities>
  <alny:AccruedIntraperiodTaxAllocation contextRef="eol_PE375375--1610-Q0004_STD_0_20150331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1002_5">2004000</alny:AccruedIntraperiodTaxAllocation>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_31">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_32">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_34">85463258</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_27">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_28">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_33">85463258</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_29">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_26">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_18">66369000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_20">53952000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_15">30805000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_22">127898000</us-gaap:Liabilities>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_16">1178000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_30">855000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_35">2546884000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1006_2">279000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_21">1373000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_17">16944000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_36">-9011000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_23" />
  <us-gaap:PreferredStockValue contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_25" />
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_37">-1349677000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_19">6204000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_38">1189051000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_39">1316949000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_14">17442000</us-gaap:AccountsPayableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_9">36814000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_8">228590000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_7">1050074000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_826C0159-78D3-4DD2-BA18-6EFEF82623FD_1_2">228532000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_826C0159-78D3-4DD2-BA18-6EFEF82623FD_1_1">748722000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_BDC1E4DA-B44C-4C0E-B561-941852EC9FF2_1_1">748422000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_4">33934000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_2">231278000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1006_4">977012000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:ReceivablesNetCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_5">8814000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:Assets contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_11">1316949000</us-gaap:Assets>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1006_3">521000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_BDC1E4DA-B44C-4C0E-B561-941852EC9FF2_1_2">228590000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_6">27626000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1006_1">977254000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_10">1471000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_1_3">748422000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_2_5">-8769000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_2_1">24023000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
  <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_2_4">32792000</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_2_2">33934000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <alny:CarryingValueInEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_2_0">9911000</alny:CarryingValueInEquitySecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1105790_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_1003_4">13799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1105790_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_1001_4">13799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1108237_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_2002_2">193735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1108237_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_2001_2">193735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1111781_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_3003_7">146667000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1111781_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_3001_7">146667000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1113789_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_4003_6">703502000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1113789_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_4001_6">703502000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1114216_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_5003_8">81383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1114216_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_5001_8">81383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1116395_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_6003_1">4199000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1116395_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_6003_5">31661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1116395_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_6001_1">4199000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1116395_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_6001_5">31661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_7002_11">229140000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_7002_10">1471000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_7002_9">33934000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_7003_11">981211000</us-gaap:AssetsFairValueDisclosure>
  <alny:PotentialMilestonePaymentsToBeReceived contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115253x1107704_1116223x1157030_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_53367E3A-E94F-4378-80EA-ECEA2A2EE5ED_2003_4">5000000</alny:PotentialMilestonePaymentsToBeReceived>
  <alny:PotentialMilestonePaymentsToBeReceived contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115253x1116460_1116223x1157030_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_53367E3A-E94F-4378-80EA-ECEA2A2EE5ED_3003_5">25000000</alny:PotentialMilestonePaymentsToBeReceived>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_7001_11">1210351000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_7001_10">1471000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_8E716DCB-988C-47A8-889E-301E62FF29DD_7001_9">33934000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <us-gaap:DeferredRevenue contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116223x1207741_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_5B28F172-CE2B-45B0-A14A-7B366D9AE511_4004_1">34000000</us-gaap:DeferredRevenue>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1004_2">42000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1004_4">146667000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1004_3">17000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1004_1">146642000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1003_2">207000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1003_4">703502000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1003_3">501000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1003_1">703796000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1005_2">30000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1005_4">81383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1005_3">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1005_1">81356000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116509x1105790" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1001_4">13799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116509x1105790" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1001_1">13799000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116509x1116395" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1002_4">31661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116509x1116395" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5BA0CEB3-6A7B-4E25-83B0-884D404F4694_1002_1">31661000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="eol_PE375375--1610-Q0004_STD_0_20160331_0_1251668x1317809" unitRef="pure" decimals="2" id="id_5871536_42CA090E-2A6F-4F47-8BCB-405C2EA5AFCB_1001_0">0.12</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:DeferredRevenue contextRef="eol_PE375375--1610-Q0004_STD_0_20131231_0_1116223x1207741_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_AE318811-2C7F-4345-A0CD-433583879EBD_1001_0">33500000</us-gaap:DeferredRevenue>
  <alny:PotentialMilestonePaymentsToBeReceived contextRef="eol_PE375375--1610-Q0004_STD_0_20140114_0_1115253x1107704_1116223x1212407_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_3001_6">5000000</alny:PotentialMilestonePaymentsToBeReceived>
  <alny:PotentialMilestonePaymentsToBeReceived contextRef="eol_PE375375--1610-Q0004_STD_0_20140114_0_1115253x1116460_1116223x1212407_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_4001_7">20000000</alny:PotentialMilestonePaymentsToBeReceived>
  <alny:RoyaltyRate contextRef="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1157030_1251668x1317809" unitRef="pure" decimals="2" id="id_5871536_53367E3A-E94F-4378-80EA-ECEA2A2EE5ED_4002_3">0.20</alny:RoyaltyRate>
  <alny:PotentialMilestonePaymentsToBeReceived contextRef="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1212407_1242844x1179976_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_5001_8">25000000</alny:PotentialMilestonePaymentsToBeReceived>
  <alny:RoyaltyRate contextRef="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1212407_1251668x1317809" unitRef="pure" decimals="2" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_6001_5">0.20</alny:RoyaltyRate>
  <alny:RoyaltyRate contextRef="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1234414_1251668x1317809" unitRef="pure" decimals="2" id="id_5871536_1D8C02C2-5E01-49C3-9B2C-34E2E545DD27_2001_4">0.20</alny:RoyaltyRate>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE375375--1610-Q0004_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2001_29">75179000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_0_20141231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1_6">49856000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="eol_PE375375--1610-Q0004_STD_0_20141231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1_1">82648000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
  <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome contextRef="eol_PE375375--1610-Q0004_STD_0_20141231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1_4">32792000</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20141231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1_2">94583000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <alny:CarryingValueInEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20141231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_3654D659-8B9E-478A-A527-42E70AF0B6B7_1_0">11935000</alny:CarryingValueInEquitySecurities>
  <alny:PercentageOfSharesAgreedToSell contextRef="eol_PE375375--1610-Q0004_STD_0_20141231_0_1115253x1116460_1156564x1260810_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1C1FEBEC-0C43-4FE5-B67E-65B2937AEEF2_5001_4">0.25</alny:PercentageOfSharesAgreedToSell>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_31">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_32">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_34">85090968</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_27">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_28">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_33">85090968</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_29">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_26">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_18">62099000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_20">52965000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_15">28798000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_22">121796000</us-gaap:Liabilities>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_16">1162000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_30">851000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_35">2506197000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1007_2">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_21">1301000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_17">15352000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_36">4369000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_23" />
  <us-gaap:PreferredStockValue contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_25" />
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_37">-1246703000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_19">5431000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_38">1264714000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_39">1386510000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_14">16787000</us-gaap:AccountsPayableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_9">27812000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_8">251839000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_7">1105388000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_4">51419000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_2">180895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1007_4">1100056000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:ReceivablesNetCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_5">8298000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:Assets contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_11">1386510000</us-gaap:Assets>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1007_3">2355000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_6">16559000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1007_1">1102379000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_10">1471000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_592BE932-A82E-4861-8802-46B7B24F2EB1_2_3">848217000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_1_5">6692000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_1_1">39484000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
  <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_1_4">32792000</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_1_2">51419000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <alny:CarryingValueInEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5F46AD8C-6629-4F4E-891B-76088F0EF348_1_0">11935000</alny:CarryingValueInEquitySecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1105790_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_1003_6">10498000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1105790_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_1001_6">10498000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1108237_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_2002_4">148612000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1108237_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_2001_4">148612000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1111781_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_3003_3">10000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1111781_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_3003_10">61396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1111781_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_3001_3">10000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1111781_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_3001_10">61396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1113789_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_4003_2">4843000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1113789_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_4003_8">904909000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1113789_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_4001_2">4843000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1113789_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_4001_8">904909000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1114216_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_5003_11">76143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1114216_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_5001_11">76143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1116395_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_6003_1">3998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1116395_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_6003_7">38110000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1116395_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_6001_1">3998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1116395_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_6001_7">38110000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1210074_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_7003_9">9000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1210074_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_7001_9">9000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_8002_14">201502000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_8002_13">1471000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1109902x1105250_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_8002_12">51419000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1109902x1110677_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_8003_14">1118897000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_8001_14">1320399000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_8001_13">1471000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1115400x1104862" unitRef="iso4217_USD" decimals="-3" id="id_5871536_A312E202-9FFC-4860-999A-7526C4727A09_8001_12">51419000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1005_2">24000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1005_4">61396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1005_3">91000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1005_1">61463000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1003_2">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1003_4">904909000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1003_3">2214000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1113789" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1003_1">907119000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1006_2">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1006_4">76143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1006_3">47000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1006_1">76186000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1210074" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1004_4">9000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1210074" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1004_1">9000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116509x1105790" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1001_4">10498000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116509x1105790" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1001_1">10498000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116509x1116395" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1002_4">38110000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116509x1116395" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1002_3">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116509x1116395" unitRef="iso4217_USD" decimals="-3" id="id_5871536_E7E7B93B-BE11-444D-9645-B62EA7931F06_1002_1">38113000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE375375--1610-Q0004_STD_1_20160201_0_1163455x1205894_1251668x1317809" unitRef="shares" decimals="INF" id="id_5871536_B2A8CFCB-312C-4703-A972-3E57F248980B_1002_0">205030</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE375375--1610-Q0004_STD_1_20160201_0_1163455x1205894_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_B2A8CFCB-312C-4703-A972-3E57F248980B_1002_1">14300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:PaymentsToAcquireLand contextRef="eol_PE375375--1610-Q0004_STD_1_20160404_0_1106880x1108681_1107576x1323477" unitRef="iso4217_USD" decimals="-5" id="id_5871536_958121E2-4467-42FE-BE1A-324AEC1194F1_1001_0">8000000</us-gaap:PaymentsToAcquireLand>
  <alny:CashCollateralRequiredForPrincipalAmountOutstandingPercentage contextRef="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1189687" unitRef="pure" decimals="INF" id="id_5871536_D478666D-A03B-4BF6-8217-EA41E51A6E68_1001_1">1.00</alny:CashCollateralRequiredForPrincipalAmountOutstandingPercentage>
  <alny:CashCollateralRequiredForPrincipalAmountOutstandingPercentage contextRef="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1194715" unitRef="pure" decimals="INF" id="id_5871536_D478666D-A03B-4BF6-8217-EA41E51A6E68_2001_0">1.00</alny:CashCollateralRequiredForPrincipalAmountOutstandingPercentage>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1115193x1106038_1117020x1189687" unitRef="pure" decimals="INF" id="id_5871536_0F0BDFF1-FD28-4543-A785-37D3B8BEAB7D_1001_5">0.0045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1115193x1106038_1117020x1194715" unitRef="pure" decimals="INF" id="id_5871536_0F0BDFF1-FD28-4543-A785-37D3B8BEAB7D_2001_2">0.0045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1117020x1189687" id="id_5871536_0F0BDFF1-FD28-4543-A785-37D3B8BEAB7D_3001_4">2021-04-29</us-gaap:LineOfCreditFacilityExpirationDate1>
  <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1117020x1194715" id="id_5871536_0F0BDFF1-FD28-4543-A785-37D3B8BEAB7D_4001_1">2021-04-29</us-gaap:LineOfCreditFacilityExpirationDate1>
  <alny:UpfrontFeeReceived contextRef="eol_PE375375--1610-Q0004_STD_1_20121031_0_1116223x1207741_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_287C6B11-2436-4EEE-BE4A-939455EB2324_3002_0">22500000</alny:UpfrontFeeReceived>
  <alny:LitigationDamagesSought contextRef="eol_PE375375--1610-Q0004_STD_1_20151014_0" unitRef="iso4217_USD" decimals="-5" id="id_5871536_033ABB98-AA2B-49D2-8D99-B2ADCCD2F1C6_1_0">8000000</alny:LitigationDamagesSought>
  <alny:MaximumNumberOfPotentialFutureMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1157030_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_53367E3A-E94F-4378-80EA-ECEA2A2EE5ED_1002_1">75000000</alny:MaximumNumberOfPotentialFutureMilestones>
  <alny:PercentageOfSharingInDevelopmentCost contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1157030_1251668x1317809" unitRef="pure" decimals="2" id="id_5871536_53367E3A-E94F-4378-80EA-ECEA2A2EE5ED_1002_0">0.50</alny:PercentageOfSharingInDevelopmentCost>
  <alny:FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1212407_1191697x1301396_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_1001_1">50000000</alny:FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones>
  <alny:MaximumNumberOfPotentialFutureMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1212407_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_2001_2">75000000</alny:MaximumNumberOfPotentialFutureMilestones>
  <alny:FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1212407_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_2001_4">20000000</alny:FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones>
  <alny:PercentageOfSharingInDevelopmentCost contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1212407_1251668x1317809" unitRef="pure" decimals="2" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_2001_0">0.20</alny:PercentageOfSharingInDevelopmentCost>
  <alny:FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1212407_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_21D5939D-1FF4-4BD4-AE07-064F8DE8D85C_2001_3">55000000</alny:FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones>
  <alny:MaximumNumberOfPotentialFutureMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1234414_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_1D8C02C2-5E01-49C3-9B2C-34E2E545DD27_1001_1">200000000</alny:MaximumNumberOfPotentialFutureMilestones>
  <alny:FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1234414_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_1D8C02C2-5E01-49C3-9B2C-34E2E545DD27_1001_3">140000000</alny:FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones>
  <alny:PercentageOfSharingInDevelopmentCost contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1234414_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1D8C02C2-5E01-49C3-9B2C-34E2E545DD27_1001_0">1.00</alny:PercentageOfSharingInDevelopmentCost>
  <alny:FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones contextRef="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1234414_1251668x1317809" unitRef="iso4217_USD" decimals="INF" id="id_5871536_1D8C02C2-5E01-49C3-9B2C-34E2E545DD27_1001_2">60000000</alny:FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE375375--1610-Q0004_STD_1_20150122_0_1163455x1205894_1251668x1317809" unitRef="shares" decimals="INF" id="id_5871536_B2A8CFCB-312C-4703-A972-3E57F248980B_1001_0">196251</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE375375--1610-Q0004_STD_1_20150122_0_1163455x1205894_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_B2A8CFCB-312C-4703-A972-3E57F248980B_1001_1">18300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <alny:StandstillOwnershipPercentageAmendRight contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1115253x1107704_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1B82C79B-1BD5-4C41-A699-27A9E8F796F0_1001_6">0.30</alny:StandstillOwnershipPercentageAmendRight>
  <alny:NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1116223x1157608_1251668x1317809" unitRef="Right" decimals="INF" id="id_5871536_8F6C90E5-0D3B-4BF7-A152-075A1C1FE150_1001_0">3</alny:NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" unitRef="shares" decimals="INF" id="id_5871536_1B82C79B-1BD5-4C41-A699-27A9E8F796F0_2001_0">8766338</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_1B82C79B-1BD5-4C41-A699-27A9E8F796F0_2001_1">700000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_0EA280CB-79AB-4D4E-AA9B-8A868F5704C8_1002_5">-15200000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
  <alny:MinimumStandstillOwnershipPercentageTerminate contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1B82C79B-1BD5-4C41-A699-27A9E8F796F0_2001_5">0.075</alny:MinimumStandstillOwnershipPercentageTerminate>
  <alny:ExcessOfFairValueOverCashReceivedForStockIssuance contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_0EA280CB-79AB-4D4E-AA9B-8A868F5704C8_1002_3">51500000</alny:ExcessOfFairValueOverCashReceivedForStockIssuance>
  <alny:PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" unitRef="pure" decimals="2" id="id_5871536_F66005E9-FD98-42AD-882E-10CEB8910FCE_1001_0">0.20</alny:PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors>
  <alny:FairValueOfCommonStockIssued contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_0EA280CB-79AB-4D4E-AA9B-8A868F5704C8_1002_2">751500000</alny:FairValueOfCommonStockIssued>
  <alny:LockUpPeriod contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809" id="id_5871536_1C1FEBEC-0C43-4FE5-B67E-65B2937AEEF2_3003_1">P6M</alny:LockUpPeriod>
  <alny:LockUpPeriod contextRef="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809_1273014x1275770" id="id_5871536_1C1FEBEC-0C43-4FE5-B67E-65B2937AEEF2_4003_0">P2Y</alny:LockUpPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE375375--1610-Q0004_STD_31_20150131_0" unitRef="shares" decimals="INF" id="id_5871536_48A12113-F83C-4615-ADBA-39CA12AE838A_1_0">5447368</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE375375--1610-Q0004_STD_31_20150131_0" unitRef="iso4217_USD" decimals="-5" id="id_5871536_48A12113-F83C-4615-ADBA-39CA12AE838A_1_2">496400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE375375--1610-Q0004_STD_31_20150131_0" unitRef="iso4217_USD" decimals="-5" id="id_5871536_48A12113-F83C-4615-ADBA-39CA12AE838A_1_3">21100000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE375375--1610-Q0004_STD_31_20150131_0_1163455x1267440_1251668x1317809" unitRef="shares" decimals="INF" id="id_5871536_535E78C4-336D-482D-A1DE-C12597BB5A74_1002_0">744566</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE375375--1610-Q0004_STD_31_20150131_0_1163455x1267440_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_535E78C4-336D-482D-A1DE-C12597BB5A74_1002_1">70700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE375375--1610-Q0004_STD_31_20140331_0_1251668x1317809" unitRef="shares" decimals="INF" id="id_5871536_535E78C4-336D-482D-A1DE-C12597BB5A74_1001_0">344448</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE375375--1610-Q0004_STD_31_20140331_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_535E78C4-336D-482D-A1DE-C12597BB5A74_1001_1">23000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <alny:CommonStockClosingPricePercentage contextRef="eol_PE375375--1610-Q0004_STD_365_20141231_0_1115253x1107704_1156564x1260810_1251668x1317809" unitRef="pure" decimals="INF" id="id_5871536_1C1FEBEC-0C43-4FE5-B67E-65B2937AEEF2_1001_2">1.00</alny:CommonStockClosingPricePercentage>
  <alny:NumberOfTrailingPeriodForAverageMarketPriceCalculation contextRef="eol_PE375375--1610-Q0004_STD_365_20141231_0_1156564x1260810_1251668x1317809" id="id_5871536_1C1FEBEC-0C43-4FE5-B67E-65B2937AEEF2_2001_3">P10D</alny:NumberOfTrailingPeriodForAverageMarketPriceCalculation>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE375375--1610-Q0004_STD_365_20151231_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_5B28F172-CE2B-45B0-A14A-7B366D9AE511_3003_3">33900000</us-gaap:ReimbursementRevenue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="shares" decimals="-3" id="id_5871536_2F8B653C-4C04-4EB4-87F0-F21A6D7D96CE_2_2">7805000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_14">-26255000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_13">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="shares" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_14">82074000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_18">507617000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_19">-47155000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_16">2110000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_5">-52222000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_9">-29830000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_10">-51208000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_0">18537000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_17">288000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InvestmentIncomeNet contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_7">1014000</us-gaap:InvestmentIncomeNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_9">1014000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_10">3179000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:NetIncomeLoss contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_1">-50777000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_17">3622000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_24">496400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_19">168687000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:OperatingExpenses contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_4">70759000</us-gaap:OperatingExpenses>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_27">598984000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_3">3690000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_12">-8432000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_23">13566000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_3">12724000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_13">-6189000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_25">89018000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_28">231401000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_5">247000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_7">-431000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_11">750000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_4">8236000</us-gaap:ShareBasedCompensation>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_2_21">-341328000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_2">58035000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_26EB85CC-017E-454B-AD3E-449C0D3CF8B8_2_2">5307000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_26EB85CC-017E-454B-AD3E-449C0D3CF8B8_2_1">5307000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_26EB85CC-017E-454B-AD3E-449C0D3CF8B8_2_6">2872000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_26EB85CC-017E-454B-AD3E-449C0D3CF8B8_2_4">431000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
  <alny:IncreaseDecreaseInAccruedIntraperiodTaxAllocation contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_26EB85CC-017E-454B-AD3E-449C0D3CF8B8_2_5">-2004000</alny:IncreaseDecreaseInAccruedIntraperiodTaxAllocation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1112578x1105469" unitRef="shares" decimals="-3" id="id_5871536_2F8B653C-4C04-4EB4-87F0-F21A6D7D96CE_1002_1">30000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1112578x1107650" unitRef="shares" decimals="-3" id="id_5871536_2F8B653C-4C04-4EB4-87F0-F21A6D7D96CE_2002_0">7775000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1113993x1105782" unitRef="iso4217_USD" decimals="-3" id="id_5871536_57121177-600B-4E20-9426-8892539BE13B_1002_1">2890000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1113993x1109593" unitRef="iso4217_USD" decimals="-3" id="id_5871536_57121177-600B-4E20-9426-8892539BE13B_2002_0">5346000</us-gaap:ShareBasedCompensation>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1136250" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_1002_3">5621000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1172541" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_2002_2">5493000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1174119" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_3002_1">1983000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1219135" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_4002_4">3623000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1317809" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_5002_0">1817000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:MarketableSecuritiesPolicy contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_56A30AFF-C24D-4D31-BBA1-E7B6211D4397_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Investments in Marketable Securities and Cash
 Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 We invest our excess cash balances in short-term and long-term
 marketable debt and equity securities. We classify our investments
 in marketable debt securities as either held-to-maturity or
 available-for-sale based on facts and circumstances present at the
 time we purchased the securities. At each balance sheet date
 presented, we classified all of our investments in debt and equity
 securities as available-for-sale. We report available-for-sale
 investments at fair value at each balance sheet date and include
 any unrealized holding gains and losses (the adjustment to fair
 value) in accumulated other comprehensive income (loss), a
 component of stockholders&amp;#x2019; equity. At March&amp;#xA0;31, 2016,
 the balance in our accumulated other comprehensive loss was
 composed solely of activity related to our available-for-sale
 marketable securities, including our investment in equity
 securities of Regulus Therapeutics Inc., or Regulus. Realized gains
 and losses are determined using the specific identification method
 and are included in other income (expense). We recognized $5.2
 million of realized gains from sales of our Regulus
 available-for-sale securities as other income on our condensed
 consolidated statements of comprehensive loss during the three
 months ended March&amp;#xA0;31, 2016. If any adjustment to fair value
 reflects a decline in the value of the investment, we consider all
 available evidence to evaluate the extent to which the decline is
 &amp;#x201C;other than temporary,&amp;#x201D; including our intention to sell
 and, if so, mark the investment to market through a charge to our
 condensed consolidated statements of comprehensive income (loss).
 We did not record any impairment charges related to our fixed
 income marketable securities during the three months ended
 March&amp;#xA0;31, 2016 or 2015. Our marketable securities are
 classified as cash equivalents if the original maturity, from the
 date of purchase, is 90&amp;#xA0;days or less, and as marketable
 securities if the original maturity, from the date of purchase, is
 in excess of 90&amp;#xA0;days. Our cash equivalents are composed of
 commercial paper, corporate notes, U.S. government-sponsored
 enterprise securities and money market funds.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 We account for our investment in Regulus as an available-for-sale
 marketable security.&amp;#xA0;Intraperiod tax allocation rules require
 us to allocate our provision for income taxes between continuing
 operations and other categories of earnings, such as other
 comprehensive income. In periods in which we have a year-to-date
 pre-tax loss from continuing operations and pre-tax income in other
 categories of earnings, such as other comprehensive income, we must
 allocate the tax provision to the other categories of earnings. We
 then record a related tax benefit in continuing operations. Upon
 sales of our available-for-sale marketable securities, we apply the
 aggregate portfolio approach to recognize the related tax provision
 or benefit into income (loss) from continuing operations. As a
 result, the disproportionate tax effect remains in accumulated
 other comprehensive income (loss) as long as we maintain an
 investment portfolio.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_959C6B9D-495C-4298-A487-C3DB1E733FDF_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The fair value is the price that would be received to sell an asset
 or paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. In general, fair
 values determined by Level&amp;#xA0;1 inputs utilize quoted prices
 (unadjusted) in active markets for identical assets or liabilities.
 Fair values determined by Level&amp;#xA0;2 inputs utilize data points
 that are observable, such as quoted prices (adjusted), interest
 rates and yield curves. Fair values determined by Level&amp;#xA0;3
 inputs utilize unobservable data points for the asset or liability,
 and include situations where there is little, if any, market
 activity for the asset or liability. The fair value hierarchy level
 is determined by the lowest level of significant input.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <dei:DocumentType contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_36ECB4A9-A628-4D2E-86F6-E1D5D7884FE7_1_0">10-Q</dei:DocumentType>
  <dei:TradingSymbol contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_29A7188E-9849-4A06-83E2-D9B2402DD54B_1_400000">ALNY</dei:TradingSymbol>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_B4A131C5-2A33-43C9-A51D-EC83CA4AAC8C_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables summarize our marketable securities, other
 than our holdings in Regulus noted above, at March&amp;#xA0;31, 2016
 and December&amp;#xA0;31, 2015, in thousands:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;At March&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,796&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;207&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(501&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,502&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,642&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,667&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,356&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,383&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,254&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(521&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,012&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;At December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,113&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,110&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;907,119&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,214&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;904,909&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Municipal debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,463&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(91&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,396&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,186&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,143&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,102,379&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,355&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,100,056&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_29A7188E-9849-4A06-83E2-D9B2402DD54B_1_400002">0001178670</dei:EntityCentralIndexKey>
  <dei:DocumentPeriodEndDate contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_36ECB4A9-A628-4D2E-86F6-E1D5D7884FE7_1_2">2016-03-31</dei:DocumentPeriodEndDate>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_16CF2636-1D65-44F6-A51E-CF731978FD49_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. MARKETABLE SECURITIES&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The following tables summarize the fair value, accumulated other
 comprehensive income (loss) and intraperiod tax allocation
 regarding our investment in Regulus available-for-sale marketable
 securities at March&amp;#xA0;31, 2016 and 2015, and for the activity
 recorded for the three months ended March&amp;#xA0;31, 2016 and 2015,
 in thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;At&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Sales&amp;#xA0;of&amp;#xA0;Regulus&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;During Three&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;All&amp;#xA0;Other&amp;#xA0;Activity&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;During Three&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Balance at&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Carrying value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,024&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,911&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,484&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,023&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investment in equity securities of Regulus, as reported&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,484&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,023&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Intraperiod tax allocation recorded as a benefit from income
 taxes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,792&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,792&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated other comprehensive income (loss), net of tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,769&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;At&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Sales&amp;#xA0;of&amp;#xA0;Regulus&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;During Three&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;All&amp;#xA0;Other&amp;#xA0;Activity&lt;br /&gt;
 During Three&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Balance at&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Carrying value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;82,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87,955&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investment in equity securities of Regulus, as reported&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94,583&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99,890&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;82,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87,955&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Intraperiod tax allocation recorded as a benefit from income
 taxes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,792&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(431&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Intraperiod tax allocation recorded as an accrued liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,004&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,004&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated other comprehensive income (loss), net of tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,872&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,728&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 We obtain fair value measurement data for our marketable securities
 from independent pricing services. We perform validation procedures
 to ensure the reasonableness of this data. This includes meeting
 with the independent pricing services to understand the methods and
 data sources used. Additionally, we perform our own review of
 prices received from the independent pricing services by comparing
 these prices to other sources and confirming those securities are
 trading in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following tables summarize our marketable securities, other
 than our holdings in Regulus noted above, at March&amp;#xA0;31, 2016
 and December&amp;#xA0;31, 2015, in thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;At March&amp;#xA0;31, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;207&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,642&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(521&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;At December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;907,119&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,214&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;904,909&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Municipal debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,102,379&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,100,056&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 We classify our debt security investments based on their
 contractual maturity dates. The following table summarizes our
 available-for-sale debt securities by contractual maturity, at
 March&amp;#xA0;31, 2016, in thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;At March&amp;#xA0;31, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less than one year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;748,722&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;748,422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Greater than one year but less than two years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;228,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;228,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <dei:EntityFilerCategory contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_29A7188E-9849-4A06-83E2-D9B2402DD54B_1_400004">Large Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="shares" decimals="-3" id="id_5871536_2F8B653C-4C04-4EB4-87F0-F21A6D7D96CE_1_2">10368000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_4D81EDC0-48E8-42A4-8A7D-680FC34B6E2B_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The accompanying condensed consolidated financial statements of
 Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared
 in accordance with accounting principles generally accepted in the
 United States of America, or GAAP, applicable to interim periods
 and, in the opinion of management, include all normal and recurring
 adjustments that are necessary to state fairly the results of
 operations for the reported periods. Our condensed consolidated
 financial statements have also been prepared on a basis
 substantially consistent with, and should be read in conjunction
 with, our audited consolidated financial statements for the year
 ended December&amp;#xA0;31, 2015, which were included in our Annual
 Report on Form 10-K that was filed with the Securities and Exchange
 Commission, or SEC, on February&amp;#xA0;12, 2016. The year-end
 condensed consolidated balance sheet data was derived from our
 audited financial statements, but does not include all disclosures
 required by GAAP. The results of our operations for any interim
 period are not necessarily indicative of the results of our
 operations for any other interim period or for a full fiscal
 year.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The accompanying condensed consolidated financial statements
 reflect the operations of Alnylam and our wholly-owned
 subsidiaries. All significant intercompany accounts and
 transactions have been eliminated.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_29A7188E-9849-4A06-83E2-D9B2402DD54B_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_B0D53164-8386-4B01-AA61-0A9B1EC003E7_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables summarize the fair value, accumulated other
 comprehensive income (loss) and intraperiod tax allocation
 regarding our investment in Regulus available-for-sale marketable
 securities at March&amp;#xA0;31, 2016 and 2015, and for the activity
 recorded for the three months ended March&amp;#xA0;31, 2016 and 2015,
 in thousands:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;At&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Sales&amp;#xA0;of&amp;#xA0;Regulus&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;During Three&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;All&amp;#xA0;Other&amp;#xA0;Activity&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;During Three&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Balance at&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Carrying value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,935&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,024&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,911&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,484&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,156&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,023&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Investment in equity securities of Regulus, as reported&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,419&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,180&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,934&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,484&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,156&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,023&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Intraperiod tax allocation recorded as a benefit from income
 taxes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,792&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,792&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated other comprehensive income (loss), net of tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,692&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,156&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,769&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;At&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Sales&amp;#xA0;of&amp;#xA0;Regulus&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;During Three&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;All&amp;#xA0;Other&amp;#xA0;Activity&lt;br /&gt;
 During Three&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Balance at&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Carrying value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,935&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,935&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;82,648&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,307&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87,955&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Investment in equity securities of Regulus, as reported&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94,583&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,307&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99,890&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated other comprehensive income (loss), before tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;82,648&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,307&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87,955&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Intraperiod tax allocation recorded as a benefit from income
 taxes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,792&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(431&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,223&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Intraperiod tax allocation recorded as an accrued liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,004&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,004&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated other comprehensive income (loss), net of tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,856&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,872&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,728&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_36ECB4A9-A628-4D2E-86F6-E1D5D7884FE7_1_4">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_ACF74D6F-D2BB-468E-9447-10A387425612_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 We compute basic net loss per common share by dividing net loss by
 the weighted-average number of common shares outstanding. We
 compute diluted net loss per common share by dividing net loss by
 the weighted-average number of common shares and dilutive potential
 common share equivalents then outstanding. Potential common shares
 consist of shares issuable upon the exercise of stock options
 (using the treasury stock method), and unvested restricted stock
 awards. Because the inclusion of potential common shares would be
 anti-dilutive for all periods presented, diluted net loss per
 common share is the same as basic net loss per common share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would be anti-dilutive, in
 thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;At March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,805&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_DFDEB407-759D-4D73-805A-D3CF9C25B776_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;3. FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The following tables present information about our assets that are
 measured at fair value on a recurring basis at March&amp;#xA0;31, 2016
 and December&amp;#xA0;31, 2015, and indicate the fair value hierarchy
 of the valuation techniques we utilized to determine such fair
 value, in thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;At&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Markets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,199&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,199&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (fixed income):&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (Regulus equity holdings)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash (money market funds)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,210,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;229,140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;981,211&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;At&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Markets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (fixed income):&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;904,909&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;904,909&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Municipal debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (Regulus equity holdings)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash (money market funds)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,320,399&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;201,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,118,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 During the three months ended March&amp;#xA0;31, 2016, there were no
 transfers between Level 1 and Level 2 financial assets. The
 carrying amounts reflected in our condensed consolidated balance
 sheets for cash, billed and unbilled collaboration receivables,
 other current assets, accounts payable and accrued expenses
 approximate fair value due to their short-term maturities.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_5E214DF7-8CCF-429A-A6C1-3B86263E136F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 In May 2014, the Financial Accounting Standards Board, or FASB,
 issued a new revenue recognition standard which amends revenue
 recognition principles and provides a single, comprehensive set of
 criteria for revenue recognition within and across all industries.
 The new standard provides a five step framework whereby revenue is
 recognized when promised goods or services are transferred to a
 customer at an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The standard also requires enhanced disclosures
 pertaining to revenue recognition in both interim and annual
 periods. In August 2015, the FASB deferred the effective date of
 the new revenue standard from January&amp;#xA0;1, 2017 to
 January&amp;#xA0;1, 2018. In March 2016, the FASB issued amendments to
 clarify the implementation guidance on principal versus agent
 considerations. In April 2016, the FASB issued amendments to
 clarify the guidance on accounting for licenses of intellectual
 property and identifying performance obligations. Early adoption is
 permitted any time after the original effective date, which for us
 is January&amp;#xA0;1, 2017. The standard allows for adoption using a
 full retrospective method or a modified retrospective method. We
 are currently evaluating the timing, method of adoption and the
 expected impact that the standard could have on our condensed
 consolidated financial statements and related disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 In January 2016, the FASB issued new guidance on recognition and
 measurement of financial assets and financial liabilities. The new
 guidance will impact the accounting for equity investments,
 financial liabilities under the fair value option, and the
 presentation and disclosure requirements for financial instruments.
 All equity investments in unconsolidated entities (other than those
 accounted for under the equity method of accounting) will generally
 be measured at fair value with changes in fair value recognized
 through earnings. There will no longer be an available-for-sale
 classification (changes in fair value reported in other
 comprehensive income (loss)) for equity securities with readily
 determinable fair values. In addition, the FASB clarified the need
 for a valuation allowance on deferred tax assets resulting from
 unrealized losses on available-for-sale debt securities. In
 general, the new guidance will require modified retrospective
 application to all outstanding instruments, with a cumulative
 effect adjustment recorded to opening retained earnings. This
 guidance will be effective for us on January&amp;#xA0;1, 2018. We are
 currently evaluating the expected impact that the standard could
 have on our condensed consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 In February 2016, the FASB issued a new leasing standard that
 requires that all lessees recognize the assets and liabilities that
 arise from leases on the condensed consolidated balance sheet and
 disclose qualitative and quantitative information about its leasing
 arrangements. The new standard will be effective for us on
 January&amp;#xA0;1, 2019. Early adoption is permitted. We are currently
 evaluating the expected impact that this standard may have on our
 condensed consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 In March 2016, the FASB issued guidance that will update the
 accounting for certain aspects of share-based payments to
 employees, including the income tax consequences, classification of
 awards as either equity or liabilities and classification on the
 condensed consolidated statement of cash flows. The new standard
 will be effective for us on January&amp;#xA0;1, 2017. Early adoption is
 permitted. We are currently evaluating the expected impact that
 this standard may have on our condensed consolidated financial
 statements and related disclosures.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_2610DD63-0B13-4414-8469-D7B0C5E7CF72_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes our total consolidated net revenues
 from collaborators, for the periods indicated, in thousands:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Sanofi Genzyme&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,415&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,817&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 The Medicines Company&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,657&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,983&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Takeda&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,493&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Monsanto&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,621&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;273&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,623&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total net revenues from collaborators&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,345&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,537&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_0A5AE212-80B1-4C54-B49B-FFB3F33FBAC4_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2. SIGNIFICANT AGREEMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes our total consolidated net revenues
 from collaborators, for the periods indicated, in thousands:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Sanofi Genzyme&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,415&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,817&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 The Medicines Company&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,657&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,983&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Takeda&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,493&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Monsanto&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,621&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;273&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,623&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total net revenues from collaborators&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,345&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,537&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Product Alliances&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Sanofi Genzyme Collaboration&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2014, we entered into a global, strategic collaboration
 with Sanofi Genzyme, the specialty care global business unit of
 Sanofi, or Sanofi Genzyme, to discover, develop and commercialize
 RNAi therapeutics as Genetic Medicines to treat orphan diseases.
 The 2014 Sanofi Genzyme collaboration superseded and replaced the
 previous collaboration between us and Sanofi Genzyme entered into
 in October 2012 to develop and commercialize RNAi therapeutics
 targeting transthyretin, or TTR, for the treatment of TTR-mediated
 amyloidosis, or ATTR amyloidosis, including patisiran and
 revusiran, in Japan and the Asia-Pacific region.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2012 Sanofi Genzyme Agreement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the 2012 Sanofi Genzyme agreement, Sanofi Genzyme paid us an
 upfront cash payment of $22.5 million. We were also entitled to
 receive certain milestone payments under the 2012 Sanofi Genzyme
 agreement. In the fourth quarter of 2013, we earned a milestone of
 $7.0 million based upon the completion of a successful patisiran
 Phase 2 clinical trial and a milestone of $4.0 million based upon
 the initiation of the Phase 3 clinical trial for patisiran.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the 2012 Sanofi Genzyme agreement, the parties agreed to
 collaborate in the development and commercialization of licensed
 products, with Sanofi Genzyme assuming primary responsibility in
 the Sanofi Genzyme territory, which included Japan and the
 Asia-Pacific region, and us retaining primary responsibility in the
 rest of the world.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;We
 determined that the deliverables under the 2012 Sanofi Genzyme
 agreement included the license, a joint steering committee and any
 additional TTR-specific RNAi therapeutic compounds that comprised
 the ALN-TTR program. We also determined that, pursuant to the
 accounting guidance governing revenue recognition on multiple
 element arrangements, the license and undelivered joint steering
 committee and any additional TTR-specific RNAi therapeutic
 compounds did not have standalone value due to the specialized
 nature of the services to be provided by us. In addition, while
 Sanofi Genzyme had the ability to grant sublicenses, it could not
 sublicense all or substantially all of its rights under the 2012
 Sanofi Genzyme agreement. The uniqueness of our services and the
 limited sublicense right were indicators that standalone value was
 not present in the arrangement. Therefore the deliverables were not
 separable and, accordingly, the license and undelivered services
 were treated as a single unit of accounting. We were unable to
 reasonably estimate the period of performance under the 2012 Sanofi
 Genzyme agreement, as we were unable to estimate the timeline of
 our deliverables related to the deliverable for any additional
 TTR-specific RNAi therapeutic compounds. Through December&amp;#xA0;31,
 2013, we had deferred all revenue, or $33.5 million, under the 2012
 Sanofi Genzyme agreement.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2014 Sanofi Genzyme Collaboration&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2014, we entered into the 2014 Sanofi Genzyme
 collaboration. As noted above, the 2014 Sanofi Genzyme
 collaboration superseded and replaced the 2012 Sanofi Genzyme
 agreement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The 2014 Sanofi Genzyme collaboration is structured as an exclusive
 relationship for the worldwide development and commercialization of
 RNAi therapeutics in the field of Genetic Medicines, which includes
 our current and future Genetic Medicine programs that reach Human
 Proof-of-Principle Study Completion (as defined in the Sanofi
 Genzyme master agreement), or Human POP, by the end of 2019,
 subject to extension to the end of 2021 in various circumstances.
 We will retain product rights in North America and Western Europe,
 referred to as the Alnylam Territory, while Sanofi Genzyme will
 obtain exclusive rights to develop and commercialize collaboration
 products in the rest of the world, referred to as the Sanofi
 Genzyme Territory, together with certain broader
 co-development/co-promote or worldwide rights for certain products.
 Sanofi Genzyme&amp;#x2019;s rights, described in detail below, are
 structured as an opt-in that is triggered upon achievement of Human
 POP. We maintain development control for all programs prior to
 Sanofi Genzyme&amp;#x2019;s opt-in and maintain development and
 commercialization control after Sanofi Genzyme&amp;#x2019;s opt-in for
 all programs in the Alnylam Territory.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Specifically, in addition to its regional rights for our current
 and future Genetic Medicine programs in the Sanofi Genzyme
 Territory, Sanofi Genzyme has the right to either
 (i)&amp;#xA0;co-develop and co-promote fitusiran for the treatment of
 hemophilia and other rare bleeding disorders in the Alnylam
 Territory, with us maintaining development and commercialization
 control, or (ii)&amp;#xA0;obtain a global license to ALN-AS1 for the
 treatment of hepatic porphyrias. Sanofi Genzyme may exercise this
 selection right upon the completion of Human POP for both the
 fitusiran and ALN-AS1 programs. Finally, Sanofi Genzyme has the
 right for a global license to a single, future Genetic Medicine
 program that was not one of our defined Genetic Medicine programs
 as of the effective date of the 2014 Sanofi Genzyme collaboration.
 We will retain global rights to any RNAi therapeutic Genetic
 Medicine program that does not reach Human POP by the end of 2019,
 subject to certain limited exceptions. We retain full rights to all
 current and future RNAi therapeutic programs outside of the field
 of Genetic Medicines, including the right to form new
 collaborations.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the 2014 Sanofi Genzyme collaboration, Sanofi Genzyme&amp;#x2019;s
 specific license rights and the programs into which Sanofi Genzyme
 has opted include the following:&lt;/p&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="9%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="3%" valign="top" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;Regional license terms and programs
 &amp;#x2014; Upon opt-in, we will retain product rights in the Alnylam
 Territory, while Sanofi Genzyme will obtain exclusive rights to
 develop and commercialize the product in the Sanofi Genzyme
 Territory. Sanofi Genzyme can elect this license for any of our
 current and future Genetic Medicine programs that complete Human
 POP by the end of 2019, subject to limited extension. Development
 costs for products once Sanofi Genzyme exercises an option will be
 shared between Sanofi Genzyme and us, with Sanofi Genzyme
 responsible for twenty percent of the global development costs.
 Upon the effective date of the 2014 Sanofi Genzyme collaboration,
 Sanofi Genzyme expanded the scope of its regional license and
 collaboration for patisiran, an investigational RNAi therapeutic
 currently in a Phase 3 clinical trial, which was originally
 established under the 2012 Sanofi Genzyme agreement. In September
 2015, Sanofi Genzyme elected to opt into our fitusiran clinical
 development program for the treatment of hemophilia and other rare
 bleeding disorders under the regional license terms. As described
 above, Sanofi Genzyme retains its future opt-in right to co-develop
 and co-promote fitusiran in the Alnylam Territory pursuant to the
 co-development/co-promote license terms described below.
 Cost-sharing for the fitusiran program began in January 2016.
 Sanofi Genzyme will be required to make payments totaling up to
 $50.0 million upon the achievement of certain patisiran development
 milestones. We could potentially earn the next patisiran milestone
 payment, ranging between $5.0 million and $20.0 million based on
 the geographic region, upon the achievement of specified events in
 connection with a regulatory filing or approval. In addition,
 Sanofi Genzyme will be required to make payments totaling up to
 $75.0 million per product other than patisiran, including
 fitusiran, consisting of up to $55.0 million in development
 milestones and $20.0 million in commercial milestones. We could
 potentially earn the first fitusiran milestone payment of $25.0
 million based upon the initiation of the first global Phase 3
 clinical trial for fitusiran. Sanofi Genzyme will also be required
 to pay tiered double-digit royalties up to twenty percent for each
 regional product based on annual net sales, if any, of such
 regional product by Sanofi Genzyme, its affiliates and
 sublicensees.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="9%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="3%" valign="top" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"&gt;
 Co-development/co-promote license terms and programs &amp;#x2014; Upon
 opt-in, we will retain product rights in the Alnylam Territory,
 while Sanofi Genzyme will obtain exclusive rights to develop and
 commercialize the product in the Sanofi Genzyme Territory, and will
 co-promote the product in the Alnylam Territory. Upon the effective
 date of the 2014 Sanofi Genzyme collaboration, Sanofi Genzyme
 expanded its regional rights for revusiran, an investigational RNAi
 therapeutic currently in a Phase 3 clinical trial, which were
 originally granted under the 2012 Sanofi Genzyme agreement, to
 include a co-development/co-promote license and collaboration. As
 noted above, Sanofi Genzyme also has the right to elect a
 co-development/co-promote license and collaboration for fitusiran,
 if it does not elect a global license and collaboration for
 ALN-AS1. Development costs for co-development/co-promote products,
 once Sanofi Genzyme exercises an option, will be shared between
 Sanofi Genzyme and us, with Sanofi Genzyme responsible for fifty
 percent of the global development costs. Sanofi Genzyme will be
 required to make payments totaling up to $75.0 million in
 development milestones for revusiran and, if selected, fitusiran.
 In December 2014, we earned a development milestone payment of
 $25.0 million based upon the initiation of the first global Phase 3
 clinical trial for revusiran. We could potentially earn the next
 revusiran milestone payment, ranging between $5.0 million and $25.0
 million based on the geographic region, upon the achievement of
 specified events in connection with regulatory approval. Sanofi
 Genzyme will also be required to pay tiered double-digit royalties
 up to twenty percent for each co-development/co-promote product
 based on annual net sales, if any, in the Sanofi Genzyme Territory
 for such co-development/co-promote product by Sanofi Genzyme, its
 affiliates and sublicensees. The parties will share profits equally
 and we expect to book product sales in the Alnylam Territory.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="9%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td width="3%" valign="top" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;Global license terms and programs
 &amp;#x2014; Upon opt-in, Sanofi Genzyme will obtain a worldwide license
 to develop and commercialize the product. Sanofi Genzyme can elect
 a global license for ALN-AS1, if it does not elect a
 co-development/co-promote license for fitusiran, as described
 above. Sanofi Genzyme will also have one right to a global license
 through 2019, subject to limited extension, for a future Genetic
 Medicine program that was not one of our defined Genetic Medicine
 programs as of the effective date of the 2014 Sanofi Genzyme
 collaboration. Sanofi Genzyme shall be responsible for one hundred
 percent of global development costs. Sanofi Genzyme will be
 required to make payments totaling up to $200.0 million per global
 product, including up to $60.0 million in development milestones
 and $140.0 million in commercial milestones. Sanofi Genzyme will
 also be required to pay tiered double-digit royalties up to twenty
 percent for each global product based on annual net sales, if any,
 of each global product by Sanofi Genzyme, its affiliates and
 sublicensees.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Due to the uncertainty of pharmaceutical development and the high
 historical failure rates generally associated with drug
 development, we may not receive any additional milestone payments
 or any royalty payments from Sanofi Genzyme under the 2014 Sanofi
 Genzyme collaboration.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the master agreement, the parties will collaborate in the
 development of option products, with us leading development for all
 programs prior to Sanofi Genzyme&amp;#x2019;s opt-in and also leading
 development and commercialization for all programs in the Alnylam
 Territory after Sanofi Genzyme&amp;#x2019;s opt-in. If Sanofi Genzyme
 does not exercise its option to license rights to a particular
 program, we will retain the exclusive right to develop and
 commercialize such program throughout the world, including the
 right to sublicense to third parties.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The 2014 Sanofi Genzyme collaboration is governed by an alliance
 joint steering committee that is comprised of an equal number of
 representatives from each party. There are additional committees to
 manage various aspects of each regional, co-developed/co-promoted
 and global program. We and Sanofi Genzyme intend to enter into
 supply agreements to provide for supply of collaboration products
 to Sanofi Genzyme for clinical studies, and, at Sanofi
 Genzyme&amp;#x2019;s request, commercial sales. Sanofi Genzyme also has
 certain rights to manufacture collaboration products. Additionally,
 Sanofi Genzyme has certain limited opt-out rights, as specified in
 the master agreement, upon which products revert fully back to us
 with no further obligations to Sanofi Genzyme.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The master agreement (including the license terms appended thereto)
 contains certain termination provisions, including for material
 breach by the other party. Unless terminated earlier pursuant to
 its terms, the master agreement will terminate upon the last to
 expire of any of the option periods under the master agreement or
 the license terms appended thereto.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Upon the closing of the equity transaction in February 2014, we
 sold to Sanofi Genzyme 8,766,338 shares of our common stock and
 Sanofi Genzyme paid $700.0 million in aggregate cash consideration
 to us. As a condition to the closing of the equity transaction,
 Sanofi Genzyme entered into an investor agreement with us. Under
 the investor agreement, until the earlier of the fifth anniversary
 of the expiration or earlier termination of the 2014 Sanofi Genzyme
 collaboration and the date on which Sanofi Genzyme and its
 affiliates cease to beneficially own at least 5% of our outstanding
 common stock, Sanofi Genzyme and its affiliates are bound by
 certain &amp;#x201C;standstill&amp;#x201D; provisions. The standstill
 provisions include agreements not to acquire more than 30% of our
 outstanding common stock, call stockholder meetings, nominate
 directors other than those approved by our board of directors,
 subject to certain limited exceptions, or propose or support a
 proposal to acquire us. Further, Sanofi Genzyme has agreed to vote,
 and cause its affiliates to vote, all shares of our voting
 securities they are entitled to vote, up to a maximum of 20% of our
 outstanding common stock, in a manner either as recommended by our
 board of directors or proportionally with the votes cast by our
 other stockholders, except with respect to certain change of
 control transactions or our liquidation or dissolution. Until
 Sanofi Genzyme owns less than 7.5% of our outstanding common stock,
 subject to Sanofi Genzyme&amp;#x2019;s limited right to maintain its
 ownership percentage as described below, if we issue common stock
 or securities convertible into or exercisable for common stock to a
 third party that holds at least 30% of our outstanding common stock
 or, in connection with a collaboration or license transaction, to a
 third party that will initially hold at least the percentage of our
 outstanding common stock represented by the shares purchased by
 Sanofi Genzyme at the closing of the equity transaction, we will
 offer Sanofi Genzyme an opportunity to amend the standstill and
 voting provisions in the investor agreement to be consistent with
 the terms provided to such third party.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the investor agreement, Sanofi Genzyme has also agreed not to
 dispose of any shares of common stock beneficially owned by it
 immediately after the closing of the stock purchase until the
 earlier of (i)&amp;#xA0;December&amp;#xA0;31, 2019 (subject to extension by
 up to two years if Sanofi Genzyme&amp;#x2019;s option to select
 additional compounds under the master agreement is extended beyond
 December&amp;#xA0;31, 2019) and (ii)&amp;#xA0;six months after the
 expiration or earlier valid termination of the collaboration, in
 each case subject to earlier termination in the event certain
 clinical activities under the collaboration fail to occur.
 Following the expiration of this lock-up period, Sanofi Genzyme
 will be permitted to sell such shares of common stock subject to
 certain limitations, including volume and manner of sale
 restrictions. Notwithstanding the foregoing, following the two-year
 anniversary of the closing of the stock purchase, in the event that
 the market price per share of our common stock is at least 100%
 higher than the market price per share of our common stock at
 closing of the stock purchase (in each case based upon a ten-day
 trailing average), Sanofi Genzyme may sell up to 25% of its initial
 shares, subject to certain restrictions on post-lock-up period
 dispositions as described above.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the investor agreement, following the lock-up period, Sanofi
 Genzyme will have three demand rights to require us to conduct a
 registered underwritten public offering with respect to the shares
 of common stock beneficially owned by Sanofi Genzyme immediately
 after the closing of the stock purchase, subject to certain
 conditions. In addition, following the lock-up period, subject to
 certain conditions, Sanofi Genzyme will be entitled to participate
 in registered underwritten public offerings by us if other selling
 stockholders are included in the registration.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The investor agreement provides that, until Sanofi Genzyme owns
 less than 7.5% of our outstanding common stock, subject to Sanofi
 Genzyme&amp;#x2019;s limited right to maintain its ownership percentage
 as described herein, in connection with new issuances of common
 stock, subject to certain exceptions, Sanofi Genzyme will be
 entitled to a right of first offer to participate proportionally to
 maintain its then-current ownership percentage of our common stock.
 If Sanofi Genzyme is not entitled to a right of first offer with
 respect to a new issuance, Sanofi Genzyme will have the
 opportunity, on a post-transaction basis, to purchase additional
 shares sufficient to maintain its pre-transaction ownership
 percentage of our common stock (subject to the same 7.5% ownership
 threshold).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Finally, in the event Sanofi Genzyme and its affiliates acquire at
 least 20% or more of our outstanding common stock, Sanofi Genzyme
 will be entitled to appoint one individual to our board of
 directors. Sanofi Genzyme will also be entitled to certain
 information rights, including with respect to financial information
 in the event Sanofi Genzyme or its affiliates require such
 information for its own financial reporting purposes. The rights
 and restrictions under the investor agreement are subject to
 termination upon the occurrence of certain events.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 We recorded the issuance of 8,766,338 shares of our common stock
 under the stock purchase agreement using the price of our common
 stock on the date the shares were issued to Sanofi Genzyme. Based
 on the common stock price of $85.72, the fair value of the shares
 issued was $751.5 million, which was $51.5 million in excess of the
 proceeds received from Sanofi Genzyme for the issuance of our
 common stock. This $51.5 million is being amortized on a
 straight-line basis over the performance period, which is currently
 approximately six years as described below. In addition, due to
 intraperiod tax allocation rules, upon closing of the equity
 transaction we recorded a benefit from income taxes of $15.2
 million due to the Sanofi Genzyme equity purchase being recorded in
 additional paid-in capital, net of tax.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 In accordance with the investor agreement, as a result of our
 issuance of shares in connection with our acquisition of Sirna
 Therapeutics, Inc., in March 2014, Sanofi Genzyme exercised its
 right to purchase an additional 344,448 shares of our common stock
 for $23.0 million. In addition, in January 2015, in connection with
 our public offering, Sanofi Genzyme exercised its right to purchase
 directly from us, in concurrent private placements, 744,566 shares
 of common stock at the public offering price resulting in $70.7
 million in proceeds to us. The sales of common stock to Sanofi
 Genzyme were not registered as part of the public offering, though
 they were consummated simultaneously with the public offering.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 Sanofi Genzyme also has the right at the beginning of each year to
 purchase a number of shares of our common stock based on the number
 of shares we issued during the previous year for
 compensation-related purposes. Sanofi Genzyme exercised this right
 to purchase directly from us 196,251 shares of our common stock on
 January&amp;#xA0;22, 2015 for $18.3 million and 205,030 shares of our
 common stock on February&amp;#xA0;1, 2016 for $14.3 million. The sales
 of these shares to Sanofi Genzyme were consummated as private
 placements.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 In each instance, the purchase by Sanofi Genzyme described above
 allowed Sanofi Genzyme to maintain its ownership level of our
 common stock of approximately 12%.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;We
 determined that the deliverables for the programs on which Sanofi
 Genzyme was collaborating with us upon initiation of the 2014
 collaboration included the licenses to our patisiran and revusiran
 clinical programs, which licenses were delivered to Sanofi Genzyme
 upon the closing date of the transaction, and the associated
 development activities, joint steering committee participation and
 information exchange for these clinical programs. We also
 determined that, pursuant to the accounting guidance governing
 revenue recognition on multiple element arrangements, the license
 and associated undelivered development activities, joint steering
 committee participation and information exchange activities did not
 have standalone value due to the specialized nature of the services
 to be provided by us. In addition, while Sanofi Genzyme has the
 ability to grant sublicenses, it cannot sublicense all or
 substantially all of its rights under the 2014 Sanofi Genzyme
 collaboration. The uniqueness of our services and the limited
 sublicense rights are indicators that standalone value is not
 present in the arrangement. Therefore the deliverables are not
 separable and, accordingly, the license and undelivered services
 were treated as a single unit of accounting. When multiple
 deliverables are accounted for as a single unit of accounting, we
 base our revenue recognition model on the final deliverable. Under
 the 2014 Sanofi Genzyme collaboration, the last deliverables for
 patisiran and revusiran are expected to be completed within
 approximately six years from the closing date of the transaction
 and the last deliverables for fitusiran are expected to be
 completed within approximately five years from the date Sanofi
 Genzyme elected to opt into our fitusiran clinical development
 program under the regional license terms. We determined that the
 total cash received from Sanofi Genzyme under the now superseded
 2012 Sanofi Genzyme agreement reflects consideration for certain of
 the performance obligations for ALN-TTR programs included in the
 2014 Sanofi Genzyme collaboration. Therefore we are recognizing the
 $33.5 million of deferred revenue under the 2012 Sanofi Genzyme
 agreement on a straight-line basis over the period of performance
 of the ALN-TTR programs, which, as noted above, is currently
 approximately six years. In addition, during the fourth quarter of
 2014, we recognized as revenue a portion of the $25.0 million
 milestone payment earned in December 2014 equal to the percentage
 of the performance period completed when the milestone was earned.
 During the year ended December&amp;#xA0;31, 2015, we also recognized as
 revenue a portion of the expense reimbursement of $33.9 million due
 to us under the terms of the 2014 Sanofi Genzyme collaboration
 equal to the percentage of the performance period completed to
 date. During the three months ended March&amp;#xA0;31, 2016, we also
 recognized as revenue a portion of the expense reimbursement of
 $8.8 million due to us under the terms of the 2014 Sanofi Genzyme
 collaboration equal to the percentage of the performance period
 completed to date. As future consideration is achieved, including
 any milestones or reimbursement for development activities, we will
 recognize as revenue a portion of these payments equal to the
 percentage of the performance period completed when the milestone
 or activities have been satisfied, multiplied by the amount of the
 payment. We will recognize the remaining portion of consideration
 received over the remaining performance period on a straight-line
 basis. At March&amp;#xA0;31, 2016, deferred revenue under the 2014
 Sanofi Genzyme collaboration was $34.0 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 We determined that the opt-in rights that Sanofi Genzyme has for
 future Genetic Medicine programs represent separate and additional
 deliverables that Sanofi Genzyme may receive from us in future
 periods. Upon each opt-in by Sanofi Genzyme, we have determined
 that each program and the related activities will represent a
 single unit of accounting and, consistent with our accounting
 policies, we will base our revenue recognition period on the final
 deliverable associated with each future opt-in.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_14">-83623000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_ABF3237E-D266-416E-9C19-FB3A1FE59B39_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following table summarizes our available-for-sale debt
 securities by contractual maturity, at March&amp;#xA0;31, 2016, in
 thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;At March&amp;#xA0;31, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less than one year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;748,722&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;748,422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Greater than one year but less than two years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;228,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;228,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;977,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_36ECB4A9-A628-4D2E-86F6-E1D5D7884FE7_1_1">false</dei:AmendmentFlag>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_13">-1.21</us-gaap:EarningsPerShareBasicAndDiluted>
  <dei:EntityRegistrantName contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_29A7188E-9849-4A06-83E2-D9B2402DD54B_1_400001">ALNYLAM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_EC8643F9-1E30-4628-A7B6-B350D6E86D9C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 The accompanying condensed consolidated financial statements of
 Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared
 in accordance with accounting principles generally accepted in the
 United States of America, or GAAP, applicable to interim periods
 and, in the opinion of management, include all normal and recurring
 adjustments that are necessary to state fairly the results of
 operations for the reported periods. Our condensed consolidated
 financial statements have also been prepared on a basis
 substantially consistent with, and should be read in conjunction
 with, our audited consolidated financial statements for the year
 ended December&amp;#xA0;31, 2015, which were included in our Annual
 Report on Form 10-K that was filed with the Securities and Exchange
 Commission, or SEC, on February&amp;#xA0;12, 2016. The year-end
 condensed consolidated balance sheet data was derived from our
 audited financial statements, but does not include all disclosures
 required by GAAP. The results of our operations for any interim
 period are not necessarily indicative of the results of our
 operations for any other interim period or for a full fiscal
 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 The accompanying condensed consolidated financial statements
 reflect the operations of Alnylam and our wholly-owned
 subsidiaries. All significant intercompany accounts and
 transactions have been eliminated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and the disclosure
 of contingent assets and liabilities at the date of the condensed
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 We compute basic net loss per common share by dividing net loss by
 the weighted-average number of common shares outstanding. We
 compute diluted net loss per common share by dividing net loss by
 the weighted-average number of common shares and dilutive potential
 common share equivalents then outstanding. Potential common shares
 consist of shares issuable upon the exercise of stock options
 (using the treasury stock method), and unvested restricted stock
 awards. Because the inclusion of potential common shares would be
 anti-dilutive for all periods presented, diluted net loss per
 common share is the same as basic net loss per common share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would be anti-dilutive, in
 thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;At March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,805&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 13%; -webkit-text-stroke-width: 0px"&gt;
 In January 2015, we sold an aggregate of 5,447,368 shares of our
 common stock through an underwritten public offering at a price to
 the public of $95.00 per share. As a result of the offering, which
 included the full exercise of the underwriters&amp;#x2019; option to
 purchase additional shares, we received aggregate net proceeds of
 $496.4 million, after deducting underwriting discounts and
 commissions and other offering expenses of $21.1 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 The fair value is the price that would be received to sell an asset
 or paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. In general, fair
 values determined by Level&amp;#xA0;1 inputs utilize quoted prices
 (unadjusted) in active markets for identical assets or liabilities.
 Fair values determined by Level&amp;#xA0;2 inputs utilize data points
 that are observable, such as quoted prices (adjusted), interest
 rates and yield curves. Fair values determined by Level&amp;#xA0;3
 inputs utilize unobservable data points for the asset or liability,
 and include situations where there is little, if any, market
 activity for the asset or liability. The fair value hierarchy level
 is determined by the lowest level of significant input.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Investments in Marketable Securities and Cash
 Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 We invest our excess cash balances in short-term and long-term
 marketable debt and equity securities. We classify our investments
 in marketable debt securities as either held-to-maturity or
 available-for-sale based on facts and circumstances present at the
 time we purchased the securities. At each balance sheet date
 presented, we classified all of our investments in debt and equity
 securities as available-for-sale. We report available-for-sale
 investments at fair value at each balance sheet date and include
 any unrealized holding gains and losses (the adjustment to fair
 value) in accumulated other comprehensive income (loss), a
 component of stockholders&amp;#x2019; equity. At March&amp;#xA0;31, 2016,
 the balance in our accumulated other comprehensive loss was
 composed solely of activity related to our available-for-sale
 marketable securities, including our investment in equity
 securities of Regulus Therapeutics Inc., or Regulus. Realized gains
 and losses are determined using the specific identification method
 and are included in other income (expense). We recognized $5.2
 million of realized gains from sales of our Regulus
 available-for-sale securities as other income on our condensed
 consolidated statements of comprehensive loss during the three
 months ended March&amp;#xA0;31, 2016. If any adjustment to fair value
 reflects a decline in the value of the investment, we consider all
 available evidence to evaluate the extent to which the decline is
 &amp;#x201C;other than temporary,&amp;#x201D; including our intention to sell
 and, if so, mark the investment to market through a charge to our
 condensed consolidated statements of comprehensive income (loss).
 We did not record any impairment charges related to our fixed
 income marketable securities during the three months ended
 March&amp;#xA0;31, 2016 or 2015. Our marketable securities are
 classified as cash equivalents if the original maturity, from the
 date of purchase, is 90&amp;#xA0;days or less, and as marketable
 securities if the original maturity, from the date of purchase, is
 in excess of 90&amp;#xA0;days. Our cash equivalents are composed of
 commercial paper, corporate notes, U.S. government-sponsored
 enterprise securities and money market funds.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 We account for our investment in Regulus as an available-for-sale
 marketable security.&amp;#xA0;Intraperiod tax allocation rules require
 us to allocate our provision for income taxes between continuing
 operations and other categories of earnings, such as other
 comprehensive income. In periods in which we have a year-to-date
 pre-tax loss from continuing operations and pre-tax income in other
 categories of earnings, such as other comprehensive income, we must
 allocate the tax provision to the other categories of earnings. We
 then record a related tax benefit in continuing operations. Upon
 sales of our available-for-sale marketable securities, we apply the
 aggregate portfolio approach to recognize the related tax provision
 or benefit into income (loss) from continuing operations. As a
 result, the disproportionate tax effect remains in accumulated
 other comprehensive income (loss) as long as we maintain an
 investment portfolio.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 We did not have any material recognized subsequent events. However,
 we did have the following nonrecognized subsequent events, which
 are more fully described in Note 5:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;On April&amp;#xA0;4, 2016, we completed
 our purchase of land in Norton, Massachusetts for the construction
 of our new drug substance manufacturing facility.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;On April&amp;#xA0;29, 2016, we and
 Alnylam U.S., Inc., our wholly-owned subsidiary, entered into
 credit agreements with Bank of America N.A., or BOA, and Wells
 Fargo Bank, National Association, or Wells, related to the build
 out of our new drug substance manufacturing facility.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the Financial Accounting Standards Board, or FASB,
 issued a new revenue recognition standard which amends revenue
 recognition principles and provides a single, comprehensive set of
 criteria for revenue recognition within and across all industries.
 The new standard provides a five step framework whereby revenue is
 recognized when promised goods or services are transferred to a
 customer at an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The standard also requires enhanced disclosures
 pertaining to revenue recognition in both interim and annual
 periods. In August 2015, the FASB deferred the effective date of
 the new revenue standard from January&amp;#xA0;1, 2017 to
 January&amp;#xA0;1, 2018. In March 2016, the FASB issued amendments to
 clarify the implementation guidance on principal versus agent
 considerations. In April 2016, the FASB issued amendments to
 clarify the guidance on accounting for licenses of intellectual
 property and identifying performance obligations. Early adoption is
 permitted any time after the original effective date, which for us
 is January&amp;#xA0;1, 2017. The standard allows for adoption using a
 full retrospective method or a modified retrospective method. We
 are currently evaluating the timing, method of adoption and the
 expected impact that the standard could have on our condensed
 consolidated financial statements and related disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 In January 2016, the FASB issued new guidance on recognition and
 measurement of financial assets and financial liabilities. The new
 guidance will impact the accounting for equity investments,
 financial liabilities under the fair value option, and the
 presentation and disclosure requirements for financial instruments.
 All equity investments in unconsolidated entities (other than those
 accounted for under the equity method of accounting) will generally
 be measured at fair value with changes in fair value recognized
 through earnings. There will no longer be an available-for-sale
 classification (changes in fair value reported in other
 comprehensive income (loss)) for equity securities with readily
 determinable fair values. In addition, the FASB clarified the need
 for a valuation allowance on deferred tax assets resulting from
 unrealized losses on available-for-sale debt securities. In
 general, the new guidance will require modified retrospective
 application to all outstanding instruments, with a cumulative
 effect adjustment recorded to opening retained earnings. This
 guidance will be effective for us on January&amp;#xA0;1, 2018. We are
 currently evaluating the expected impact that the standard could
 have on our condensed consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 In February 2016, the FASB issued a new leasing standard that
 requires that all lessees recognize the assets and liabilities that
 arise from leases on the condensed consolidated balance sheet and
 disclose qualitative and quantitative information about its leasing
 arrangements. The new standard will be effective for us on
 January&amp;#xA0;1, 2019. Early adoption is permitted. We are currently
 evaluating the expected impact that this standard may have on our
 condensed consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 In March 2016, the FASB issued guidance that will update the
 accounting for certain aspects of share-based payments to
 employees, including the income tax consequences, classification of
 awards as either equity or liabilities and classification on the
 condensed consolidated statement of cash flows. The new standard
 will be effective for us on January&amp;#xA0;1, 2017. Early adoption is
 permitted. We are currently evaluating the expected impact that
 this standard may have on our condensed consolidated financial
 statements and related disclosures.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_1DBE1B5B-891B-4898-A947-D7C91E1BA33B_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and the disclosure
 of contingent assets and liabilities at the date of the condensed
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="shares" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_14">85277000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_CD3E60A6-B38E-4021-BB39-582718EC5CC7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 The following tables present information about our assets that are
 measured at fair value on a recurring basis at March&amp;#xA0;31, 2016
 and December&amp;#xA0;31, 2015, and indicate the fair value hierarchy
 of the valuation techniques we utilized to determine such fair
 value, in thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;At&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Markets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,199&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,199&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (fixed income):&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,661&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (Regulus equity holdings)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash (money market funds)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,210,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;229,140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;981,211&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;At&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Markets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (fixed income):&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;904,909&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;904,909&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Municipal debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. government-sponsored enterprise securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76,143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Marketable securities (Regulus equity holdings)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash (money market funds)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,320,399&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;201,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,118,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_36ECB4A9-A628-4D2E-86F6-E1D5D7884FE7_1_3">2016</dei:DocumentFiscalYearFocus>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_C9BC8050-99A3-4D2C-82AC-575E15BB1F49_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;5. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Manufacturing Facility&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 13%"&gt;
 On February&amp;#xA0;10, 2016, we entered into an agreement with 20
 Commerce LLC to purchase 12 acres of undeveloped land in Norton,
 Massachusetts for approximately $8.0 million in cash payable for
 the land and related acquisition costs. We completed the purchase
 and closed this transaction on April&amp;#xA0;4, 2016. We intend to
 construct a manufacturing facility at this site for drug substance,
 including siRNAs and siRNA conjugates, for clinical and commercial
 use. As of March&amp;#xA0;31, 2016, the cash payable for the land and
 related acquisition costs was put in escrow and recorded in prepaid
 expenses and other current assets on our condensed consolidated
 balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Credit Facility&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 13%"&gt;
 On April&amp;#xA0;29, 2016, we entered into (i) a Credit Agreement, or
 the BOA Credit Agreement, with Alnylam U.S., Inc., as the borrower,
 us, as a guarantor, and BOA, as the lender and (ii)&amp;#xA0;a Credit
 Agreement, or the Wells Credit Agreement, together with the BOA
 Credit Agreement, the Credit Agreements, by and among Alnylam U.S.,
 Inc., as the borrower, us, as a guarantor, and Wells, as the
 lender. The Credit Agreements were entered into in connection with
 the planned build out of our new drug substance manufacturing
 facility.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%"&gt;
 The BOA Credit Agreement provides for a $120 million term loan
 facility, and matures on April&amp;#xA0;29, 2021. The Wells Credit
 Agreement provides for a $30 million term loan facility, and
 matures on April&amp;#xA0;29, 2021. The proceeds of the borrowing under
 each of the BOA Credit Agreement and the Wells Credit Agreement are
 to be used for working capital and general corporate purposes.
 Interest on borrowings under the Credit Agreements will be
 calculated based on LIBOR plus 0.45 percent, except in the event of
 default. The borrower may prepay loans under each of the BOA Credit
 Agreement and the Wells Credit Agreement at any time, without
 premium or penalty, subject to certain notice requirements and
 LIBOR breakage costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%"&gt;
 The obligations of the borrower under each Credit Agreement are
 guaranteed by us. The obligations of Alnylam U.S., Inc. and us
 under each Credit Agreement are secured by cash collateral in an
 amount equal to, at any given time, at least 100% of the principal
 amount of all term loans outstanding under such Credit Agreement at
 such time. Each of the lenders and the borrower have agreed to
 consider the appropriateness of a change in the type of approved
 collateral on a periodic basis throughout the term of the Credit
 Agreements; provided that any such change to the type of such
 approved collateral shall be made only upon each of the
 lender&amp;#x2019;s and the borrower&amp;#x2019;s consent.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%"&gt;
 Each Credit Agreement contains limited representations and
 warranties and limited affirmative and negative covenants. Each
 Credit Agreement also contains certain customary events of default,
 including nonpayment of principal or interest, material inaccuracy
 of representations, failure to comply with covenants,
 cross-defaults to certain other indebtedness, invalidity of any
 loan document relating to such Credit Agreement, judgments having a
 material adverse effect, insolvency events and change of control.
 If an event of default occurs and is continuing under either Credit
 Agreement, the entire outstanding balance under such Credit
 Agreement may become immediately due and payable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%"&gt;
 Several of the lenders under each of the Credit Agreements, as well
 as their affiliates, have various relationships with us and our
 subsidiaries involving the provision of financial services, such as
 investment banking, commercial banking, advisory, cash management,
 custody and corporate credit card services for which they receive
 customary fees and may do so in the future.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;University of Utah Litigation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 On March&amp;#xA0;22, 2011, The University of Utah, or Utah, filed a
 civil complaint in the United States District Court for the
 District of Massachusetts, or the MA District Court, against us,
 Max Planck Gesellschaft Zur Foerderung Der Wissenschaften e.V. and
 Max Planck Innovation GmbH, the Whitehead Institute for Biomedical
 Research, the Massachusetts Institute of Technology and the
 University of Massachusetts, claiming a professor at Utah is the
 sole inventor or, in the alternative, a joint inventor, of the
 Tuschl patents. Utah was seeking changes to the inventorship of the
 Tuschl patents, unspecified damages and other relief. After several
 years of court proceedings and discovery, on September&amp;#xA0;28,
 2015, the MA District Court granted both of our motions for summary
 judgment, finding that there was no collaboration between
 Dr.&amp;#xA0;Bass and Dr.&amp;#xA0;Tuschl, which is a pre-requisite for
 co-inventorship, and dismissing Utah&amp;#x2019;s state law damages
 claims as well. On October&amp;#xA0;28, 2015, Utah filed a notice of
 appeal to the United States Court of Appeals for the Federal
 Circuit, or the CAFC. On December&amp;#xA0;18, 2015, the CAFC entered
 an order dismissing Utah&amp;#x2019;s appeal following a joint motion
 filed by us and Utah seeking dismissal of the appeal with
 prejudice. This disposed of Utah&amp;#x2019;s inventorship claims and
 its state law claims for damages.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On October&amp;#xA0;14, 2015, we filed a motion with the MA District
 Court seeking reimbursement of costs and fees associated with
 defending this action in the amount of approximately $8.0 million.
 On November&amp;#xA0;30, 2015, the MA District Court denied our motion
 and on December&amp;#xA0;15, 2015, we filed a notice of appeal of this
 ruling with the CAFC. On February&amp;#xA0;16, 2016, we filed our
 appeal brief with the CAFC. Utah filed a response on April&amp;#xA0;11,
 2016 and our reply is due May&amp;#xA0;9, 2016. While we believe a fee
 award is merited in this case, such awards are not customary and
 are made at the discretion of the court. We anticipate a ruling on
 our appeal by the end of the third quarter of 2016, however, the
 timing will be determined by the CAFC.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;i&gt;Dicerna Litigation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 On June&amp;#xA0;10, 2015, we filed a trade secret misappropriation
 lawsuit against Dicerna Pharmaceuticals, Inc., or Dicerna, in the
 Superior Court of Middlesex County, Massachusetts, seeking to stop
 misappropriation by Dicerna of our confidential, proprietary and
 trade secret information related to the RNAi assets we purchased
 from Merck Sharp &amp;amp; Dohme Corp., including certain GalNAc
 conjugate technology. In addition to permanent injunctive relief,
 we are also seeking monetary damages from Dicerna. On July&amp;#xA0;10,
 2015, Dicerna filed its answer to our complaint, in which it denied
 our claims, along with initial discovery requests, to which we
 responded in a timely fashion. On July&amp;#xA0;27, 2015, Dicerna filed
 a motion seeking removal of the case to the Business Litigation
 Session of the Superior Court of Suffolk County, which we opposed.
 On August&amp;#xA0;31, 2015, the Court denied Dicerna&amp;#x2019;s motion.
 We and Dicerna agreed to a protective order, which was entered by
 the Court on November&amp;#xA0;12, 2015. Discovery is ongoing and we
 expect discovery to close September&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 Although we believe we have meritorious claims in this matter,
 litigation is subject to inherent uncertainty and a court could
 ultimately rule against us. In addition, litigation and related
 matters are costly and may divert the attention of our management
 and other resources that would otherwise be engaged in other
 activities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 Our accounting policy for accrual of legal costs is to recognize
 such expenses as incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_DFEAF154-6C9A-498B-BC95-462A0C529D26_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would be anti-dilutive, in
 thousands:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;At March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,805&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_D1DB1119-03A6-4579-8EEF-ACCC88D35929_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"&gt;
 We did not have any material recognized subsequent events. However,
 we did have the following nonrecognized subsequent events, which
 are more fully described in Note 5:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;On April&amp;#xA0;4, 2016, we completed
 our purchase of land in Norton, Massachusetts for the construction
 of our new drug substance manufacturing facility.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;On April&amp;#xA0;29, 2016, we and
 Alnylam U.S., Inc., our wholly-owned subsidiary, entered into
 credit agreements with Bank of America N.A., or BOA, and Wells
 Fargo Bank, National Association, or Wells, related to the build
 out of our new drug substance manufacturing facility.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_18">164561000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_6">5156000</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_19">-116354000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_16">2759000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_8">5241000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_5">-110028000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_9">516000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_10">-102974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_0">7345000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:InvestmentIncomeNet contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_7">1813000</us-gaap:InvestmentIncomeNet>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_26">59000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_9">7054000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:PaymentsForCapitalImprovements contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_20">9057000</us-gaap:PaymentsForCapitalImprovements>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_10">2010000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:NetIncomeLoss contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_1">-102974000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_17">-8224000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_19">294317000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:OperatingExpenses contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_4">117373000</us-gaap:OperatingExpenses>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_27">16066000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_18">5156000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_3">4601000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_12">-4305000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_23">1824000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_3">21100000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_13">2579000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_25">14301000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_28">50383000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_5">331000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_11">347000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_4">23480000</us-gaap:ShareBasedCompensation>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_5FDB4A78-43CA-42E1-8F33-C70CB7B6EFF3_1_21">117940000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_2">96273000</us-gaap:ResearchAndDevelopmentExpense>
  <alny:InvestmentMaturityPeriodMinimum contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_D30AC497-C10B-4D84-9177-B46AE02486C2_1_2">P90D</alny:InvestmentMaturityPeriodMinimum>
  <alny:PublicOfferingsOfCommonStockPolicyPolicyTextBlock contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_6D8EE37E-5012-4BF0-A351-4F4A17A48DD4_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2015, we sold an aggregate of 5,447,368 shares of our
 common stock through an underwritten public offering at a price to
 the public of $95.00 per share. As a result of the offering, which
 included the full exercise of the underwriters&amp;#x2019; option to
 purchase additional shares, we received aggregate net proceeds of
 $496.4 million, after deducting underwriting discounts and
 commissions and other offering expenses of $21.1 million.&lt;/p&gt;
 &lt;/div&gt;</alny:PublicOfferingsOfCommonStockPolicyPolicyTextBlock>
  <alny:InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0" id="id_5871536_D30AC497-C10B-4D84-9177-B46AE02486C2_1_1">P90D</alny:InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400" unitRef="iso4217_USD" decimals="-3" id="id_5871536_D30AC497-C10B-4D84-9177-B46AE02486C2_1001_0">5156000</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308524" unitRef="iso4217_USD" decimals="-3" id="id_5871536_0CDBED1B-5279-45FF-B1AD-B7BD6BDA5DC3_1_2">-7180000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308524" unitRef="iso4217_USD" decimals="-3" id="id_5871536_0CDBED1B-5279-45FF-B1AD-B7BD6BDA5DC3_1_1">-5156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308524" unitRef="iso4217_USD" decimals="-3" id="id_5871536_0CDBED1B-5279-45FF-B1AD-B7BD6BDA5DC3_1_5">-5156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <alny:ChangeInCarryingValueOfEquitySecurities contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308524" unitRef="iso4217_USD" decimals="-3" id="id_5871536_0CDBED1B-5279-45FF-B1AD-B7BD6BDA5DC3_1_0">-2024000</alny:ChangeInCarryingValueOfEquitySecurities>
  <us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_0CDBED1B-5279-45FF-B1AD-B7BD6BDA5DC3_2_2">-10305000</us-gaap:AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_0CDBED1B-5279-45FF-B1AD-B7BD6BDA5DC3_2_1">-10305000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308525" unitRef="iso4217_USD" decimals="-3" id="id_5871536_0CDBED1B-5279-45FF-B1AD-B7BD6BDA5DC3_2_5">-10305000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <alny:PerformancePeriod contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1109648x1526904_1116223x1207741_1251668x1317809" id="id_5871536_5B28F172-CE2B-45B0-A14A-7B366D9AE511_1004_4">P5Y</alny:PerformancePeriod>
  <alny:PerformancePeriod contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1109648x1526991_1116223x1207741_1251668x1317809" id="id_5871536_5B28F172-CE2B-45B0-A14A-7B366D9AE511_2004_0">P6Y</alny:PerformancePeriod>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1112578x1105469" unitRef="shares" decimals="-3" id="id_5871536_2F8B653C-4C04-4EB4-87F0-F21A6D7D96CE_1001_1">185000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1112578x1107650" unitRef="shares" decimals="-3" id="id_5871536_2F8B653C-4C04-4EB4-87F0-F21A6D7D96CE_2001_0">10183000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1113993x1105782" unitRef="iso4217_USD" decimals="-3" id="id_5871536_57121177-600B-4E20-9426-8892539BE13B_1001_1">9124000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1113993x1109593" unitRef="iso4217_USD" decimals="-3" id="id_5871536_57121177-600B-4E20-9426-8892539BE13B_2001_0">14356000</us-gaap:ShareBasedCompensation>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1116223x1174119" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_3001_1">2657000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1116223x1219135" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_4001_4">273000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1116223x1317809" unitRef="iso4217_USD" decimals="-3" id="id_5871536_60E07DA6-33DF-49F2-8FE7-803BBEBD25E0_5001_0">4415000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE375375--1610-Q0004_STD_91_20160331_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_5B28F172-CE2B-45B0-A14A-7B366D9AE511_3004_3">8800000</us-gaap:ReimbursementRevenue>
  <alny:MilestonePaymentEarned contextRef="eol_PE375375--1610-Q0004_STD_92_20131231_0_1116223x1207741_1242844x1179976_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_287C6B11-2436-4EEE-BE4A-939455EB2324_1001_2">4000000</alny:MilestonePaymentEarned>
  <alny:MilestonePaymentEarned contextRef="eol_PE375375--1610-Q0004_STD_92_20131231_0_1116223x1207741_1242844x1245967_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_287C6B11-2436-4EEE-BE4A-939455EB2324_2001_1">7000000</alny:MilestonePaymentEarned>
  <alny:MilestonePaymentEarned contextRef="eol_PE375375--1610-Q0004_STD_92_20141231_0_1251668x1317809" unitRef="iso4217_USD" decimals="-5" id="id_5871536_5B28F172-CE2B-45B0-A14A-7B366D9AE511_3002_2">25000000</alny:MilestonePaymentEarned>
  <context id="eol_PE375375--1610-Q0004_STD_92_20141231_0_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_92_20131231_0_1116223x1207741_1242844x1245967_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:RequirementOfEligibleFutureMilestonePaymentsAxis">alny:PhaseTwoClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_92_20131231_0_1116223x1207741_1242844x1179976_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:RequirementOfEligibleFutureMilestonePaymentsAxis">alny:PhaseThreeClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1116223x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1116223x1219135">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1116223x1174119">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:MdcoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1113993x1109593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1113993x1105782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1112578x1107650">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1112578x1105469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1109648x1526991_1116223x1207741_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">alny:PatisiranAndRevusiranMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1109648x1526904_1116223x1207741_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">alny:FitusiranMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308525">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">alny:AllOtherActivityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400_1116388x1308524">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">alny:SalesOfRegulusSharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0_1107059x1280400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_91_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1219135">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1174119">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:MdcoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1172541">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:TakedaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1116223x1136250">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:MonsantoCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1113993x1109593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1113993x1105782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1112578x1107650">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1112578x1105469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0_1107059x1280400_1116388x1308525">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">alny:AllOtherActivityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_365_20151231_0_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_365_20141231_0_1156564x1260810_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:AgreementsAxis">alny:SecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_365_20141231_0_1115253x1107704_1156564x1260810_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:AgreementsAxis">alny:SecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_31_20140331_0_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-03-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_31_20150131_0_1163455x1267440_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:SaleOfStockAxis">alny:ConcurrentPrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_31_20150131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809_1273014x1275770">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:PeriodAxis">alny:ExtensionOfTermMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_28_20140228_0_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_28_20140228_0_1116223x1157608_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:InvestorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_28_20140228_0_1115253x1107704_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20150122_0_1163455x1205894_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:SaleOfStockAxis">alny:CompensatoryPurposesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-22</startDate>
      <endDate>2015-01-22</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1234414_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-14</startDate>
      <endDate>2014-01-14</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1212407_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:RegionalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-14</startDate>
      <endDate>2014-01-14</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1212407_1191697x1301396_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:AgreementTypeAxis">alny:PatisiranMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:RegionalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-14</startDate>
      <endDate>2014-01-14</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20140114_0_1116223x1157030_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CoDevelopedOrCoPromotedCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-14</startDate>
      <endDate>2014-01-14</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20151014_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2015-10-14</startDate>
      <endDate>2015-10-14</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20121031_0_1116223x1207741_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-31</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1117020x1194715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:BankOfAmericaNALineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-29</startDate>
      <endDate>2016-04-29</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1117020x1189687">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-29</startDate>
      <endDate>2016-04-29</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1115193x1106038_1117020x1194715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:BankOfAmericaNALineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-29</startDate>
      <endDate>2016-04-29</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1287013_1115193x1106038_1117020x1189687">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-29</startDate>
      <endDate>2016-04-29</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1194715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:BankOfAmericaNALineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-29</startDate>
      <endDate>2016-04-29</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160429_0_1106880x1108681_1107053x1189687">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-29</startDate>
      <endDate>2016-04-29</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160404_0_1106880x1108681_1107576x1323477">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-04</startDate>
      <endDate>2016-04-04</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_1_20160201_0_1163455x1205894_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:SaleOfStockAxis">alny:CompensatoryPurposesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-01</endDate>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116509x1116395">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116509x1105790">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1210074">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">alny:MunicipalDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1114216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1113789">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1116388x1111781">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1109902x1105250_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1210074_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alny:MunicipalDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1210074_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alny:MunicipalDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1116395_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1116395_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1114216_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1114216_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1113789_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1113789_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1111781_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1111781_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1108237_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1108237_1109902x1105250_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1105790_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107455x1105790_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0_1107059x1280400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20141231_0_1115253x1116460_1156564x1260810_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:AgreementsAxis">alny:SecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20141231_0_1107059x1280400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1234414_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-14</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1212407_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:RegionalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-14</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1212407_1242844x1179976_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:RequirementOfEligibleFutureMilestonePaymentsAxis">alny:PhaseThreeClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:RegionalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-14</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140114_0_1116223x1157030_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CoDevelopedOrCoPromotedCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-14</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140114_0_1115253x1116460_1116223x1212407_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:RegionalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-14</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140114_0_1115253x1107704_1116223x1212407_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:RegionalCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-14</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20131231_0_1116223x1207741_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116509x1116395">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116509x1105790">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1114216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1113789">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116388x1111781">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1116223x1207741_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115253x1116460_1116223x1157030_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CoDevelopedOrCoPromotedCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1115253x1107704_1116223x1157030_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CoDevelopedOrCoPromotedCollaborationProductMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1109902x1105250_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1116395_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1116395_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1114216_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1114216_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1113789_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1113789_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1111781_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1111781_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1108237_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1108237_1109902x1105250_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1105790_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107455x1105790_1109902x1110677_1115400x1104862">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0_1107059x1280400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20150331_0_1107059x1280400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="invest:InvestmentAxis">alny:RegulusTherapeuticsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160429_0_1106880x1108681_1107053x1287013_1117020x1194715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:BankOfAmericaNALineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-04-29</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160429_0_1106880x1108681_1107053x1287013_1117020x1189687">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-04-29</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160429_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2016-04-29</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20160404_0_1106880x1108681_1107576x1323477">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-04-04</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20150131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140228_0_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140228_0_1115253x1116460_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE375375--1610-Q0004_STD_0_20140228_0_1115253x1107704_1251668x1317809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
      <segment><xbrldi:explicitMember dimension="alny:CollaboratorAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="acre">
    <measure>utr:acre</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Right">
    <measure>alny:Right</measure>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_2" xlink:label="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_3" xlink:label="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_2" xlink:label="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_3" xlink:label="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_3" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_434965361" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation expenses included in operating expenses are as follows:                 Research and development     $ 14,356      $ 5,346        General and administrative       9,124        2,890</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_2" xlink:to="footnote_434965361" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_1_3" xlink:to="footnote_434965361" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_2" xlink:to="footnote_434965361" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_5871536_232BFF66-A1B6-4600-8C1F-248DB84FAE58_2_3" xlink:to="footnote_434965361" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>alny-20160331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 5 -->
<!-- Creation date: 2016-05-04T17:43:12Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31"
  xmlns:us-types="http://fasb.org/us-types/2015-01-31"
  xmlns:alny="http://www.alnylam.com/20160331"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.alnylam.com/20160331"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical" id="Role_StatementOfIncomeParen">
        <link:definition>106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>109 - Disclosure - SIGNIFICANT AGREEMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock">
        <link:definition>110 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <link:definition>111 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>112 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>113 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>114 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
        <link:definition>115 - Disclosure - SIGNIFICANT AGREEMENTS (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
        <link:definition>116 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
        <link:definition>117 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare" id="DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare">
        <link:definition>118 - Disclosure - Potential Common Shares Common Shares Excluded from Calculation of Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>119 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators" id="DisclosureRevenueFromCollaborators">
        <link:definition>120 - Disclosure - Revenue from Collaborators (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation" id="DisclosureSignificantAgreementsAdditionalInformation">
        <link:definition>121 - Disclosure - Significant Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis" id="DisclosureFairValueMeasuredOnRecurringBasis">
        <link:definition>122 - Disclosure - Fair Value Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities" id="DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities">
        <link:definition>123 - Disclosure - Summary of Fair Value Accumulated Other Comprehensive Income (Loss) and Intraperiod Tax Allocation in Available-for-Sale Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities" id="DisclosureSummaryOfCompanysMarketableSecurities">
        <link:definition>124 - Disclosure - Summary of Company's Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity" id="DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity">
        <link:definition>125 - Disclosure - Summary of Available-For-Sale Debt Securities by Contractual Maturity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>126 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="alny-20160331_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="alny-20160331_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="alny-20160331_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="alny-20160331_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedIntraperiodTaxAllocation" id="alny_AccruedIntraperiodTaxAllocation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementsAxis" id="alny_AgreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="AgreementsDomain" id="alny_AgreementsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementTypeAxis" id="alny_AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="AgreementTypeDomain" id="alny_AgreementTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AllOtherActivityMember" id="alny_AllOtherActivityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BankOfAmericaNALineOfCreditMember" id="alny_BankOfAmericaNALineOfCreditMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CarryingValueInEquitySecurities" id="alny_CarryingValueInEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashCollateralRequiredForPrincipalAmountOutstandingPercentage" id="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangeInCarryingValueOfEquitySecurities" id="alny_ChangeInCarryingValueOfEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CoDevelopedOrCoPromotedCollaborationProductMember" id="alny_CoDevelopedOrCoPromotedCollaborationProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaboratorAxis" id="alny_CollaboratorAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="CollaboratorDomain" id="alny_CollaboratorDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesLineItems" id="alny_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesTable" id="alny_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CommonStockClosingPricePercentage" id="alny_CommonStockClosingPricePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CompensatoryPurposesMember" id="alny_CompensatoryPurposesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConcurrentPrivatePlacementMember" id="alny_ConcurrentPrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="alny_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExcessOfFairValueOverCashReceivedForStockIssuance" id="alny_ExcessOfFairValueOverCashReceivedForStockIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExtensionOfTermMember" id="alny_ExtensionOfTermMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfCommonStockIssued" id="alny_FairValueOfCommonStockIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FitusiranMember" id="alny_FitusiranMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" id="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" id="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GlobalCollaborationProductMember" id="alny_GlobalCollaborationProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInAccruedIntraperiodTaxAllocation" id="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestmentMaturityPeriodMinimum" id="alny_InvestmentMaturityPeriodMinimum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" id="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestorsMember" id="alny_InvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationDamagesSought" id="alny_LitigationDamagesSought" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LockUpPeriod" id="alny_LockUpPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumNumberOfPotentialFutureMilestones" id="alny_MaximumNumberOfPotentialFutureMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumPercentageOfVotingPerCompanyRecommendation" id="alny_MaximumPercentageOfVotingPerCompanyRecommendation" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MdcoMember" id="alny_MdcoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePaymentEarned" id="alny_MilestonePaymentEarned" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumStandstillOwnershipPercentageTerminate" id="alny_MinimumStandstillOwnershipPercentageTerminate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MonsantoCompanyMember" id="alny_MonsantoCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MunicipalDebtSecuritiesMember" id="alny_MunicipalDebtSecuritiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NortonMassachusettsMember" id="alny_NortonMassachusettsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" id="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfTrailingPeriodForAverageMarketPriceCalculation" id="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherCollaborationsMember" id="alny_OtherCollaborationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatisiranAndRevusiranMember" id="alny_PatisiranAndRevusiranMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatisiranMember" id="alny_PatisiranMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" id="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSharesAgreedToSell" id="alny_PercentageOfSharesAgreedToSell" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSharingInDevelopmentCost" id="alny_PercentageOfSharingInDevelopmentCost" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PerformancePeriod" id="alny_PerformancePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodAxis" id="alny_PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="PeriodDomain" id="alny_PeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PhaseThreeClinicalTrialMember" id="alny_PhaseThreeClinicalTrialMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PhaseTwoClinicalTrialMember" id="alny_PhaseTwoClinicalTrialMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMilestonePaymentsToBeReceived" id="alny_PotentialMilestonePaymentsToBeReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProductAlliancesMember" id="alny_ProductAlliancesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PublicOfferingsOfCommonStockPolicyPolicyTextBlock" id="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegionalCollaborationProductMember" id="alny_RegionalCollaborationProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulusTherapeuticsIncMember" id="alny_RegulusTherapeuticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RequirementOfEligibleFutureMilestonePaymentsAxis" id="alny_RequirementOfEligibleFutureMilestonePaymentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="RequirementOfEligibleFutureMilestonePaymentsDomain" id="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyRate" id="alny_RoyaltyRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SaleOfStockAxis" id="alny_SaleOfStockAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="SaleOfStockDomain" id="alny_SaleOfStockDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesOfRegulusSharesMember" id="alny_SalesOfRegulusSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SanofiGenzymeMember" id="alny_SanofiGenzymeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondAnniversaryMember" id="alny_SecondAnniversaryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAccountingPoliciesLineItems" id="alny_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAccountingPoliciesTable" id="alny_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="StandstillOwnershipPercentageAmendRight" id="alny_StandstillOwnershipPercentageAmendRight" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StandstillRangeOfOutstandingCommonStockAcquiredPercentage" id="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TakedaMember" id="alny_TakedaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TermLoanFacilityMember" id="alny_TermLoanFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontFeeReceived" id="alny_UpfrontFeeReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WellsFargoCreditFacilityMember" id="alny_WellsFargoCreditFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>alny-20160331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 5 -->
<!-- Creation date: 2016-05-04T17:43:12Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DocumentandEntityInformation" roleURI="http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfIncome" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfIncomeParen" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare" roleURI="http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureRevenueFromCollaborators" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSignificantAgreementsAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureFairValueMeasuredOnRecurringBasis" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfCompanysMarketableSecurities" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="us-gaap_PaymentsForCapitalImprovements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForCapitalImprovements" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ChangeInCarryingValueOfEquitySecurities" xlink:label="alny_ChangeInCarryingValueOfEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" xlink:label="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:to="alny_ChangeInCarryingValueOfEquitySecurities" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>alny-20160331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 5 -->
<!-- Creation date: 2016-05-04T17:43:12Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DocumentandEntityInformation" roleURI="http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfIncome" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfIncomeParen" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare" roleURI="http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureRevenueFromCollaborators" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSignificantAgreementsAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureFairValueMeasuredOnRecurringBasis" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfCompanysMarketableSecurities" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="us-gaap_PaymentsForCapitalImprovements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsForCapitalImprovements" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="invest_InvestmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="invest_InvestmentDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestmentMaturityPeriodMinimum" xlink:label="alny_InvestmentMaturityPeriodMinimum"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" xlink:label="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegulusTherapeuticsIncMember" xlink:label="alny_RegulusTherapeuticsIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SignificantAccountingPoliciesLineItems" xlink:label="alny_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SignificantAccountingPoliciesTable" xlink:label="alny_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="invest_InvestmentAxis" xlink:to="invest_InvestmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentDomain" xlink:to="alny_RegulusTherapeuticsIncMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="alny_SignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="alny_InvestmentMaturityPeriodMinimum" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_SignificantAccountingPoliciesTable" xlink:to="invest_InvestmentAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MdcoMember" xlink:label="alny_MdcoMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MonsantoCompanyMember" xlink:label="alny_MonsantoCompanyMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_OtherCollaborationsMember" xlink:label="alny_OtherCollaborationsMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SanofiGenzymeMember" xlink:label="alny_SanofiGenzymeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_TakedaMember" xlink:label="alny_TakedaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_SanofiGenzymeMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_MdcoMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_TakedaMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_MonsantoCompanyMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_OtherCollaborationsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementsAxis" xlink:label="alny_AgreementsAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementsDomain" xlink:label="alny_AgreementsDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementsDomain" xlink:label="alny_AgreementsDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementTypeAxis" xlink:label="alny_AgreementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementTypeDomain" xlink:label="alny_AgreementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementTypeDomain" xlink:label="alny_AgreementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CoDevelopedOrCoPromotedCollaborationProductMember" xlink:label="alny_CoDevelopedOrCoPromotedCollaborationProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CollaboratorAxis" xlink:label="alny_CollaboratorAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CollaboratorDomain" xlink:label="alny_CollaboratorDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CollaboratorDomain" xlink:label="alny_CollaboratorDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommonStockClosingPricePercentage" xlink:label="alny_CommonStockClosingPricePercentage"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CompensatoryPurposesMember" xlink:label="alny_CompensatoryPurposesMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ConcurrentPrivatePlacementMember" xlink:label="alny_ConcurrentPrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ExcessOfFairValueOverCashReceivedForStockIssuance" xlink:label="alny_ExcessOfFairValueOverCashReceivedForStockIssuance"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ExtensionOfTermMember" xlink:label="alny_ExtensionOfTermMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FairValueOfCommonStockIssued" xlink:label="alny_FairValueOfCommonStockIssued"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FitusiranMember" xlink:label="alny_FitusiranMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_GlobalCollaborationProductMember" xlink:label="alny_GlobalCollaborationProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestorsMember" xlink:label="alny_InvestorsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_LockUpPeriod" xlink:label="alny_LockUpPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MaximumNumberOfPotentialFutureMilestones" xlink:label="alny_MaximumNumberOfPotentialFutureMilestones"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MaximumPercentageOfVotingPerCompanyRecommendation" xlink:label="alny_MaximumPercentageOfVotingPerCompanyRecommendation"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MilestonePaymentEarned" xlink:label="alny_MilestonePaymentEarned"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MinimumStandstillOwnershipPercentageTerminate" xlink:label="alny_MinimumStandstillOwnershipPercentageTerminate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" xlink:label="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation" xlink:label="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PatisiranAndRevusiranMember" xlink:label="alny_PatisiranAndRevusiranMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PatisiranMember" xlink:label="alny_PatisiranMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" xlink:label="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfSharesAgreedToSell" xlink:label="alny_PercentageOfSharesAgreedToSell"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfSharingInDevelopmentCost" xlink:label="alny_PercentageOfSharingInDevelopmentCost"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PerformancePeriod" xlink:label="alny_PerformancePeriod"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PeriodAxis" xlink:label="alny_PeriodAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PeriodDomain" xlink:label="alny_PeriodDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PeriodDomain" xlink:label="alny_PeriodDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PhaseThreeClinicalTrialMember" xlink:label="alny_PhaseThreeClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PhaseTwoClinicalTrialMember" xlink:label="alny_PhaseTwoClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PotentialMilestonePaymentsToBeReceived" xlink:label="alny_PotentialMilestonePaymentsToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ProductAlliancesMember" xlink:label="alny_ProductAlliancesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegionalCollaborationProductMember" xlink:label="alny_RegionalCollaborationProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RequirementOfEligibleFutureMilestonePaymentsAxis" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RoyaltyRate" xlink:label="alny_RoyaltyRate"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SaleOfStockAxis" xlink:label="alny_SaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SaleOfStockDomain" xlink:label="alny_SaleOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SaleOfStockDomain" xlink:label="alny_SaleOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SanofiGenzymeMember" xlink:label="alny_SanofiGenzymeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SecondAnniversaryMember" xlink:label="alny_SecondAnniversaryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_StandstillOwnershipPercentageAmendRight" xlink:label="alny_StandstillOwnershipPercentageAmendRight"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage" xlink:label="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_UpfrontFeeReceived" xlink:label="alny_UpfrontFeeReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="alny_AgreementsAxis" xlink:to="alny_AgreementsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="alny_AgreementsAxis" xlink:to="alny_AgreementsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_AgreementsDomain" xlink:to="alny_SecondAnniversaryMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="alny_AgreementTypeAxis" xlink:to="alny_AgreementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="alny_AgreementTypeAxis" xlink:to="alny_AgreementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_AgreementTypeDomain" xlink:to="alny_PatisiranMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_ProductAlliancesMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_InvestorsMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_RegionalCollaborationProductMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_CoDevelopedOrCoPromotedCollaborationProductMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_GlobalCollaborationProductMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_UpfrontFeeReceived" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MilestonePaymentEarned" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PercentageOfSharingInDevelopmentCost" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MaximumNumberOfPotentialFutureMilestones" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_RoyaltyRate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PotentialMilestonePaymentsToBeReceived" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MaximumPercentageOfVotingPerCompanyRecommendation" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MinimumStandstillOwnershipPercentageTerminate" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_StandstillOwnershipPercentageAmendRight" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_LockUpPeriod" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_CommonStockClosingPricePercentage" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PercentageOfSharesAgreedToSell" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_FairValueOfCommonStockIssued" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_ExcessOfFairValueOverCashReceivedForStockIssuance" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PerformancePeriod" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="alny_CollaboratorAxis" xlink:to="alny_CollaboratorDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="alny_CollaboratorAxis" xlink:to="alny_CollaboratorDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CollaboratorDomain" xlink:to="alny_SanofiGenzymeMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="alny_PeriodAxis" xlink:to="alny_PeriodDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="alny_PeriodAxis" xlink:to="alny_PeriodDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_PeriodDomain" xlink:to="alny_ExtensionOfTermMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="alny_PatisiranAndRevusiranMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="alny_FitusiranMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsAxis" xlink:to="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsAxis" xlink:to="alny_RequirementOfEligibleFutureMilestonePaymentsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:to="alny_PhaseTwoClinicalTrialMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:to="alny_PhaseThreeClinicalTrialMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="alny_SaleOfStockAxis" xlink:to="alny_SaleOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="alny_SaleOfStockAxis" xlink:to="alny_SaleOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SaleOfStockDomain" xlink:to="alny_ConcurrentPrivatePlacementMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_SaleOfStockDomain" xlink:to="alny_CompensatoryPurposesMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_CollaboratorAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_AgreementsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_SaleOfStockAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ProductOrServiceAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_PeriodAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_RequirementOfEligibleFutureMilestonePaymentsAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_AgreementTypeAxis" order="10.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MunicipalDebtSecuritiesMember" xlink:label="alny_MunicipalDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alny_MunicipalDebtSecuritiesMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities">
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AccruedIntraperiodTaxAllocation" xlink:label="alny_AccruedIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AllOtherActivityMember" xlink:label="alny_AllOtherActivityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CarryingValueInEquitySecurities" xlink:label="alny_CarryingValueInEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ChangeInCarryingValueOfEquitySecurities" xlink:label="alny_ChangeInCarryingValueOfEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" xlink:label="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="invest_InvestmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="invest_InvestmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="invest_InvestmentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegulusTherapeuticsIncMember" xlink:label="alny_RegulusTherapeuticsIncMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SalesOfRegulusSharesMember" xlink:label="alny_SalesOfRegulusSharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="invest_InvestmentAxis" xlink:to="invest_InvestmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="invest_InvestmentAxis" xlink:to="invest_InvestmentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentDomain" xlink:to="alny_RegulusTherapeuticsIncMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="alny_SalesOfRegulusSharesMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="alny_AllOtherActivityMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_CarryingValueInEquitySecurities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_AccruedIntraperiodTaxAllocation" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_ChangeInCarryingValueOfEquitySecurities" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="invest_InvestmentAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MunicipalDebtSecuritiesMember" xlink:label="alny_MunicipalDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="alny_MunicipalDebtSecuritiesMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_BankOfAmericaNALineOfCreditMember" xlink:label="alny_BankOfAmericaNALineOfCreditMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:label="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommitmentsAndContingenciesLineItems" xlink:label="alny_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommitmentsAndContingenciesTable" xlink:label="alny_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_LitigationDamagesSought" xlink:label="alny_LitigationDamagesSought"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NortonMassachusettsMember" xlink:label="alny_NortonMassachusettsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireLand" xlink:label="us-gaap_PaymentsToAcquireLand"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_TermLoanFacilityMember" xlink:label="alny_TermLoanFacilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_WellsFargoCreditFacilityMember" xlink:label="alny_WellsFargoCreditFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="alny_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PaymentsToAcquireLand" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AreaOfLand" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="alny_LitigationDamagesSought" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_VariableRateAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="alny_TermLoanFacilityMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="alny_BankOfAmericaNALineOfCreditMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="alny_WellsFargoCreditFacilityMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="alny_BankOfAmericaNALineOfCreditMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="alny_WellsFargoCreditFacilityMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="alny_NortonMassachusettsMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock" xlink:label="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>alny-20160331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 5 -->
<!-- Creation date: 2016-05-04T17:43:12Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_5871536_1114462_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_5871536_1114462_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_5871536_1120517_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_5871536_1120517_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AccruedIntraperiodTaxAllocation" xlink:label="alny_AccruedIntraperiodTaxAllocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_AccruedIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1217282_3_1">Carrying value as of the balance sheet date of obligations incurred, pertaining to costs that are related to income tax expense or benefit for the period that has been allocated among continuing operations, discontinued operations, extraordinary items, other comprehensive income, and items charged or credited directly to shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_AccruedIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1217282_1_1">Accrued Intraperiod Tax Allocation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="alny_AccruedIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1217282_14_1">Intraperiod tax allocation recorded as an accrued liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_AccruedIntraperiodTaxAllocation" xlink:to="alny_AccruedIntraperiodTaxAllocation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1117931_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1117931_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1117938_1_1">Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1117938_2_1">Accumulated other comprehensive income (loss), net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US" id="id_5871536_1118123_1_1">AOCI Including Portion Attributable to Noncontrolling Interest, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US" id="id_5871536_1118123_2_1">Accumulated other comprehensive income (loss), before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US" id="id_5871536_1118123_12_1">Accumulated other comprehensive income (loss), before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1119401_1_1">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1119401_2_1">Accumulated other comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_5871536_1118734_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_5871536_1118734_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_5871536_1105757_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_5871536_1105757_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementsAxis" xlink:label="alny_AgreementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_AgreementsAxis_lbl" xml:lang="en-US" id="id_5871536_1156564_3_1">Agreements [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_AgreementsAxis_lbl" xml:lang="en-US" id="id_5871536_1156564_1_1">Agreements [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_AgreementsAxis_lbl" xml:lang="en-US" id="id_5871536_1156564_2_1">Agreements [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_AgreementsAxis" xlink:to="alny_AgreementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementsDomain" xlink:label="alny_AgreementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_AgreementsDomain_lbl" xml:lang="en-US" id="id_5871536_1150489_3_1">Agreements [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_AgreementsDomain_lbl" xml:lang="en-US" id="id_5871536_1150489_1_1">Agreements [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_AgreementsDomain_lbl" xml:lang="en-US" id="id_5871536_1150489_2_1">Agreements [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_AgreementsDomain" xlink:to="alny_AgreementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementTypeAxis" xlink:label="alny_AgreementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_AgreementTypeAxis_lbl" xml:lang="en-US" id="id_5871536_1191697_3_1">Agreement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_AgreementTypeAxis_lbl" xml:lang="en-US" id="id_5871536_1191697_1_1">Agreement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_AgreementTypeAxis_lbl" xml:lang="en-US" id="id_5871536_1191697_2_1">Agreement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_AgreementTypeAxis" xlink:to="alny_AgreementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementTypeDomain" xlink:label="alny_AgreementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_AgreementTypeDomain_lbl" xml:lang="en-US" id="id_5871536_1272398_3_1">Agreement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_AgreementTypeDomain_lbl" xml:lang="en-US" id="id_5871536_1272398_1_1">Agreement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_AgreementTypeDomain_lbl" xml:lang="en-US" id="id_5871536_1272398_2_1">Agreement Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_AgreementTypeDomain" xlink:to="alny_AgreementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AllOtherActivityMember" xlink:label="alny_AllOtherActivityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_AllOtherActivityMember_lbl" xml:lang="en-US" id="id_5871536_1308525_3_1">All Other Activity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_AllOtherActivityMember_lbl" xml:lang="en-US" id="id_5871536_1308525_1_1">All Other Activity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_AllOtherActivityMember_lbl" xml:lang="en-US" id="id_5871536_1308525_2_1">All Other Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_AllOtherActivityMember" xlink:to="alny_AllOtherActivityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_5871536_1111599_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_5871536_1111599_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_5871536_1107326_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_5871536_1107326_2_1">Anti-dilutive securities excluded from computation of earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_5871536_1112578_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_5871536_1112578_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_5871536_1111080_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_5871536_1111080_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_5871536_1104730_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_5871536_1104730_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" id="id_5871536_1114059_1_1">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" id="id_5871536_1114059_2_1">Undeveloped land acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_5871536_1113479_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_5871536_1113479_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_5871536_1123375_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_5871536_1123375_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_5871536_1110678_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_5871536_1110678_2_1">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_5871536_1121346_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_5871536_1121346_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_5871536_1104780_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_5871536_1104780_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_5871536_1123377_1_1">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_5871536_1123377_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" id="id_5871536_1124010_1_1">Available-for-sale Debt Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" id="id_5871536_1124010_6_1">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" id="id_5871536_1118971_1_1">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" id="id_5871536_1118971_2_1">Gross Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" id="id_5871536_1123518_1_1">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" id="id_5871536_1123518_14_1">Gross Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_lbl" xml:lang="en-US" id="id_5871536_1117196_1_1">Available-for-sale Securities, Change in Net Unrealized Holding Gain (Loss) before Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_lbl" xml:lang="en-US" id="id_5871536_1117196_6_1">Investment in equity securities of Regulus Therapeutics Inc., as reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xml:lang="en-US" id="id_5871536_1121390_1_1">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xml:lang="en-US" id="id_5871536_1121390_2_1">Greater than one year but less than two years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xml:lang="en-US" id="id_5871536_1123564_1_1">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xml:lang="en-US" id="id_5871536_1123564_2_1">Greater than one year but less than two years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl" xml:lang="en-US" id="id_5871536_1104763_1_1">Available-for-sale Securities, Debt Maturities, Amortized Cost Basis, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl" xml:lang="en-US" id="id_5871536_1104763_2_1">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xml:lang="en-US" id="id_5871536_1116047_1_1">Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xml:lang="en-US" id="id_5871536_1116047_2_1">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" id="id_5871536_1121853_1_1">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" id="id_5871536_1121853_2_1">Less than one year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" id="id_5871536_1122139_1_1">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" id="id_5871536_1122139_2_1">Less than one year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" id="id_5871536_1122969_1_1">Available-for-sale Securities, Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" id="id_5871536_1122969_2_1">Available for sale debt securities, Fair value disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" id="id_5871536_1122969_6_1">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" id="id_5871536_1122969_12_1">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1124441_1_1">Available-for-sale Securities, Debt Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1124441_2_1">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1121253_1_1">Available-for-sale Securities, Debt Securities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1121253_2_1">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1124150_1_1">Available-for-sale Securities, Equity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1124150_2_1">Available for sale equity securities, Fair value disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1124150_12_1">Investment in equity securities of Regulus Therapeutics Inc., as reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1122622_1_1">Available-for-sale Securities, Equity Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1122622_2_1">Investment in equity securities of Regulus Therapeutics Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US" id="id_5871536_1117382_1_1">Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US" id="id_5871536_1117382_2_1">Realized gain on sale of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US" id="id_5871536_1117382_14_1">Realized gain on sale of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US" id="id_5871536_1107619_1_1">Available-for-sale Securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US" id="id_5871536_1107619_2_1">Summary of Fair Value Accumulated Other Comprehensive Income (Loss) and Intraperiod Tax Allocation in Regulus Available-for-Sale Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_BankOfAmericaNALineOfCreditMember" xlink:label="alny_BankOfAmericaNALineOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_BankOfAmericaNALineOfCreditMember_lbl" xml:lang="en-US" id="id_5871536_1194715_3_1">Bank Of America N A Line Of Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_BankOfAmericaNALineOfCreditMember_lbl" xml:lang="en-US" id="id_5871536_1194715_1_1">Bank Of America N A Line Of Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_BankOfAmericaNALineOfCreditMember_lbl" xml:lang="en-US" id="id_5871536_1194715_2_1">Bank of America N.A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_BankOfAmericaNALineOfCreditMember" xlink:to="alny_BankOfAmericaNALineOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CarryingValueInEquitySecurities" xlink:label="alny_CarryingValueInEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CarryingValueInEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1140743_3_1">Represents the Company's carrying value in equity securities categorized neither as held-to-maturity nor as trading.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CarryingValueInEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1140743_1_1">Carrying Value in Equity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CarryingValueInEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1140743_2_1">Carrying value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CarryingValueInEquitySecurities" xlink:to="alny_CarryingValueInEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_5871536_1122823_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_5871536_1122823_4_1">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_5871536_1122823_5_1">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_5871536_1122823_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_5871536_1122293_1_1">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_5871536_1122293_2_1">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_5871536_1122809_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_5871536_1122809_6_1">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:label="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_lbl" xml:lang="en-US" id="id_5871536_1527180_3_1">Cash Collateral required for Principal Amount Outstanding, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_lbl" xml:lang="en-US" id="id_5871536_1527180_1_1">Cash Collateral required for Principal Amount Outstanding, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_lbl" xml:lang="en-US" id="id_5871536_1527180_2_1">Cash collateral required for principal amount outstanding, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:to="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_5871536_1105790_1_1">Certificates of Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_5871536_1105790_2_1">Certificates of deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ChangeInCarryingValueOfEquitySecurities" xlink:label="alny_ChangeInCarryingValueOfEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_ChangeInCarryingValueOfEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1156924_3_1">Change in Carrying Value of Equity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_ChangeInCarryingValueOfEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1156924_1_1">Change in Carrying Value of Equity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_ChangeInCarryingValueOfEquitySecurities_lbl" xml:lang="en-US" id="id_5871536_1156924_2_1">Carrying value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_ChangeInCarryingValueOfEquitySecurities" xlink:to="alny_ChangeInCarryingValueOfEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CoDevelopedOrCoPromotedCollaborationProductMember" xlink:label="alny_CoDevelopedOrCoPromotedCollaborationProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CoDevelopedOrCoPromotedCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1157030_3_1">Co Developed or Co Promoted Collaboration Product Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CoDevelopedOrCoPromotedCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1157030_1_1">Co Developed or Co Promoted Collaboration Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CoDevelopedOrCoPromotedCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1157030_2_1">Co-developed/ Co-promoted Collaboration Product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CoDevelopedOrCoPromotedCollaborationProductMember" xlink:to="alny_CoDevelopedOrCoPromotedCollaborationProductMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_5871536_1110745_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_5871536_1110745_2_1">SIGNIFICANT AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_5871536_1114243_1_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_5871536_1114243_2_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CollaboratorAxis" xlink:label="alny_CollaboratorAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CollaboratorAxis_lbl" xml:lang="en-US" id="id_5871536_1251668_3_1">Collaborator [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CollaboratorAxis_lbl" xml:lang="en-US" id="id_5871536_1251668_1_1">Collaborator [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CollaboratorAxis_lbl" xml:lang="en-US" id="id_5871536_1251668_2_1">Collaborator [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CollaboratorAxis" xlink:to="alny_CollaboratorAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CollaboratorDomain" xlink:label="alny_CollaboratorDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CollaboratorDomain_lbl" xml:lang="en-US" id="id_5871536_1160362_3_1">Collaborator [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CollaboratorDomain_lbl" xml:lang="en-US" id="id_5871536_1160362_1_1">Collaborator [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CollaboratorDomain_lbl" xml:lang="en-US" id="id_5871536_1160362_2_1">Collaborator [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CollaboratorDomain" xlink:to="alny_CollaboratorDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" id="id_5871536_1116395_1_1">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" id="id_5871536_1116395_2_1">Commercial paper</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_5871536_1119602_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_5871536_1119602_2_1">Commitments and contingencies (Note 5)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_5871536_1110978_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_5871536_1110978_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_5871536_1114461_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_5871536_1114461_2_1">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommitmentsAndContingenciesLineItems" xlink:label="alny_CommitmentsAndContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_5871536_1200190_3_1">Commitments and Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_5871536_1200190_1_1">Commitments and Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_5871536_1200190_2_1">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="alny_CommitmentsAndContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommitmentsAndContingenciesTable" xlink:label="alny_CommitmentsAndContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_5871536_1252802_3_1">Commitments and Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_5871536_1252802_1_1">Commitments and Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_5871536_1252802_2_1">Commitments and Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="alny_CommitmentsAndContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommonStockClosingPricePercentage" xlink:label="alny_CommonStockClosingPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CommonStockClosingPricePercentage_lbl" xml:lang="en-US" id="id_5871536_1243629_3_1">Market price per share of our common stock is at least this percentage higher than the market price per share of our common stock at closing of the stock purchase for Genzyme to sell up to 25% of its initial shares, subject to certain restrictions on post-lock-up period dispositions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CommonStockClosingPricePercentage_lbl" xml:lang="en-US" id="id_5871536_1243629_1_1">Common Stock Closing Price Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CommonStockClosingPricePercentage_lbl" xml:lang="en-US" id="id_5871536_1243629_2_1">Percentage of market price per share of common stock compared to share of common stock at closing of stock purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CommonStockClosingPricePercentage" xlink:to="alny_CommonStockClosingPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_5871536_1106440_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_5871536_1106440_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_5871536_1108209_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_5871536_1108209_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_5871536_1115337_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_5871536_1115337_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_5871536_1110276_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_5871536_1110276_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_5871536_1118710_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_5871536_1118710_2_1">Common stock, $0.01 par value per share, 125,000,000 shares authorized; 85,463,258 shares issued and outstanding at March 31, 2016; 85,090,968 shares issued and outstanding at December 31, 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CompensatoryPurposesMember" xlink:label="alny_CompensatoryPurposesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_CompensatoryPurposesMember_lbl" xml:lang="en-US" id="id_5871536_1205894_3_1">Compensatory Purposes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_CompensatoryPurposesMember_lbl" xml:lang="en-US" id="id_5871536_1205894_1_1">Compensatory Purposes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_CompensatoryPurposesMember_lbl" xml:lang="en-US" id="id_5871536_1205894_2_1">Compensatory Purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_CompensatoryPurposesMember" xlink:to="alny_CompensatoryPurposesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1117403_1_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1117403_6_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" id="id_5871536_1106228_1_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" id="id_5871536_1106228_2_1">Comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ConcurrentPrivatePlacementMember" xlink:label="alny_ConcurrentPrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_ConcurrentPrivatePlacementMember_lbl" xml:lang="en-US" id="id_5871536_1267440_3_1">Concurrent Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_ConcurrentPrivatePlacementMember_lbl" xml:lang="en-US" id="id_5871536_1267440_1_1">Concurrent Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_ConcurrentPrivatePlacementMember_lbl" xml:lang="en-US" id="id_5871536_1267440_2_1">Concurrent Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_ConcurrentPrivatePlacementMember" xlink:to="alny_ConcurrentPrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1107528_1_1">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1107528_2_1">Basis of Presentation and Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1113789_1_1">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1113789_2_1">Corporate notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="id_5871536_1107053_1_1">Credit Facility [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="id_5871536_1107053_2_1">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="id_5871536_1111796_1_1">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="id_5871536_1111796_2_1">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_5871536_1107588_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_5871536_1107588_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_5871536_1113705_1_1">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_5871536_1113705_2_1">Debt instrument, basis spread on variable rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_5871536_1118349_1_1">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_5871536_1118349_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1119952_1_1">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1119952_2_1">Deferred rent, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_5871536_1117248_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_5871536_1117248_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_5871536_1119295_1_1">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_5871536_1119295_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1117807_1_1">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1117807_2_1">Deferred revenue, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_5871536_1118924_1_1">Deferred Tax Liabilities, Other Comprehensive Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_5871536_1118924_14_1">Intraperiod tax allocation recorded as a benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_5871536_1121432_1_1">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_5871536_1121432_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_DocumentAndEntityInformationAbstract" xlink:label="alny_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_5871536_1164234_3_1">Document and Entity Information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_5871536_1164234_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_5871536_1164234_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="alny_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_5871536_1108117_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_5871536_1108117_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_5871536_1114425_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_5871536_1114425_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_5871536_1104406_1_1">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_5871536_1104406_2_1">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" id="id_5871536_1111508_1_1">Document Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" id="id_5871536_1111508_2_1">Document Information [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_5871536_1105779_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_5871536_1105779_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_5871536_1104186_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_5871536_1104186_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_5871536_1111180_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_5871536_1111180_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_5871536_1112315_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_5871536_1112315_2_1">Net loss per common share - basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1108356_1_1">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1108356_2_1">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_5871536_1107650_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_5871536_1107650_2_1">Employee Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_5871536_1105747_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_5871536_1105747_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_5871536_1105436_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_5871536_1105436_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_5871536_1105520_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_5871536_1105520_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_5871536_1106302_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_5871536_1106302_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_5871536_1113330_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_5871536_1113330_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ExcessOfFairValueOverCashReceivedForStockIssuance" xlink:label="alny_ExcessOfFairValueOverCashReceivedForStockIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_ExcessOfFairValueOverCashReceivedForStockIssuance_lbl" xml:lang="en-US" id="id_5871536_1230467_3_1">The fair value amount in excess of the cash proceeds received for the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_ExcessOfFairValueOverCashReceivedForStockIssuance_lbl" xml:lang="en-US" id="id_5871536_1230467_1_1">Excess Of Fair Value Over Cash Received For Stock Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_ExcessOfFairValueOverCashReceivedForStockIssuance_lbl" xml:lang="en-US" id="id_5871536_1230467_2_1">Excess of fair value over cash received for stock issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_ExcessOfFairValueOverCashReceivedForStockIssuance" xlink:to="alny_ExcessOfFairValueOverCashReceivedForStockIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ExtensionOfTermMember" xlink:label="alny_ExtensionOfTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_ExtensionOfTermMember_lbl" xml:lang="en-US" id="id_5871536_1275770_3_1">Extension Of Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_ExtensionOfTermMember_lbl" xml:lang="en-US" id="id_5871536_1275770_1_1">Extension Of Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_ExtensionOfTermMember_lbl" xml:lang="en-US" id="id_5871536_1275770_2_1">Extension on Lock-up Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_ExtensionOfTermMember" xlink:to="alny_ExtensionOfTermMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_5871536_1111468_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_5871536_1111468_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_5871536_1104485_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_5871536_1104485_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_5871536_1115387_1_1">Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_5871536_1115387_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_5871536_1107455_1_1">Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_5871536_1107455_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_5871536_1109902_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_5871536_1109902_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_5871536_1115400_1_1">Measurement Frequency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_5871536_1115400_2_1">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_5871536_1108753_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_5871536_1108753_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_5871536_1108503_1_1">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_5871536_1108503_2_1">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_5871536_1105250_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_5871536_1105250_2_1">Quoted Prices in Active Markets (Level 1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_5871536_1110677_1_1">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_5871536_1110677_2_1">Significant Observable Inputs (Level 2)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_5871536_1109172_1_1">Fair Value, Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_5871536_1109172_2_1">Fair Value, Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_5871536_1104516_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_5871536_1104516_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_5871536_1104862_1_1">Fair Value, Measurements, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_5871536_1104862_2_1">Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FairValueOfCommonStockIssued" xlink:label="alny_FairValueOfCommonStockIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_5871536_1263182_3_1">Fair value of common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_5871536_1263182_1_1">Fair value of common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_5871536_1263182_2_1">Fair value of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_FairValueOfCommonStockIssued" xlink:to="alny_FairValueOfCommonStockIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_5871536_1104180_1_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_5871536_1104180_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FitusiranMember" xlink:label="alny_FitusiranMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_FitusiranMember_lbl" xml:lang="en-US" id="id_5871536_1526904_3_1">Fitusiran [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_FitusiranMember_lbl" xml:lang="en-US" id="id_5871536_1526904_1_1">Fitusiran [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_FitusiranMember_lbl" xml:lang="en-US" id="id_5871536_1526904_2_1">Fitusiran</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_FitusiranMember" xlink:to="alny_FitusiranMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_lbl" xml:lang="en-US" id="id_5871536_1167953_3_1">Future payments on achievement of specified commercialization milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_lbl" xml:lang="en-US" id="id_5871536_1167953_1_1">Future Payments On Achievement Of Specified Commercialization Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_lbl" xml:lang="en-US" id="id_5871536_1167953_2_1">Potential future payment for the achievement of specified commercialization milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:to="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones_lbl" xml:lang="en-US" id="id_5871536_1216166_3_1">Represents the maximum amount of pre-specified development milestone payments that could potentially be received under the collaborative and licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones_lbl" xml:lang="en-US" id="id_5871536_1216166_1_1">Future Payments On Achievement Of Specified Development Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones_lbl" xml:lang="en-US" id="id_5871536_1216166_2_1">Potential future payment for the achievement of certain development milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" xlink:to="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_5871536_1121835_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_5871536_1121835_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_5871536_1105782_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_5871536_1105782_2_1">General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_GlobalCollaborationProductMember" xlink:label="alny_GlobalCollaborationProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_GlobalCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1234414_3_1">Global Collaboration Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_GlobalCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1234414_1_1">Global Collaboration Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_GlobalCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1234414_2_1">Global Collaboration Product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_GlobalCollaborationProductMember" xlink:to="alny_GlobalCollaborationProductMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_5871536_1118461_1_1">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_5871536_1118461_6_1">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_5871536_1105195_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_5871536_1105195_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_5871536_1113993_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_5871536_1113993_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_5871536_1112681_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_5871536_1112681_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1123360_1_1">Income Tax Expense (Benefit), Intraperiod Tax Allocation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1123360_2_1">Benefit from intraperiod tax allocation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1123360_12_1">Provision for (Benefit from) income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1123360_14_1">Benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_5871536_1123908_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_5871536_1123908_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" xlink:label="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1292960_3_1">Increase (Decrease) in Accrued Intraperiod Tax Allocation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1292960_1_1">Increase (Decrease) in Accrued Intraperiod Tax Allocation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation_lbl" xml:lang="en-US" id="id_5871536_1292960_2_1">Intraperiod tax allocation recorded as an accrued liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" xlink:to="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_5871536_1122320_1_1">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_5871536_1122320_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_5871536_1111632_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_5871536_1111632_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" id="id_5871536_1121568_1_1">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" id="id_5871536_1121568_2_1">Accrued expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_5871536_1119835_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_5871536_1119835_14_1">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" id="id_5871536_1118403_1_1">Increase (Decrease) in Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" id="id_5871536_1118403_14_1">Billed and unbilled collaboration receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_5871536_1118852_1_1">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_5871536_1118852_14_1">Increase in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="invest_InvestmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentAxis_lbl" xml:lang="en-US" id="id_5871536_1107059_1_1">Investment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentAxis_lbl" xml:lang="en-US" id="id_5871536_1107059_2_1">Investment [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentAxis" xlink:to="invest_InvestmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="invest_InvestmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentDomain_lbl" xml:lang="en-US" id="id_5871536_1109340_1_1">Investment [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentDomain_lbl" xml:lang="en-US" id="id_5871536_1109340_2_1">Investment [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentDomain" xlink:to="invest_InvestmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" id="id_5871536_1118943_1_1">Investment Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" id="id_5871536_1118943_2_1">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestmentMaturityPeriodMinimum" xlink:label="alny_InvestmentMaturityPeriodMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_InvestmentMaturityPeriodMinimum_lbl" xml:lang="en-US" id="id_5871536_1156090_3_1">Purchases are classified as marketable securities if their original maturity, from the date of purchase, is in excess of 90 days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_InvestmentMaturityPeriodMinimum_lbl" xml:lang="en-US" id="id_5871536_1156090_1_1">Investment Maturity Period Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_InvestmentMaturityPeriodMinimum_lbl" xml:lang="en-US" id="id_5871536_1156090_2_1">Policy for marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_InvestmentMaturityPeriodMinimum" xlink:to="alny_InvestmentMaturityPeriodMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" xlink:label="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities_lbl" xml:lang="en-US" id="id_5871536_1236214_3_1">Purchases are classified as cash equivalents if their original maturity, from the date of purchase, is 90 days or less.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities_lbl" xml:lang="en-US" id="id_5871536_1236214_1_1">Investments Classified As Cash and Cash Equivalent Original Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities_lbl" xml:lang="en-US" id="id_5871536_1236214_2_1">Marketable securities classified as cash equivalents, maximum original maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" xlink:to="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1111042_1_1">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1111042_2_1">Summary of Available-For-Sale Debt Securities by Contractual Maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_5871536_1109639_1_1">Investments, Debt and Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_5871536_1109639_2_1">Investments, Debt and Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_5871536_1105987_1_1">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_5871536_1105987_2_1">MARKETABLE SECURITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_5871536_1116509_1_1">Investment Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_5871536_1116509_2_1">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_5871536_1106626_1_1">Investments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_5871536_1106626_2_1">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestorsMember" xlink:label="alny_InvestorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_InvestorsMember_lbl" xml:lang="en-US" id="id_5871536_1157608_3_1">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_InvestorsMember_lbl" xml:lang="en-US" id="id_5871536_1157608_1_1">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_InvestorsMember_lbl" xml:lang="en-US" id="id_5871536_1157608_2_1">Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_InvestorsMember" xlink:to="alny_InvestorsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_5871536_1116663_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_5871536_1116663_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_5871536_1118197_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_5871536_1118197_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_5871536_1120090_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_5871536_1120090_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_5871536_1104367_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_5871536_1104367_2_1">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1117290_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_5871536_1117290_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_5871536_1105566_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_5871536_1105566_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_5871536_1118554_1_1">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_5871536_1118554_2_1">Net revenues from collaborators</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_5871536_1118554_12_1">Total net revenues from collaborators</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" id="id_5871536_1117020_1_1">Lender Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" id="id_5871536_1117020_2_1">Lender Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US" id="id_5871536_1112905_1_1">Line of Credit Facility, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US" id="id_5871536_1112905_2_1">Line of credit facility, expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" id="id_5871536_1108805_1_1">Line of Credit Facility, Lender [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" id="id_5871536_1108805_2_1">Line of Credit Facility, Lender [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_5871536_1120471_1_1">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_5871536_1120471_2_1">Line of credit facility, maximum borrowing capacity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_LitigationDamagesSought" xlink:label="alny_LitigationDamagesSought"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_LitigationDamagesSought_lbl" xml:lang="en-US" id="id_5871536_1310735_3_1">Describes the amount of monetary award for reimbursement of costs and fees associated with defending legal action.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_LitigationDamagesSought_lbl" xml:lang="en-US" id="id_5871536_1310735_1_1">Litigation, Damages Sought</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_LitigationDamagesSought_lbl" xml:lang="en-US" id="id_5871536_1310735_2_1">Litigation, motion filed for reimbursement of costs and fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_LitigationDamagesSought" xlink:to="alny_LitigationDamagesSought_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_LockUpPeriod" xlink:label="alny_LockUpPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_LockUpPeriod_lbl" xml:lang="en-US" id="id_5871536_1285953_3_1">Period of time before entity can sell common stock of the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_LockUpPeriod_lbl" xml:lang="en-US" id="id_5871536_1285953_1_1">Lock-Up Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_LockUpPeriod_lbl" xml:lang="en-US" id="id_5871536_1285953_2_1">Agreement lock-up period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_LockUpPeriod" xlink:to="alny_LockUpPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" id="id_5871536_1106038_1_1">London Interbank Offered Rate (LIBOR) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" id="id_5871536_1106038_2_1">LIBOR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_5871536_1116388_1_1">Major Types of Debt and Equity Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_5871536_1116388_2_1">Major Types of Debt and Equity Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_5871536_1105924_1_1">Major Types of Debt and Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_5871536_1105924_2_1">Major Types of Debt and Equity Securities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" id="id_5871536_1104175_1_1">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" id="id_5871536_1104175_2_1">Investments in Marketable Securities and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_5871536_1116460_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_5871536_1116460_2_1">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MaximumNumberOfPotentialFutureMilestones" xlink:label="alny_MaximumNumberOfPotentialFutureMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_MaximumNumberOfPotentialFutureMilestones_lbl" xml:lang="en-US" id="id_5871536_1158193_3_1">Represents the maximum amount of pre-specified milestone payments that could potentially be received under the collaborative and licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_MaximumNumberOfPotentialFutureMilestones_lbl" xml:lang="en-US" id="id_5871536_1158193_1_1">Maximum Number Of Potential Future Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_MaximumNumberOfPotentialFutureMilestones_lbl" xml:lang="en-US" id="id_5871536_1158193_2_1">Maximum number of potential future milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_MaximumNumberOfPotentialFutureMilestones" xlink:to="alny_MaximumNumberOfPotentialFutureMilestones_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MaximumPercentageOfVotingPerCompanyRecommendation" xlink:label="alny_MaximumPercentageOfVotingPerCompanyRecommendation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_MaximumPercentageOfVotingPerCompanyRecommendation_lbl" xml:lang="en-US" id="id_5871536_1284869_3_1">The maximum percentage of voting, based on the collaboration partner's ownership in company stock, that must be voted per the company's recommendation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_MaximumPercentageOfVotingPerCompanyRecommendation_lbl" xml:lang="en-US" id="id_5871536_1284869_1_1">Maximum Percentage Of Voting Per Company Recommendation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_MaximumPercentageOfVotingPerCompanyRecommendation_lbl" xml:lang="en-US" id="id_5871536_1284869_2_1">Voting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_MaximumPercentageOfVotingPerCompanyRecommendation" xlink:to="alny_MaximumPercentageOfVotingPerCompanyRecommendation_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MdcoMember" xlink:label="alny_MdcoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_MdcoMember_lbl" xml:lang="en-US" id="id_5871536_1174119_3_1">The Medicines Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_MdcoMember_lbl" xml:lang="en-US" id="id_5871536_1174119_1_1">Mdco [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_MdcoMember_lbl" xml:lang="en-US" id="id_5871536_1174119_2_1">The Medicines Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_MdcoMember" xlink:to="alny_MdcoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MilestonePaymentEarned" xlink:label="alny_MilestonePaymentEarned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_MilestonePaymentEarned_lbl" xml:lang="en-US" id="id_5871536_1231175_3_1">Represents the amount earned upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_MilestonePaymentEarned_lbl" xml:lang="en-US" id="id_5871536_1231175_1_1">Milestone Payment Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_MilestonePaymentEarned_lbl" xml:lang="en-US" id="id_5871536_1231175_2_1">Amount earned upon achievement of milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_MilestonePaymentEarned" xlink:to="alny_MilestonePaymentEarned_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_5871536_1107704_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_5871536_1107704_2_1">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MinimumStandstillOwnershipPercentageTerminate" xlink:label="alny_MinimumStandstillOwnershipPercentageTerminate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_MinimumStandstillOwnershipPercentageTerminate_lbl" xml:lang="en-US" id="id_5871536_1196863_3_1">Minimum threshold for ownership percentage below which the right to amend standstill and voting provisions terminate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_MinimumStandstillOwnershipPercentageTerminate_lbl" xml:lang="en-US" id="id_5871536_1196863_1_1">Minimum Standstill Ownership Percentage Terminate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_MinimumStandstillOwnershipPercentageTerminate_lbl" xml:lang="en-US" id="id_5871536_1196863_2_1">Minimum percentage of ownership interest terminate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_MinimumStandstillOwnershipPercentageTerminate" xlink:to="alny_MinimumStandstillOwnershipPercentageTerminate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="id_5871536_1108401_1_1">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="id_5871536_1108401_2_1">Percentage ownership interest owned by noncontrolling owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_5871536_1108237_1_1">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_5871536_1108237_2_1">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MonsantoCompanyMember" xlink:label="alny_MonsantoCompanyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_MonsantoCompanyMember_lbl" xml:lang="en-US" id="id_5871536_1136250_3_1">Monsanto Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_MonsantoCompanyMember_lbl" xml:lang="en-US" id="id_5871536_1136250_1_1">Monsanto Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_MonsantoCompanyMember_lbl" xml:lang="en-US" id="id_5871536_1136250_2_1">Monsanto</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_MonsantoCompanyMember" xlink:to="alny_MonsantoCompanyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MunicipalDebtSecuritiesMember" xlink:label="alny_MunicipalDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_MunicipalDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1210074_3_1">Municipal Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_MunicipalDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1210074_1_1">Municipal Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_MunicipalDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1210074_2_1">Municipal debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_MunicipalDebtSecuritiesMember" xlink:to="alny_MunicipalDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_5871536_1121242_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_5871536_1121242_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_5871536_1111965_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_5871536_1111965_2_1">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_5871536_1124621_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_5871536_1124621_6_1">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_5871536_1109601_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_5871536_1109601_2_1">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_5871536_1110793_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_5871536_1110793_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_5871536_1105190_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_5871536_1105190_2_1">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_5871536_1119943_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_5871536_1119943_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_5871536_1119943_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1108780_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1108780_2_1">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_5871536_1119287_1_1">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_5871536_1119287_6_1">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_5871536_1115985_1_1">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_5871536_1115985_2_1">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NortonMassachusettsMember" xlink:label="alny_NortonMassachusettsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NortonMassachusettsMember_lbl" xml:lang="en-US" id="id_5871536_1323477_3_1">Norton, Massachusetts [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NortonMassachusettsMember_lbl" xml:lang="en-US" id="id_5871536_1323477_1_1">Norton, Massachusetts [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_NortonMassachusettsMember_lbl" xml:lang="en-US" id="id_5871536_1323477_2_1">Norton, Massachusetts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NortonMassachusettsMember" xlink:to="alny_NortonMassachusettsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" xlink:label="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering_lbl" xml:lang="en-US" id="id_5871536_1145246_3_1">Number of Demand Rights to Conduct Registered Underwritten Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering_lbl" xml:lang="en-US" id="id_5871536_1145246_1_1">Number of Demand Rights to Conduct Registered Underwritten Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering_lbl" xml:lang="en-US" id="id_5871536_1145246_2_1">Number of demand rights to conduct registered underwritten public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" xlink:to="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation" xlink:label="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation_lbl" xml:lang="en-US" id="id_5871536_1310551_3_1">Number of Trailing Period for Average Market Price Calculation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation_lbl" xml:lang="en-US" id="id_5871536_1310551_1_1">Number of Trailing Period for Average Market Price Calculation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation_lbl" xml:lang="en-US" id="id_5871536_1310551_2_1">Number of trailing days on which average is calculated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation" xlink:to="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_5871536_1120986_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_5871536_1120986_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_5871536_1115413_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_5871536_1115413_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_5871536_1118206_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_5871536_1118206_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_5871536_1105148_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_5871536_1105148_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1124048_1_1">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1124048_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_OtherCollaborationsMember" xlink:label="alny_OtherCollaborationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_OtherCollaborationsMember_lbl" xml:lang="en-US" id="id_5871536_1219135_3_1">Other Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_OtherCollaborationsMember_lbl" xml:lang="en-US" id="id_5871536_1219135_1_1">Other Collaborations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_OtherCollaborationsMember_lbl" xml:lang="en-US" id="id_5871536_1219135_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_OtherCollaborationsMember" xlink:to="alny_OtherCollaborationsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1121357_1_1">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1121357_14_1">Reclassification adjustment for realized gain on marketable securities included in net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US" id="id_5871536_1120070_1_1">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US" id="id_5871536_1120070_2_1">Accumulated other comprehensive income (loss), before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US" id="id_5871536_1120070_12_1">Accumulated other comprehensive income (loss), before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1120165_1_1">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1120165_2_1">Unrealized (loss) gain on marketable securities, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_5871536_1120165_6_1">Accumulated other comprehensive income (loss), net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xml:lang="en-US" id="id_5871536_1121431_1_1">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xml:lang="en-US" id="id_5871536_1121431_14_1">Intraperiod tax allocation recorded as a benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1119182_1_1">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_5871536_1119182_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_5871536_1117832_1_1">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_5871536_1117832_2_1">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PatisiranAndRevusiranMember" xlink:label="alny_PatisiranAndRevusiranMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PatisiranAndRevusiranMember_lbl" xml:lang="en-US" id="id_5871536_1526991_3_1">Patisiran and Revusiran [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PatisiranAndRevusiranMember_lbl" xml:lang="en-US" id="id_5871536_1526991_1_1">Patisiran and Revusiran [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PatisiranAndRevusiranMember_lbl" xml:lang="en-US" id="id_5871536_1526991_2_1">Patisiran and Revusiran</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PatisiranAndRevusiranMember" xlink:to="alny_PatisiranAndRevusiranMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PatisiranMember" xlink:label="alny_PatisiranMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PatisiranMember_lbl" xml:lang="en-US" id="id_5871536_1301396_3_1">Patisiran [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PatisiranMember_lbl" xml:lang="en-US" id="id_5871536_1301396_1_1">Patisiran [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PatisiranMember_lbl" xml:lang="en-US" id="id_5871536_1301396_2_1">Patisiran</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PatisiranMember" xlink:to="alny_PatisiranMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="us-gaap_PaymentsForCapitalImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCapitalImprovements_lbl" xml:lang="en-US" id="id_5871536_1119488_1_1">Payments for Capital Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForCapitalImprovements_lbl" xml:lang="en-US" id="id_5871536_1119488_14_1">Deposit for manufacturing facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCapitalImprovements" xlink:to="us-gaap_PaymentsForCapitalImprovements_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_5871536_1119385_1_1">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_5871536_1119385_2_1">Underwriting discounts and commissions and other offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_5871536_1119212_1_1">Payments Related to Tax Withholding for Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_5871536_1119212_14_1">Payments for repurchase of common stock for employee tax withholding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" id="id_5871536_1117142_1_1">Payments to Acquire Available-for-sale Securities, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" id="id_5871536_1117142_14_1">Purchases of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireLand" xlink:label="us-gaap_PaymentsToAcquireLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLand_lbl" xml:lang="en-US" id="id_5871536_1120460_1_1">Payments to Acquire Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireLand_lbl" xml:lang="en-US" id="id_5871536_1120460_2_1">Payment to acquire land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLand" xlink:to="us-gaap_PaymentsToAcquireLand_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_5871536_1117468_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_5871536_1117468_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US" id="id_5871536_1123239_1_1">Pension and Other Postretirement Benefit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US" id="id_5871536_1123239_2_1">Charge for 401(k) company stock match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" xlink:label="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors_lbl" xml:lang="en-US" id="id_5871536_1251796_3_1">Percentage of Acquired Outstanding Common Stock to Appoint Individual to Board of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors_lbl" xml:lang="en-US" id="id_5871536_1251796_1_1">Percentage of Acquired Outstanding Common Stock to Appoint Individual to Board of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors_lbl" xml:lang="en-US" id="id_5871536_1251796_2_1">Percentage of acquired outstanding common stock for Genzyme to appoint individual to board of directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" xlink:to="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfSharesAgreedToSell" xlink:label="alny_PercentageOfSharesAgreedToSell"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PercentageOfSharesAgreedToSell_lbl" xml:lang="en-US" id="id_5871536_1253079_3_1">Percentage of shares agreed to sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PercentageOfSharesAgreedToSell_lbl" xml:lang="en-US" id="id_5871536_1253079_1_1">Percentage of shares agreed to sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PercentageOfSharesAgreedToSell_lbl" xml:lang="en-US" id="id_5871536_1253079_2_1">Percentage of sale of initial shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PercentageOfSharesAgreedToSell" xlink:to="alny_PercentageOfSharesAgreedToSell_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfSharingInDevelopmentCost" xlink:label="alny_PercentageOfSharingInDevelopmentCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PercentageOfSharingInDevelopmentCost_lbl" xml:lang="en-US" id="id_5871536_1196804_3_1">Percentage of sharing in development cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PercentageOfSharingInDevelopmentCost_lbl" xml:lang="en-US" id="id_5871536_1196804_1_1">Percentage Of Sharing In Development Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PercentageOfSharingInDevelopmentCost_lbl" xml:lang="en-US" id="id_5871536_1196804_2_1">Percentage of sharing in development cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PercentageOfSharingInDevelopmentCost" xlink:to="alny_PercentageOfSharingInDevelopmentCost_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PerformancePeriod" xlink:label="alny_PerformancePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PerformancePeriod_lbl" xml:lang="en-US" id="id_5871536_1161507_3_1">Performance Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PerformancePeriod_lbl" xml:lang="en-US" id="id_5871536_1161507_1_1">Performance Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PerformancePeriod_lbl" xml:lang="en-US" id="id_5871536_1161507_2_1">Performance period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PerformancePeriod" xlink:to="alny_PerformancePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PeriodAxis" xlink:label="alny_PeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PeriodAxis_lbl" xml:lang="en-US" id="id_5871536_1273014_3_1">Period [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PeriodAxis_lbl" xml:lang="en-US" id="id_5871536_1273014_1_1">Period [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PeriodAxis_lbl" xml:lang="en-US" id="id_5871536_1273014_2_1">Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PeriodAxis" xlink:to="alny_PeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PeriodDomain" xlink:label="alny_PeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PeriodDomain_lbl" xml:lang="en-US" id="id_5871536_1202794_3_1">Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PeriodDomain_lbl" xml:lang="en-US" id="id_5871536_1202794_1_1">Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PeriodDomain_lbl" xml:lang="en-US" id="id_5871536_1202794_2_1">Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PeriodDomain" xlink:to="alny_PeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PhaseThreeClinicalTrialMember" xlink:label="alny_PhaseThreeClinicalTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US" id="id_5871536_1179976_3_1">Phase Three Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US" id="id_5871536_1179976_1_1">Phase Three Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US" id="id_5871536_1179976_2_1">Phase Three Clinical Trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PhaseThreeClinicalTrialMember" xlink:to="alny_PhaseThreeClinicalTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PhaseTwoClinicalTrialMember" xlink:label="alny_PhaseTwoClinicalTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US" id="id_5871536_1245967_3_1">Phase Two Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US" id="id_5871536_1245967_1_1">Phase Two Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US" id="id_5871536_1245967_2_1">Phase Two Clinical Trial ALN-TTR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PhaseTwoClinicalTrialMember" xlink:to="alny_PhaseTwoClinicalTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PotentialMilestonePaymentsToBeReceived" xlink:label="alny_PotentialMilestonePaymentsToBeReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PotentialMilestonePaymentsToBeReceived_lbl" xml:lang="en-US" id="id_5871536_1256309_3_1">Potential Milestone Payments To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PotentialMilestonePaymentsToBeReceived_lbl" xml:lang="en-US" id="id_5871536_1256309_1_1">Potential Milestone Payments To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PotentialMilestonePaymentsToBeReceived_lbl" xml:lang="en-US" id="id_5871536_1256309_2_1">Potential milestone payments to be earned</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PotentialMilestonePaymentsToBeReceived" xlink:to="alny_PotentialMilestonePaymentsToBeReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_5871536_1116186_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_5871536_1116186_2_1">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_5871536_1110884_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_5871536_1110884_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_5871536_1113611_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_5871536_1113611_2_1">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_5871536_1115342_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_5871536_1115342_2_1">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_5871536_1119717_1_1">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_5871536_1119717_2_1">Preferred stock, $0.01 par value per share, 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2016 and December 31, 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_5871536_1123793_1_1">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_5871536_1123793_2_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_5871536_1120882_1_1">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_5871536_1120882_2_1">Proceeds from issuance of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_5871536_1122432_1_1">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_5871536_1122432_2_1">Proceeds from issuance of common stock to Genzyme</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_5871536_1122432_12_1">Proceeds from issuance of common stock to Sanofi Genzyme</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" id="id_5871536_1121655_1_1">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" id="id_5871536_1121655_2_1">Proceeds from exercise of stock options and other types of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_5871536_1120889_1_1">Proceeds from Sale and Maturity of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_5871536_1120889_2_1">Sales and maturities of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ProductAlliancesMember" xlink:label="alny_ProductAlliancesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_ProductAlliancesMember_lbl" xml:lang="en-US" id="id_5871536_1207741_3_1">Product alliances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_ProductAlliancesMember_lbl" xml:lang="en-US" id="id_5871536_1207741_1_1">Product Alliances [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_ProductAlliancesMember_lbl" xml:lang="en-US" id="id_5871536_1207741_2_1">Product Alliances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_ProductAlliancesMember" xlink:to="alny_ProductAlliancesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_5871536_1109648_1_1">Products and Services [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_5871536_1109648_2_1">Products and Services [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_5871536_1114361_1_1">Products and Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_5871536_1114361_2_1">Products and Services [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_5871536_1121241_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_5871536_1121241_2_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock" xlink:label="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1180600_3_1">Disclosure of accounting policy related to common stock public offering, including proceeds net of the underwriting discount and commissions and other offering expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1180600_1_1">Public Offerings of Common Stock, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1180600_2_1">Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock" xlink:to="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_5871536_1115253_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_5871536_1115253_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_5871536_1111418_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_5871536_1111418_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" id="id_5871536_1123191_1_1">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" id="id_5871536_1123191_2_1">Billed and unbilled collaboration receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegionalCollaborationProductMember" xlink:label="alny_RegionalCollaborationProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_RegionalCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1212407_3_1">Regional Collaboration Product Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_RegionalCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1212407_1_1">Regional Collaboration Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_RegionalCollaborationProductMember_lbl" xml:lang="en-US" id="id_5871536_1212407_2_1">Regional Collaboration Product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_RegionalCollaborationProductMember" xlink:to="alny_RegionalCollaborationProductMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegulusTherapeuticsIncMember" xlink:label="alny_RegulusTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_RegulusTherapeuticsIncMember_lbl" xml:lang="en-US" id="id_5871536_1280400_3_1">Regulus Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_RegulusTherapeuticsIncMember_lbl" xml:lang="en-US" id="id_5871536_1280400_1_1">Regulus Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_RegulusTherapeuticsIncMember_lbl" xml:lang="en-US" id="id_5871536_1280400_2_1">Regulus Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_RegulusTherapeuticsIncMember" xlink:to="alny_RegulusTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReimbursementRevenue_lbl" xml:lang="en-US" id="id_5871536_1117631_1_1">Reimbursement Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReimbursementRevenue_lbl" xml:lang="en-US" id="id_5871536_1117631_2_1">Revenue from reimbursement due from collaborator</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReimbursementRevenue" xlink:to="us-gaap_ReimbursementRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RequirementOfEligibleFutureMilestonePaymentsAxis" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsAxis_lbl" xml:lang="en-US" id="id_5871536_1242844_3_1">Requirement Of Eligible Future Milestone Payments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsAxis_lbl" xml:lang="en-US" id="id_5871536_1242844_1_1">Requirement Of Eligible Future Milestone Payments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsAxis_lbl" xml:lang="en-US" id="id_5871536_1242844_2_1">Requirement Of Eligible Future Milestone Payments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsAxis" xlink:to="alny_RequirementOfEligibleFutureMilestonePaymentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsDomain_lbl" xml:lang="en-US" id="id_5871536_1208832_3_1">Requirement Of Eligible Future Milestone Payments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsDomain_lbl" xml:lang="en-US" id="id_5871536_1208832_1_1">Requirement Of Eligible Future Milestone Payments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsDomain_lbl" xml:lang="en-US" id="id_5871536_1208832_2_1">Requirement Of Eligible Future Milestone Payments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:to="alny_RequirementOfEligibleFutureMilestonePaymentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_5871536_1124668_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_5871536_1124668_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_5871536_1109593_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_5871536_1109593_2_1">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_5871536_1124019_1_1">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_5871536_1124019_2_1">Restricted cash (money market funds)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_5871536_1105469_1_1">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_5871536_1105469_2_1">Restricted stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_5871536_1119892_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_5871536_1119892_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RoyaltyRate" xlink:label="alny_RoyaltyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_RoyaltyRate_lbl" xml:lang="en-US" id="id_5871536_1180481_3_1">Potential maximum royalty percentage that will received for sales completed by collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_RoyaltyRate_lbl" xml:lang="en-US" id="id_5871536_1180481_1_1">Royalty Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_RoyaltyRate_lbl" xml:lang="en-US" id="id_5871536_1180481_2_1">Royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_RoyaltyRate" xlink:to="alny_RoyaltyRate_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SaleOfStockAxis" xlink:label="alny_SaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_SaleOfStockAxis_lbl" xml:lang="en-US" id="id_5871536_1163455_3_1">Sale Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_SaleOfStockAxis_lbl" xml:lang="en-US" id="id_5871536_1163455_1_1">Sale Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_SaleOfStockAxis_lbl" xml:lang="en-US" id="id_5871536_1163455_2_1">Sale Of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_SaleOfStockAxis" xlink:to="alny_SaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SaleOfStockDomain" xlink:label="alny_SaleOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_SaleOfStockDomain_lbl" xml:lang="en-US" id="id_5871536_1148634_3_1">Sale Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_SaleOfStockDomain_lbl" xml:lang="en-US" id="id_5871536_1148634_1_1">Sale Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_SaleOfStockDomain_lbl" xml:lang="en-US" id="id_5871536_1148634_2_1">Sale Of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_SaleOfStockDomain" xlink:to="alny_SaleOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SalesOfRegulusSharesMember" xlink:label="alny_SalesOfRegulusSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_SalesOfRegulusSharesMember_lbl" xml:lang="en-US" id="id_5871536_1308524_3_1">Sales of Regulus Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_SalesOfRegulusSharesMember_lbl" xml:lang="en-US" id="id_5871536_1308524_1_1">Sales of Regulus Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_SalesOfRegulusSharesMember_lbl" xml:lang="en-US" id="id_5871536_1308524_2_1">Sales of Regulus Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_SalesOfRegulusSharesMember" xlink:to="alny_SalesOfRegulusSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SanofiGenzymeMember" xlink:label="alny_SanofiGenzymeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_SanofiGenzymeMember_lbl" xml:lang="en-US" id="id_5871536_1317809_3_1">Sanofi Genzyme [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_SanofiGenzymeMember_lbl" xml:lang="en-US" id="id_5871536_1317809_1_1">Sanofi Genzyme [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_SanofiGenzymeMember_lbl" xml:lang="en-US" id="id_5871536_1317809_2_1">Sanofi Genzyme</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_SanofiGenzymeMember" xlink:to="alny_SanofiGenzymeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_5871536_1116150_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_5871536_1116150_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_5871536_1115087_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_5871536_1115087_2_1">Common Shares Excluded from the Calculation of Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" id="id_5871536_1108643_1_1">Schedule of Available-for-sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" id="id_5871536_1108643_2_1">Schedule of Available-for-sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1105012_1_1">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1105012_2_1">Summary of Company's Marketable Securities Excluding Regulus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" id="id_5871536_1116999_1_1">Schedule of Available-for-sale Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" id="id_5871536_1116999_2_1">Schedule of Available-for-sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_5871536_1108027_1_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_5871536_1108027_2_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1109841_1_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1109841_2_1">Revenue from Collaborators</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1114398_1_1">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_5871536_1114398_2_1">Fair Value of Assets Measured on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SecondAnniversaryMember" xlink:label="alny_SecondAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_SecondAnniversaryMember_lbl" xml:lang="en-US" id="id_5871536_1260810_3_1">Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_SecondAnniversaryMember_lbl" xml:lang="en-US" id="id_5871536_1260810_1_1">Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_SecondAnniversaryMember_lbl" xml:lang="en-US" id="id_5871536_1260810_2_1">Following the two-year anniversary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_SecondAnniversaryMember" xlink:to="alny_SecondAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_5871536_1104519_1_1">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_5871536_1104519_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_5871536_1124071_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_5871536_1124071_2_1">Non-cash stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_5871536_1110796_1_1">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_5871536_1110796_2_1">Common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_5871536_1110796_12_1">Underwritten public offering amount per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SignificantAccountingPoliciesLineItems" xlink:label="alny_SignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_5871536_1140391_3_1">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_5871536_1140391_1_1">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_5871536_1140391_2_1">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="alny_SignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SignificantAccountingPoliciesTable" xlink:label="alny_SignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_5871536_1182862_3_1">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_5871536_1182862_1_1">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_5871536_1182862_2_1">Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_SignificantAccountingPoliciesTable" xlink:to="alny_SignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_5871536_1113490_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_5871536_1113490_2_1">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_StandstillOwnershipPercentageAmendRight" xlink:label="alny_StandstillOwnershipPercentageAmendRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_StandstillOwnershipPercentageAmendRight_lbl" xml:lang="en-US" id="id_5871536_1212459_3_1">Ownership percentage threshold related to right to amend standstill and voting provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_StandstillOwnershipPercentageAmendRight_lbl" xml:lang="en-US" id="id_5871536_1212459_1_1">Standstill Ownership Percentage Amend Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_StandstillOwnershipPercentageAmendRight_lbl" xml:lang="en-US" id="id_5871536_1212459_2_1">Percentage of ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_StandstillOwnershipPercentageAmendRight" xlink:to="alny_StandstillOwnershipPercentageAmendRight_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage" xlink:label="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage_lbl" xml:lang="en-US" id="id_5871536_1180835_3_1">The range of common stock ownership percentage that dictates a standstill provision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage_lbl" xml:lang="en-US" id="id_5871536_1180835_1_1">Standstill Range Of Outstanding Common Stock Acquired Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage_lbl" xml:lang="en-US" id="id_5871536_1180835_2_1">Agreement to acquire outstanding shares of common stock percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage" xlink:to="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_5871536_1107576_1_1">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_5871536_1107576_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_5871536_1107485_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_5871536_1107485_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_5871536_1114174_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_5871536_1114174_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_5871536_1109954_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_5871536_1109954_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_5871536_1113040_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_5871536_1113040_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_5871536_1119999_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_5871536_1119999_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_5871536_1110838_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_5871536_1110838_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_5871536_1109759_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_5871536_1109759_2_1">Issuance of common stock, net of offering costs (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_5871536_1117804_1_1">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_5871536_1117804_2_1">Issuance of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_5871536_1108681_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_5871536_1108681_2_1">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1116895_1_1">Subsequent Events, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_5871536_1116895_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_5871536_1106880_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_5871536_1106880_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_5871536_1110811_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_5871536_1110811_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_TakedaMember" xlink:label="alny_TakedaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_TakedaMember_lbl" xml:lang="en-US" id="id_5871536_1172541_3_1">Takeda.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_TakedaMember_lbl" xml:lang="en-US" id="id_5871536_1172541_1_1">Takeda [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_TakedaMember_lbl" xml:lang="en-US" id="id_5871536_1172541_2_1">Takeda</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_TakedaMember" xlink:to="alny_TakedaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_TermLoanFacilityMember" xlink:label="alny_TermLoanFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_TermLoanFacilityMember_lbl" xml:lang="en-US" id="id_5871536_1287013_3_1">Term Loan Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_TermLoanFacilityMember_lbl" xml:lang="en-US" id="id_5871536_1287013_1_1">Term Loan Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_TermLoanFacilityMember_lbl" xml:lang="en-US" id="id_5871536_1287013_2_1">Term Loan Facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_TermLoanFacilityMember" xlink:to="alny_TermLoanFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_5871536_1104492_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_5871536_1104492_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_5871536_1116223_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_5871536_1116223_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_UpfrontFeeReceived" xlink:label="alny_UpfrontFeeReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_UpfrontFeeReceived_lbl" xml:lang="en-US" id="id_5871536_1247814_3_1">Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_UpfrontFeeReceived_lbl" xml:lang="en-US" id="id_5871536_1247814_1_1">Upfront Fee Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_UpfrontFeeReceived_lbl" xml:lang="en-US" id="id_5871536_1247814_2_1">Upfront fee received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_UpfrontFeeReceived" xlink:to="alny_UpfrontFeeReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_5871536_1113910_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_5871536_1113910_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1111781_1_1">US Government-sponsored Enterprises Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1111781_2_1">U.S. government-sponsored enterprise securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1114216_1_1">US Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_5871536_1114216_2_1">U.S. treasury securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="id_5871536_1115193_1_1">Variable Rate [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="id_5871536_1115193_2_1">Variable Rate [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="id_5871536_1104337_1_1">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="id_5871536_1104337_2_1">Variable Rate [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_5871536_1113925_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_5871536_1113925_2_1">Weighted-average common shares used to compute basic and diluted net loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_WellsFargoCreditFacilityMember" xlink:label="alny_WellsFargoCreditFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_WellsFargoCreditFacilityMember_lbl" xml:lang="en-US" id="id_5871536_1189687_3_1">Wells Fargo Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_WellsFargoCreditFacilityMember_lbl" xml:lang="en-US" id="id_5871536_1189687_1_1">Wells Fargo Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alny_WellsFargoCreditFacilityMember_lbl" xml:lang="en-US" id="id_5871536_1189687_2_1">Wells Fargo Bank, National Association</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_WellsFargoCreditFacilityMember" xlink:to="alny_WellsFargoCreditFacilityMember_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>alny-20160331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 5 -->
<!-- Creation date: 2016-05-04T17:43:12Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DocumentandEntityInformation" roleURI="http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfIncome" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfIncomeParen" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare" roleURI="http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureRevenueFromCollaborators" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSignificantAgreementsAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureFairValueMeasuredOnRecurringBasis" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfCompanysMarketableSecurities" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="alny-20160331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_DocumentAndEntityInformationAbstract" xlink:label="alny_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfIncome" xlink:title="124000 - Statement - Statement of Income (Including Gross Margin)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="1.2000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="us-gaap_PaymentsForCapitalImprovements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.2200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1.2600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsForCapitalImprovements" order="1.2800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="invest_InvestmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="invest_InvestmentDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestmentMaturityPeriodMinimum" xlink:label="alny_InvestmentMaturityPeriodMinimum"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" xlink:label="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegulusTherapeuticsIncMember" xlink:label="alny_RegulusTherapeuticsIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SignificantAccountingPoliciesLineItems" xlink:label="alny_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SignificantAccountingPoliciesTable" xlink:label="alny_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alny_SignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentAxis" xlink:to="invest_InvestmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentDomain" xlink:to="alny_RegulusTherapeuticsIncMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesLineItems" xlink:to="alny_InvestmentMaturityPeriodMinimum" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesTable" xlink:to="invest_InvestmentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SignificantAccountingPoliciesTable" xlink:to="alny_SignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MdcoMember" xlink:label="alny_MdcoMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MonsantoCompanyMember" xlink:label="alny_MonsantoCompanyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_OtherCollaborationsMember" xlink:label="alny_OtherCollaborationsMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SanofiGenzymeMember" xlink:label="alny_SanofiGenzymeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_TakedaMember" xlink:label="alny_TakedaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_SanofiGenzymeMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_MdcoMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_TakedaMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_MonsantoCompanyMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_OtherCollaborationsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementsAxis" xlink:label="alny_AgreementsAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementsDomain" xlink:label="alny_AgreementsDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementTypeAxis" xlink:label="alny_AgreementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AgreementTypeDomain" xlink:label="alny_AgreementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CoDevelopedOrCoPromotedCollaborationProductMember" xlink:label="alny_CoDevelopedOrCoPromotedCollaborationProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CollaboratorAxis" xlink:label="alny_CollaboratorAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CollaboratorDomain" xlink:label="alny_CollaboratorDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommonStockClosingPricePercentage" xlink:label="alny_CommonStockClosingPricePercentage"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CompensatoryPurposesMember" xlink:label="alny_CompensatoryPurposesMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ConcurrentPrivatePlacementMember" xlink:label="alny_ConcurrentPrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ExcessOfFairValueOverCashReceivedForStockIssuance" xlink:label="alny_ExcessOfFairValueOverCashReceivedForStockIssuance"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ExtensionOfTermMember" xlink:label="alny_ExtensionOfTermMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FairValueOfCommonStockIssued" xlink:label="alny_FairValueOfCommonStockIssued"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FitusiranMember" xlink:label="alny_FitusiranMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" xlink:label="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_GlobalCollaborationProductMember" xlink:label="alny_GlobalCollaborationProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_InvestorsMember" xlink:label="alny_InvestorsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_LockUpPeriod" xlink:label="alny_LockUpPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MaximumNumberOfPotentialFutureMilestones" xlink:label="alny_MaximumNumberOfPotentialFutureMilestones"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MaximumPercentageOfVotingPerCompanyRecommendation" xlink:label="alny_MaximumPercentageOfVotingPerCompanyRecommendation"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MilestonePaymentEarned" xlink:label="alny_MilestonePaymentEarned"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MinimumStandstillOwnershipPercentageTerminate" xlink:label="alny_MinimumStandstillOwnershipPercentageTerminate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" xlink:label="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation" xlink:label="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PatisiranAndRevusiranMember" xlink:label="alny_PatisiranAndRevusiranMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PatisiranMember" xlink:label="alny_PatisiranMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" xlink:label="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfSharesAgreedToSell" xlink:label="alny_PercentageOfSharesAgreedToSell"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PercentageOfSharingInDevelopmentCost" xlink:label="alny_PercentageOfSharingInDevelopmentCost"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PerformancePeriod" xlink:label="alny_PerformancePeriod"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PeriodAxis" xlink:label="alny_PeriodAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PeriodDomain" xlink:label="alny_PeriodDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PhaseThreeClinicalTrialMember" xlink:label="alny_PhaseThreeClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PhaseTwoClinicalTrialMember" xlink:label="alny_PhaseTwoClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PotentialMilestonePaymentsToBeReceived" xlink:label="alny_PotentialMilestonePaymentsToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ProductAlliancesMember" xlink:label="alny_ProductAlliancesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegionalCollaborationProductMember" xlink:label="alny_RegionalCollaborationProductMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RequirementOfEligibleFutureMilestonePaymentsAxis" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:label="alny_RequirementOfEligibleFutureMilestonePaymentsDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RoyaltyRate" xlink:label="alny_RoyaltyRate"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SaleOfStockAxis" xlink:label="alny_SaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SaleOfStockDomain" xlink:label="alny_SaleOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SanofiGenzymeMember" xlink:label="alny_SanofiGenzymeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SecondAnniversaryMember" xlink:label="alny_SecondAnniversaryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_StandstillOwnershipPercentageAmendRight" xlink:label="alny_StandstillOwnershipPercentageAmendRight"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage" xlink:label="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_UpfrontFeeReceived" xlink:label="alny_UpfrontFeeReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_AgreementsAxis" xlink:to="alny_AgreementsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_AgreementsDomain" xlink:to="alny_SecondAnniversaryMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_AgreementTypeAxis" xlink:to="alny_AgreementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_AgreementTypeDomain" xlink:to="alny_PatisiranMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_ProductAlliancesMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_InvestorsMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_RegionalCollaborationProductMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_CoDevelopedOrCoPromotedCollaborationProductMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alny_GlobalCollaborationProductMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_UpfrontFeeReceived" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MilestonePaymentEarned" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PercentageOfSharingInDevelopmentCost" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MaximumNumberOfPotentialFutureMilestones" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_RoyaltyRate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PotentialMilestonePaymentsToBeReceived" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MaximumPercentageOfVotingPerCompanyRecommendation" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_MinimumStandstillOwnershipPercentageTerminate" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_StandstillOwnershipPercentageAmendRight" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_LockUpPeriod" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_CommonStockClosingPricePercentage" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PercentageOfSharesAgreedToSell" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_FairValueOfCommonStockIssued" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_ExcessOfFairValueOverCashReceivedForStockIssuance" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alny_PerformancePeriod" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CollaboratorAxis" xlink:to="alny_CollaboratorDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CollaboratorDomain" xlink:to="alny_SanofiGenzymeMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_PeriodAxis" xlink:to="alny_PeriodDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_PeriodDomain" xlink:to="alny_ExtensionOfTermMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="alny_PatisiranAndRevusiranMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="alny_FitusiranMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsAxis" xlink:to="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:to="alny_PhaseTwoClinicalTrialMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_RequirementOfEligibleFutureMilestonePaymentsDomain" xlink:to="alny_PhaseThreeClinicalTrialMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SaleOfStockAxis" xlink:to="alny_SaleOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SaleOfStockDomain" xlink:to="alny_ConcurrentPrivatePlacementMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_SaleOfStockDomain" xlink:to="alny_CompensatoryPurposesMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="4.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_CollaboratorAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_AgreementsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_SaleOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ProductOrServiceAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_PeriodAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_RequirementOfEligibleFutureMilestonePaymentsAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="alny_AgreementTypeAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MunicipalDebtSecuritiesMember" xlink:label="alny_MunicipalDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="4.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alny_MunicipalDebtSecuritiesMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities">
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AccruedIntraperiodTaxAllocation" xlink:label="alny_AccruedIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_2"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_AllOtherActivityMember" xlink:label="alny_AllOtherActivityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CarryingValueInEquitySecurities" xlink:label="alny_CarryingValueInEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_ChangeInCarryingValueOfEquitySecurities" xlink:label="alny_ChangeInCarryingValueOfEquitySecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" xlink:label="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="invest_InvestmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="invest_InvestmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_RegulusTherapeuticsIncMember" xlink:label="alny_RegulusTherapeuticsIncMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_SalesOfRegulusSharesMember" xlink:label="alny_SalesOfRegulusSharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentAxis" xlink:to="invest_InvestmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentDomain" xlink:to="alny_RegulusTherapeuticsIncMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="alny_SalesOfRegulusSharesMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="alny_AllOtherActivityMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_CarryingValueInEquitySecurities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_AccruedIntraperiodTaxAllocation" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_ChangeInCarryingValueOfEquitySecurities" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_2" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="dei_LegalEntityAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="invest_InvestmentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_MunicipalDebtSecuritiesMember" xlink:label="alny_MunicipalDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="alny_MunicipalDebtSecuritiesMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="dei_LegalEntityAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_BankOfAmericaNALineOfCreditMember" xlink:label="alny_BankOfAmericaNALineOfCreditMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:label="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommitmentsAndContingenciesLineItems" xlink:label="alny_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_CommitmentsAndContingenciesTable" xlink:label="alny_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_LitigationDamagesSought" xlink:label="alny_LitigationDamagesSought"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_NortonMassachusettsMember" xlink:label="alny_NortonMassachusettsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireLand" xlink:label="us-gaap_PaymentsToAcquireLand"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_TermLoanFacilityMember" xlink:label="alny_TermLoanFacilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_WellsFargoCreditFacilityMember" xlink:label="alny_WellsFargoCreditFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="alny_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PaymentsToAcquireLand" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AreaOfLand" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesLineItems" xlink:to="alny_LitigationDamagesSought" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="dei_LegalEntityAxis" order="5.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="us-gaap_VariableRateAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_CommitmentsAndContingenciesTable" xlink:to="alny_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="alny_TermLoanFacilityMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="alny_BankOfAmericaNALineOfCreditMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="alny_WellsFargoCreditFacilityMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="alny_BankOfAmericaNALineOfCreditMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="alny_WellsFargoCreditFacilityMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="alny_NortonMassachusettsMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="alny-20160331.xsd#alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock" xlink:label="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g166732img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g166732img001.jpg
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M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4 9,
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M?1:W9+]F]Z53C(,K4@4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MZK[[<F3FM^SN!>@PQ)&>$LFV6XPY@BB^1AG404;*CZYM#:IS"E,<W1%>/9!
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MN())YI5KW]F]BS! M>^CL:;VM6Q&\&A0"@)!&?TE?\V-_KE5>/A*N)_68H*
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M4?TDUBDZ!9O"1*L9<4 M>]KVO:][7M>U[7M?1>U[>Q>U[=FVB@,2!B8BDJ-
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M"@% * 4 H!0"@% * 4 H!0"@*L<?]O6?G)W]>]8']LID;P&SJI(H!0"@% *
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M;1[.YQLCM!=;,Y_%J,YL;AT,S,3787L6BHCF*YKDZ*.:JHJ45%5%/M<P5_\
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MZT]S=E9#8C)1%*7-Q4W$H<'$\LBPSCS+W&:9<0A=F]Z S% * 4 H!0"@% *
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MJ:%=332I]*/U1-KWV.D.CL__ !2R!['9Z#]JOF_\VO\ FZ_^[+7_ +P^T?R
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M]&Y?Z,/6S*^C\?\ T5XU]%:>[.7>$ON>7?EA[^9YX+*_T;E_HP];,KZ/Q_\
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M!0%39ZB3S/L&9G@T<3D*Y#-,3Y%B;"E5*"D:92\R.'O#.UIU"LZUR4I!ZY8
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MY7:UL/E25H@R09"YR,:E*]4YB2I&-0>F"!2!O<C[=F4(1*YQ%@PN"B5%N&-
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M*J\?"5<3^LQ04 H!0"@% * 4 H!0&)??T4K^Y*_+E55_:J2G"5M6 R"@% *
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MP@V,!K/=]05@WO;3;LZ+WH#3X8KTBOU0<M(S@*1WW:-:1J"[ " \5^>KZQP
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MK)(VDCT8KD8WL^ROL+->,Y@!G4N>0DD?OL]YBR -QDK"E8EJC*>$6Q<.6,*
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M^N55X^$JXG]9B@H!0"@% * 4 H!0"@,2^_HI7]R5^7*JK^U4E.$K:L!D% *
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MO\P6S=G+DM_9;+K%FF0I?0VKDS!ZQ):7LM_*MNZ);;2L7+E:V7'54B;5NG1
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M,9-' YC;ETMJL#+9E895IH."6U0PQ",YH?66%0]=!FI$TQ<I>S*&B2L38HE
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M.HXV@Y10#AJ_H=1QM!RB@'#5_0ZCC:#E% .&K^AU'&T'** <-7]#J.-H.44
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M OP2C>: =9V+I OP2C>: =9V+I OP2C>: =9V+I OP2C>: =9V+I OP2C>:
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MS<KOSLZLC65ZUJZ16-5ZU542I]:7U.U[7V(8C>U]-NO.1_8_]Y5%?,7YIO\
M.&\_JEK_ "+3[E_(?H^73+D7AY=>_P NX[2*\ZGL<4 H!0"@% * 4 H!0$.E
M0;W&AT6O?WJCV+7O]DFL4G0+-X2)Z@_@B[F_:K&7&H/X(NYOVJ :@_@B[F_:
MH!J#^"+N;]J@&H/X(NYOVJ :@_@B[F_:H!J#^"+N;]J@&H/X(NYOVJ :@_@B
M[F_:H!J#^"+N;]J@)!&@BLXBO<(K6X,;V;VO;_7*J\?"5<3VLQ04 H!0"@%
M* 4 H!0&*?+7NUJ[6MIOJE?ERJJ_M5)3A*WU!_!%W-^U6 R#4'\$7<W[5 -0
M?P1=S?M4 U!_!%W-^U0#4'\$7<W[5 -0?P1=S?M4 U!_!%W-^U0#4'\$7<W[
M5 -0?P1=S?M4 U!_!%W-^U0&H2 6[D>]%^/)^Q?OH/\ 10A> MFM28Q0"@%
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M_*CXE[9^=1\WMO(GU._50GGS78YC#_)31+G91-)\2<I)L%K (M+(#BB+62-
M4"(%PEAM:]PEV$+V;WO?LU\T_F:L;7+M[-U:V;59 EK;*B8G.TK"U5TN5R_2
M?;?Y(\UO\Z^7_+[_ #%Z/N77MXBJC6,2B3N1.Q8UK?H.R;JVS^+G^4'+E==
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M&M=91(2<=M&5L@SW*$<9&*!P5N=2X-D!A?4G67*TYG*5P51MI>',346D7KE
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MYW#Z*/X/VR%W[+_GVV>BM/O>;V/!Y3S=_EA^KTW!>$S[G</HH_@_;(/?\O\
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M5_:J2G"5M6 R"@% * 4 H!0"@% * U"?QY']N3^5!0A> MNM28Q0"@% * 4
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MZ+;K/$JQW*M:C7).W"Y['M25K9FR(<O:T1UF* 4 H!0"@% * 4 H!0"@% *
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M*"6%I4?!5C;LY822IVU_;WHZ2))XU-Y,$LD;,@IWY0)6%X)"!78RP0ZVY@
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MFJO[524X2M]T*[Z5X4'WU8#(-T*[Z5X4'WU -T*[Z5X4'WU -T*[Z5X4'WU
M-T*[Z5X4'WU -T*[Z5X4'WU -T*[Z5X4'WU -T*[Z5X4'WU -T*[Z5X4'WU
M-T*[Z5X4'WU :I!A=SR+6,+O?=R=%K& O>_X4/8M:U[WO>A"\!;M:DQB@% *
M BLI<8I$8[(YE*;($#!&&5WDTA=3D/"N!,[(@4.CJO,+3ISU9_!4*4PRX2P#
M,%8.@-KWT6H#$MLIQ^[OR*,-YK:H?'"'HI\C0<U&EC.B;@MYO1NUC#D19  &
MK/>;D(5C@W[-P6MV: F'-;5IM;FYOTWM>]K<$3Z;VMHTWT;G]C3;W: QKN9%
MX^T.;\] 9VQE9F]8[.KFL(2E)$#:WIS%:Q:I-N7J@3IDQ0AB%]@-J +;Q]O,
M:BCVT Q/3A9M0B1L*EQ*LI$A6N-AKCV]"I):D-TS>9_>E0B4VZW 5NFZFE &
M!BE;["4,P8H&IL@*E4DC\DD[,V<UB'PQCB*Z,ML@6\* E$C)X"LF#>#4,,"8
M9N^D 16 .X8KIH31:5Z!)^;&O3:W-S?IO:][6X(GTWM;1IO:VY]G1IM[M20;
M%P+8FQ$:X*FX@:8FP+BX&S&.2@5C!@+!N*-N1JEBC2(=KWW,L6@.D5] ;7O8
M#2$;&P.]F(29OLZ7;3'C@UT)78;BE):0Q0(W<;$AL%0:$.BXM;LZ=&BU[T!D
M[MC5;V6]OMV-/92)[=BVBU__  _8M>]J V*4#&L/<$Q+:2$UL6A;U5U#,:C*
M&I&A1N5N!*%:,DES3\%7 TG)A&DV-L,JXK&%F "!O^:FOHU!Q-/O= .:FOHU
M!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .
M:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-
M/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FO
MHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O= .:FOHU!Q-/O=
M .:FOHU!Q-/O= ?F;?6*9>RRQ;>>V(S,F4,A,[0V[1F5T3:U-<SD;<W-Z)/+
M7(LA(B1)7(E,E2D%AL$ "PA"&UM%K5W?D-I:R91;O?&Q7+$W2K47]ZG2/T![
MB-EMF+O<QLO=766V$MP_(K-SG/@B<YRK Q557*U55572JJ<,_7GFWYXLI^?\
MJ^-:W?D-GX*/N4ZQVO[F[(>RLNYM#W@]>>;?GBRGY_RKXUIR&S\%'W*=8>YN
MR'LK+N;0]X/7GFWYXLI^?\J^-:<AL_!1]RG6'N;LA[*R[FT/>#UYYM^>+*?G
M_*OC6G(;/P4?<IUA[F[(>RLNYM#WA*H1.]IS)<NCT Q]/,V3*;2US(98S%H[
M,9BYO;ZZJKWW% V($[F,Y4I.U;WL$-O8M>_L6K#<6^6VT2S3LB;$U*JJM:B?
MN&VYQDV[O9_*Y\[SRRRBURFVC5\LTL$#(XV)PN<Y6HB(G&INS9;M5D,]Y ?,
M<Y$,EIR=C03H;+)H4C#D%,D+6J(8,X;F$()&0D-"8-+?08$%[7O:JMCRK'A1
ML.+#BI1O!Q_@,3<MW:ON^0MM,F6[6T2ZP)# KN3*N%)Z8?\ 1JY*(_@5>B9>
M5+=L>#%3,^9O6T)%BL<S1%CF>F/\@G;7U0G;BD=E[=$G\*M>4)M?5Z%C6'$D
M&6L,PI.,8=(;::K$F43JU(FP.5[<241JU1*57^,G5-+ED6ZG.7VC,IAR.Y??
MVCKFWU<5N_76[%8UTT>%JXHVND8USDT(KD1=*FPO(MK6V-2\R7E.>O50=-!8
MZ*R)>3S;JB9.P- 7X42+>N<>!C?@LPK*>#V%K[E[[15L&5I/R7##KL&+#1M<
M-:5IP\)J.0;LO7Z[*\FR7WD2TY4MMJK?7);X]7KM7AQ:O'V.*E*Z"\;X(^LY
M"X0UHO =K_G7(+0N?X<V:,D\X/;.VIF]6X+B4?#+J$I:-,[)##+* E#"%43?
M1^%!K:/EFSRH]R+;]AH7M.']B'#4VS^7M8+NX2\V7Y/8RMCG=_1<+'O5S6M5
MU*+56/1,*JE6.^JZG&1ZRSM"QQW=(_(<F9D8GYC<%;2],CQ,IDVNS0Z-YXTB
M]M<FY8XDJT*Y$I*$6:48 (RQAO:]K7M6X,M+"1B21QQ.C5*HJ-:J+]!V':;,
M[#9A:1WUCE^5364S&OCD9! ]CV.2K7,<UJM<UR*BHJ*J*FE#[K/J$8W'LF_5
MRP&69'867($I59$RND5R:;-+?*)"J2H)>K3HDZIY?$ZYQ4$HT]K%E!&9>Q9=
MK!#H#:UJZEVK<Z#.I(H%5D:(W0BT3@XDT'QT^<R^O=G]^U]EF0S3666MLK16
MQ0/=#&BNA17*C(U:U%<NE51-*Z5TG<]ZG<1?-7CCS'C'Q97'>47'A']TO7/*
MOO3M-[1O^<2]^/4[B+YJ\<>8\8^+*<HN/"/[I>N/>G:;VC?\XE[\>IW$7S5X
MX\QXQ\64Y1<>$?W2]<>].TWM&_YQ+WX]3N(OFKQQYCQCXLIRBX\(_NEZX]Z=
MIO:-_P XE[\>IW$7S5XX\QXQ\64Y1<>$?W2]<>].TWM&_P"<2]^/4[B+YJ\<
M>8\8^+*<HN/"/[I>N/>G:;VC?\XE[\>IW$7S5XX\QXQ\64Y1<>$?W2]<>].T
MWM&_YQ+WX]3N(OFKQQYCQCXLIRBX\(_NEZX]Z=IO:-_SB7OQZG<1?-7CCS'C
M'Q93E%QX1_=+UQ[T[3>T;_G$O?CU.XB^:O''F/&/BRG*+CPC^Z7KCWIVF]HW
M_.)>_(=*<.X@UT5Q8EQ@;?5/M:Y^/8@HN&VL5V W/9S+@"+3V=&C36-]S<I2
MDCT_ZR]<NS:K:E.US/,4_!<SI^X]")>IW#WS08H^C:%?$54Y7=>%D[I>N6]Z
M=JO:F9\[N/*#U.X>^:#%'T;0KXBIRNZ\+)W2]<>].U7M3,^=W'E!ZG</?-!B
MCZ-H5\14Y7=>%D[I>N/>G:KVIF?.[CR@]3N'OF@Q1]&T*^(J<KNO"R=TO7'O
M3M5[4S/G=QY0>IW#WS08H^C:%?$5.5W7A9.Z7KCWIVJ]J9GSNX\H;ZV,<9!#
M8(<9XY"$-K!"$,%B@0A#:VBP0@LT6L$-K6[%K=BU8M?)]9_TF/WFVE]HYASF
M?OQZL<9?-KCKS%BGQ14ZZ7ZSNJI/O+M+[2S#G,W?CU8XR^;7'7F+%/BBFNE^
ML[JJ/>7:7VEF'.9N_'JQQE\VN.O,6*?%%-=+]9W54>\NTOM+,.<S=^/5CC+Y
MM<=>8L4^**:Z7ZSNJH]Y=I?:68<YF[\D48QIC8#D*Y>.8 2+@QMM<B%QE./1
MKE:;:Y+6 >K?VM.B]69+(JZ7.X.-3!/GV?3LP7%]>R1UK1\\KDKQT<]4KTRP
MO5QCSY!PSS78^0UEQOXUZII?6F9^<3^,?UQZN,>?(.&>:['R&F-_&O5'K3,_
M.)_&/ZYDV^*QEI*&2U1QB;"31V--*;VAO1EF&6#8&N,*9.6$8]2UK:;VOV+:
M**Y572:::XGN'(ZX>][D2B*Y5<J)Q:54R/-37T:@XFGWNJF(<U-?1J#B:?>Z
M <U-?1J#B:?>Z <U-?1J#B:?>Z <U-?1J#B:?>Z <U-?1J#B:?>Z <U-?1J#
MB:?>Z P[\T-0FE9838WBMJE=BZ)->WX\K[%RZJ[M05GS(S=$MG$$N]5AQ.XU
M,F%!S(S=$MG$$N]4Q.XU&%!S(S=$MG$$N]4Q.XU&%!S(S=$MG$$N]4Q.XU&%
M!S(S=$MG$$N]4Q.XU&%!S(S=$MG$$N]4Q.XU&%!S(S=$MG$$N]4Q.XU&%!S(
MS=$MG$$N]4Q.XU&%!S(S=$MG$$N]4Q.XU&%!S(S=$MG$$N]4Q.XU&%#<)6AI
M*5)3"VQO 8!208 8$28 P""<"X1@$$G6"(-_8O;LVIB<G1&%"ZZU!C% * 4!
M767H8LR/B;*&/&Y8F;G">8[FL,0N"T!QB- LE$;<V-*L5E)_PYB9*>N",P(/
M?W &]K=G14*E4H2FA3@E*-C^38D:'.8;.RA21DA+B3%D%AZ1RD4[EZ([),'G
MA;TU.LAO,)BHX'C%8D7J$KV2F/)4";#CAV"8<61:T4['"*Z:J9J0[*N09"\Y
M#C$:.C^.(US G8H?F)"]O2O+"@RVSP1BM,WD-G-HD2.,(7QU.<#SC'09QZQ+
M>_!-<055HHM*?LX"45$6JZ3)$[(,C=XV[@E HB:^+L.9_@:!E<GYUF\;:I;F
M(^+!3OR=4*%P9 6U!01P12DLEB(/3@5&@)$9NIXSIP_N4(K^Z;?)FR_-W*-9
M%EC.4AM.Y/,54\6QB%2=X:U:UC;]DMWPBSXKB<L<K,29J(0SET-<D!XDZ!$&
MQEU!A):H0A6*B_22BTZG_24E$]G_ #*?CU_G*R(J8[DN+1[)5XU=F36:U^0L
MO/Q^S5)H%/F"$"4M9>-X2RS/"UT*]@6K#0G(K'G\(&2J&.]<"UK72%5/V?ME
MZ/&RODI=!9M FERA;4JG^+TS8?EE0^RE5DN(SLYH6WDK2U .9EI3A")3)W%6
MK.4 <D"D@MT6@X*?:Y6K>FBG0&):](U(ILB2E!=6].;NU-T@40R0L;:AM+I-
M,448>99E\W(\D5,SH9'H,B);W5L 2DU$K*@NF]^25:Q Q[I:I./3TB-N>R3F
ME:S/3<5*8$C<6R<M\H:9.UNDA0R[,#8FS$_Y,5LF7'MSBTA2,214UNY*,!"=
M%($I2Q)NUB^"C B(QX5XUJ1B3B,HT[#XBUL5<'A5&G ;+*$+DK3NZM^ERL47
M0;)*O B*(#?75*WC>43=/%7/@+FI$R<P  F\'+5A!<$JBKU?^@52M?V<)A<A
M[(N>9)=$RQ_)<.1QD^28ZDRY8KN]))6R.L C.SNPV/9G>S*].2EK>/5(\7.;
MDJUDL8<Z)U"A0IW,U,*Q&BG3.RVA H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MV;WOP+L:* !0#&&P@NSD((K6$$5C$=["#>VFUPWLCT7M>@//-QO2KGW:/D5
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M"S>$B58RXH!0"@% * 4 H!0"@)!&?TE?\V-_KE5>/A*N)_68H* 4 H!0"@%
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MIV/\+Z!V72&L_P#>F+C#ER6G8_POH'9=(:S_ -Z8N,.7):=C_"^@=ETAK/\
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M(:(9!H+#+O>X@OB@% * 4 H!0"@% * 4 H!0"@% * 4 H#\N/ZRG_J"[:/\
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M!WU1&/B8WL7)W1WDS/+Y#+&6(;6Z5OEL0>'<;]DC%;OF['D=@\=2K7)QA3T
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M,/ZC9?R#3O*KC)Y#% * 4 H!0"@% * 4!#97]NA^Y4?TDUBDZ!9O"1*L9<4
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M=F^D#(%I(J2XK'@J"[D[.(DXW!T+B:4#BN$D+"2E$L6A3V4JQ)BP6"7<8A7
M&UK6T6H VI8JS)1(6>"7:40['V&C;8DE0I164E$$J;"3I2"BKV4$IBP#TV]^
M$L-KZ;!MH QJZ/PITDK9+W*#*5\@94ZLAJ<%D<"I,;Q+5;8M4+$ECRQA3N(U
M#,FOPD&@ZUB0VUM%K4)JM*= W=FN%A(<4H<>DA3.ZA2L=DX88AL0Z*UB92C5
MJG$JR;<UJA4E6'%&#-L(0RS1A%>X1"M<095K4,[&D WLL57-" L9AA:%KCH6
M]& PTP1A@P)D@"B0C-'>XA7L'2*]]-Z R//X.B'_ ,E']N@'/X.B'_R4?VZ
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M*7J#W\C]DY[S-_7,Z5B:7DL949(VA,($QM._@E9#"3G!$4SE2<I&%N)D9;:
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MG$I:)Q,MLV%RB91]M7L[%*'W:96.;\RM3LC4MSN@:714H-5-R1W1+#BE8"1
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M/OE<;/)8YU:^DD''$^^4 YU:^DD''$^^4 YU:^DD''$^^4 YU:^DD''$^^4
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M#HS;G;O:G>/M#)M3ME<I=Y[+&QCI$CCBJV-N%B8(VM8E&Z*HE5Z)R.K"<0%
M* 4 H!0"@% * 4!#97]NA^Y4?TDUBDZ!9O"1*L9<4 H!0"@% * 4 H!0$@C/
MZ2O^;&_URJO'PE7$_K,4% * 4 H!0"@% * 4!B7W]%*_N2ORY55?VJDIPE;5
M@,@H!0"@% * 4 H!0"@-0G\>1_;D_E04(7@+;K4F,4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 58X_P"WK/SD[^O>
ML#^V4R-X#9U4D4 H!0"@% * 4 H!0$_C7Z-O^<F_T K-'VIC7A)!5R!0"@%
M* 4 H!0"@% 0V5_;H?N5'])-8I.@6;PD2K&7% * 4 H!0"@% * 4!((S^DK_
M )L;_7*J\?"5<3^LQ04 H!0"@% * 4 H!0&)??T4K^Y*_+E55_:J2G"5M6 R
M"@% * 4 H!0"@% * U"?QY']N3^5!0A> MNM28Q0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!5KG^D5OYT?^4%6!_;
M*9&\!LJJ2* 4 H!0"@% * 4 H"?QK]&W_.3?Z 5FC[4QKPD@JY H!0"@% *
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M(\L&86+=$;DAN.3Q-23!BPN;_I$HB*O9I^^III1=#E4S6V:9:UR)$]+>XY)
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MX-INK^QER1UHZ1%NTN'.;@8J*Y%<M72JYM%2E%8J*CDKA<VFE.PVMB.,"@%
M* 4 H!0"@% * 4 H!0"@% 58X_[>L_.3OZ]ZP/[93(W@-G5210"@% * 4 H!
M0"@% 3^-?HV_YR;_ $ K-'VIC7A)!5R!0"@% * 4 H!0"@% 0V5_;H?N5'])
M-8I.@6;PD2K&7% * 4 H!0"@% * 4!((S^DK_FQO]<JKQ\)5Q/ZS%!0"@% *
M 4 H!0"@% 8E]_12O[DK\N557]JI*<)6U8#(* 4 H!0"@% * 4 H#4)_'D?V
MY/Y4%"%X"VZU)C% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0'QK[67^84VF,%;4.T)A5@P/@=[8<49@G4 9GAZ69"
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M GR01PUT:D[!(WY8@**=8T=?<G M(H$F.3FV!^$$$N45%2J$*E"Z:D"@% *
M4 H!0"@% * 4 H!0"@% * 4 H#\N'ZR#_J"[:_\ ZG,O_P"+5]>C]G_]AVG]
M79^*A[ V5_W8R_\ J<7XJ'"VMX-^% * 4!R9V/<#VVD=H6#XO7-TP<HC<J0S
M7)(( C"OFI&,<?L#A+)L.*)C$JT@V3KFMLX"UA,*,+,<EB<%PBUM%]NS:]]7
MV#[E%8DNAK,6AN-RHUN+@T(JU7I(IM&>YEZJRN2[:L:3]BR/&M&:QZHUF+@[
M%%6KOX**<A]I;8GC>S_&]I5Q4N$T)<L6[6N$<28W)D@43=S[AS-^,9QE&-R"
M1(+H2S[R\+.TMQ0Q$#*3@/X2"Y5[VM8&@R[-WWTMNU$;AEM9'OIII)&]K%1-
M/:U5>'3P:3;,HV@ES.6T:U(\$UE+))AJN&6*1D;FM6O:U5RZ=-*:>/D'M*?5
M;Q?'4:S3+,%3AZRFQ-^>,1X7PLO>GV)18E+*WF^3F[-F+\M+WZ[$PM,_Q\[P
MA$H1J;K$")6S.J55JBX2&P=!E^TDMS)#%>,2)ZP222(B.7L4P+&]B)55:Y'*
MBI151S53H&UY5MC-=36\&8QMAD6WEEE1$<ZK4U:Q21HE55CT>J*E'*CFJWH$
M>Q!]6A&)U$\0S"4Y,BT>ZP;/6UUD/(L#OER"$93.R'L_.&:&Z-$XPA0$CDJE
M< -/QXAYU6IC590P\+&2>$%@W#:[VBDAEEBBC<Y6SP-8[ [!@E2-5QNT87=D
MN%%IT*H9;[:V:VN)X(87OPW5LQC]6_5X)DB5VL?5,+Z/7"BT7M:H35[V#MCB
MV3I; 29CG"!MVS^X[(!F>YE,)-!'>+R.)[5Z."LP7:#*$41:5D*D6/I;/DZT
MQ XV<R7)B1*Q -)-!85L;,[S?D[)L$+W3I/JFM1R.1T.):.[)<2.:U4JE*.5
M-"H:>/:3/>2,NECMY'727.I8UKT<UULKUH^KE1[7M8J5;A5KU;H5#@OM:[*E
MMD9JQ/!)XM= ;1,C-RM(<F16YJ:S%$8&R9!7P'$AJ9+9/9>6[3Q/$W5]N,TT
M98VI6@$6$.M<0MZRO,TS5TMQ B<@;@1CNBYRMQ/Z5&XFM_"CCD>2YSZ[?/<V
MR)ZK;JVQNZ+GJQ'R:>"C,36:$[9'5/M1_P NG_TQ,?\ _%3-7^.E]=1;>_[Q
MR?ZJ/\5#H/>C_O=+_J8OQ$.]"N&'78H!0"@% * 4 H!0"@(;*_MT/W*C^DFL
M4G0+-X2)5C+B@% * 4 H!0"@% * D$9_25_S8W^N55X^$JXG]9B@H!0"@% *
M 4 H!0"@,2^_HI7]R5^7*JK^U4E.$K:L!D% * 4 H!0"@% * 4!J$_CR/[<G
M\J"A"\!;=:DQB@% * B<CM$Y"SOL4DQ2-T97UL<H^_LZT@XY&Y-3JD.;W1M5
MEV+U34JQ&H&49;3H$$5[4!!WS'^'9%=(-V8&PX]O:H^R-R]+=T;'1K;(J\%/
M\;3-3LUG(W-LYF>"0GD#(-+, .U_?:+WM<*Z:]$C0\+834NKFZN[8*0<X-R9
MH*;WYSD+LU(6Y/$#H.,*=N6K3T9SDJCJQ4G,<#@&. BU9H-WU17M0FJTIT#-
M)<8X62$73EL28TLTF6IU8EKA(G(YT(G29L2RTI[4N"Y2I?2WM.R([&V6#/T7
M2E7!JB+!>P@R!D'Q28N<G2R"Y#HZ'/1ZAT1.DE0N:<<D71MT?[-+@A7IUC$4
M\.40;E"@"(:<!IZ6Q@K7$(=Q 8IZQ7A&0-,-9'..HQ(,>D.":%<!6R%H71PA
MV:#V!U+;G9H7(74%G-G4F$*;B.%<\([W'K"[- 9MRA6('?&RS#KC%XRIQ:X1
M<Z%K(&)HL",G14]%=O-8^;2B"R (1(Q7!JAM:]O9M>PNS0&Y.B^+#Y(WR\UB
M8QR9J R%MSU=";9<B+C;?+VIA F-L7:Q8&INGSR23:UM "W(^W^O0%;E[/FS
M:03(DZ6$MR(F6(C6R0EH7.5H N3(<ME#B?&S.!NA%R8LH735V-&U%:C<,;@=
M>Y%]>]":KQEDG1C%BA>TNAK"Q77L36T,K*H"W"+$UM# \MTA96Y"$LH!:9&V
M/32F4DEAM8(#" 7M;L:*$$:/Q3@LY(-&&*,Z(L2AD6 /:>=F5Q3*XW(Y/+F-
M6A=FA0A<V]2V2.:NZLLP@XL=C'%1:][A,$&X&H+&.&1$/R83-8223L1<<D*,
M3Q*!(GEN):T#(6<O17<KI5#W9I:TQ'.=P<Y7+(+M<_WMM &HX8TPJZNR-]7Q
MQM.=D;@%TX<$QX).7K +V5U -\X.H*!(B0.L=1*K$K[*2;*DX3=7=-(K@3)E
M2P6.V*"QI&]LL0ALVE<$3'E[F@LN6.04H;[G>^Y67KSC='PS17^S0$AZP,_C
MH/!G[U0#K S^.@\&?O5 .L#/XZ#P9^]4 ZP,_CH/!G[U0#K S^.@\&?O5 .L
M#/XZ#P9^]4 ZP,_CH/!G[U0#K S^.@\&?O5 .L#/XZ#P9^]4 ZP,_CH/!G[U
M0#K S^.@\&?O5 .L#/XZ#P9^]4 ZP,_CH/!G[U0#K S^.@\&?O5 .L#/XZ#P
M9^]4 ZP,_CH/!G[U0#K S^.@\&?O5 .L#/XZ#P9^]4!^:K]8+@?,$EV[=L60
M,4$<'%F>MH[+#DU+RW2.$EK$*J5+S$ZD!2I\3J"@F@O:]@F  .WV;6KT)D5]
M9QY+:,?(B*ENRNA?JITCUELQF5A%LW81OD1'MM(T5*.T+A3I'$']FS.WS<.?
MEB)^D%;IZSL?")U'=8WWUIE_A4[EW>C]FS.WS<.?EB)^D%/6=CX1.H[K#UIE
M_A4[EW>C]FS.WS<.?EB)^D%/6=CX1.H[K#UIE_A4[EW>C]FS.WS<.?EB)^D%
M/6=CX1.H[K#UIE_A4[EW>DQBF+=JR#(9JW0Z.R6.(\C1!3 IR4UOL.(')(6N
M=&QY71I<IN]C5%M2YR9TIIX"1E7.W (1WN#6#?'+=97.K'3.:Y8WXFU1VAU%
M2O!PHBK2O&:>:\R:=8W3N:]\3\;*M=V+T141R:*51%6E>"I=3/.?K&6&(N,!
M;)!. 0UWA\7@+C'EJK%KNA4Q"$M;TQQ!E%=X$O4%@C3/(UR9&> P*HDE2((3
M=%@ZNC?%D$DJ3N:S6(]SD5,:+B<J*Y='&J(JIP:. V^2WV6EG2Y>R/7)(YZ.
M1)$5'/5%<NBG;*U%5.!53@*^D3)MMS".9 A\GZ\/L5RMD)#EG(L=<9)#3FF6
MY*;$RI&CFKFCYX"4%_)2+#"A&D[E8P%PV'86H#5SQR9-'(R6+ V2*-6,5$=5
MK%TX4T<!JHI-G[>6*>!(VS0Q+&QR-?5L:Z58BT[6O06IZ,+!MJ18R&FQTB8L
MX\=P><8T@YB-\@X;QF!9+O([SZ*M>NZCL!JE5Y>Y\*"/7%?AIFH(/O="23)I
M5?C5BI(]KW:':7,IA<NCA;A2GX$$LF03:Q)<#DED9(^J/[)\>' Y='"W"VGX
M$)9E5\^L%SA%6V"Y7>9_-(<U*&56FCJYZQ\WMQZR-LH(U'5[N!D6M1L@7L#
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MY8;*//3G90@A DL7.FRDT^3-*=(1$DQ1:I5(3EQJD"(MK2(S0*#C;F6"4F,
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MNA;SSM0.D6YDC%HT!O0&*"LQD,!A@'B+# 3);0PP87U'<!<ON<!/:*F"LMT
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MR3BS8EPFU8#PW>3"@K,_220HKRY\M(GOATI=#'=SL<YV1-^Z$66'"W,.Y6U
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MKZ8Q*>Y<7. 86.ZLJ]@& '>VY"[.H*PM'VWV=%-7TQB4F59"HH!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MN6,8= K["]K&O5K'8F(NA=*5Z=%TZ>GI-\8KE8BN3"Y4X.&G2T:#.54L* 4
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M2@7"2QUM7,;(8].1Q)!8'%S3I')>I,-L$(#0A!8L>I<L5[ :S6]S!6Q2A[?
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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??=-35T[IH#IU]7_7U='L]G1HH#WH!0"@% * 4!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6806687376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Apr. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALNY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALNYLAM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,560,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6807176608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 231,278<span></span>
</td>
<td class="nump">$ 180,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">748,422<span></span>
</td>
<td class="nump">848,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent', window );">Investment in equity securities of Regulus Therapeutics Inc.</a></td>
<td class="nump">33,934<span></span>
</td>
<td class="nump">51,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Billed and unbilled collaboration receivables</a></td>
<td class="nump">8,814<span></span>
</td>
<td class="nump">8,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">27,626<span></span>
</td>
<td class="nump">16,559<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,050,074<span></span>
</td>
<td class="nump">1,105,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">228,590<span></span>
</td>
<td class="nump">251,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">36,814<span></span>
</td>
<td class="nump">27,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,316,949<span></span>
</td>
<td class="nump">1,386,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,442<span></span>
</td>
<td class="nump">16,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">30,805<span></span>
</td>
<td class="nump">28,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">16,944<span></span>
</td>
<td class="nump">15,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">66,369<span></span>
</td>
<td class="nump">62,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">6,204<span></span>
</td>
<td class="nump">5,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">53,952<span></span>
</td>
<td class="nump">52,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 127,898<span></span>
</td>
<td class="nump">$ 121,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value per share, 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2016 and December 31, 2015</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share, 125,000,000 shares authorized; 85,463,258 shares issued and outstanding at March 31, 2016; 85,090,968 shares issued and outstanding at December 31, 2015</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,546,884<span></span>
</td>
<td class="nump">2,506,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(9,011)<span></span>
</td>
<td class="nump">4,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,349,677)<span></span>
</td>
<td class="num">(1,246,703)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,189,051<span></span>
</td>
<td class="nump">1,264,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,316,949<span></span>
</td>
<td class="nump">$ 1,386,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in equity securities and other forms of securities that provide ownership interests classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6807189152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,463,258<span></span>
</td>
<td class="nump">85,090,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,463,258<span></span>
</td>
<td class="nump">85,090,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6806764224">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Net revenues from collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,345<span></span>
</td>
<td class="nump">$ 18,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">96,273<span></span>
</td>
<td class="nump">58,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,100<span></span>
</td>
<td class="nump">12,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,373<span></span>
</td>
<td class="nump">70,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(110,028)<span></span>
</td>
<td class="num">(52,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,054<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(102,974)<span></span>
</td>
<td class="num">(51,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Benefit from income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (102,974)<span></span>
</td>
<td class="num">$ (50,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used to compute basic and diluted net loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,277<span></span>
</td>
<td class="nump">82,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (102,974)<span></span>
</td>
<td class="num">$ (50,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,224)<span></span>
</td>
<td class="nump">3,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustment for realized gain on marketable securities included in net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (116,354)<span></span>
</td>
<td class="num">$ (47,155)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Non-cash stock-based compensation expenses included in operating expenses are as follows:                 Research and development     $ 14,356      $ 5,346        General and administrative       9,124        2,890</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of income tax expense or benefit for the period that has been allocated among continuing operations, discontinued operations, extraordinary items, other comprehensive income, and items charged or credited directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6683612896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">$ 23,480<span></span>
</td>
<td class="nump">$ 8,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">14,356<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">$ 9,124<span></span>
</td>
<td class="nump">$ 2,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6807108608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (102,974)<span></span>
</td>
<td class="num">$ (50,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,601<span></span>
</td>
<td class="nump">3,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">23,480<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Charge for 401(k) company stock match</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gain on sale of marketable securities</a></td>
<td class="num">(5,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Benefit from intraperiod tax allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Billed and unbilled collaboration receivables</a></td>
<td class="num">(516)<span></span>
</td>
<td class="nump">29,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,010)<span></span>
</td>
<td class="num">(3,179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="num">(4,305)<span></span>
</td>
<td class="num">(8,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">2,579<span></span>
</td>
<td class="num">(6,189)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(83,623)<span></span>
</td>
<td class="num">(26,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,759)<span></span>
</td>
<td class="num">(2,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(164,561)<span></span>
</td>
<td class="num">(507,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">294,317<span></span>
</td>
<td class="nump">168,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Deposit for manufacturing facility</a></td>
<td class="num">(9,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">117,940<span></span>
</td>
<td class="num">(341,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and other types of equity</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">13,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock to Sanofi Genzyme</a></td>
<td class="nump">14,301<span></span>
</td>
<td class="nump">89,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for repurchase of common stock for employee tax withholding</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,066<span></span>
</td>
<td class="nump">598,984<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">50,383<span></span>
</td>
<td class="nump">231,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">180,895<span></span>
</td>
<td class="nump">75,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 231,278<span></span>
</td>
<td class="nump">$ 306,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26805-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of income tax expense or benefit for the period that has been allocated among continuing operations, discontinued operations, extraordinary items, other comprehensive income, and items charged or credited directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6797402608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 The accompanying condensed consolidated financial statements of
 Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared
 in accordance with accounting principles generally accepted in the
 United States of America, or GAAP, applicable to interim periods
 and, in the opinion of management, include all normal and recurring
 adjustments that are necessary to state fairly the results of
 operations for the reported periods. Our condensed consolidated
 financial statements have also been prepared on a basis
 substantially consistent with, and should be read in conjunction
 with, our audited consolidated financial statements for the year
 ended December&#xA0;31, 2015, which were included in our Annual
 Report on Form 10-K that was filed with the Securities and Exchange
 Commission, or SEC, on February&#xA0;12, 2016. The year-end
 condensed consolidated balance sheet data was derived from our
 audited financial statements, but does not include all disclosures
 required by GAAP. The results of our operations for any interim
 period are not necessarily indicative of the results of our
 operations for any other interim period or for a full fiscal
 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 The accompanying condensed consolidated financial statements
 reflect the operations of Alnylam and our wholly-owned
 subsidiaries. All significant intercompany accounts and
 transactions have been eliminated.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and the disclosure
 of contingent assets and liabilities at the date of the condensed
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Net Loss Per Common Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 We compute basic net loss per common share by dividing net loss by
 the weighted-average number of common shares outstanding. We
 compute diluted net loss per common share by dividing net loss by
 the weighted-average number of common shares and dilutive potential
 common share equivalents then outstanding. Potential common shares
 consist of shares issuable upon the exercise of stock options
 (using the treasury stock method), and unvested restricted stock
 awards. Because the inclusion of potential common shares would be
 anti-dilutive for all periods presented, diluted net loss per
 common share is the same as basic net loss per common share.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would be anti-dilutive, in
 thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>At March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">185</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,805</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Public Offering</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 13%; -webkit-text-stroke-width: 0px">
 In January 2015, we sold an aggregate of 5,447,368 shares of our
 common stock through an underwritten public offering at a price to
 the public of $95.00 per share. As a result of the offering, which
 included the full exercise of the underwriters&#x2019; option to
 purchase additional shares, we received aggregate net proceeds of
 $496.4 million, after deducting underwriting discounts and
 commissions and other offering expenses of $21.1 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 The fair value is the price that would be received to sell an asset
 or paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. In general, fair
 values determined by Level&#xA0;1 inputs utilize quoted prices
 (unadjusted) in active markets for identical assets or liabilities.
 Fair values determined by Level&#xA0;2 inputs utilize data points
 that are observable, such as quoted prices (adjusted), interest
 rates and yield curves. Fair values determined by Level&#xA0;3
 inputs utilize unobservable data points for the asset or liability,
 and include situations where there is little, if any, market
 activity for the asset or liability. The fair value hierarchy level
 is determined by the lowest level of significant input.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Investments in Marketable Securities and Cash
 Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 We invest our excess cash balances in short-term and long-term
 marketable debt and equity securities. We classify our investments
 in marketable debt securities as either held-to-maturity or
 available-for-sale based on facts and circumstances present at the
 time we purchased the securities. At each balance sheet date
 presented, we classified all of our investments in debt and equity
 securities as available-for-sale. We report available-for-sale
 investments at fair value at each balance sheet date and include
 any unrealized holding gains and losses (the adjustment to fair
 value) in accumulated other comprehensive income (loss), a
 component of stockholders&#x2019; equity. At March&#xA0;31, 2016,
 the balance in our accumulated other comprehensive loss was
 composed solely of activity related to our available-for-sale
 marketable securities, including our investment in equity
 securities of Regulus Therapeutics Inc., or Regulus. Realized gains
 and losses are determined using the specific identification method
 and are included in other income (expense). We recognized $5.2
 million of realized gains from sales of our Regulus
 available-for-sale securities as other income on our condensed
 consolidated statements of comprehensive loss during the three
 months ended March&#xA0;31, 2016. If any adjustment to fair value
 reflects a decline in the value of the investment, we consider all
 available evidence to evaluate the extent to which the decline is
 &#x201C;other than temporary,&#x201D; including our intention to sell
 and, if so, mark the investment to market through a charge to our
 condensed consolidated statements of comprehensive income (loss).
 We did not record any impairment charges related to our fixed
 income marketable securities during the three months ended
 March&#xA0;31, 2016 or 2015. Our marketable securities are
 classified as cash equivalents if the original maturity, from the
 date of purchase, is 90&#xA0;days or less, and as marketable
 securities if the original maturity, from the date of purchase, is
 in excess of 90&#xA0;days. Our cash equivalents are composed of
 commercial paper, corporate notes, U.S. government-sponsored
 enterprise securities and money market funds.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 We account for our investment in Regulus as an available-for-sale
 marketable security.&#xA0;Intraperiod tax allocation rules require
 us to allocate our provision for income taxes between continuing
 operations and other categories of earnings, such as other
 comprehensive income. In periods in which we have a year-to-date
 pre-tax loss from continuing operations and pre-tax income in other
 categories of earnings, such as other comprehensive income, we must
 allocate the tax provision to the other categories of earnings. We
 then record a related tax benefit in continuing operations. Upon
 sales of our available-for-sale marketable securities, we apply the
 aggregate portfolio approach to recognize the related tax provision
 or benefit into income (loss) from continuing operations. As a
 result, the disproportionate tax effect remains in accumulated
 other comprehensive income (loss) as long as we maintain an
 investment portfolio.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Subsequent Events</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 We did not have any material recognized subsequent events. However,
 we did have the following nonrecognized subsequent events, which
 are more fully described in Note 5:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="4%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">On April&#xA0;4, 2016, we completed
 our purchase of land in Norton, Massachusetts for the construction
 of our new drug substance manufacturing facility.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="4%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">On April&#xA0;29, 2016, we and
 Alnylam U.S., Inc., our wholly-owned subsidiary, entered into
 credit agreements with Bank of America N.A., or BOA, and Wells
 Fargo Bank, National Association, or Wells, related to the build
 out of our new drug substance manufacturing facility.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 In May 2014, the Financial Accounting Standards Board, or FASB,
 issued a new revenue recognition standard which amends revenue
 recognition principles and provides a single, comprehensive set of
 criteria for revenue recognition within and across all industries.
 The new standard provides a five step framework whereby revenue is
 recognized when promised goods or services are transferred to a
 customer at an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The standard also requires enhanced disclosures
 pertaining to revenue recognition in both interim and annual
 periods. In August 2015, the FASB deferred the effective date of
 the new revenue standard from January&#xA0;1, 2017 to
 January&#xA0;1, 2018. In March 2016, the FASB issued amendments to
 clarify the implementation guidance on principal versus agent
 considerations. In April 2016, the FASB issued amendments to
 clarify the guidance on accounting for licenses of intellectual
 property and identifying performance obligations. Early adoption is
 permitted any time after the original effective date, which for us
 is January&#xA0;1, 2017. The standard allows for adoption using a
 full retrospective method or a modified retrospective method. We
 are currently evaluating the timing, method of adoption and the
 expected impact that the standard could have on our condensed
 consolidated financial statements and related disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 In January 2016, the FASB issued new guidance on recognition and
 measurement of financial assets and financial liabilities. The new
 guidance will impact the accounting for equity investments,
 financial liabilities under the fair value option, and the
 presentation and disclosure requirements for financial instruments.
 All equity investments in unconsolidated entities (other than those
 accounted for under the equity method of accounting) will generally
 be measured at fair value with changes in fair value recognized
 through earnings. There will no longer be an available-for-sale
 classification (changes in fair value reported in other
 comprehensive income (loss)) for equity securities with readily
 determinable fair values. In addition, the FASB clarified the need
 for a valuation allowance on deferred tax assets resulting from
 unrealized losses on available-for-sale debt securities. In
 general, the new guidance will require modified retrospective
 application to all outstanding instruments, with a cumulative
 effect adjustment recorded to opening retained earnings. This
 guidance will be effective for us on January&#xA0;1, 2018. We are
 currently evaluating the expected impact that the standard could
 have on our condensed consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 In February 2016, the FASB issued a new leasing standard that
 requires that all lessees recognize the assets and liabilities that
 arise from leases on the condensed consolidated balance sheet and
 disclose qualitative and quantitative information about its leasing
 arrangements. The new standard will be effective for us on
 January&#xA0;1, 2019. Early adoption is permitted. We are currently
 evaluating the expected impact that this standard may have on our
 condensed consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 In March 2016, the FASB issued guidance that will update the
 accounting for certain aspects of share-based payments to
 employees, including the income tax consequences, classification of
 awards as either equity or liabilities and classification on the
 condensed consolidated statement of cash flows. The new standard
 will be effective for us on January&#xA0;1, 2017. Early adoption is
 permitted. We are currently evaluating the expected impact that
 this standard may have on our condensed consolidated financial
 statements and related disclosures.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6774533968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>2. SIGNIFICANT AGREEMENTS</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes our total consolidated net revenues
 from collaborators, for the periods indicated, in thousands:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Sanofi Genzyme</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,415</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,817</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 The Medicines Company</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,657</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,983</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Takeda</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,493</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Monsanto</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,621</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">273</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,623</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total net revenues from collaborators</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,345</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,537</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Product Alliances</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>Sanofi Genzyme Collaboration</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 In January 2014, we entered into a global, strategic collaboration
 with Sanofi Genzyme, the specialty care global business unit of
 Sanofi, or Sanofi Genzyme, to discover, develop and commercialize
 RNAi therapeutics as Genetic Medicines to treat orphan diseases.
 The 2014 Sanofi Genzyme collaboration superseded and replaced the
 previous collaboration between us and Sanofi Genzyme entered into
 in October 2012 to develop and commercialize RNAi therapeutics
 targeting transthyretin, or TTR, for the treatment of TTR-mediated
 amyloidosis, or ATTR amyloidosis, including patisiran and
 revusiran, in Japan and the Asia-Pacific region.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>2012 Sanofi Genzyme Agreement</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Under the 2012 Sanofi Genzyme agreement, Sanofi Genzyme paid us an
 upfront cash payment of $22.5 million. We were also entitled to
 receive certain milestone payments under the 2012 Sanofi Genzyme
 agreement. In the fourth quarter of 2013, we earned a milestone of
 $7.0 million based upon the completion of a successful patisiran
 Phase 2 clinical trial and a milestone of $4.0 million based upon
 the initiation of the Phase 3 clinical trial for patisiran.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Under the 2012 Sanofi Genzyme agreement, the parties agreed to
 collaborate in the development and commercialization of licensed
 products, with Sanofi Genzyme assuming primary responsibility in
 the Sanofi Genzyme territory, which included Japan and the
 Asia-Pacific region, and us retaining primary responsibility in the
 rest of the world.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;We
 determined that the deliverables under the 2012 Sanofi Genzyme
 agreement included the license, a joint steering committee and any
 additional TTR-specific RNAi therapeutic compounds that comprised
 the ALN-TTR program. We also determined that, pursuant to the
 accounting guidance governing revenue recognition on multiple
 element arrangements, the license and undelivered joint steering
 committee and any additional TTR-specific RNAi therapeutic
 compounds did not have standalone value due to the specialized
 nature of the services to be provided by us. In addition, while
 Sanofi Genzyme had the ability to grant sublicenses, it could not
 sublicense all or substantially all of its rights under the 2012
 Sanofi Genzyme agreement. The uniqueness of our services and the
 limited sublicense right were indicators that standalone value was
 not present in the arrangement. Therefore the deliverables were not
 separable and, accordingly, the license and undelivered services
 were treated as a single unit of accounting. We were unable to
 reasonably estimate the period of performance under the 2012 Sanofi
 Genzyme agreement, as we were unable to estimate the timeline of
 our deliverables related to the deliverable for any additional
 TTR-specific RNAi therapeutic compounds. Through December&#xA0;31,
 2013, we had deferred all revenue, or $33.5 million, under the 2012
 Sanofi Genzyme agreement.</p>
 <p style="font-size:1px;margin-top:18px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>2014 Sanofi Genzyme Collaboration</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 In January 2014, we entered into the 2014 Sanofi Genzyme
 collaboration. As noted above, the 2014 Sanofi Genzyme
 collaboration superseded and replaced the 2012 Sanofi Genzyme
 agreement.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The 2014 Sanofi Genzyme collaboration is structured as an exclusive
 relationship for the worldwide development and commercialization of
 RNAi therapeutics in the field of Genetic Medicines, which includes
 our current and future Genetic Medicine programs that reach Human
 Proof-of-Principle Study Completion (as defined in the Sanofi
 Genzyme master agreement), or Human POP, by the end of 2019,
 subject to extension to the end of 2021 in various circumstances.
 We will retain product rights in North America and Western Europe,
 referred to as the Alnylam Territory, while Sanofi Genzyme will
 obtain exclusive rights to develop and commercialize collaboration
 products in the rest of the world, referred to as the Sanofi
 Genzyme Territory, together with certain broader
 co-development/co-promote or worldwide rights for certain products.
 Sanofi Genzyme&#x2019;s rights, described in detail below, are
 structured as an opt-in that is triggered upon achievement of Human
 POP. We maintain development control for all programs prior to
 Sanofi Genzyme&#x2019;s opt-in and maintain development and
 commercialization control after Sanofi Genzyme&#x2019;s opt-in for
 all programs in the Alnylam Territory.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Specifically, in addition to its regional rights for our current
 and future Genetic Medicine programs in the Sanofi Genzyme
 Territory, Sanofi Genzyme has the right to either
 (i)&#xA0;co-develop and co-promote fitusiran for the treatment of
 hemophilia and other rare bleeding disorders in the Alnylam
 Territory, with us maintaining development and commercialization
 control, or (ii)&#xA0;obtain a global license to ALN-AS1 for the
 treatment of hepatic porphyrias. Sanofi Genzyme may exercise this
 selection right upon the completion of Human POP for both the
 fitusiran and ALN-AS1 programs. Finally, Sanofi Genzyme has the
 right for a global license to a single, future Genetic Medicine
 program that was not one of our defined Genetic Medicine programs
 as of the effective date of the 2014 Sanofi Genzyme collaboration.
 We will retain global rights to any RNAi therapeutic Genetic
 Medicine program that does not reach Human POP by the end of 2019,
 subject to certain limited exceptions. We retain full rights to all
 current and future RNAi therapeutic programs outside of the field
 of Genetic Medicines, including the right to form new
 collaborations.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Under the 2014 Sanofi Genzyme collaboration, Sanofi Genzyme&#x2019;s
 specific license rights and the programs into which Sanofi Genzyme
 has opted include the following:</p>
 <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="9%">&#xA0;</td>
 <td width="3%" valign="top" align="left">&#x2022;</td>
 <td width="1%" valign="top">&#xA0;</td>
 <td align="left" valign="top">Regional license terms and programs
 &#x2014; Upon opt-in, we will retain product rights in the Alnylam
 Territory, while Sanofi Genzyme will obtain exclusive rights to
 develop and commercialize the product in the Sanofi Genzyme
 Territory. Sanofi Genzyme can elect this license for any of our
 current and future Genetic Medicine programs that complete Human
 POP by the end of 2019, subject to limited extension. Development
 costs for products once Sanofi Genzyme exercises an option will be
 shared between Sanofi Genzyme and us, with Sanofi Genzyme
 responsible for twenty percent of the global development costs.
 Upon the effective date of the 2014 Sanofi Genzyme collaboration,
 Sanofi Genzyme expanded the scope of its regional license and
 collaboration for patisiran, an investigational RNAi therapeutic
 currently in a Phase 3 clinical trial, which was originally
 established under the 2012 Sanofi Genzyme agreement. In September
 2015, Sanofi Genzyme elected to opt into our fitusiran clinical
 development program for the treatment of hemophilia and other rare
 bleeding disorders under the regional license terms. As described
 above, Sanofi Genzyme retains its future opt-in right to co-develop
 and co-promote fitusiran in the Alnylam Territory pursuant to the
 co-development/co-promote license terms described below.
 Cost-sharing for the fitusiran program began in January 2016.
 Sanofi Genzyme will be required to make payments totaling up to
 $50.0 million upon the achievement of certain patisiran development
 milestones. We could potentially earn the next patisiran milestone
 payment, ranging between $5.0 million and $20.0 million based on
 the geographic region, upon the achievement of specified events in
 connection with a regulatory filing or approval. In addition,
 Sanofi Genzyme will be required to make payments totaling up to
 $75.0 million per product other than patisiran, including
 fitusiran, consisting of up to $55.0 million in development
 milestones and $20.0 million in commercial milestones. We could
 potentially earn the first fitusiran milestone payment of $25.0
 million based upon the initiation of the first global Phase 3
 clinical trial for fitusiran. Sanofi Genzyme will also be required
 to pay tiered double-digit royalties up to twenty percent for each
 regional product based on annual net sales, if any, of such
 regional product by Sanofi Genzyme, its affiliates and
 sublicensees.</td>
 </tr>
 </table>
 <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="9%">&#xA0;</td>
 <td width="3%" valign="top" align="left">&#x2022;</td>
 <td width="1%" valign="top">&#xA0;</td>
 <td align="left" valign="top">
 <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
 Co-development/co-promote license terms and programs &#x2014; Upon
 opt-in, we will retain product rights in the Alnylam Territory,
 while Sanofi Genzyme will obtain exclusive rights to develop and
 commercialize the product in the Sanofi Genzyme Territory, and will
 co-promote the product in the Alnylam Territory. Upon the effective
 date of the 2014 Sanofi Genzyme collaboration, Sanofi Genzyme
 expanded its regional rights for revusiran, an investigational RNAi
 therapeutic currently in a Phase 3 clinical trial, which were
 originally granted under the 2012 Sanofi Genzyme agreement, to
 include a co-development/co-promote license and collaboration. As
 noted above, Sanofi Genzyme also has the right to elect a
 co-development/co-promote license and collaboration for fitusiran,
 if it does not elect a global license and collaboration for
 ALN-AS1. Development costs for co-development/co-promote products,
 once Sanofi Genzyme exercises an option, will be shared between
 Sanofi Genzyme and us, with Sanofi Genzyme responsible for fifty
 percent of the global development costs. Sanofi Genzyme will be
 required to make payments totaling up to $75.0 million in
 development milestones for revusiran and, if selected, fitusiran.
 In December 2014, we earned a development milestone payment of
 $25.0 million based upon the initiation of the first global Phase 3
 clinical trial for revusiran. We could potentially earn the next
 revusiran milestone payment, ranging between $5.0 million and $25.0
 million based on the geographic region, upon the achievement of
 specified events in connection with regulatory approval. Sanofi
 Genzyme will also be required to pay tiered double-digit royalties
 up to twenty percent for each co-development/co-promote product
 based on annual net sales, if any, in the Sanofi Genzyme Territory
 for such co-development/co-promote product by Sanofi Genzyme, its
 affiliates and sublicensees. The parties will share profits equally
 and we expect to book product sales in the Alnylam Territory.</p>
 </td>
 </tr>
 </table>
 <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="9%">&#xA0;</td>
 <td width="3%" valign="top" align="left">&#x2022;</td>
 <td width="1%" valign="top">&#xA0;</td>
 <td align="left" valign="top">Global license terms and programs
 &#x2014; Upon opt-in, Sanofi Genzyme will obtain a worldwide license
 to develop and commercialize the product. Sanofi Genzyme can elect
 a global license for ALN-AS1, if it does not elect a
 co-development/co-promote license for fitusiran, as described
 above. Sanofi Genzyme will also have one right to a global license
 through 2019, subject to limited extension, for a future Genetic
 Medicine program that was not one of our defined Genetic Medicine
 programs as of the effective date of the 2014 Sanofi Genzyme
 collaboration. Sanofi Genzyme shall be responsible for one hundred
 percent of global development costs. Sanofi Genzyme will be
 required to make payments totaling up to $200.0 million per global
 product, including up to $60.0 million in development milestones
 and $140.0 million in commercial milestones. Sanofi Genzyme will
 also be required to pay tiered double-digit royalties up to twenty
 percent for each global product based on annual net sales, if any,
 of each global product by Sanofi Genzyme, its affiliates and
 sublicensees.</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Due to the uncertainty of pharmaceutical development and the high
 historical failure rates generally associated with drug
 development, we may not receive any additional milestone payments
 or any royalty payments from Sanofi Genzyme under the 2014 Sanofi
 Genzyme collaboration.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Under the master agreement, the parties will collaborate in the
 development of option products, with us leading development for all
 programs prior to Sanofi Genzyme&#x2019;s opt-in and also leading
 development and commercialization for all programs in the Alnylam
 Territory after Sanofi Genzyme&#x2019;s opt-in. If Sanofi Genzyme
 does not exercise its option to license rights to a particular
 program, we will retain the exclusive right to develop and
 commercialize such program throughout the world, including the
 right to sublicense to third parties.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The 2014 Sanofi Genzyme collaboration is governed by an alliance
 joint steering committee that is comprised of an equal number of
 representatives from each party. There are additional committees to
 manage various aspects of each regional, co-developed/co-promoted
 and global program. We and Sanofi Genzyme intend to enter into
 supply agreements to provide for supply of collaboration products
 to Sanofi Genzyme for clinical studies, and, at Sanofi
 Genzyme&#x2019;s request, commercial sales. Sanofi Genzyme also has
 certain rights to manufacture collaboration products. Additionally,
 Sanofi Genzyme has certain limited opt-out rights, as specified in
 the master agreement, upon which products revert fully back to us
 with no further obligations to Sanofi Genzyme.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The master agreement (including the license terms appended thereto)
 contains certain termination provisions, including for material
 breach by the other party. Unless terminated earlier pursuant to
 its terms, the master agreement will terminate upon the last to
 expire of any of the option periods under the master agreement or
 the license terms appended thereto.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Upon the closing of the equity transaction in February 2014, we
 sold to Sanofi Genzyme 8,766,338 shares of our common stock and
 Sanofi Genzyme paid $700.0 million in aggregate cash consideration
 to us. As a condition to the closing of the equity transaction,
 Sanofi Genzyme entered into an investor agreement with us. Under
 the investor agreement, until the earlier of the fifth anniversary
 of the expiration or earlier termination of the 2014 Sanofi Genzyme
 collaboration and the date on which Sanofi Genzyme and its
 affiliates cease to beneficially own at least 5% of our outstanding
 common stock, Sanofi Genzyme and its affiliates are bound by
 certain &#x201C;standstill&#x201D; provisions. The standstill
 provisions include agreements not to acquire more than 30% of our
 outstanding common stock, call stockholder meetings, nominate
 directors other than those approved by our board of directors,
 subject to certain limited exceptions, or propose or support a
 proposal to acquire us. Further, Sanofi Genzyme has agreed to vote,
 and cause its affiliates to vote, all shares of our voting
 securities they are entitled to vote, up to a maximum of 20% of our
 outstanding common stock, in a manner either as recommended by our
 board of directors or proportionally with the votes cast by our
 other stockholders, except with respect to certain change of
 control transactions or our liquidation or dissolution. Until
 Sanofi Genzyme owns less than 7.5% of our outstanding common stock,
 subject to Sanofi Genzyme&#x2019;s limited right to maintain its
 ownership percentage as described below, if we issue common stock
 or securities convertible into or exercisable for common stock to a
 third party that holds at least 30% of our outstanding common stock
 or, in connection with a collaboration or license transaction, to a
 third party that will initially hold at least the percentage of our
 outstanding common stock represented by the shares purchased by
 Sanofi Genzyme at the closing of the equity transaction, we will
 offer Sanofi Genzyme an opportunity to amend the standstill and
 voting provisions in the investor agreement to be consistent with
 the terms provided to such third party.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Under the investor agreement, Sanofi Genzyme has also agreed not to
 dispose of any shares of common stock beneficially owned by it
 immediately after the closing of the stock purchase until the
 earlier of (i)&#xA0;December&#xA0;31, 2019 (subject to extension by
 up to two years if Sanofi Genzyme&#x2019;s option to select
 additional compounds under the master agreement is extended beyond
 December&#xA0;31, 2019) and (ii)&#xA0;six months after the
 expiration or earlier valid termination of the collaboration, in
 each case subject to earlier termination in the event certain
 clinical activities under the collaboration fail to occur.
 Following the expiration of this lock-up period, Sanofi Genzyme
 will be permitted to sell such shares of common stock subject to
 certain limitations, including volume and manner of sale
 restrictions. Notwithstanding the foregoing, following the two-year
 anniversary of the closing of the stock purchase, in the event that
 the market price per share of our common stock is at least 100%
 higher than the market price per share of our common stock at
 closing of the stock purchase (in each case based upon a ten-day
 trailing average), Sanofi Genzyme may sell up to 25% of its initial
 shares, subject to certain restrictions on post-lock-up period
 dispositions as described above.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Under the investor agreement, following the lock-up period, Sanofi
 Genzyme will have three demand rights to require us to conduct a
 registered underwritten public offering with respect to the shares
 of common stock beneficially owned by Sanofi Genzyme immediately
 after the closing of the stock purchase, subject to certain
 conditions. In addition, following the lock-up period, subject to
 certain conditions, Sanofi Genzyme will be entitled to participate
 in registered underwritten public offerings by us if other selling
 stockholders are included in the registration.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The investor agreement provides that, until Sanofi Genzyme owns
 less than 7.5% of our outstanding common stock, subject to Sanofi
 Genzyme&#x2019;s limited right to maintain its ownership percentage
 as described herein, in connection with new issuances of common
 stock, subject to certain exceptions, Sanofi Genzyme will be
 entitled to a right of first offer to participate proportionally to
 maintain its then-current ownership percentage of our common stock.
 If Sanofi Genzyme is not entitled to a right of first offer with
 respect to a new issuance, Sanofi Genzyme will have the
 opportunity, on a post-transaction basis, to purchase additional
 shares sufficient to maintain its pre-transaction ownership
 percentage of our common stock (subject to the same 7.5% ownership
 threshold).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Finally, in the event Sanofi Genzyme and its affiliates acquire at
 least 20% or more of our outstanding common stock, Sanofi Genzyme
 will be entitled to appoint one individual to our board of
 directors. Sanofi Genzyme will also be entitled to certain
 information rights, including with respect to financial information
 in the event Sanofi Genzyme or its affiliates require such
 information for its own financial reporting purposes. The rights
 and restrictions under the investor agreement are subject to
 termination upon the occurrence of certain events.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 We recorded the issuance of 8,766,338 shares of our common stock
 under the stock purchase agreement using the price of our common
 stock on the date the shares were issued to Sanofi Genzyme. Based
 on the common stock price of $85.72, the fair value of the shares
 issued was $751.5 million, which was $51.5 million in excess of the
 proceeds received from Sanofi Genzyme for the issuance of our
 common stock. This $51.5 million is being amortized on a
 straight-line basis over the performance period, which is currently
 approximately six years as described below. In addition, due to
 intraperiod tax allocation rules, upon closing of the equity
 transaction we recorded a benefit from income taxes of $15.2
 million due to the Sanofi Genzyme equity purchase being recorded in
 additional paid-in capital, net of tax.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 In accordance with the investor agreement, as a result of our
 issuance of shares in connection with our acquisition of Sirna
 Therapeutics, Inc., in March 2014, Sanofi Genzyme exercised its
 right to purchase an additional 344,448 shares of our common stock
 for $23.0 million. In addition, in January 2015, in connection with
 our public offering, Sanofi Genzyme exercised its right to purchase
 directly from us, in concurrent private placements, 744,566 shares
 of common stock at the public offering price resulting in $70.7
 million in proceeds to us. The sales of common stock to Sanofi
 Genzyme were not registered as part of the public offering, though
 they were consummated simultaneously with the public offering.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 Sanofi Genzyme also has the right at the beginning of each year to
 purchase a number of shares of our common stock based on the number
 of shares we issued during the previous year for
 compensation-related purposes. Sanofi Genzyme exercised this right
 to purchase directly from us 196,251 shares of our common stock on
 January&#xA0;22, 2015 for $18.3 million and 205,030 shares of our
 common stock on February&#xA0;1, 2016 for $14.3 million. The sales
 of these shares to Sanofi Genzyme were consummated as private
 placements.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 In each instance, the purchase by Sanofi Genzyme described above
 allowed Sanofi Genzyme to maintain its ownership level of our
 common stock of approximately 12%.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;We
 determined that the deliverables for the programs on which Sanofi
 Genzyme was collaborating with us upon initiation of the 2014
 collaboration included the licenses to our patisiran and revusiran
 clinical programs, which licenses were delivered to Sanofi Genzyme
 upon the closing date of the transaction, and the associated
 development activities, joint steering committee participation and
 information exchange for these clinical programs. We also
 determined that, pursuant to the accounting guidance governing
 revenue recognition on multiple element arrangements, the license
 and associated undelivered development activities, joint steering
 committee participation and information exchange activities did not
 have standalone value due to the specialized nature of the services
 to be provided by us. In addition, while Sanofi Genzyme has the
 ability to grant sublicenses, it cannot sublicense all or
 substantially all of its rights under the 2014 Sanofi Genzyme
 collaboration. The uniqueness of our services and the limited
 sublicense rights are indicators that standalone value is not
 present in the arrangement. Therefore the deliverables are not
 separable and, accordingly, the license and undelivered services
 were treated as a single unit of accounting. When multiple
 deliverables are accounted for as a single unit of accounting, we
 base our revenue recognition model on the final deliverable. Under
 the 2014 Sanofi Genzyme collaboration, the last deliverables for
 patisiran and revusiran are expected to be completed within
 approximately six years from the closing date of the transaction
 and the last deliverables for fitusiran are expected to be
 completed within approximately five years from the date Sanofi
 Genzyme elected to opt into our fitusiran clinical development
 program under the regional license terms. We determined that the
 total cash received from Sanofi Genzyme under the now superseded
 2012 Sanofi Genzyme agreement reflects consideration for certain of
 the performance obligations for ALN-TTR programs included in the
 2014 Sanofi Genzyme collaboration. Therefore we are recognizing the
 $33.5 million of deferred revenue under the 2012 Sanofi Genzyme
 agreement on a straight-line basis over the period of performance
 of the ALN-TTR programs, which, as noted above, is currently
 approximately six years. In addition, during the fourth quarter of
 2014, we recognized as revenue a portion of the $25.0 million
 milestone payment earned in December 2014 equal to the percentage
 of the performance period completed when the milestone was earned.
 During the year ended December&#xA0;31, 2015, we also recognized as
 revenue a portion of the expense reimbursement of $33.9 million due
 to us under the terms of the 2014 Sanofi Genzyme collaboration
 equal to the percentage of the performance period completed to
 date. During the three months ended March&#xA0;31, 2016, we also
 recognized as revenue a portion of the expense reimbursement of
 $8.8 million due to us under the terms of the 2014 Sanofi Genzyme
 collaboration equal to the percentage of the performance period
 completed to date. As future consideration is achieved, including
 any milestones or reimbursement for development activities, we will
 recognize as revenue a portion of these payments equal to the
 percentage of the performance period completed when the milestone
 or activities have been satisfied, multiplied by the amount of the
 payment. We will recognize the remaining portion of consideration
 received over the remaining performance period on a straight-line
 basis. At March&#xA0;31, 2016, deferred revenue under the 2014
 Sanofi Genzyme collaboration was $34.0 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 We determined that the opt-in rights that Sanofi Genzyme has for
 future Genetic Medicine programs represent separate and additional
 deliverables that Sanofi Genzyme may receive from us in future
 periods. Upon each opt-in by Sanofi Genzyme, we have determined
 that each program and the related activities will represent a
 single unit of accounting and, consistent with our accounting
 policies, we will base our revenue recognition period on the final
 deliverable associated with each future opt-in.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6797325088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>3. FAIR VALUE MEASUREMENTS</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%">
 The following tables present information about our assets that are
 measured at fair value on a recurring basis at March&#xA0;31, 2016
 and December&#xA0;31, 2015, and indicate the fair value hierarchy
 of the valuation techniques we utilized to determine such fair
 value, in thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>At&#xA0;March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted</b><br />
 <b>Prices in</b><br />
 <b>Active</b><br />
 <b>Markets</b><br />
 <b>(Level 1)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Observable</b><br />
 <b>Inputs</b><br />
 <b>(Level 2)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b><br />
 <b>(Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,199</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,199</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (fixed income):</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,383</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,383</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (Regulus equity holdings)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash (money market funds)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,210,351</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">229,140</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">981,211</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>At</b><br />
 <b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted</b><br />
 <b>Prices in</b><br />
 <b>Active</b><br />
 <b>Markets</b><br />
 <b>(Level 1)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Observable</b><br />
 <b>Inputs</b><br />
 <b>(Level 2)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b><br />
 <b>(Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,843</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,843</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (fixed income):</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">904,909</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">904,909</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Municipal debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,396</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,396</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,143</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,143</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (Regulus equity holdings)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash (money market funds)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,320,399</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">201,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,118,897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 During the three months ended March&#xA0;31, 2016, there were no
 transfers between Level 1 and Level 2 financial assets. The
 carrying amounts reflected in our condensed consolidated balance
 sheets for cash, billed and unbilled collaboration receivables,
 other current assets, accounts payable and accrued expenses
 approximate fair value due to their short-term maturities.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6771719056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>4. MARKETABLE SECURITIES</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%">
 The following tables summarize the fair value, accumulated other
 comprehensive income (loss) and intraperiod tax allocation
 regarding our investment in Regulus available-for-sale marketable
 securities at March&#xA0;31, 2016 and 2015, and for the activity
 recorded for the three months ended March&#xA0;31, 2016 and 2015,
 in thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>At</b><br />
 <b>December&#xA0;31,</b><br />
 <b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Sales&#xA0;of&#xA0;Regulus</b><br />
 <b>Shares</b><br />
 <b>During Three</b><br />
 <b>Months Ended</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>All&#xA0;Other&#xA0;Activity</b><br />
 <b>During Three</b><br />
 <b>Months Ended</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance at</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Carrying value</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2,024</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,911</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,484</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,156</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,305</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,023</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investment in equity securities of Regulus, as reported</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">51,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,180</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10,305</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,484</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,156</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10,305</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24,023</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Intraperiod tax allocation recorded as a benefit from income
 taxes</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,792</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,792</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated other comprehensive income (loss), net of tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,692</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,156</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10,305</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(8,769</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>At</b><br />
 <b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Sales&#xA0;of&#xA0;Regulus</b><br />
 <b>Shares</b><br />
 <b>During Three</b><br />
 <b>Months&#xA0;Ended</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>All&#xA0;Other&#xA0;Activity<br />
 During Three<br />
 Months&#xA0;Ended<br />
 March&#xA0;31,</b><br />
 <b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance at</b><br />
 <b>March&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Carrying value</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">82,648</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">87,955</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investment in equity securities of Regulus, as reported</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">94,583</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">99,890</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">82,648</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">87,955</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Intraperiod tax allocation recorded as a benefit from income
 taxes</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,792</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(431</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,223</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Intraperiod tax allocation recorded as an accrued liability</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,004</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,004</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated other comprehensive income (loss), net of tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">49,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,872</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52,728</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 We obtain fair value measurement data for our marketable securities
 from independent pricing services. We perform validation procedures
 to ensure the reasonableness of this data. This includes meeting
 with the independent pricing services to understand the methods and
 data sources used. Additionally, we perform our own review of
 prices received from the independent pricing services by comparing
 these prices to other sources and confirming those securities are
 trading in active markets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 The following tables summarize our marketable securities, other
 than our holdings in Regulus noted above, at March&#xA0;31, 2016
 and December&#xA0;31, 2015, in thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>At March&#xA0;31, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized</b><br />
 <b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross</b><br />
 <b>Unrealized</b><br />
 <b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">207</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(501</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,642</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,383</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(521</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,012</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>At December&#xA0;31, 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized</b><br />
 <b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross</b><br />
 <b>Unrealized</b><br />
 <b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,113</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">907,119</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,214</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">904,909</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Municipal debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,463</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(91</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,396</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,186</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,143</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,102,379</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2,355</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,100,056</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 We classify our debt security investments based on their
 contractual maturity dates. The following table summarizes our
 available-for-sale debt securities by contractual maturity, at
 March&#xA0;31, 2016, in thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>At March&#xA0;31, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized</b><br />
 <b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Less than one year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">748,722</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">748,422</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Greater than one year but less than two years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">228,532</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">228,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,012</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Debt Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Equity Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6789460256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>5. COMMITMENTS AND CONTINGENCIES</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <b><i>Manufacturing Facility</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 13%">
 On February&#xA0;10, 2016, we entered into an agreement with 20
 Commerce LLC to purchase 12 acres of undeveloped land in Norton,
 Massachusetts for approximately $8.0 million in cash payable for
 the land and related acquisition costs. We completed the purchase
 and closed this transaction on April&#xA0;4, 2016. We intend to
 construct a manufacturing facility at this site for drug substance,
 including siRNAs and siRNA conjugates, for clinical and commercial
 use. As of March&#xA0;31, 2016, the cash payable for the land and
 related acquisition costs was put in escrow and recorded in prepaid
 expenses and other current assets on our condensed consolidated
 balance sheets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Credit Facility</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 13%">
 On April&#xA0;29, 2016, we entered into (i) a Credit Agreement, or
 the BOA Credit Agreement, with Alnylam U.S., Inc., as the borrower,
 us, as a guarantor, and BOA, as the lender and (ii)&#xA0;a Credit
 Agreement, or the Wells Credit Agreement, together with the BOA
 Credit Agreement, the Credit Agreements, by and among Alnylam U.S.,
 Inc., as the borrower, us, as a guarantor, and Wells, as the
 lender. The Credit Agreements were entered into in connection with
 the planned build out of our new drug substance manufacturing
 facility.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%">
 The BOA Credit Agreement provides for a $120 million term loan
 facility, and matures on April&#xA0;29, 2021. The Wells Credit
 Agreement provides for a $30 million term loan facility, and
 matures on April&#xA0;29, 2021. The proceeds of the borrowing under
 each of the BOA Credit Agreement and the Wells Credit Agreement are
 to be used for working capital and general corporate purposes.
 Interest on borrowings under the Credit Agreements will be
 calculated based on LIBOR plus 0.45 percent, except in the event of
 default. The borrower may prepay loans under each of the BOA Credit
 Agreement and the Wells Credit Agreement at any time, without
 premium or penalty, subject to certain notice requirements and
 LIBOR breakage costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%">
 The obligations of the borrower under each Credit Agreement are
 guaranteed by us. The obligations of Alnylam U.S., Inc. and us
 under each Credit Agreement are secured by cash collateral in an
 amount equal to, at any given time, at least 100% of the principal
 amount of all term loans outstanding under such Credit Agreement at
 such time. Each of the lenders and the borrower have agreed to
 consider the appropriateness of a change in the type of approved
 collateral on a periodic basis throughout the term of the Credit
 Agreements; provided that any such change to the type of such
 approved collateral shall be made only upon each of the
 lender&#x2019;s and the borrower&#x2019;s consent.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%">
 Each Credit Agreement contains limited representations and
 warranties and limited affirmative and negative covenants. Each
 Credit Agreement also contains certain customary events of default,
 including nonpayment of principal or interest, material inaccuracy
 of representations, failure to comply with covenants,
 cross-defaults to certain other indebtedness, invalidity of any
 loan document relating to such Credit Agreement, judgments having a
 material adverse effect, insolvency events and change of control.
 If an event of default occurs and is continuing under either Credit
 Agreement, the entire outstanding balance under such Credit
 Agreement may become immediately due and payable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%">
 Several of the lenders under each of the Credit Agreements, as well
 as their affiliates, have various relationships with us and our
 subsidiaries involving the provision of financial services, such as
 investment banking, commercial banking, advisory, cash management,
 custody and corporate credit card services for which they receive
 customary fees and may do so in the future.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Litigation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <i>University of Utah Litigation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%">
 On March&#xA0;22, 2011, The University of Utah, or Utah, filed a
 civil complaint in the United States District Court for the
 District of Massachusetts, or the MA District Court, against us,
 Max Planck Gesellschaft Zur Foerderung Der Wissenschaften e.V. and
 Max Planck Innovation GmbH, the Whitehead Institute for Biomedical
 Research, the Massachusetts Institute of Technology and the
 University of Massachusetts, claiming a professor at Utah is the
 sole inventor or, in the alternative, a joint inventor, of the
 Tuschl patents. Utah was seeking changes to the inventorship of the
 Tuschl patents, unspecified damages and other relief. After several
 years of court proceedings and discovery, on September&#xA0;28,
 2015, the MA District Court granted both of our motions for summary
 judgment, finding that there was no collaboration between
 Dr.&#xA0;Bass and Dr.&#xA0;Tuschl, which is a pre-requisite for
 co-inventorship, and dismissing Utah&#x2019;s state law damages
 claims as well. On October&#xA0;28, 2015, Utah filed a notice of
 appeal to the United States Court of Appeals for the Federal
 Circuit, or the CAFC. On December&#xA0;18, 2015, the CAFC entered
 an order dismissing Utah&#x2019;s appeal following a joint motion
 filed by us and Utah seeking dismissal of the appeal with
 prejudice. This disposed of Utah&#x2019;s inventorship claims and
 its state law claims for damages.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 On October&#xA0;14, 2015, we filed a motion with the MA District
 Court seeking reimbursement of costs and fees associated with
 defending this action in the amount of approximately $8.0 million.
 On November&#xA0;30, 2015, the MA District Court denied our motion
 and on December&#xA0;15, 2015, we filed a notice of appeal of this
 ruling with the CAFC. On February&#xA0;16, 2016, we filed our
 appeal brief with the CAFC. Utah filed a response on April&#xA0;11,
 2016 and our reply is due May&#xA0;9, 2016. While we believe a fee
 award is merited in this case, such awards are not customary and
 are made at the discretion of the court. We anticipate a ruling on
 our appeal by the end of the third quarter of 2016, however, the
 timing will be determined by the CAFC.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <i>Dicerna Litigation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%">
 On June&#xA0;10, 2015, we filed a trade secret misappropriation
 lawsuit against Dicerna Pharmaceuticals, Inc., or Dicerna, in the
 Superior Court of Middlesex County, Massachusetts, seeking to stop
 misappropriation by Dicerna of our confidential, proprietary and
 trade secret information related to the RNAi assets we purchased
 from Merck Sharp &amp; Dohme Corp., including certain GalNAc
 conjugate technology. In addition to permanent injunctive relief,
 we are also seeking monetary damages from Dicerna. On July&#xA0;10,
 2015, Dicerna filed its answer to our complaint, in which it denied
 our claims, along with initial discovery requests, to which we
 responded in a timely fashion. On July&#xA0;27, 2015, Dicerna filed
 a motion seeking removal of the case to the Business Litigation
 Session of the Superior Court of Suffolk County, which we opposed.
 On August&#xA0;31, 2015, the Court denied Dicerna&#x2019;s motion.
 We and Dicerna agreed to a protective order, which was entered by
 the Court on November&#xA0;12, 2015. Discovery is ongoing and we
 expect discovery to close September&#xA0;30, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 Although we believe we have meritorious claims in this matter,
 litigation is subject to inherent uncertainty and a court could
 ultimately rule against us. In addition, litigation and related
 matters are costly and may divert the attention of our management
 and other resources that would otherwise be engaged in other
 activities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 Our accounting policy for accrual of legal costs is to recognize
 such expenses as incurred.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6806908448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The accompanying condensed consolidated financial statements of
 Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared
 in accordance with accounting principles generally accepted in the
 United States of America, or GAAP, applicable to interim periods
 and, in the opinion of management, include all normal and recurring
 adjustments that are necessary to state fairly the results of
 operations for the reported periods. Our condensed consolidated
 financial statements have also been prepared on a basis
 substantially consistent with, and should be read in conjunction
 with, our audited consolidated financial statements for the year
 ended December&#xA0;31, 2015, which were included in our Annual
 Report on Form 10-K that was filed with the Securities and Exchange
 Commission, or SEC, on February&#xA0;12, 2016. The year-end
 condensed consolidated balance sheet data was derived from our
 audited financial statements, but does not include all disclosures
 required by GAAP. The results of our operations for any interim
 period are not necessarily indicative of the results of our
 operations for any other interim period or for a full fiscal
 year.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The accompanying condensed consolidated financial statements
 reflect the operations of Alnylam and our wholly-owned
 subsidiaries. All significant intercompany accounts and
 transactions have been eliminated.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Use of Estimates</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and the disclosure
 of contingent assets and liabilities at the date of the condensed
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Net Loss Per Common Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%">
 We compute basic net loss per common share by dividing net loss by
 the weighted-average number of common shares outstanding. We
 compute diluted net loss per common share by dividing net loss by
 the weighted-average number of common shares and dilutive potential
 common share equivalents then outstanding. Potential common shares
 consist of shares issuable upon the exercise of stock options
 (using the treasury stock method), and unvested restricted stock
 awards. Because the inclusion of potential common shares would be
 anti-dilutive for all periods presented, diluted net loss per
 common share is the same as basic net loss per common share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would be anti-dilutive, in
 thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>At March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">185</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,805</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock', window );">Public Offering</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Public Offering</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">
 In January 2015, we sold an aggregate of 5,447,368 shares of our
 common stock through an underwritten public offering at a price to
 the public of $95.00 per share. As a result of the offering, which
 included the full exercise of the underwriters&#x2019; option to
 purchase additional shares, we received aggregate net proceeds of
 $496.4 million, after deducting underwriting discounts and
 commissions and other offering expenses of $21.1 million.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The fair value is the price that would be received to sell an asset
 or paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. In general, fair
 values determined by Level&#xA0;1 inputs utilize quoted prices
 (unadjusted) in active markets for identical assets or liabilities.
 Fair values determined by Level&#xA0;2 inputs utilize data points
 that are observable, such as quoted prices (adjusted), interest
 rates and yield curves. Fair values determined by Level&#xA0;3
 inputs utilize unobservable data points for the asset or liability,
 and include situations where there is little, if any, market
 activity for the asset or liability. The fair value hierarchy level
 is determined by the lowest level of significant input.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Investments in Marketable Securities and Cash
 Equivalents</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 We invest our excess cash balances in short-term and long-term
 marketable debt and equity securities. We classify our investments
 in marketable debt securities as either held-to-maturity or
 available-for-sale based on facts and circumstances present at the
 time we purchased the securities. At each balance sheet date
 presented, we classified all of our investments in debt and equity
 securities as available-for-sale. We report available-for-sale
 investments at fair value at each balance sheet date and include
 any unrealized holding gains and losses (the adjustment to fair
 value) in accumulated other comprehensive income (loss), a
 component of stockholders&#x2019; equity. At March&#xA0;31, 2016,
 the balance in our accumulated other comprehensive loss was
 composed solely of activity related to our available-for-sale
 marketable securities, including our investment in equity
 securities of Regulus Therapeutics Inc., or Regulus. Realized gains
 and losses are determined using the specific identification method
 and are included in other income (expense). We recognized $5.2
 million of realized gains from sales of our Regulus
 available-for-sale securities as other income on our condensed
 consolidated statements of comprehensive loss during the three
 months ended March&#xA0;31, 2016. If any adjustment to fair value
 reflects a decline in the value of the investment, we consider all
 available evidence to evaluate the extent to which the decline is
 &#x201C;other than temporary,&#x201D; including our intention to sell
 and, if so, mark the investment to market through a charge to our
 condensed consolidated statements of comprehensive income (loss).
 We did not record any impairment charges related to our fixed
 income marketable securities during the three months ended
 March&#xA0;31, 2016 or 2015. Our marketable securities are
 classified as cash equivalents if the original maturity, from the
 date of purchase, is 90&#xA0;days or less, and as marketable
 securities if the original maturity, from the date of purchase, is
 in excess of 90&#xA0;days. Our cash equivalents are composed of
 commercial paper, corporate notes, U.S. government-sponsored
 enterprise securities and money market funds.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 We account for our investment in Regulus as an available-for-sale
 marketable security.&#xA0;Intraperiod tax allocation rules require
 us to allocate our provision for income taxes between continuing
 operations and other categories of earnings, such as other
 comprehensive income. In periods in which we have a year-to-date
 pre-tax loss from continuing operations and pre-tax income in other
 categories of earnings, such as other comprehensive income, we must
 allocate the tax provision to the other categories of earnings. We
 then record a related tax benefit in continuing operations. Upon
 sales of our available-for-sale marketable securities, we apply the
 aggregate portfolio approach to recognize the related tax provision
 or benefit into income (loss) from continuing operations. As a
 result, the disproportionate tax effect remains in accumulated
 other comprehensive income (loss) as long as we maintain an
 investment portfolio.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Subsequent Events</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px">
 We did not have any material recognized subsequent events. However,
 we did have the following nonrecognized subsequent events, which
 are more fully described in Note 5:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="4%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">On April&#xA0;4, 2016, we completed
 our purchase of land in Norton, Massachusetts for the construction
 of our new drug substance manufacturing facility.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="4%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">On April&#xA0;29, 2016, we and
 Alnylam U.S., Inc., our wholly-owned subsidiary, entered into
 credit agreements with Bank of America N.A., or BOA, and Wells
 Fargo Bank, National Association, or Wells, related to the build
 out of our new drug substance manufacturing facility.</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%">
 In May 2014, the Financial Accounting Standards Board, or FASB,
 issued a new revenue recognition standard which amends revenue
 recognition principles and provides a single, comprehensive set of
 criteria for revenue recognition within and across all industries.
 The new standard provides a five step framework whereby revenue is
 recognized when promised goods or services are transferred to a
 customer at an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The standard also requires enhanced disclosures
 pertaining to revenue recognition in both interim and annual
 periods. In August 2015, the FASB deferred the effective date of
 the new revenue standard from January&#xA0;1, 2017 to
 January&#xA0;1, 2018. In March 2016, the FASB issued amendments to
 clarify the implementation guidance on principal versus agent
 considerations. In April 2016, the FASB issued amendments to
 clarify the guidance on accounting for licenses of intellectual
 property and identifying performance obligations. Early adoption is
 permitted any time after the original effective date, which for us
 is January&#xA0;1, 2017. The standard allows for adoption using a
 full retrospective method or a modified retrospective method. We
 are currently evaluating the timing, method of adoption and the
 expected impact that the standard could have on our condensed
 consolidated financial statements and related disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 In January 2016, the FASB issued new guidance on recognition and
 measurement of financial assets and financial liabilities. The new
 guidance will impact the accounting for equity investments,
 financial liabilities under the fair value option, and the
 presentation and disclosure requirements for financial instruments.
 All equity investments in unconsolidated entities (other than those
 accounted for under the equity method of accounting) will generally
 be measured at fair value with changes in fair value recognized
 through earnings. There will no longer be an available-for-sale
 classification (changes in fair value reported in other
 comprehensive income (loss)) for equity securities with readily
 determinable fair values. In addition, the FASB clarified the need
 for a valuation allowance on deferred tax assets resulting from
 unrealized losses on available-for-sale debt securities. In
 general, the new guidance will require modified retrospective
 application to all outstanding instruments, with a cumulative
 effect adjustment recorded to opening retained earnings. This
 guidance will be effective for us on January&#xA0;1, 2018. We are
 currently evaluating the expected impact that the standard could
 have on our condensed consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 In February 2016, the FASB issued a new leasing standard that
 requires that all lessees recognize the assets and liabilities that
 arise from leases on the condensed consolidated balance sheet and
 disclose qualitative and quantitative information about its leasing
 arrangements. The new standard will be effective for us on
 January&#xA0;1, 2019. Early adoption is permitted. We are currently
 evaluating the expected impact that this standard may have on our
 condensed consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 In March 2016, the FASB issued guidance that will update the
 accounting for certain aspects of share-based payments to
 employees, including the income tax consequences, classification of
 awards as either equity or liabilities and classification on the
 condensed consolidated statement of cash flows. The new standard
 will be effective for us on January&#xA0;1, 2017. Early adoption is
 permitted. We are currently evaluating the expected impact that
 this standard may have on our condensed consolidated financial
 statements and related disclosures.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to common stock public offering, including proceeds net of the underwriting discount and commissions and other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PublicOfferingsOfCommonStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62652-112803<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section M<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 2, 12<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6797285376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Shares Excluded from the Calculation of Net Loss Per Common Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 The following table sets forth for the periods presented the
 potential common shares (prior to consideration of the treasury
 stock method) excluded from the calculation of net loss per common
 share because their inclusion would be anti-dilutive, in
 thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>At March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">185</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,805</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6797297408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenue from Collaborators</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes our total consolidated net revenues
 from collaborators, for the periods indicated, in thousands:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Sanofi Genzyme</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,415</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,817</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 The Medicines Company</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,657</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,983</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Takeda</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,493</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Monsanto</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,621</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">273</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,623</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total net revenues from collaborators</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,345</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,537</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6797333712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value of Assets Measured on a Recurring Basis</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%">
 The following tables present information about our assets that are
 measured at fair value on a recurring basis at March&#xA0;31, 2016
 and December&#xA0;31, 2015, and indicate the fair value hierarchy
 of the valuation techniques we utilized to determine such fair
 value, in thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>At&#xA0;March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted</b><br />
 <b>Prices in</b><br />
 <b>Active</b><br />
 <b>Markets</b><br />
 <b>(Level 1)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Observable</b><br />
 <b>Inputs</b><br />
 <b>(Level 2)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b><br />
 <b>(Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,199</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,199</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (fixed income):</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,383</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,383</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (Regulus equity holdings)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash (money market funds)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,210,351</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">229,140</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">981,211</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>At</b><br />
 <b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted</b><br />
 <b>Prices in</b><br />
 <b>Active</b><br />
 <b>Markets</b><br />
 <b>(Level 1)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Observable</b><br />
 <b>Inputs</b><br />
 <b>(Level 2)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b><br />
 <b>(Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,843</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,843</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (fixed income):</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">904,909</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">904,909</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Municipal debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,396</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,396</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,143</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,143</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Marketable securities (Regulus equity holdings)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash (money market funds)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,320,399</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">201,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,118,897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6798162400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Summary of Fair Value Accumulated Other Comprehensive Income (Loss) and Intraperiod Tax Allocation in Regulus Available-for-Sale Marketable Securities</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The following tables summarize the fair value, accumulated other
 comprehensive income (loss) and intraperiod tax allocation
 regarding our investment in Regulus available-for-sale marketable
 securities at March&#xA0;31, 2016 and 2015, and for the activity
 recorded for the three months ended March&#xA0;31, 2016 and 2015,
 in thousands:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>At</b><br />
 <b>December&#xA0;31,</b><br />
 <b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Sales&#xA0;of&#xA0;Regulus</b><br />
 <b>Shares</b><br />
 <b>During Three</b><br />
 <b>Months Ended</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>All&#xA0;Other&#xA0;Activity</b><br />
 <b>During Three</b><br />
 <b>Months Ended</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Balance at</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Carrying value</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,935</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2,024</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,911</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,484</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,156</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,305</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,023</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Investment in equity securities of Regulus, as reported</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">51,419</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,180</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10,305</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,934</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,484</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,156</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10,305</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24,023</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Intraperiod tax allocation recorded as a benefit from income
 taxes</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,792</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,792</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated other comprehensive income (loss), net of tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,692</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,156</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10,305</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(8,769</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>At</b><br />
 <b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Sales&#xA0;of&#xA0;Regulus</b><br />
 <b>Shares</b><br />
 <b>During Three</b><br />
 <b>Months&#xA0;Ended</b><br />
 <b>March&#xA0;31,</b><br />
 <b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>All&#xA0;Other&#xA0;Activity<br />
 During Three<br />
 Months&#xA0;Ended<br />
 March&#xA0;31,</b><br />
 <b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Balance at</b><br />
 <b>March&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Carrying value</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,935</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,935</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">82,648</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,307</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">87,955</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Investment in equity securities of Regulus, as reported</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">94,583</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,307</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">99,890</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated other comprehensive income (loss), before tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">82,648</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,307</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">87,955</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Intraperiod tax allocation recorded as a benefit from income
 taxes</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,792</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(431</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,223</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Intraperiod tax allocation recorded as an accrued liability</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,004</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,004</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated other comprehensive income (loss), net of tax</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">49,856</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,872</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52,728</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Company's Marketable Securities Excluding Regulus</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">
 The following tables summarize our marketable securities, other
 than our holdings in Regulus noted above, at March&#xA0;31, 2016
 and December&#xA0;31, 2015, in thousands:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"><b>At March&#xA0;31,
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Amortized</b><br />
 <b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gross</b><br />
 <b>Unrealized</b><br />
 <b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gross<br />
 Unrealized<br />
 Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Fair Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,799</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,799</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,661</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,796</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">207</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(501</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703,502</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,642</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146,667</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,356</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81,383</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,254</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">279</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(521</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,012</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"><b>At December&#xA0;31,
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Amortized</b><br />
 <b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gross</b><br />
 <b>Unrealized</b><br />
 <b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gross<br />
 Unrealized<br />
 Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Fair Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,498</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,498</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,113</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,110</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">907,119</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,214</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">904,909</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Municipal debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 U.S. government-sponsored enterprise securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,463</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(91</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,396</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 U.S. treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,186</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76,143</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,102,379</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2,355</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,100,056</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-For-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%">
 The following table summarizes our available-for-sale debt
 securities by contractual maturity, at March&#xA0;31, 2016, in
 thousands:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>At March&#xA0;31, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized</b><br />
 <b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Less than one year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">748,722</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">748,422</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Greater than one year but less than two years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">228,532</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">228,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">977,012</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6806976688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Potential Common Shares Common Shares Excluded from Calculation of Net Loss Per Common Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">10,368<span></span>
</td>
<td class="nump">7,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">10,183<span></span>
</td>
<td class="nump">7,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6795973616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="nump">5,447,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underwritten public offering amount per share</a></td>
<td class="nump">$ 95.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 496,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="nump">$ 21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gain on sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities', window );">Marketable securities classified as cash equivalents, maximum original maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_InvestmentMaturityPeriodMinimum', window );">Policy for marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember', window );">Regulus Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gain on sale of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InvestmentMaturityPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases are classified as marketable securities if their original maturity, from the date of purchase, is in excess of 90 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InvestmentMaturityPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases are classified as cash equivalents if their original maturity, from the date of purchase, is 90 days or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26805-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6793735216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Collaborators (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Total net revenues from collaborators</a></td>
<td class="nump">$ 7,345<span></span>
</td>
<td class="nump">$ 18,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Total net revenues from collaborators</a></td>
<td class="nump">4,415<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_MdcoMember', window );">The Medicines Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Total net revenues from collaborators</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_TakedaMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Total net revenues from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_MonsantoCompanyMember', window );">Monsanto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Total net revenues from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherCollaborationsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Total net revenues from collaborators</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 3,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_SanofiGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_SanofiGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_MdcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_MdcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_MonsantoCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_MonsantoCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_OtherCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_OtherCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6816504784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 22, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 14, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>USD ($) </div>
<div>Right </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,447,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock to Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,301,000<span></span>
</td>
<td class="nump">$ 89,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Provision for (Benefit from) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (431,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MilestonePaymentEarned', window );">Amount earned upon achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,448<span></span>
</td>
<td class="nump">8,766,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock to Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumPercentageOfVotingPerCompanyRecommendation', window );">Voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MinimumStandstillOwnershipPercentageTerminate', window );">Minimum percentage of ownership interest terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LockUpPeriod', window );">Agreement lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors', window );">Percentage of acquired outstanding common stock for Genzyme to appoint individual to board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FairValueOfCommonStockIssued', window );">Fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ExcessOfFairValueOverCashReceivedForStockIssuance', window );">Excess of fair value over cash received for stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Provision for (Benefit from) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage ownership interest owned by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReimbursementRevenue', window );">Revenue from reimbursement due from collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage', window );">Agreement to acquire outstanding shares of common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandstillOwnershipPercentageAmendRight', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage', window );">Agreement to acquire outstanding shares of common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Extension on Lock-up Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LockUpPeriod', window );">Agreement lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Product Alliances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_UpfrontFeeReceived', window );">Upfront fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Product Alliances | Phase Two Clinical Trial ALN-TTR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MilestonePaymentEarned', window );">Amount earned upon achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Product Alliances | Phase Three Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MilestonePaymentEarned', window );">Amount earned upon achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Product Alliances | Patisiran and Revusiran</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PerformancePeriod', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Product Alliances | Fitusiran</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PerformancePeriod', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering', window );">Number of demand rights to conduct registered underwritten public offering | Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Regional Collaboration Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PercentageOfSharingInDevelopmentCost', window );">Percentage of sharing in development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones', window );">Potential future payment for the achievement of certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumNumberOfPotentialFutureMilestones', window );">Maximum number of potential future milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones', window );">Potential future payment for the achievement of specified commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Regional Collaboration Product | Patisiran</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones', window );">Potential future payment for the achievement of certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Regional Collaboration Product | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialMilestonePaymentsToBeReceived', window );">Potential milestone payments to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Regional Collaboration Product | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialMilestonePaymentsToBeReceived', window );">Potential milestone payments to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Regional Collaboration Product | Phase Three Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialMilestonePaymentsToBeReceived', window );">Potential milestone payments to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Co-developed/ Co-promoted Collaboration Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PercentageOfSharingInDevelopmentCost', window );">Percentage of sharing in development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumNumberOfPotentialFutureMilestones', window );">Maximum number of potential future milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Co-developed/ Co-promoted Collaboration Product | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialMilestonePaymentsToBeReceived', window );">Potential milestone payments to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Co-developed/ Co-promoted Collaboration Product | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialMilestonePaymentsToBeReceived', window );">Potential milestone payments to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Global Collaboration Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PercentageOfSharingInDevelopmentCost', window );">Percentage of sharing in development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones', window );">Potential future payment for the achievement of certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumNumberOfPotentialFutureMilestones', window );">Maximum number of potential future milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones', window );">Potential future payment for the achievement of specified commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Concurrent Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock to Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Compensatory Purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares) | shares</a></td>
<td class="nump">205,030<span></span>
</td>
<td class="nump">196,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock to Genzyme</a></td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Following the two-year anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation', window );">Number of trailing days on which average is calculated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Following the two-year anniversary | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommonStockClosingPricePercentage', window );">Percentage of market price per share of common stock compared to share of common stock at closing of stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme | Following the two-year anniversary | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PercentageOfSharesAgreedToSell', window );">Percentage of sale of initial shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CommonStockClosingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market price per share of our common stock is at least this percentage higher than the market price per share of our common stock at closing of the stock purchase for Genzyme to sell up to 25% of its initial shares, subject to certain restrictions on post-lock-up period dispositions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CommonStockClosingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExcessOfFairValueOverCashReceivedForStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount in excess of the cash proceeds received for the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExcessOfFairValueOverCashReceivedForStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_FairValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_FairValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments on achievement of specified commercialization milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of pre-specified development milestone payments that could potentially be received under the collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_FuturePaymentsOnAchievementOfSpecifiedDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before entity can sell common stock of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumNumberOfPotentialFutureMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of pre-specified milestone payments that could potentially be received under the collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumNumberOfPotentialFutureMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumPercentageOfVotingPerCompanyRecommendation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of voting, based on the collaboration partner's ownership in company stock, that must be voted per the company's recommendation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumPercentageOfVotingPerCompanyRecommendation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount earned upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MinimumStandstillOwnershipPercentageTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum threshold for ownership percentage below which the right to amend standstill and voting provisions terminate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MinimumStandstillOwnershipPercentageTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Demand Rights to Conduct Registered Underwritten Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfDemandRightsToConductRegisteredUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Trailing Period for Average Market Price Calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfTrailingPeriodForAverageMarketPriceCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Acquired Outstanding Common Stock to Appoint Individual to Board of Directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PercentageOfAcquiredOutstandingCommonStockToAppointIndividualToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PercentageOfSharesAgreedToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares agreed to sell</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PercentageOfSharesAgreedToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PercentageOfSharingInDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PercentageOfSharingInDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PotentialMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PotentialMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential maximum royalty percentage that will received for sales completed by collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_StandstillOwnershipPercentageAmendRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage threshold related to right to amend standstill and voting provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_StandstillOwnershipPercentageAmendRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The range of common stock ownership percentage that dictates a standstill provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_StandstillRangeOfOutstandingCommonStockAcquiredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_UpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_UpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of income tax expense or benefit for the period that has been allocated among continuing operations, discontinued operations, extraordinary items, other comprehensive income, and items charged or credited directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReimbursementRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=51671805&amp;loc=d3e60722-111653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReimbursementRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaboratorAxis=alny_SanofiGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaboratorAxis=alny_SanofiGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PeriodAxis=alny_ExtensionOfTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PeriodAxis=alny_ExtensionOfTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ProductAlliancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ProductAlliancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RequirementOfEligibleFutureMilestonePaymentsAxis=alny_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RequirementOfEligibleFutureMilestonePaymentsAxis=alny_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RequirementOfEligibleFutureMilestonePaymentsAxis=alny_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RequirementOfEligibleFutureMilestonePaymentsAxis=alny_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=alny_PatisiranAndRevusiranMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=alny_PatisiranAndRevusiranMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=alny_FitusiranMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=alny_FitusiranMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_RegionalCollaborationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_RegionalCollaborationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_AgreementTypeAxis=alny_PatisiranMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_AgreementTypeAxis=alny_PatisiranMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_CoDevelopedOrCoPromotedCollaborationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_CoDevelopedOrCoPromotedCollaborationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalCollaborationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalCollaborationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_SaleOfStockAxis=alny_ConcurrentPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_SaleOfStockAxis=alny_ConcurrentPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_SaleOfStockAxis=alny_CompensatoryPurposesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_SaleOfStockAxis=alny_CompensatoryPurposesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_AgreementsAxis=alny_SecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_AgreementsAxis=alny_SecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6814484400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measured on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">$ 977,012<span></span>
</td>
<td class="nump">$ 1,100,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Available for sale equity securities, Fair value disclosure</a></td>
<td class="nump">33,934<span></span>
</td>
<td class="nump">51,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,210,351<span></span>
</td>
<td class="nump">1,320,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">13,799<span></span>
</td>
<td class="nump">10,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,199<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">31,661<span></span>
</td>
<td class="nump">38,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">703,502<span></span>
</td>
<td class="nump">904,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">146,667<span></span>
</td>
<td class="nump">61,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">81,383<span></span>
</td>
<td class="nump">76,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">193,735<span></span>
</td>
<td class="nump">148,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Available for sale equity securities, Fair value disclosure</a></td>
<td class="nump">33,934<span></span>
</td>
<td class="nump">51,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">229,140<span></span>
</td>
<td class="nump">201,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">193,735<span></span>
</td>
<td class="nump">148,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">981,211<span></span>
</td>
<td class="nump">1,118,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Observable Inputs (Level 2) | Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">13,799<span></span>
</td>
<td class="nump">10,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Observable Inputs (Level 2) | Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,199<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">31,661<span></span>
</td>
<td class="nump">38,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Observable Inputs (Level 2) | Recurring | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">703,502<span></span>
</td>
<td class="nump">904,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Observable Inputs (Level 2) | Recurring | Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Observable Inputs (Level 2) | Recurring | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">146,667<span></span>
</td>
<td class="nump">61,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Observable Inputs (Level 2) | Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale debt securities, Fair value disclosure</a></td>
<td class="nump">$ 81,383<span></span>
</td>
<td class="nump">$ 76,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=alny_MunicipalDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=alny_MunicipalDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6807618832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Fair Value Accumulated Other Comprehensive Income (Loss) and Intraperiod Tax Allocation in Available-for-Sale Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (8,224)<span></span>
</td>
<td class="nump">$ 3,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember', window );">Regulus Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CarryingValueInEquitySecurities', window );">Carrying value</a></td>
<td class="nump">9,911<span></span>
</td>
<td class="nump">11,935<span></span>
</td>
<td class="nump">$ 11,935<span></span>
</td>
<td class="nump">$ 11,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive income (loss), before tax</a></td>
<td class="nump">24,023<span></span>
</td>
<td class="nump">87,955<span></span>
</td>
<td class="nump">39,484<span></span>
</td>
<td class="nump">82,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Investment in equity securities of Regulus Therapeutics Inc., as reported</a></td>
<td class="nump">33,934<span></span>
</td>
<td class="nump">99,890<span></span>
</td>
<td class="nump">51,419<span></span>
</td>
<td class="nump">94,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive income (loss), before tax</a></td>
<td class="nump">24,023<span></span>
</td>
<td class="nump">87,955<span></span>
</td>
<td class="nump">39,484<span></span>
</td>
<td class="nump">82,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome', window );">Intraperiod tax allocation recorded as a benefit from income taxes</a></td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(33,223)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_AccruedIntraperiodTaxAllocation', window );">Intraperiod tax allocation recorded as an accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">(8,769)<span></span>
</td>
<td class="nump">52,728<span></span>
</td>
<td class="nump">$ 6,692<span></span>
</td>
<td class="nump">$ 49,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember', window );">Regulus Therapeutics Inc | Sales of Regulus Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ChangeInCarryingValueOfEquitySecurities', window );">Carrying value</a></td>
<td class="num">(2,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Accumulated other comprehensive income (loss), before tax</a></td>
<td class="num">(5,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss', window );">Investment in equity securities of Regulus Therapeutics Inc., as reported</a></td>
<td class="num">(7,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Accumulated other comprehensive income (loss), before tax</a></td>
<td class="num">(5,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">(5,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember', window );">Regulus Therapeutics Inc | All Other Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Accumulated other comprehensive income (loss), before tax</a></td>
<td class="num">(10,305)<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss', window );">Investment in equity securities of Regulus Therapeutics Inc., as reported</a></td>
<td class="num">(10,305)<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Accumulated other comprehensive income (loss), before tax</a></td>
<td class="num">(10,305)<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Intraperiod tax allocation recorded as a benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation', window );">Intraperiod tax allocation recorded as an accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (10,305)<span></span>
</td>
<td class="nump">$ 2,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_AccruedIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred, pertaining to costs that are related to income tax expense or benefit for the period that has been allocated among continuing operations, discontinued operations, extraordinary items, other comprehensive income, and items charged or credited directly to shareholders' equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_AccruedIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CarryingValueInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Company's carrying value in equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CarryingValueInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ChangeInCarryingValueOfEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Carrying Value of Equity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ChangeInCarryingValueOfEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Intraperiod Tax Allocation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_IncreaseDecreaseInAccruedIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the pretax change in net unrealized holding gain (loss) on available-for-sale securities that has been included in accumulated other comprehensive income, a separate component of shareholders' equity, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e39076-109324<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e,f)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=alny_RegulusTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=alny_SalesOfRegulusSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=alny_SalesOfRegulusSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=alny_AllOtherActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=alny_AllOtherActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6795983792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Company's Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 977,254<span></span>
</td>
<td class="nump">$ 1,102,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(521)<span></span>
</td>
<td class="num">(2,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">977,012<span></span>
</td>
<td class="nump">1,100,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,799<span></span>
</td>
<td class="nump">10,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">13,799<span></span>
</td>
<td class="nump">10,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">31,661<span></span>
</td>
<td class="nump">38,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">31,661<span></span>
</td>
<td class="nump">38,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">703,796<span></span>
</td>
<td class="nump">907,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(501)<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">703,502<span></span>
</td>
<td class="nump">904,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=alny_MunicipalDebtSecuritiesMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">146,642<span></span>
</td>
<td class="nump">61,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">146,667<span></span>
</td>
<td class="nump">61,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">81,356<span></span>
</td>
<td class="nump">76,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 81,383<span></span>
</td>
<td class="nump">$ 76,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=alny_MunicipalDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=alny_MunicipalDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6796641264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Available-For-Sale Debt Securities by Contractual Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than one year</a></td>
<td class="nump">$ 748,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Greater than one year but less than two years</a></td>
<td class="nump">228,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">977,254<span></span>
</td>
<td class="nump">$ 1,102,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than one year</a></td>
<td class="nump">748,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Greater than one year but less than two years</a></td>
<td class="nump">228,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 977,012<span></span>
</td>
<td class="nump">$ 1,100,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6796161984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Apr. 29, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 04, 2016 </div>
<div>USD ($) </div>
<div>a</div>
</th>
<th class="th">
<div>Oct. 14, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LitigationDamagesSought', window );">Litigation, motion filed for reimbursement of costs and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bank of America N.A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage', window );">Cash collateral required for principal amount outstanding, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Wells Fargo Bank, National Association</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage', window );">Cash collateral required for principal amount outstanding, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bank of America N.A | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit facility, expiration date</a></td>
<td class="text">Apr. 29,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bank of America N.A | Term Loan Facility | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Wells Fargo Bank, National Association | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit facility, expiration date</a></td>
<td class="text">Apr. 29,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Wells Fargo Bank, National Association | Term Loan Facility | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=alny_NortonMassachusettsMember', window );">Norton, Massachusetts | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLand', window );">Payment to acquire land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Undeveloped land acquired | a</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Collateral required for Principal Amount Outstanding, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LitigationDamagesSought">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the amount of monetary award for reimbursement of costs and fees associated with defending legal action.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LitigationDamagesSought</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of real estate intended to generate income for the owner; excludes land acquired for use by the owner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alny_BankOfAmericaNALineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alny_BankOfAmericaNALineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alny_WellsFargoCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alny_WellsFargoCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=alny_BankOfAmericaNALineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=alny_BankOfAmericaNALineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=alny_NortonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=alny_NortonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>@"%,;X[)9J4@B,WHX*[O]C\ E!+ P04    " #NA:1(>Q>T)50!  !8$
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M?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_
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MNV# XY@-1F-G@6NOX-(Q"]S- "X!G1 )]*WE4M&^?A[)IRO%EW\!4$L#!!0
M   ( .Z%I$B(%EFK5@(  /0'   8    >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL?97+CILP%(9?!?$ 8VRNB0C2)%75+BJ-9M&N'>($-("I[83IV]<7(&9D
MV  V_W\^WXY//E#VP2M"A/?9-AT_^)40_1X 7E:DQ?R%]J23?ZZ4M5C()KL!
MWC."+]K4-@ %00):7'=^D>N^-U;D]"Z:NB-OS./WML7LWY$T=#CXT)\ZWNM;
M)50'*'(P^RYU2SI>T\YCY'KP7^'^!",ET8K?-1FX]>VIP9\I_5"-GY>#'Z@Q
MD(:40H7 \O4@)](T*I(D_QV#/IG*:']/T;_KZ<KAGS$G)]K\J2^BDJ,-?.]"
MKOC>B'<Z_"#C'&(5L*0-UT^OO'-!V\GB>RW^-.^ZT^_!_(G@:',;T&A LR$,
M-@WA: AG@UDZ8$:FY_4-"USDC X>,YO18[7G<!_*E2L]KCN962XY,RY['T60
M@X<*,RJ05AQM!9P50,:> <@%&.W(LB,7X&0K0C<@= %",X/0LD=N>^2R1\8>
M6?9X.3ZC.-J*Q V(-P"Q94^= %N1N0')!B"Q[#LGP%; P$U(-PBI[8=+1&(0
M1M*9;0[@RCIE&Y#,AGPY*;&!+"0K1V6W@=C9_LBY5 M)[$:HVV&5H7X^(R1.
MR%*3KE"<:3M1%EF9.;=DU'3CMJ59DJ[L/70F\(2R\Q.Z#]A"@]8HSBR>*'8:
M(^BF+#1HA;*5[-#.912ZENTT:LRR97&<!''X]2  ZY)M";OIXL.]DMX[7>NL
MWKG O2)]23_E1=[C&_F%V:WNN'>F0E[U^EZ^4BJ('$KP(L]])4OPW&C(5:C/
M5"6$*4JF(6@_U=BYT!?_ 5!+ P04    " #NA:1(R5BX%0X$  #$$@  &
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MN%'8C2/=*-2-$$Y(T@Q6*9#@:"\ZX44C+X*17C0>L@7:2B#BSM).3,*)P4Z
M=&)PQAB-\A);P2K02D5FQ2:\6.R%3(2]Q;TPQ9BA)R;0#4)A(W/C$G[<S_/7
MX;GA5CER,8M IL"*R.R,N(W:&1_^F!]!^EDT2PKK6-X$L@$!P"-^2&+>_6#:
MT7MEOVB6A9"&S+ BK@K=D.B\N\'L%(IVPW$_ K23) B*E=!J!2SBB<3Q@G/
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M=A=".!+A@ITXBIUXUM8!1A<NN[GH4WW3ZP$GT^/=6A_/^A]02P,$%     @
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M P63<N)3P.?,D6/K4W?NJ 9)B2?I"4C8QH>QIV1B@?,Y]^/8_A1M?QP;FQ)
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MA#X\3)IBA^@AB"AN;BD9POJO@8+.1_=K\&W>B!QX'"_[O?YD]5]02P,$%
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MWX-M\T9DQ^-PV>_E)ZO^ 5!+ P04    " #NA:1(*/<SQ98!  !P P  &0
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M']U=\&W>B!QX'"[[O?QDU7]02P,$%     @ [H6D2$8D4'R9 0  < ,  !D
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MM6ZI&VPZ#;0*),$Q2=,=%I3)I,A#[$47N>HM9Q)>-#*]$%3_/P)7PR'9))?
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MI*PKL5 /M5(6G(GTRKEH72-/"PZU]=,;-]>QMN/"JN[2J=/OHO@"4$L#!!0
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M+31B(H/9+# 3PE?J4XK(E6*D1S.Z,\%VCL@R=X;8E2&V1<2+(F*W0.(22*Q
MLA!(EB8S6X;%=!83Q%GA0FWGJ+P(4K>7](Z7=.'EAD!VIQO9(]W([SC('^A&
MONA&6,3.;LQ1>9[?**:XXZ58>+GQ;3S?Z<;S(]W0]_VF!?WPRWZ,H+$A1>IL
MQP(4!Y^\^+.;2X$?S403J&:G3NJK,HM.4_,ETC?_4WRCIZF9"%>9JNSQ$7YA
M?FP[@79,JKEBAL"!,0G*7/"D/KQ&S?OI0. @]397>VXGH#U(UE\&^O2O4OT'
M4$L#!!0    ( .Z%I$A9G\TI1@(  (('   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;(V5VVZC,!"&7\7B 0KF&"*"U%*M=B]6JGJQ>^T0)Z "IK83
MNF^_/@"U*Y/=F_C /_/-V!E/,1'ZQAJ,.?CHNX$=O(;S<>_[K&YPC]@#&?$@
MOIP)[1$72WKQV4@Q.BFCOO/#($C]'K6#5Q9J[X66!;GRKAWP"P7LVO>(_GG"
M'9D.'O26C=?VTG"YX9>%O]J=VAX/K"4#H/A\\![AOH*1E"C%KQ9/S)@#&?R1
MD#>Y^'$Z>(&, 7>XYM(%$L,-5[CKI"=!?I^=?C*EH3E?O']3Z8KPCXCABG2_
MVQ-O1+2!!T[XC*X=?R73=SSGD$B'->F8^@7UE7'2+R8>Z-&''MM!C9/^L@MF
M,[=!.!N$J\'*<1M$LT'TQ<#7D:F\GA%'94')!*B^C!').X?[2)Q<#9C:I/JX
M1&9,[-Y*F&:%?Y..9DVH-$^V9N?25)9F5?@B@C6,T!7&C @M1.Y$F)K0C8A<
MB$AG&IF(+' [B%T.8NT@MAQ .\94YZ$U@](D<9Q%QG%9H.0.*+% H0W*-"@Q
M0'GB9J1W&*G%B)R,U&#$>1H'&X>6W>%D%B=V<C*#$T*XA=G=P>P,3)ZY*-7.
MO!J8I&Y(?@>26[DD-D5K*ENS 9'/RR9%?C1<9$[,%]$6QUGY"\<JV6SC?PJ=
M53N7% S_IZ:@LRJ7**)_W]RLV;PZWWCR>DPOJA4P4)/KH#J/L;NVF\=0/9F?
M\K(8T07_1/32#@P<"1</KWHESX1P+,(('D3--:(AKHL.G[F<9F).=8O0"T[&
MI>.M;;?\"U!+ P04    " #NA:1(MCA93HP"  !5"0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6R-5MN.FS 4_!7$!RS8W"."M*&JVH=*JWUHGQWB
M!+2 J>V$[=_7%V!A95A>@FWFS)DYX=A.>T+?6(DQM]Z;NF5'N^2\.S@.*TK<
M(/9$.MR*-U="&\3%E-X<UE&,+BJHJ1WHNJ'3H*JULU2MO= L)7=>5RU^H1:[
M-PVB_TZX)OW1!O:X\%K=2BX7G"QUIKA+U>"65:2U*+X>[6=PR$$B(0KQN\(]
MFXTM*?Y,R)N<_+P<;5=JP#4NN*1 XO' .:YKR20R_QU(/W+*P/EX9/^N[ KY
M9\1P3NH_U8670JUK6Q=\1?>:OY+^!QX\!)*P(#53OU9Q9YPT8XAM->A=/ZM6
M/7O])G:',', ' +@%##E,0=X0X#W$> KIUJ9\O4-<92EE/06U7]&A^1_#@Z>
MJ%QA,;5(=;F$,R96'QF(DM1Y2*(! Q7FM,!,"$>P3RF@*<40#F?AT)0@GR/"
MT)S!,V7PM EO+C!VS02^B<#7!/Z" "Q%1MJ&QK0*$WE^8 +E<Q"( R\R:PDV
MM 0++=!,$&Y4(]Q3C6A#0;15C5!7(YH9]7T0F$!YM*@&6"E&O"$E7DCQS 3)
M1C&2/<60[;XJ0;[\LAP#2%N%81 9Z[% @63-#S V["AGT8VQOT)A;,BA)@#N
M*HJQXT85WM=%R0>0MAOXR9K=K<X$R]8,5BB,#37:#7;9-;;4J"+<8S><VPWA
MRE8)MEH/+'MO92\$QI89[<:[[!J;9E21[-@/!]#PR4>><3]<@+P0?OX$G-EI
MU6!Z4Z<XLPIR;[D\'F:KTTWA&<K3[M/Z2=X@U"GX09.E';KA7XC>JI999\+%
M6:H.OBLA' MY[I/X-$IQQYDF-;YR.8S$F.I37T\XZ<9+S'23ROX#4$L#!!0
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M>M%#-CUG,U$Y><BFSV(S0#9#QHW&JS!ETVEM;*+H"9#,D''_\"KPNX(.+&6
M*3.P;&@2%\D!'H.$K&.0 /$,^O@,GP=V^BB,H"A8%TPG@TU&]0 A#N;X2IP'
MPZBBY"'E!5=Z0FL&:0^,=I/:9?"0,F0=4@9(9^!TNE@8N#T0)6K#@)\I8-6L
M2=TK%O"$LOOYN,M2X+O[@N%IH_<%;@]4J8PE!;YA+QB<-G7K6D ZNY]S_,:W
MV@4#U$9C_J=#%25F)Z7J1[28/!OW7#R67XKMXW*SF_VHZKI:=X_$/515739]
MB;<-5$]E<;__L"H?ZO9M6\MN^Z=&^P]U]7PZ/ 6[?Q3W[#]02P,$%     @
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M.RQ!243WPP!&;(@E)6P)A1W?$DLH;&1/C*,@'4K5$JHZOBV6X>Y;B)RK**Z
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MDS)3K.?"761NH7A_NY:G_X;R'U!+ P04    " #NA:1(@H[6"ZH"  "B"P
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MD\?7_+KXDM4-H2(L&$<#X+C'=?F 2-,NVAIV W!=96V3SVHX[EF$$:_SQ0+
MCFMKBWO^8U8N%NE]6?$]K[)9!LN%)44+N:FR59K/=?834+T:9L9AR@;FU+,
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M2R,87"SA+&9IH@$AO[^XN$ETNEHMX!ND.X#N.>H+^5*.K%:PM$0&@RL+8@*
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M7^U:\.8+06(K905(!!K6^J!\+N"2(++G\QPVF<%MNH EU?EC0:HE>51@[4;
M38WQ'P92Z(.KTQE/XDA8MLA!I<!5CM1G9H=7(&4LD0K1_OC",26&'WOO E\G
M=*ZB+X?0%4_3'&_M$2&D(<OTQTQG9A:6X(&O+T7.8,(#0L&L40$- 3&_99H]
M(!;3W_B*PS%%_%WL\\W@>WP,>%H&6^Q1JNVTP$S;LU)E35XDQQII>\ZBH'N)
M^ 0A'!PJ2(HP@> KS(^D:YZCF,2WKWDJ:P^"(X7R!)EX;M!=*8Y&M'NH'[*.
MN6301()W< [R"AG$[5/W:SJ#YZYEIFB)TGG24V22'.D?,F4FWVJA^7FFM\8@
MO/>K$KD G)4*)O+D'CR (ESSC7DI'%D)6R&QV!EJB1FWJY+9[J#LK$",-^?=
MH-375E;_S. TYZ\2<6*BC$\^+:O+T&,J?4XK9)^OLUD**@&-1%2UEHNYZE^W
M?A;&IY!!'EC8$$D#XB%\6:]8XLI AN@[JA"".0$.E.(E&8"V(!;32;82$1!$
M<V(F"K3"L-)H+208#6UL'\0J?+%DCC_/')'RP:P",,,1"1>6BP37(UW,T-\B
M[_9L0PF".M#GE0=\ V$=0!BE+<!=,:G\6EUX[BE%;C24$-1'0_1*;5620!^9
MC)/)V:$^34Y/CT%(C/$C?/KL6!^.%;QT>'(&+YV-C]5->P]BH_XH:I:Z+O3O
M02%%P4"$%#@-4'!@_3I]?*RR1R&#Q\G1T2D-9"XW<\Y0\7JJRO81U0K 7CB$
M9Q!0&A34>%:KW"%-1TEXAL(K76K[A-X[/QZ-Q\XI""00KK(00'.@9B01JI25
MI_!'XLW^]<,O[7JRJO[;7_]=+B-.;T&=.J<>[Y&@P4$#2,<M.! M5D85!;*^
M=W1^,CK2RWRQ(+$K?8!90$::MS.BY79N_ /9D>/$,RNM^3JU!93E$0B8Z60T
M,9.,U%L0N_4?R8'ZGK!;1 FZ7_@;.U?E>@JP299TTJ_L#$7Y;+&@,T>>J. J
MD04)?B!1 9E-:IDDRE/X+*@X&4G^3IJ 89MG$"44FT70.08*5 X22&,9Z]*M
MEICL"'0KHPLEM'1%2T<I$^ ($@G+A._0+*HG,#DPD5K#Q4*SG/YS6Y).@1M$
MVEJPWI+-7]$R9T3A>#DLW %U*$BK,P) &40 "&0W+&':70*)Q:LR1_!;3:F\
M1[<^DK=$URV:=NMPK7K?KC1A60WNL:JL&+3.,S@G$/*_H'"W;5&'JK.HMG K
M\%=H*2SMWM_\.D&]T<KG=0Z2!Q.DYR=46AKZ?T H>+;!;>4/*"DG ETE)H[U
MAAE8IO?0\RF'8X?[M]8+W(;*N[O#<8!7H"^,GB!V&@BYL.N1<H%$)(%ZP4<=
M/0G-'NK*<7T4BMB:1N(UL 30&M@F(KH/#0@Z8]4<X,)87BR+1_I+>?:_>7;?
M6 ME$,>$TH\6M\^:YLG=>M%@T!W%<_0 VF0Y484GP(>#ICP0 R0,!'K7ES1?
MX'L' /0#LDRSMP'N(EH9)2@EKV;M$N4:W(ZP5+F/"@1'%*HLRV$BZB\>V%66
MSIYB91 8LA,5GNT6<Z26BX71V?+P;#I@4N%>XPT1\%@P[OE5^:/#CCS<2@>7
MK3T\5Z@=M<Z_)^8]LO:+<@ 2 %Y70FGGK /BZ(B5$)O-L1[B0V4/(K )$HC+
M @<S0J)$8B"'8O 0],-8EH0XIMF56!"VS4UB#*CN/">>,K#Y#*@W*E#FXE89
M#P!;HS%C: ^X.QF69&\,#MQ%]:D=H_K(:"&_CG3@>R&SECD-)+$>I7 B=;W*
M9D@<A,Y;-RL+?31$VK7 >,YRO2\\]Y7@W:P$8H-+V#L>396P7]Q"X*@5DW2=
M+JQH9';1=T=#G _F+_D\!U3.P%K9=\2>,@G26 8GQG'4;)4*$0DX+U'P'JSF
M*V3L$BB S;/9 L.DQ:K(5TR$*W?@3 9$!D<BX':O,S2+%R3SP6=X'V\BJTJ-
M3,TF,E*_S72U^MM?_T-<#4\@=<#V@12 P)K\[:__*T(\4@](KB.11@RA<+E*
M9E.=Y;(%@D05*[OJ&7L)^1(,&<8V'41PST?(8>;YG(Q2B$[5G,U62Q"Q*EH$
M3UAWK]]#_A.9DVFP_BB [FEK_[15)U0/+A;*^&QV[1\/K00^$:\C[P "DR3P
M*G_,450VW"BQ6I0RIA/#41(4&L['0'K7+&T!BTW$U.,MQ"<1VV?1?;,@+Q46
M#K_(E&)G[FX$J8 EAB#%HRB..@/%]('ZD<"O%:):0P9%)'.?1[<C_5A^R:H"
M#^Z@7B%*H-$?>6 %<ET=@A/=A4#@UP;)'D 5J DCQ!Y'LE),,PUY1(98[$:'
MURA'#[F7==4N",'(!J=:TC'EYXSF)Z\5J; D(WO1/D:F%]-9BVJC9Z/T J4Y
M-%XH?)96Z("JG?1+3ZF^JT(J@-'X8?O&4BX&?[92@^1C1(X#W-W"!EFYA>G.
MPLRSLA]#Z]5.2^V]U43@ED ME04?W3Z8Q($0]2;$W@U@(8,869P,37#7'\:Z
ME["!O.C?W4A_7J$QPN<W/7QF@%W#%M!_1-*U<GHMBE@/0.%*_+4J47:2: UB
M@6*A=(NT&T:%T:V8_%$>!=QP2*S<*U;N$V.N17<_QVL3>&&FC"S ,/F2>&TH
M:ZFMLA8>*8KL^"\>'PS2I*3$>N*CV_Y(W;:@._VYQ6^OOA@UP1!Q1LH"+S4Z
M!\@Z:Z6$VKV9T9LC_3M07X!D).J9QZ#WF\ ,5I3%IC&,F0-)UA+#]M#$L08>
M6<^J_)Z%&(XT_S5PR_^M/Q;Z HC10A^)Q,A<>;E:9 0OO.^>SWO!XC ,435H
MOW@/#  .OP7MS=,7D?TU5<M>,D&Y(GO6\ZI]U.)VFV4#\0VC<%TF/8M1L9A;
MORM2V,0(@AUWA[;NCC7ZJ%%AGA.ZJ1E\ M1+ 9&%)Y/?X75:_.AY3_6'T07+
MEZ\_7C#_^0%DA!H4_NJQI*<3_2$5$]!%79<25T3OT*.)SZ-)"F_S!0*TT2^'
MR*=LAD=\X9S#-U59P.>9F'*N49$EP]P1WXVWUN'@O72+YFHT".O7)?Q#BWU[
M<?LZ42; G18EO@>#J\05:GE5"&Z*J6NU>5+Y3WIN:Z:K%.. <B$*WF@,"*\?
M*?[ 4\G@EJ<2:!&O ,\IE\"M6844'17'O)BW:--$:PP:#'#]=JW>W \T59.M
M@,3 XI]+$/#(5G&_MK/EM?*NUO,3^8W+98Y<_[%$A@-+0T,)V63PAAF35\7'
M#&H:+ :(245VRT(<.FQ,LP*RN2'.]NR+LR@?H(*%NL6,@^#N,TU?+OCZ9N*_
ME>N&/AVS.F56Q]83"PARA%NW6E8\(;;- Y\J1DT!H2,9L>P] )CZ'NBG=732
M2; WVKKI 0\OVD< @MB("14!PS G0<"$4CS1:#P1D<Q(3?51SZZ<&(*Q.[-X
M>HJFV/"K,YJ9A5@F%G9B@]DFUQ(ABH)KA?85$O&1UBUMV,ACFW,XAD-EN$1
ME&L4LM ;J(+#DTTSK7KAU/Y<7N#' ]G!9M:<BP!?(.X0J/T -U%<U^(&I#Q5
M&N]^D3^:Y5VE:'I-YV+'SNFLEVAN9_6"K#ILB X$Z?"43% "+@XT51#3.Z<2
MH1S'DZ'#R$S-JG>JR.Q>90W<XI5,P3JW)H_YLIRS4M'W"$E#))!SOA9L331$
MJ]Z@:_HQL4,^N 6(QU7QY<+K!*K53"YHXR^?O:?$?S>KV8.>74/^O4LVZCA1
M>I %+X&/%OX%1.[GF\0#O[KGHG9?^L9J+>11V>&?<R2@!@)9%P7%-NE9S1+5
M.S1[+5A.<38U!GEB8;[J!F<YP!C2Y$)DW#PYB1+TRTAAW$*\+*1,P K]4R%Z
M26EUOCT ::627>+1(2K;I<NX'M98<+QB4-DH+'5O?1/SCB61I(F9"\GU?G*\
M11D+@A/Q[\AB3M,4)4F@6<7.P3Z=KI,7L#\TH<05.&5F6/!]Y9^YIYC2AC#Z
M*8=]&S,:J0EN)J:!QBGF(343NUS(?I%AM!9=<;FQB E()PRV.RZ!.BEC-$O\
MA)3 "Y1G?Q7[7MD'HJYQ'%>HK.O(L)OP*@@6#M ?)7%TAF.3V=I+!O00-9%8
M/BV*![XM>HEG/V-M3HPXJXQ8+\R8DI72QPR@V.%"[WT6R@09H1#Q1#0>H)EF
MB%+N2 95+QG<(=C-(X.J2P9ME-D TZ3S6< EP\7:]> *77P0>]  (&@FRLAJ
MX2N@ U$[-$9*!AB2+G 21J,@@&=3=!M28MD0NA4!'QN.&<.YX&^D/OQ%[A6/
M2.]1^L]A2;(O6$6%%Y>IFR'0GJP]?-@= >B\A\UKR^8-)CB>J7;#!!C$+F8)
M^H6'"$/6SA<CPB:IS:(]NZ,1'.UJ+I84U>%7,Y9@X=A9<C8A-Y)4LS*1W""$
MF4CMP!\AL3%BS:)=D6H]P\<Z%!=$5@ZM\9QN0CM#'S$[U3HO<^CN-G,Q68MM
M9'Z,'FIW6G"Z40J,T6,70J$VHL=6.J%V$)>B@'(_$/S[3U><GM1]:CK2_0_V
M!Q2URV6*:;8U+;OAX@/^D@LO U7%&:A)%(@D,:29":RVP3QW9'CWR]5XP3UO
MR$3#I^,"?<+L!+VGCY*CR3&FP25GDU/:T?L,I@.F46,('T5P3I.3XU-XXOSL
M4-VE/V;S5/WMK_\3 W/.#Q5,#\N!2\!?G4PGBI-$IZ>'^A#^AG<("/Z^>S)O
M80VGR>$1K>4L.3X\53=5B7$L&%V:D_^XN_I+O\9&1Q8^(@./;ZL!'O"X*.^1
M7U/J6O:8S\(R'12!W4G@2)QK+UW =9PA8O,X^AX5$+3XMR!1XQWF5SGZN3M*
MR?$W:(XS68A2ML$8_P%IU*</%SF%.UC7)! $S+V#S][)4'A,EF*(PPI%41B:
MN X;+7#[G05TZI'4+2 77";))0#);I'.,BM8?\D!QSJO&%M\R_>K,WQ@% ,L
M_3AK2@R-A*5,:>]#.];1CE6#/BFF%6@/:9[6%?Y)8+V[^^0N"(' D#;XY6 )
M "*FD"[7BS*?EW5>TVL7\*L.OG1T>@7[J_,J984(-M_27W39?I^N4JOFZ8LZ
M3P]N4G;R5H _& U%.^Q X\*8 ]5GJP_T/6?-ADGW%PJ"(E"K=@67I3 I/LQU
M."IK.CJV45E(<RG GVPSUKX#IR'!5I:?P1N@Z91%YEA8NVF5RJZ2Q'(V'[<8
M,0F22=5P_"N\=\@W#@1-DK?<-!BG=CH:FZ5*F(@-5Q7KL/BV4_2$H!L-E'IW
M-.J&+,93C:Y9BJ!JR/Q--J-@*KUWU#N58G8,3#2(S^1Q#[OC/E <FDP^VOT4
MB6QCY!ER:OR:3L!=).O$]O.0NW?"+E",-G,TTB E-(I =WZ,6I<,GR62/^!U
MZ![,;<P<;;[S%AP<J#(E6K39$F/C$@*D5SU(+U'"M:@7&Z>F,:B@@$#\N:P6
M<W1$*B^(PFH*\VR18W U5DK:%2UU$(,I0(,UZC]AV!E::4UBWY($E$Q,C6OE
MQ5TB^; !'%V:Q-Y:]*#R2DGO13LN ?;BW8<#I"]P2H]5NF3Q!V]A9X,)NCXP
M<; 1&[XO<5K1E)V\K+S%1E,,)T'U%6Z,RMC.J'VI/_%A(,'< E-810@0%0%$
M[PH0Y0 2^*98?%O@562;P;S-C,-">"@9+ ITJML@#FL#9^.TG\;8=FT!@*NP
M]0XN/Z5\]B9*%,9YI&)O-07WDN43Z'DC9CA8KG*_L.9=Z3!_2Z+(4+NJ,.J_
MBXW=)7A$\HZ"?K$L82'A "@).D._7"Q,>6G8MV160C.9/"T2^E P(I2+((L1
M50AW$U,GA,5#!K$"4;6-Z&[1) 0(2JQ!T94B5CB!$#TKZ\VX9/:C:"1BQ1RW
M81PS1BKR#%^.2[6%)! J#) O\:^U327QI%_)!K66Z%Z2H'HH,?M;P[G""=!.
M38$^F#/85B%X.LXV[S>;IN7NBMJ1>."!L*'.S]%3EG<B&EN354H6)*DI!E/N
M'1XZ=I_LC(VJ3QA\H>#<],N4*A 0R:%>4)0Q?/=%!.>MKVT21;=((SO*NJ15
MHO>8S:L4UT+Y%VBT5'30Z-AXRE=6L"0>]0PT:"<^W2.TRV5\H$!J0.%(@N\P
MW9HPT-;R0Z-[2Q2R^Z)A,K5Q F*HQ._:)8I(55D^',!_;9:ROFW:.95\- +6
M/F50/A!+DC5VKM RK5&DLU!^1<A',^B;CS>)B8R63&VT%25(3/]$280E1]3Y
MH2CVP2D&T /QJEBY\ .#*2Y);*8DHXK 8TBO1 @\67\Z>]!QI86^:M&%E2A;
M3@M5/7:+&M_^72#K+")9"*=6Y3U-;5'#3+Y1>PGU1R.G&=A&<@]Z\:-5=D[
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M:RL(D>0WE'OCV9)YKW^-+7A&<V+<+]IY,B 7B%$'IA2(8Z2#F$0&#MJ8\N]
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M\V!BN,Y="R!!&UQ#^9 \-.J:=9:Q2$HDJ#:LS@Q J8R]8V!U&5<E>)XNT\=
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M WE>O[,?> BJ&-YF%U'R!5M]*#R#"'T8^(LJ6&80E<+]_6IYGA0_:+^CQ7^
M.\5.@+%_<O$]FF<%WF9W?<A05_IG?]RS?XMYYE#$HZ>J=F&3CP-<<K;/$\^X
MQ..1:9K'N0=&_M!]/4!ZZ2&2.2T?V)JRL2H<@(UB(F)%BV1[K<^M79%22)\Q
MMV"!:1382"7+5/J,+#I'YV.5-R9%*Z?*L9D1%/ 9FSSIB<*(4?@MJ0 FB1O(
M6F7;<)-Y$,$M->QMD:E4"[RP[5U;&6"&/70Y3@=+:;JT)X'@$R@17]# A-2Z
M899B"A-YR0$R'@$3>/,,V4='3/A]6V3&+!T>-3H@24>%_0".U4YSPU?A M5
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M]OKVXO9U8KJK<3O&OMJOM;PJ])V:<=L:RRJH$NL""9B,2PJDZ860=&X[V2^
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MQD=>.,OPZ?P<(^\(]>\7Y?VNY&$RWA4.A>F?>U/E7]!0?;-(.2UXAY>7:*9
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M %!+ 0(4 Q0    ( .Z%I$C6X#P>EP$  +H1   3              "  0
M  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L! A0#%     @ [H6D2$AU!>[%
M*P(   L              ( !R $  %]R96QS+RYR96QS4$L! A0#%     @
M[H6D2'L7M"54 0  6!   !H              ( !M@(  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ [H6D2,V]$)S' @  5 @  !
M             ( !0@0  &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #N
MA:1(H<I2>C\!  !I P  $0              @ $W!P  9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #NA:1(F5R<(Q &  "<)P  $P
M@ &E"   >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .Z%I$@=4#PK
M,P(  .<(   -              "  >8.  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ [H6D2'N+7#%T P  FPD   \              ( !1!$  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( .Z%I$B(%EFK5@(  /0'   8
M      "  >44  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #NA:1(R5BX%0X$  #$$@  &               @ %Q%P  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ [H6D2/NA5CX: @  2 <  !@
M             ( !M1L  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( .Z%I$@M[_O*AP,  (L.   8              "  04>  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #NA:1(N5YA2?\!  "6
M!0  &               @ '"(0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ [H6D2!1(C*(F!   =1(  !@              ( !]R,
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .Z%I$B$FMA>
MEP$  ' #   8              "  5,H  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " #NA:1()HI2EI4!  !P P  &
M@ $@*@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ [H6D
M2#)'XU*7 0  < ,  !@              ( !ZRL  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( .Z%I$CV<V?WEP$  ' #   9
M      "  ;@M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ [H6D2"CW,\66 0  < ,  !D              ( !AB\  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #NA:1(MIV(%?H!   W!@
M&0              @ %3,0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( .Z%I$A=5@7\F0$  ' #   9              "  80S  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ [H6D2$8D4'R9
M 0  < ,  !D              ( !5#4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " #NA:1(QNK]E)@!  !P P  &0
M@ $D-P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .Z%
MI$C^;T.2LP$  #H$   9              "  ?,X  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ [H6D2+.)B H8 @  808  !D
M         ( !W3H  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " #NA:1(69_-*48"  ""!P  &0              @ $L/0  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .Z%I$BV.%E.C (  %4)
M   9              "  :D_  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ [H6D2&*9QI/-!@  EBL  !D              ( !;$(
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #NA:1(JENH
M=, $  #S&@  &0              @ %P20  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( .Z%I$B-]HH[L@,  #D1   9
M  "  6=.  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M[H6D2%QE%^6V P  J1(  !D              ( !4%(  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " #NA:1(D_US3PH"   G!@  &0
M            @ $]5@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( .Z%I$B"CM8+J@(  *(+   9              "  7Y8  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ [H6D2!\457SZ50
MG4T! !0              ( !7UL  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%
3!@     B "( ( D  (NQ      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.4.0.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>124</ContextCount>
  <ElementCount>163</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/StatementOfIncomeParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - SIGNIFICANT AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>SIGNIFICANT AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - SIGNIFICANT AGREEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables</Role>
      <ShortName>SIGNIFICANT AGREEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Potential Common Shares Common Shares Excluded from Calculation of Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosurePotentialCommonSharesCommonSharesExcludedFromCalculationOfNetLossPerCommonShare</Role>
      <ShortName>Potential Common Shares Common Shares Excluded from Calculation of Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Revenue from Collaborators (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureRevenueFromCollaborators</Role>
      <ShortName>Revenue from Collaborators (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Significant Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformation</Role>
      <ShortName>Significant Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Fair Value Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureFairValueMeasuredOnRecurringBasis</Role>
      <ShortName>Fair Value Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Summary of Fair Value Accumulated Other Comprehensive Income (Loss) and Intraperiod Tax Allocation in Available-for-Sale Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfFairValueAccumulatedOtherComprehensiveIncomeLossAndIntraperiodTaxAllocationInAvailableforSaleMarketableSecurities</Role>
      <ShortName>Summary of Fair Value Accumulated Other Comprehensive Income (Loss) and Intraperiod Tax Allocation in Available-for-Sale Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Summary of Company's Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfCompanysMarketableSecurities</Role>
      <ShortName>Summary of Company's Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Summary of Available-For-Sale Debt Securities by Contractual Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureSummaryOfAvailableForSaleDebtSecuritiesByContractualMaturity</Role>
      <ShortName>Summary of Available-For-Sale Debt Securities by Contractual Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="alny-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>alny-20160331.xml</File>
    <File>alny-20160331.xsd</File>
    <File>alny-20160331_cal.xml</File>
    <File>alny-20160331_def.xml</File>
    <File>alny-20160331_lab.xml</File>
    <File>alny-20160331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001193125-16-577773-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-16-577773-xbrl.zip
M4$L#!!0    ( .Z%I$BM&%DZ!K4  '4H"  1    86QN>2TR,#$V,#,S,2YX
M;6SL?6ESXT:2Z/>)Z/^ IQUOM",(->Y#/E[P]/;;[I:F)8]W]HL"(HHBQB#
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M1)+ @_2[;9&S$AG)7GK_^VWO?DJ"^Y#.O X]0K\M&4*WP^MFN\,K/:7/M]N
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M-.S4HF'WROK7 /H6UVF_D"KH-BF:+*G&*X"N=)IN@F2[. &J2CJ86$6:O@[
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M]#8G>&^7#XZ "@'O820GNM4O'AS&\Z5X4%05KR2JNDD_FZ8@X:U_0=-U6@4
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M8$U_N6#_O=CU@BN_6V$=Y<"O>7$9&0L'E,I.5]A@JE:8.BT!>J.A>9)JM7
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M)&"4%-CBRE-_#ZKIIB][23VH^$85/9G8ZE3-98;ZRXIPRI[.ZHZRL$-P9FV
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M!4,"W #(B,84)0C4$DKP6WA]%8X_3N%Y>-5GG *;&COUQ"!'CN8PP@+5@6>
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MRPF02V/"V?#_R$=TP5?AV \B/B+!A(/GDB/HRV6VLITG_/CSISCD'RUK>C6
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MEBBUI9B'EJCW+S_@#X:6%_F-!)V#!&E2>46 9D_:I4Q=XT'#Z9EI^IZU:_U
MED$@CKFE,+::OOQ4SQM0FP3*\!D:'WE9$8_<[66"(RUM<Z9K:')LFIR 42?O
MVBFBAW7Y\[F2T[F#;U!;AI;TEJR<31C-:*GR,>-H[VQ'DIF*8=?):J;^=K6V
MT]N3&JH4I7#IWN%ROLP>,UX64VM6#9_=<]MYJHS05MM]291X0^B(O-)5%;ZC
MF!U^,.C( UD>=-I=99-4&=%8D2NSQ5Z*<["SO4ON]O-OWSX//G?;W^ZX]F_?
M^_VO_6]WMY1>:ZZB-7D\31Y/D\?3Y/$T>3Q-'L\))K4T>3Q-'D^3QW,. 8@F
MCZ?)XVGR>)H\GB:/9XL1FBR$)H^GR>-I)&CO$M3D\31Y/$T>3Y/'4^O$C!HO
M;7.F:VAR;)J<@%'7Y/$T>3Q-'D^-LS+JO+;3VY,:JJS-XSE8=@K^00LCWP2^
M'0\C+&KH8&FF#6LF5TA4R>]XRG:)*O/5+IX(<=U\,?#"PH^85[-8:5-I<<^T
M!C ):/5#K-#'/;K^ U;\"R-8/'ETAHN%S3_\A17J6X27%=3"8EB.Y48SK+E.
MDI&X!ZRV2D(LA>DDQ9G9R[1J]-(X/JV_Y#^1H,796-K=G[*B5OYD0@(<'R"&
M,;Y_:SNT4KPU)7'D#&EI+!B&P-^Y,PJLCQX0"R8.IECD$@:G]>'2\LZ(AL(B
M"I7<PWA*@I#82;WW@$Q=:TARA3N?'#\."R^EA>IC5EJJ,$$>Y3"&XW'7P\A_
M( $N1Z(X6 7Y,MPP0 3,0EBY+,R-B\:S #]2!-_=?<_2GB@JTE)?\ L_ 40E
M-=NLR<SU'=L/G9"^V(;?%[_,JI=- <K0":RT_"H@(::?:1K5_[.FUKR^+=<.
M'8N_L898D P>? 3TO%(3KHIZV:7<4H07R--^# C-%*R/X/X^K\):MF K77"K
M^,O4 E>&,B$,$D_!Z ;:TQIO28TZ9(2_2M*ERL'T+M(&R['1W@NTMO>\0CCE
M5-;5@,SKW\$[)(Q\CV0E[^+75HILEJZ5%D*EA7']. "-\B]02U@&&A8$;\I,
M-UF!1RM(9A-1!?)7_5)(%\RQFGOQ=%[Q$6MK)X7SL%!\/(3-(QS%;L:V,,3-
M&%[C)&[H.IXS!#T5!;1>L%><CONK4CK9A[\D1?R<R$GK]-%OV,AR<624P?D"
M*DJ 5 ..HNF20!I:71"_3G@A4WB$Y4Z25&M1OBIJKCF*D@+C-E6>=(M/B[\6
MUQ"&\81JF\"9X)85D'"*-=!IL4,L<9R0H/ >,%'@@$,Y2ZN&,[T%ZUY03/!R
MB6IB19GC,"DJ^^KTR2CP?932_MD/7/N-Q-U&G949SS7ZBQ9*3RLB$SLKDVL3
M%_1)0/ND5%<=&47QX82A@'+</WW84K$K Z&-9Y#_L,9DTEC%P\*H:>EED$C<
M *G-@N0O[JM4C_C8)IZMEE:$=L*D,C5L$E^^\;A# @\_!M:$5;%$C5D L\5-
MXR#$"K))KY8/"]5$YX5'']'D2<H9+S=(@'\F6-AY2NM:$]8[8*'6;"N/BZ0S
M38)=6,DB8JCT%E!3&3'LY00UMH.!@(A5WF2U.%U4FT^%!C6I;9B4]O:P0PU)
MA6;>_X(UI4B:;-C<PPP$L5 O&R2:HJ @\V.+\8*5"">,!%1!D,%M2CH:@&T2
M)97T8<DP1O8;JTP=X#<(!"AT%PN6XI<C6M^71D2*'+J\C-SFAL8E6+Q8TQ6-
M7Q@'L]:S5A]S)>0Z0 @LPYJMAL[&-N$D0=T/$C9<PO&SA18@TB"I(9\JXQQS
M))7380<BRU*7]%FB""&@Z--&1*P]48#VGCM[G;M2J- Y($%B9N*^G35J2:W_
M'.]GED;,JJ0G)H85^OAYQH%>93V/LHQ]'"'?;:)49< H)?N8A: 6YEN< GM1
MP)Z=V!A(K@5$I?5A$X[._<;JM"_($+H7U=0+$H<5NN^!=34!+V AW1D&FIM#
MR.7SJN\6+<!.506UU_\JRYD5U]J 55?O5HL1N$73_&7IKL-+A:A$V48H',;,
M7W+S3M5'C\K=U@63C!KR[1#E&EGE 3:75M477_-XUQKU1[=KJSGUM')T +8G
MZT^!^A@;(+EQR!H/4%G'"V9C9SKWGJEQ]PQ;4R5#MS1&D>CFD4-<JLN6 A8%
MFS5,%-&\<QSV,8GIYEE\-;5$PK0SE 7#_%<\8=Y.X/LC'OZY21MJ<;=1;,]H
M#F?B+7T$-(!VH99+LLXE?3JQ0O31YO3^D:H>.@MW<WW3PCV;ENSV[,21,UML
MI_TG-G) C?L285<-UA!BX5%)Q&F?K(#%4YQ@&$]PNQNR:,T?\Z83U/5,?(=T
M9X9OOOGH1K:!$+!C4DS]07"U'M>/L7-1B](UUUJ+=<UJN][,M2;<W8+;X"ZY
M%3@Y4N.!3C]GEG0!KP9MBB&TU/%)\;SD0K3*5KI$C=R2(_^1T++PK+M*XI\_
M!+YE)PU-^!S3?H*/V(?,QP9908ZQ$V#R->[3M5XN[2%9.I/Y4VHB8= .KXX\
M,":RD5A8,=[UGUM),XTEP?.G*/2,;4$PP5U^?*3JCOKTP,8.K#P-5LPY^OJ&
M&A 36"-=9UXF\3IGX#.?&_?)N6B "8_"[*^!)5D1$K)T?!;U6I;Z=%[6T*K"
M#"/:7&UAB0E+++'E\57K;6+,H'%, WVIN8,\2JUDZD*# Y%CHYSV0DBKZ*\%
MY9/;97+LOF3^,PEAAC-J&2=IY//1^3$S1S(A2&1T+@0C)V(!S-)0*8PS)A-_
M"FK!89J%M4T*,,P-]A^A05';">FQ39&$BRNG\@GZ+>4K^N:Z[80R&V4MJF\_
M.GFH$HV4AN[G5CJ@ 9W4]JV8 H6N:SX"/"88D!IR4PR.SP+' F.T@%ELJT!>
M<#$X(NNJ$Q+L"4>[G%)\KPB]S7<%.OT#]O=C:\B0C<"F:TS)?TE;3E(6*Z<R
MJG$Z+^N.M QUUAQR!:LQ#8RS)?T^+&HI<4G CUG^;"-<R:7(S&&JLY=Z#JZR
MM0HFVO*VED"3;2KH5BPY#\FJX/7BNAA MD\81#DK@%)B[?:<:OW4*X5]CDR3
M;GY_D'25K&U>MD:Z,Y;8*$L+G\LXMH'"#2=!%36(<'<M-8D6VZ;,A1R]P*1U
MVP):7^LY<XSHZNM,4&3SA7T"B9.ZD O1@7D$(:\VYRT_EU0GB@YL.713IH9E
M$GE/KMA7NN^N[?*Z^V[OK><NQ!?OS1?OU2=7P45!^&$AI:3\@GMZO_WUE(3D
M8?F'BX54K#2=!CW8_#!@ZDJO#B06!JJPA/Q42^]^3_?EN9(DP63>43=59_GL
M=.YWU.G,2*$>Z.NF]^K=;I4E_8H=34/%JRSIA./I_&OMA*7=;(ANGDM5'38/
M2M&1AF^8[B]796O<K63K(WG[M$S;YG5MIF,3E^B2ZV66 -5J86)%S1T&'Z->
MQ>/D9'].C6G6WI@V:D+]@8VI[/F)=#$,1$\[2@]@V-$&._)(8EPPA!?-, (W
M3$P(VDV6[5F+!GC(/(;?4]M@RRVRM1RY(B]3RTN#_^$0/+MYE+;(YZF=GG?]
M%\[A\+@GZ969=*V%M\LBWO/>5-32*C_B2WUW-"?21K:L&5N(2L\)Q\1^_9"C
M<#IZ"ULOC0BR(*"Z9!&1I)$];888L1T K9?,PDI7F D5I4]J+90F!JRT=6&0
M$FLW@V@)_U3/T$#4W"M$NXF%HPJP,.424D(F,I<X2?,-/[/?$U>BU()?Y4"5
M',2L]HH7-67FTU)/%AF["QS.HVRE/>&8&9,N(D7P WED2\IWN%UVI>>-U9)V
MB)2D$^M/DN\E%X$*A,GB*5.2?U6%W,'TW @O^,MS-WZ>LF$OZ)CY43<S\-CY
MR!10D)Z"X!E\TO_S)<H-,W\1K6FVR!:'1PZXQE3;_%7-+1$I]E=)6#I-GY^E
M/Q)$&K!>=AJ["JS$*D+M^90TN65.DI>X)DD[41@'VXDB^4<.11_J^BF>,5GN
MXMG2;HBBYR$&13G?K7*==G/J9V[:YOVB%NOU'=(30@"6#@ZXS _MK"9D":(=
M+[>/EM(<J5A&]9$3A%&.L9=2/E@&"2R-K:$L)6,Y1X*-FFP<B39%^BVG3,QG
M7MK,*77HD6N.1,A)/BZ-BQP:0V*)D[P-ZA@L%G]FN:PO,T5I83^CC7V!T>C.
MEZBRE'PIJR9]Z6DR.W;.1?=DA-9#B[)EO.+MV5*F&^HY:X1,"?MAF&Q5V2%@
MVGQPJR3-QF@_?:-]3M.%IS;)(M[B0DFWXH:8=QV6'0=TY+=P'7*. YXD;^$Z
MY!V'0H"V@NN0=UP0P"3BGT-"R1#+<=H2FQ>MKXVLWF53?&[UK@JTYG(P5]BT
M;)?-3J WLFD)-?\RLY;E5U0W:%M<DNO*P@]6!=N+67B%(\T/?UD\U"S.A_O!
M<CB8^GQ6)8MO:=;%;0A9TT%W(PNR):,7(Y&E \';2<!SP=G+N7JK5SA/ET-"
M5/,#6W,;9M$-+,D'6.T(+KF!(V<4H5]3U0]<85=]^$MERZI@5U%C+S]/SOA9
MD 66R +T"A-7J94S*-AA>YIUD3MM3[-.2V?(V3UH[TGJZE34M]@]<Q"JF.4?
M<BG8RRNM9):7&7 )&-7-\BQ<F3?,E\SRG%&>F>)+IYNE]ETEZ^[#7UZW[];+
M&'JZZPV^-;L(FO0TJ:S*C"M,1'1T%XS$11.1ICNDV;D4853.<= 1;A0$>]G3
M& 3=T-)>VC33SO?_G$]. =O@Z+$Q2\_5+/VM<-RV623Y%7/.RJ4A)*,S9ZY2
M,'AUJ!=YO[@UHU@FVW!KQ6Y>R598M PXJR3.]8K;FK2KS]DIQ852BXTE!ZZ/
M'K>2 ]'%@/7*,\(-#CVS\])PFT//8@AV"26@L]) RZ*A@6L;@X')'/N<N;%7
M4T,2A$(,ATWW89ZXDS^23%[2A)7!F9QUDBCBOXI*M>A,>0[25IOBPI:8P^9\
M4TQP6CW@P<YK2]\];+CC0(>ZO2R=/?:2N&I$3XVFL.E.K"'UJPILF1[3CD'&
M\2#6 =(&]*F1Y;@HJ %%R"/(7,#2SL/0']);><Q:LH/X<='<I58J9F:P(WYV
M)ZN0P[]\-8NZ;_0QQA.S3 )H,88"K\5E1]@Y\VQ1I&MTXE[,45R\PD05PO+=
MI8(_@0J1':05[BC%(><2RRYF[22)9GE%F:::54TTHT*=C%U837F*Z5)RV^J#
MV,H):9?<Y]&R]L[VQC03"*4Y01#=BA8R$^A&1O$]!#,_R)"R% ZBV\AB&&==
M%(=:T]E&1C='/X[RJ9,+Z2(?_I*-F[MB0>78">R4+X[/P)43E]E-(78_!CW<
MY'X\#+'R^E.:6CF_Q$1O8GC,/?C_[;UI4^/(TBC\O2/X#PJ>F8B9"(O6YJUG
MIB-L8_=P;[,\0)]^S_W2(>PR:%J6?+0 /K_^S<RJTF89S&*006>9P;:6JMPS
M*Q?%B\G_)?<M8**,A*9F",E (AX!M1"5))C)F14VR9O$^3ULR[YD22ZOC4YA
M%";:0H:O&AD3BTTR!M9$Z,E4K:0U5LOEU+!I/&*/?)XG+\NJPW@^1W$JY0 1
MIB@N$HX978"'9#D82Y;GYF?A912BD>YZ& &=H4;D]3+1DI0LI,@"O$$H-[+:
MGE3JDJ*782PD?W& ES(70#>>VI1"NV+E>THO08Z[*#G9P@A9,=4+)0!RDDSD
MA4M29SXIMER6KA0+X%'")$T!"U."B/+$%F!)C'_BNF,J$$(IZOGP4T '8CZP
M)(]2ALO0K@97%K>L_)9/2"OX0O,YD^D)(.;\W_FY)#_<EC#G)8()TJX=-.!S
MF6Y(9UB9A $AC$;P3#Z14<+/$@5'?O-<K#"3CT27P Y<!R](#[PQ:AGQBT2I
MX-*N2# G3TE#/"Y<R)_ ;N<.+]L3V3*T%J$GQ425>*4>5BCZ>3_ 7A_I20 ?
MYP2),UA256!N8W%A.H (=>Z(702Y<AV4/;X[*1$>G4:[U6J89H>':9*R0)0'
M6'@3X2PBKO7*"OE_:6L%M\&^!.A>(KJHJ)^.C0'^,FF8F([R+S#>[J79VFMM
MKBSW)M<L1!XS^'DR(C-ICUMD.[)*OG@=5JA%CLM?+>@U"9).\>S>\["^+K0I
MD"87B10H(JI!<E^6F]9W0Q/3G+NO7FGN)%VT%(<;8P\17J[J@<\\YB%9_\9#
M'0 V'#!,\U>)7$QUQ:K-M/!6HGKY](*_+.<H88HY%@H"[V>T0:I8!G_0TT,
MIIM^N_]'1J[P,&%Z&;?(Q(_ID4RJ*-'60P2/R;]49KQP%/!M:G);B)-T8X5M
M88D __L*& $P-&/4GP1$C^=S^8)F)3Q[3*6MF=R(Z,K'LQ,*"W,;!V%XX=L!
M&2W)/6OG+5/&/#QMCL\56M\/>(2'?XUQ]W2S2+HCKIQ*,]"3'@C*-5@J#6&I
MC.U8F,49W,EKR$S/<SQ\S^DA9.,8C'1T3>"5"\)WINF&> #WW6V0=[?.+)[Q
M=,*U4$&1-9!MX%V*J@A4[%A;#B:(-TE C#IF"<@)Z )I2W#V1J[!A84H=J+T
M"1R/&<0#]#DF9. _G!<0-K["*F5N?,KRF8P,HB4@P%SG/U@J+UE_XH"7[,8\
MG/0-)<FRL )^1&\M##EEM?=*>3(/KSQ5W>4P24I+O(ND4HB+"W@[[!_K!T6D
M!2UB>RF7C*(IX!;!?F*66POWUS/T >!!JXJB8SS5+Y >65*%G-,D2#(D@*6C
ML^"> .(F3$55RM0KX4)K:92=Y=@%H>H'J7K/J)*5:R&K@Q^4(7GATM*51;SP
M6T+O7G)/W1=.UY0AROD.;*'Q%86T2(X6!6^TIDJ4'BRII.F23\U/7I%?L-Z=
M^A#8,R;T3"J A8[G0B OBU>H2]$;0>2%23TKM"NWHY*^">3ICJ^RL*Z 3978
MA66V0)F<11=("%NNCTAEA%R.<Q,TE:DY*BAJ94X,#AX%.#/1\LJ509$2O/.G
M2(I)#14T@5-3)5=:5EJ[3T%[Y;?2ZE>B0AF2]94%/#A$47!/C$;8;V%RM)%S
MPD57CCML<"?D:R#!SQ8^T>'JQ?].RBU?;Q8ZMV 1X-2V%(+2.5@RS?#X:%)F
MH!7R7<B_Y&>S"/(LR$J,/!DZNJ; /]<DV6-T9-9K+C136!1R,; N%67H&.0K
MI@*,TGF3!4-S*JH%@"C4>"X\G9(4'9EJ,<>51B(O&S#E<G9<0:SI5C/F'2D7
M.RHZA=>@\H29*%0ZYAS:KFQ#%#AC4:MUY$<H(!(IR<M]P%?PX5,C.UP3Y<>-
MKR(!DBV36-T)INYBCD8>%RC2DT!!\)-AICEH SI$X2?391Z/DU%&>)A*<?++
MC$GXH*?1"N[FZ-\P?2PAMDS6A@UDYJD3&YD3Q#[/&+:QS<<E^WU)3&$(GO#+
M^=C@]H5#20^DT'9$^478*+-5LQA#_V..*>5Y*DM$GL.ORMD/_'RQXI(]3VGE
M/+132/J@@]$(YT3";F?4@R()?HDS+PS$4T6 1P=.]@Y/N@VY>TI,?Q,@$P)8
M*>K+U36NHVB)ID8"]S/74"7% &2J5,A/7$NME)$$MX&Y1"]V/KH;D*52)'U6
M^<G[1=[5X"%[9\Z],R+0M2 :\DY-J+V$ P \(;R;C"M KDW2N2OI?("OJ,HA
MTGFY[24L*U[J)0,7)<X&/.&![L:RL[$J=GRGNU'J;.Q\R(L+C*XY7JD1[P$@
MT &A9ALI#T@$EDJOK(>]\M ]2UZV6#L\GJ?!<0,Z3WA%=U,<)V2V"E3CJ;)
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M8W.IY_[='?<IL'-GS_W[.^X+/S:3NY]MD+X>@'8^W 6B<@!E3KI$+WX\/'E
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M4);"EEYKEKPU_TZX?=VWPL/'C$U(@*<TA$H!]2DR'@.U*7\M!0MN<C4'*':
ME ;$<\%06TQH&S=^\!-?,K;G3B3T"IBI+("_QTFA.BC..>C*<(\H'>DPC'!'
MR2)#OLIRU@'Z=%UX*RI,VQW'7,%<V+@&>,C7 _!V@'#!J-?VK*8R1PL#^9#=
MCMF<] T^%FP*#ZD9GC)A4SMV(PXXR6P Z0770 O"A%Q2.=ARB+T/<'C%0HF
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MLJDR$ *^LY'3''_BC)$7T0:^"OSX$JF;/P!W*I:YS#3A'U(>XL(%7&F38AG
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M!P@L1 S#D_ES;A@=V*-8%B?P-H680?!.;3 90&TM+]YH-\J6CC)3*N%4S\[
MNTD,&92^$M']&*PGC#RG3$R!F3#,B-AEZCV+IV!7_4QH5^Y#\>=D!0DUVXLO
M09XOI3!(JRZK6,4F\F83WP<^[#L/8,FM)@%U[AM%C),'687):L#:E8>M%PMQ
MKBIV4&8!Z-P3;NZAZA?(<O# [](GZQ%>3XC"G @P"U*,8OP24U#*'!)A5K0J
M8L;U7#SUNKS*:FOXDZ)EI*1]'C$3=JC4UR D(G[>[R9D@K#)'),Y'OI%P*W
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M"6)^@!4-+E:Z8$L#YX*);A414YH// G:$/9:CT2>MA$V>)93K#NWL_)$ZP'
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MM:!-PMRU7["D_)0!@8.]^,5VO*_PF7MV@--C3-L[O[*]<S;#DMI@<3";VT[
MR;%ZL&OM?F[JS58.<!O9^U*OPWG KI@7@H,,C.[/V!&+CJ?G]NU+ LDPC?YH
MU&JI/;T//BZ 0>T,])%J6)W]?L<:]8;-#A)8=_>SJNLMLVGE '7'+N[AL9/
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MV2<]_3RU9XZ[^'1'[7(^DYR#29%P>E@>>6:5K16+I!PW'(W@19]T\]='K?K
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M['2TIVZZ:#'<N^GFXZP*$]]O[G[N= I9-&6[R=A.AX[+PLCWF,CE1['/'F)
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MA;%UV*W&G(A,;!WFQ#&*Y$?,ZWJ7^!,QM:W#W^%D[+\SA.6"OY5$&#^)/(L
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MTRO>$*YTW3+TUI;C2M[P[>P\8'88!XLWBBNSW:F8A?)H7 U\,"7 IF%OF+4
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M)BSX:U??T_(8A<M7D=/3-V6^O4T9;Q%31@4P560T5.SP __Z\_\/4$L#!!0
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M+%V-7WPIK+&0 B*Q=JY&0C8AD,'>O(5FS&IK_&*N$@IS2:97-6V4]>26S1^
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MSJ&2#J'F[R,!PTWVT9_<$0K/AR!_$' BN[CQ$>=D0K!75G#-5H\)88 8+OT
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ML7+M.[IEN\ 'P^T"Y!VD:R_X'M[XCHN1'>E(*LP#A<)I\(C@H-NNATK6T6E
M('W P:L+.)^OOL&1N?$W[I*Q#=P_#<SB1W*W,I4..7;SJM$LP&'I5:.O.(G%
M2D/8UK%K5V^V%Q-#9!+6,7VQ_"E:+ -,_ R+I>7BA"0LHK4REY;D3['7OZA4
M$.MK#E9I5"+L:XS@@KE$Z;]2R#&&T('C)5H">W)3N1 M/91< "#_+0(<N;_S
MM&6AKD.ZZR&E.)8W](V_]88#&[>*?F9@LU7-7QB;[7YF8+.Y>;-:RA4WO,0
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M+WG[419R3QXZ#SS7)A@YCIL">^// KQ(@_F&*KA[K8)KIE[M)MXN M!9]IG
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M**)5,N139/E.&+F>-_GN(QR^N,M\U8B,Y?H@Z=-)*#. )LHF!F1@_PC#<E,
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MPN;QP.U$\I6S3\>+ $>$+UT$892^UD%WSD@/8U;48D$C^8J![^8,F7#BJMB
MYN-VA1HENXY":I3'-8L:W7]397B58WB50W^,JQJ:YN)0_A08E9"4AOKAO8"%
MG8-\\GNB]7 W@D#'GN$S1*4.4:D=CTK=&W;29Z6_5:V'Z+F6HN>&:MZ'7LU;
ML#H&6R8K6G1$) ?M)CVQX#-5")L>(2DO],G7932XVD--M"LJ+!YH<0==S.E0
M D6-B9KM"E.K%3TJ:-KI0AA/_>A9T8*?!D?B-%K\IA4\>WHFQ$IR:@JI&0*K
M#8^-D'=$'GA0L;#/\B!BC15X,[OP7DR+=&(_GZ,I&GL(*3(EN*;OP48T>T['
MXHKXU^?YZB(@H9=V%%O>G161KU=#N)'.D))L%0BX,] <)CZ:ON @GK]<NZ_H
M7\C"931JQ9W(SM%%*FVJ=K9$H7Q\HZE37,?Q<YB<]:84H8YI,A7R"JYJ*+ [
MGLG8_\.-7EP?MC#9MRJ9!V?@SM!#%9M@#&H>'4P(630KZ*Q?(4)#V$,WB@95
MZ_1*[GAQ'5_LPNB"<4T;X00E]BX8WEJGH8P=UUR[6V,)M/'Y+ @PVBUSIA),
M0$?L@F=VC[2C&WQU^6U[%J$R^!P[[0RIO/RZ$,.V-QI1F)'VD+<.>)#TN U(
MC**;.#S(*T;$-^#Z<^3;9*\[CIM">.// KQ(ZS/H,&]@9$UFMY:_077;@)$W
M4)(+<6[YO\(&6"#LVM;]F)R*R>P"(X>1+"G82='[)>'+1> 1+S:VO$?T6^S"
M'+!''[#K)[%8P*-B/YK$41@!1=(2$38LL#7?UHT5#*@&)_8F9!DNQ/NU#2'-
MZ"#61TLF:K(AKRWR8BO5JL5IJ!]>;LH4M6D'86Z4_=CDI9[GZ,:'&SLF6S;1
MR)^6P%B=B?^SA5VR8Q^!1[ >#Q/N/AB1330B%Z\K >[ ;&X*[%=O2Q<G$LLE
M9].*]#0%HULB[&$N-ZGLUB-<-'%)&EAWUIN[B!?G <;!=[CC+ZPE_!*M)#!C
M#J%$>KD%.7Z>;>D%2&WA$S&*;3N#N4VUT#KP'?*"*@BFSXEP/4- -'*+W-Z<
M3QZY*9)B?950]S[ 4>#?66%HV2^@V441)VN:W5@'A1^L52*?3H.QG<C]'"6+
MWE:+*S"U17U%P1Q;RQ=0MSPN*V&W[S3TFCC@4P2':!LBCJC ;J\%^O@Y3!YJ
MCZY>X7]<'D)O:P#4%05O6*T-@9R_VYGM.PV]JBH=4X07MX'E;^0&YD7#:*F#
MBD7]C[-M=YKIAI6[U)2&'8-7U9[\!_*\\-K"\V!+IF7NS8H>^W+"2=L>\P+L
ME>; 'CK;:I&K0M(TV7'6"-^BST*[]ZLM).6489,#R9238<?^9'((6"/LQ>W&
M)H=W-;@+FCGD3 [AJD\4IL5)>]15922 E+^OP_FCTG@*& #,SQ*MCS5+!9=-
M#^T0SDPOSQKICSU$FH/NIQZBNZN<9\C^8$(%*UX]+[:SDKV<QD2$BE7IJH]B
M5VIO\6(E-M($R^JEO9:0*@0% LZZ\"R2$*Y5YB+M#QCU+?A<D)VR+WLQP:#L
MTS<):PZ#58ET5UAN]>(UX4[FV?%JXRW.J<PS: E[FS?8<L(8]!<L%&-AE:[I
MDD+'IHS^4RS$O-2@:P;;$EQ@OA^\0E_OVO(J0-:,Q15@4U6.=@ZVYE2;%=O$
M+'<X2ROOV+:MAUY7-BK;WUX2%<4B%_-[5<PQN,\4L?L@0N$TN'9]RR<E[#>7
M3?CDSOVDFK\?C6V;N#:(2R/PW,3.!%.>>X']:_U$L2',O\6 )K&U*P,OV5EK
M4.*.2XH5C7A;,T%,,;S<DC7E1H.YHV&N/7./4+U;_0WDD22((,O(%UZ3,58\
MQYMZ^#J9R-WTEEY_H2.M^X*\E^"Y3A(FD "RJKJ!N%UT\/$K"_M U_ !X:<7
M"R,Q-*IZ]25%LCY=-S4D)K/-WLZ#C,*48 SJBO4=),*46K3GY[GDY730 ?\]
M^E[@;QAX8^S;J+#28D=2>A@EH=,/\3.,FJB'A!],9L2#'_A/T9HU5T!?<Y!!
M0F]90M>7HB*UZ<7Z:GD2,P3N?15&[H*\&<@ ?ZO1H!\-^I$&_8@OQFK7BI3A
MN7TD34[=D,.L4H@W.8%##-6ZTH;).1MRBRRH49B<IB&',$^P-SD30_(Z$A-_
M3,ZRD$-87M\Q/^5B,,SM&.82"C0PRYEE".J7R:10(Q0 <5POCMS7 I>]>K.]
M&+;--6QNN&*7<93(AB ];0D:E?J9^HD&U7]PS@W*9V^4SS98D7:5=9 7BO)"
MDEO\3)Z8AY4=8VSY\^2'O(:S@IB;)EX\<?!83CWQ$?KB&>N90#1<\,,%/USP
M[5B7)=CK<'-W]>8>U'V#;[>-C,U:4))M?Q_X-N/G*7P*+9MLO#0/7USO5S_C
M(!\,\L$@'_1&/FB5.0WRA%'RQ,:%F0L0_<NW41 S2B4/G8GS^PP2T'!_#_?W
M<'_O(RR%SK2&&[@[-_"@PQM\@VW$Y/QUTC!$B7!\ZUK/I*Z+B\([9)$U=2;^
M(W&AD3"YI*"MI-:N8H[AGA_N^>&>[\T]KY@!#7*!47+!C?^*PBC[2 JBPZKF
M\;=7O\6 0AZ406JS(AS!QIIBB]0#3W>"4H>^6<)$?1;?&F7IET5KTPV"V"!B
M#"+&(&*T*&*TQRH':>,@I(VF!HSZ7';\:KD>F?TZP$]6,6.IZL(6Z=F7H$$E
M4M2%9X6A.W.1<[XB+P1@RXYBR[NS(D*W%7FM2,C:T6C(01K:"=]F[F-0! .?
M%!Y.(K<E+5$UAQTDPT$R'"3#WDB&0M>K=B&OC:28FERU/[4-FMW\V@L?#()_
M.:"8^;Z3,=E 4A#2+TW)0?HBWO=,M!W$N4&<&\2Y=G*"Y)BL=LG.X%O\IQ,R
MQ;,5(OCC_P%02P,$%     @ [H6D2) 7*>IL5@  :%\$ !4   !A;&YY+3(P
M,38P,S,Q7VQA8BYX;6SE?7MSY#B2W_^.\'> YVQO3X34762]Q[?GJ);4<XI3
MJW22>N_.$XX)BD1)O&&1M21+W=I/;SSXK")(D 4BJ77$W8Y: A*9R?PE$D B
M\8__^\?60Z\XC-S __-/QL?13PC[=N"X_O.??_KV<+YZN+B^_NE__]-__2__
M^-_.S]']/;H,?!]['GY#_VYC#X=6C-&C]2/P@^T;NK&>L!>A&]?_X\F*\!FB
M_^N@P$?__OG^!ID?#81>XGCWRZ=/W[]__QB&3DKMHQUL/Z'S\W2DOW">?D&S
MCZ;Y<5+XRWVP]YU?T+3PJXL06S%IC1S"S2_('!FS\]'T?#1Y-.:_3,:_&.;_
M*;8.=F^A^_P2HP_VSZ0Q:4EZC-']Q_N/!?'^)WH(_(BTWNXL_PVM/ _=TUX1
MNL<1#E^Q\S$AZB7B(J),/_KS3P4)?SR%WL<@?/Y$AAE_2AO^]%__"^*-?_D1
MN:4.W\=I<^/3OW^]>;!?\-8Z=_THMGR[U)$2J^IJ+)?+3^ROO'7D_A(Q*C>!
MS;0DP2 2MJ#_.D^;G=-?G1OF^=CX^"-R?OHG.N _AH&'[_$&,1Y^B=]V^,\_
M1>YVY^&?DM^]A'A3S847AI]H_T\^?B;?TJ$C+.D(QHR.\ _)KYF=_81HRV_W
MUT*!EB5:O-,GSJ1'_T'MM,0F_A%CW\%.RBCM7J,N1IUIFA&E9 .[1-"C.@_"
M2L$9K8T5/3&"^^C\V;)VA+ Q_82].$I_0XV3V+*1*/D?DE__OK)M@H28(/4N
M\%S;Q='J*8I#RX[3T9B,?_Y)HL.GC'_:I21!B*-@']JXE4KXYVG)Q>_>$^VT
M]4@7ZGZP?_[MX2?D.G_^R75^GR[FQG0\^]TPC,ED9OYN_&[\]$\Y,9120[^E
M]/[O/W)&U,H6$\>$;S0(:'83<!66+= *[911\F.#A$F+3W9 G,TN/B]]R$T8
M;*6L*1T_D%;*)SC\1'?6F_7DX8M]&&*_ 3N'C?7CYH #69,R1U-C7L),A!)*
M9RBA!0J7D^0R2W+M.*4!@$-@6Q7 J!*_'2@LSW^CICX;C1-#I[^A],,]=JY]
M K8=#MW (<$:B6626.#@HTAU46ST3F#OMT3FKOQ(FHIIS,V%^?N8FLJ%%89O
MU*>^6MX>(RM"P0;%+YB$JQX-LU#T@G',HDGZE^#)<Y_96!%R?9M^(N<,$59B
MR_4IF3A =A 1TXM?K!A9(48A]FC(0?]">@1;C&+K!\(_=M@GT540HB?LXXT;
MHPWYF8[,!>,$7@A#3QC[R.)"$CK6-B#C$,LC+G1/APQV-/2F+)TAQXV2O]!8
MN_ '$LZ$5A"2:-X*WY ;XRWY94"&"PFI[2[$+X0=]Q4G/)XARW=X,V2_6.$S
M)4>:$G%=RH3CAMB.O3<J543^CE\"SR'X_A/"?]V[\5LO#J3*)ZHWB]0S4HJH
M0)(N;5!.5*V$5>%I[X).J*1%":EA6ADU8KDVL1AJ<A$Q!V0E.O%<Z\GU!!^Y
M;[?:QI-1YRJM-J"X@_)UDRB4A$*-H8>@O=[HHYH)Z9AVOAP;99@5B,''("JD
M,XO2);X^ @Y#ZDWM(!*I40(04O;;/9M(UW32NBC.6==LRKH)HFCU:KD>#9Z^
M!.&#Y>$'3*9H)L#*^<]]%-/@XA;'ZPW!O]@ E(^D%YVJV6]C^8L,URD7B+&!
M2GP@S@CZ0%GY^0QEW)R3&.@\(OR@G"&4<W2&"$\T#"-<@;D'6/6:A^H5QW#H
M@\?5ZW.EQ=5*T^B!^H+P@>_JY0L-V.M]Q@0VF#!JG&:U!3K#\U@Y<]* 61CF
M./%'ZXMKZG2\O</WST(6X*[B.'2?]C&U [J2N2563%9/A&6/-B/Q(B;2$K?S
MQ 8?O-OIJJ,N3B51B<"IG*R25QP^!:!*,=1K96"N]MAO='"D!^H=L)M4$_@-
M.*AK'5$L)R.C4\#V3L*P;@J1PCT'? +_=X!U!2$3?#CD."Z=MRWOSG*=:__"
MVKFQY1%VMX'_$ ?V'R)S:>ZH$\V-W,A/5//Q) %P1A11JL0P44+W#''*B)$&
MPJMBD<T#D7>$ZCD1V>9T0?$H;:0E",HI" 9UZ7HH>@SN,56!ZV'B#'+/\!A<
M6-'+71B\N@YV/K]]B^AFZYH?/_C/*SMV7_G:JB$MH8^AM");/?^RP!A-Y]/T
M6#=G@ZYJ,D;8M%V:R>F?*3\H90@]O:$/E"?B0'Y&&5LHYPL^J0)<R6:%DL-,
MR72WA08']+?T9YOJ=\]5FA[)$8U:&1._P+JK_M!==G ]?34U1^//(<:,N=4/
M-ZH\>2NWT'[P71I>UERGL^ELPL^Y<P($P(1$/^ 5G]">P+^ACW^A\SE9"%-:
M"#TGJ)4&GQ^8'DNJ&&>7P=9R&TP]:0.'-<Z ](<>31;+8[1Q(F!XZR+#$>+Z
ME$$6<UT$.4)=C2":<5<&0 7R"O*JQ=XCZ=HXS66-P-"7<B#[Q9?&;#D_@!^B
M1& GO&YB&'K%D,1@-UG,5K+HA>$A%HYQ6))9/1 EYL%",U PMG+ YMP<+Q?5
M<(2=$;N*4@G) 4R,7>6IA.5@YL=C;%1#4_DLZ7EL#SQ9;;Y]Q=LG'%9^@.J6
MVB%:R8:D*8Q'BZDY35#J><G13TH*_<:)Z4:J HD,"(D: *M ++-:+#BXUJ(E
M1ZQ8].X[VA&V/SX'KY\<[-+-[ G]@0)Z4MC#)K_Z?47@XU (??&LYX,/<_QW
M#;O%1X-*GWT8TV6Z.$O[(TI KS6?R+\IQW_?]BLT#6JUU2*"G+[XL>NXWIX
MIY"C=O6#IC)AYPL1A9[6[OG\L-Y<62&]AA+=X?"!7LM8;>F5(M%.NA+:.L]7
M5# LO=<_'YNS!&V%<8N9J>G(B)H4*HQ-DR/2T1$9'K'QSQ#G .C<1+_RS%1Y
MYYGVHEQ[N*0]NZP]G&IO1[3';AB!GI*H1&'I6$391WF'SNGS6S6!BLTI'2.^
M'T=6)X;T9&Q.YXMZ]P:QX30X#9G=-/1./),,!!7ZJ\;/\@Z]V(WKXVMZ4;8?
M2\[)OQ__E/$LOS(8+49*8RWT&V4",2[>IPOKJ,1:?Z5:B>_$RQU!5*%+*W^F
MX?BO6VM;?;@@W0W<W^2\2"\[)O-QO1\Y0Y0JT,9]/^+6(5Y"7%@,'YMI,S8/
M% 6"N1!;Z\V-Y3NB3YPWT(FC;%3Y E.C:;JG2#K3>8!V!\)%1_89 K[Y#G[%
M7K"C)2IH]1++_NO>#7&E+-J,_LA.2N9=EA?&D$.BX"37RW=N ]_*?_-(?HIH
MHFK@1Y4'85VI:(5$*]:D#6\\F6>XR4=@97/(&.>%05!Q%.B9IT]MF&JUH0^C
MG2!0!G)[M8*@/8IP+%RH\C_JQ"8;4;K VW@\3T]V6<=^(!3$EE<+H0Y,SRC3
MCY0RLH2L:[/WDA&4S#@7#<XZF^X(E1MIM];6%3Q'LVR?E1& OT!S@AS<Q3\\
M7#T^P)MP[7V38R'A3+JAJE>IC7:#;EMFD\SULZ(]]URP2\X==Q*BX)5MWG\P
MWKFN.->1P."&+>6R#]M"&7KK.W^3>;8W73;X@7CRD^1B#OVB9/VP]Q'K[$H(
M@X'X^2^6&_Z%UI&]="/;"Z)]B&N_7%5[[;"H8*)-<#LO0X-20XP<RNE!S@PG
MBY?/$O"XJ#&P8VR() ?!QT&YM4O\%!>.?[>T(-??L',11/%G*Q*G?[0EHQ--
M+7F3ML+)R$CGG^,ZB724TGY_-A"B(R$V%!#^>E7(C*>1%H4%Q6=' R_!MHO"
MAH#F I-Y*:%?PR"*OODAMCS*]:^6ZV>UPB0MICU=0+RW9E:^Y,UR;@@=0 G[
MA:)5;&24#XWHV .H9*A7:RR\K50%[")/%8#JW$<WU;X7?U*J/:C0V,IT!^Y/
M2LS*A[538W&Z/Z%C]^=/FA]$@-+;I-*E4(K %=Y5@>A4GW*LW&'YE(L7>C)W
M[=_B.&?ZGP./E@:F_I#RW]K6I(@.PIO(<"I?D]Q8SJ1<"1^5EL"B1<@*P$E&
M9G-R6I4L=RK5D-*_=NE3?3/^#,LKYO6QJ([X(SK%RS+!!MWCY[VWC]#C"Z;/
MF.QCUXYH.;>/9_2!EA#OR/H .-M%">;D_(_T=QB6\Z%KNJ]6G#K1#0F8USY^
M? F#_?/+%_<5_P>VPO):K[6)=AEC$*ZI ^,M3GR6XEV4HJ=B.RHY%V>(#HH>
MOP<H80113G1NM'1?4_6NT&1]A4D80!\OLWP4^!B]48T][6/DX2CBOXZ)_NBO
M!QHBG0!+.7?5]4N\1^^5;3SW9*\Y_7?DM3*F6RPWLN*':CQ6?C;S/OU41Q7^
M_^6CCL"GTC^5O\"@?5/1DS;E)YQ$<X@^J(K1%GD!LW$WOU,5$A&WXT:VY7&G
ME+1^@T^=T*=*<]@G59T0U,FI"%4Y9$>2N3Q%3N28W@ =R!&3TCL:,V+SW9Q'
M'IV\<Y=QHO*8NZ@/U8;F*H08Z>(FJM4W9!?Q;V[\XOHD7*+VJG+KIH;P )V&
MF%OY/87%M&/H<8M_Q&3)@[U7C+X&?ORB-15&E>M0I4+F0VZRA4VZWGD/OJ09
M3%V<2H-BWXUW4;6U(B Z=*_2?@> ;E.J\RCO90=%A=+^7GR(D@V1&H4.SW?D
M_^ID1H7N@_$'^;_DC7@Y:X'\_!=#1'97\<V2^(B(CYCX#A4Y*NB .;97EK;O
M0*?M]Z*)^BS^DZ62>:ZX'P-_-\O%8Z\D[X@/M#-DE]MPU[,EE0$ZX+97+2>3
MB5SV\M%5AE[OE:IRR)W4P4#[U0K_P/SM^:AV]AD:?NLNIW;0VI#1?$NTI@30
M!4(#Q'3.G?P^@]EFJZ94D2P;;-C([JJ4]PWN8XOO@N\#W0T+XE<LN_*$5=(1
M@4% ^I K^2G)F,JEQO$1!KQ6.DT%HM7243:NSO7222N+$TW"_/\@,UGD#.2\
M7J6"A^WMNBY01'0&Z?O:1N7FS#2[N<#!+E.4J.1D#_ ^0-]I15.G8% 70 PW
M*G'*+FC=%ZY\TLL1O,*UZS^SI[D>7RS_$6^)I[;"M^OMCLQOK)IAD]DI'0O"
ME:@40/[>SW@AYV[X/</[XL7EY)+4&<IX2EZ#8\<T&5NHP!>P:X)3,7-?F?:>
MJ?8"GP=UQ&EM9==HW775X1HKH$%.U*A+NW_OP^%5S@'*O\VP0L5'_"/^3$;^
MHW6PD?<<1#B8L2/_7MG,D#DM1+\],@#0 1 ;87#)B!UE9Z[R8;_=TKF#H+U0
MR*M8!H!/-?1%C!"_8#^BSPV0."_8XO3R+JWY?.W'- P,W<"AMWC1RF/V3!\:
M(3XE#1;+FJ92H,*V6?TN WP,>006N:BQ_'F4O%G\V?+_6&]66Z)OV[I=W;@^
M7F\N0NRXL?CYXN9.NE\R;N1(^MGY"?F)/VI,::+U!B54T2U:(4J8_HZ3!GKD
M6+&PQA"$K7__6+'$9B9Q4)#XXPKL+61I%&;/(LMI1(F+N+#"\(U$),RA7_L-
M.^!2772[AP9^9*UG,II/QMPYW&,RB47LH0(RJ[%)S?+?_A0A.QDJV>&MW/0@
MNL?/0<@B91^[;%JT(O2"/><\#LZWZ:T%/V"_)_,AC0@K]T/Z\S)*=<9\3$HQ
M"0V(:H /!=3+:9;D?(7*JFF#V\RER"@"8LUQ844O*]^A_Z$\$:6RIS+B$K^"
M4%>NK\9UAQ1#\ONL"S/#5O3"PF?V0X'T&;)B5$9>+R#C$?N57[M1T8/TDY+T
M-OT!%Z7'Y+=DEN?L]2CY0VR%L6;9IPVR/^%GUZ<O#O:L@<859P^RF[6R0R[[
M6OFKXL)/7DO#<</R9<OE^X.[XU/J?IOFLMDE:ZQTW@V:)VL@A^>@42E9%+V=
MDH:#SCOF\Z]].\16A"\Q_V\K2Q"0 ,=H-5\MYI#1LA&F? R4#H(^I,/\#'.]
MH3]-L"L.M+JBF\I*5F?V^YE=ZPV]&<HU.E2TAQ*]7 0>W0</+>\>\]=%OP3A
M74@T[NXL;[4-]GZ\WL=13%1.9GO"DDWW-)X/\:J H/[]EQ.XE;3DJ3DW%B.^
M.\.@G ^(PF1$EI>7C8GXH*@P*L-\,J[N[19M*C*&K:*F[1IM>LIC&%N@IUVF
M)XOK*2CJ:5>K)TU[0 K\3F&'Z%3=@X1&.(S=C4LW7:/UYA+O@DAPN"730V?@
M(V9#^GQV.D]+EQ:IT?V A![0L8YR&<TJ&1U.#S1>:;:^4GC2H \UT4A2_[BT
ML;#>2)WL2';5'F'(\25K4]/9TIPDL416??S@_(+8EY[S"W',T(?0QC"$;H@"
M^I!\4(<W[2":3]$M%*/&EP27^!5[P0X[Z_ BN",B!#$MCT/"A*<@9( EOW3V
M=DU"27LBVOU+6PZE36\^&J>KE@!E@Z" 9DJA=!Q4&@@E(R$^E&:GTZ\FC&Z:
M $Q.Z5DAW"L%YTXZR">B@O-=K3K@W%97;Y [L$[:!%E7Y"R]XE484L=+?4B^
M&]R4$]N&@LYUASQ;\B_ SR?3%-L%ZJA OG 4@GX#3Y+M30D\6?;ZU]OK+]<7
MJ]M'M/KU_NKJZ]7MXP/H.J6]-9?6+2W5-23 1BO?H9?.!7]^)#]%EDT=3W3C
M^O@ZQEO1W2:E0PP \EWXEH;#Q,PRPT0^(6+G#X2#<UOH-HI,H-\H&XCQ,3#'
MT;\J3;VJA/9,I\!6QG5U_F"*UE7IL$&X^G'TJG5U&_VKHC(#DO9J3HW9;)$N
M>G(2Z#=*1',V_6DR&#IE:%J'G"*(V4(034N):@ 45@H5\BK'WF6PM=Q&XT]:
M0>*/LR [8Q")9V85 CD90 QVD:,"A7W*(8_#+L)4(+%&&.U8+ .B$HT%J6'B
M_.T6A[9K>7?T(F']45]E6ZV1=P4#\J\^C)?9LCJE@Q@AZ'.]T\4R#\3:44*P
M@6B-794C2I'P4'!PXS2BO0C\V"4AK&^+JY?5]= ,#0$;TI:TG(W,'" )-9[N
M5Z0'!Q(E II5 MI%>NC#;1!C-*W,7-0)H 9+/(11G7H&!J9\JZOAN:=V-(8!
MN&/&Y'<]E_.%! 1+V[_ SS7UJ(A*J'94Q !P*S9Z220+]#E8;#>?Z;0B,C1T
MMS_4F$QF1EMX#^!TIS]=<(2OOWZ]?F2G.FAU>XDNUK>/U[>_7MU>7%\!G_-T
M,?+68.ZA5$G-N*)C&?E^^G=NFIF2W< ;C8QEED)2!\'>#T=J-GA4BROA<>#.
M@GJ262)V@#ZT:8W4P@:2I+KZ=B:L2E?+#\K[#,B),(:D3P#,Q<B4<B",['!\
M1P<I9?Q&CU)V=AD=1)5Q%V)1H3U%"88R7B+7D#(/$?@/,8EA+DA,0^^RA*Z-
M&Z[E-7:"\!&U',G:U&0\,Y?<2?!*>_3VDXWI+2<4O5@ARPTG_".;C8@B.B1R
M(UI_Q,-6%*/XA?PKOQ2%7MSGK/8L+:*TE2=+:-I<&OIGVIG_?D?T]T*OK]+;
M6;]B_V]O6XSB $78\]!^1W\TI_^#]G$)'ES?C>G.,ALG.D/1_ND_L1W35C8.
M8UK#E/P^)OSPC @R_"Z(B#63H<X)M:1*H>-&[)H&;:.[2)/:KYLY1R(I(XH2
MJHB1!;[YIU96YAWSSGF5VBH#+!F?38M]T2N U+ J6Y3-LVR:H+Y6RJ&5G&VS
MQJ&V:A+.[JQP'3[$M,(HN^Q N'N@'Z5FY=_44_.F3 ,[TO?@9I/)Z!C"9X@0
MIDGTG'1RCX<01XPZW/Z+4K'-@M@1%YM@%.X23P=#/=QCD=$/,/88(]%J'[_P
M:H;-7_NH!PS6#MF0-K:%.:J8)L\XEB*44P3'U6DB5N")1TG(JA41 %<B(Q3@
MJ5(O@\#1=13MY3&4M(;$#V=!>G=\.A[/Q=@Y0YS<0(#3138Q:%RA:&" *5M;
M+5@*NA@$4 KU)60_9[$+)&0*?,B?&YOS61UN"C0' I[.4HH1%-0+"0:C"ENL
MQ=*A:H !55L\][ 9#'!:%0<UR$^5BR!&93!S3 >9*J#QWT<?1T:^SLFW+,Z0
M84[/1J,1_?_CP.U_H<7T;#(;GYG317F&8EO$!:C1G8RO!!XO:&R<(;I)ROJ.
MEJ.SY4RB[R6V6?)CVGTZ$.R*:[!6?2-5^\D[[$>T_=O=/MP%$8[J*B((6P/L
M( M8D3Z]G"Z6D^Q\*2.&4FI [VBH$LP $JQQNU2)=*90.LB=S 8H%;<PZ[0
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MGZ8R-69'*[?"UO?@X*E(Y,.]$3F1(;'9:,A-**W7W&#PFAVXR\6F=5VAT7G
MC[R%+F;U$V@I>6P@4:LRP1DT,PJ#@Z' /AO15Z43)?=]\BM&FT(E!WJOZ*@
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M)&2RG>@/R2@_T[ODV4"L23X4)$I[T@?#;4*1KZ[=@OAD[8>L?L5_Q>%3 *@
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MQ;?[Z\?KJX>!>*9>@"OP8^J_ ZS7>R1#U9:(.FH(XFG2T:7C[=ET='R\3ZD
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MW9#A4<-MT"'<]RSP0);^#S%9V+\$GD.<#=\9:/Y(U=U@[+V2%^FKQZ,LJ:I
MLK###8X'!>)5@X0)&15(_XGE", >U<F:I@!28F4-$6<-!V[2W0>$N];G3)/Q
M['@2*IXP09^M]2,QC[^N5Y^O;]C&-%K=7J*'Q_7%O_SS^N;RZO[A3^CJ7[]=
M/_['D,%8=Y+62FW X+S8AR%9K#<;0-H0!G#)Z-(!TMRLF-K.4$(&?&+K)$YA
M*K-Y_P'&?0?V)(!%4?YA $!^/CKL  J(]H^Z3-,GJJN ,:09YR0)>3&L8Y2
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MAJ2,!H<#R+O0?;5B?.=9-JXK1R+7&1R:AQQ)VZLY&3?B,R&.,NI# NEIDK=
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MY^;V^A%RS(3TL?5D/#-J80)RPUBQ?'5H ;R +&UZ%: 1J 0(.=6%EV]QS2F
MN(M>_ CYD-\H,0L15['(>+G&^!DB1,%@I$A,LRAFN90X.W@#AE&C'1X@J5XK
M:A92^R?/M=?)8614.L*["\B?WOC_/N(?\6?O^#B[(Q'MRZ^V',K:W6(T&XWX
MRNS2C6POB/9A4G^5/>!&]VQWC#0*\V>O2H<L.\9;=B!\1E_]3G9[=^G>2W)H
M'+]@OG]\^$Y<FV?B="\8^U4]]VQ<A=D@AUD&Q./Q;_!;\E\Z&&*C@:PV^U6)
M6:$2N&5H5P>3KU [:0LBU+@G'Z=NQ9K_76,0D0TJGUYM3I-,.M87="W:D7M3
MAGM=,_^1612G^;* 8%9;N8%:U4*WY;:K^$)65,:B9+N@"\3.$IAR$FBUX.,-
M1)&8(%;,+J_38X>(!,CU6=#5;75:=A4#\DF_QC)9T17HL/4;<&:S K&8X7]V
M/2^Y3+#WG_@_[, CHP4ASXL(\Y% <5%G="6$"#6C9!5WCY^)5BSOHJBD9"M&
M?#0FT4OW.JV9)=DS&<.<I*5_4Z*H1!6E1S6<KMY%D6HY#0DY 8_75(MK-HL+
MMN"1QV*VPI%4CRI7L??VT>,+#JT=WL>N35-Y:IV$N#V >Q R(VM!B]$DW;%)
MR*$B/9IK!U3C39UT!IQTC8Y D8AFG8B0X&]$5Q'V]<J B:/=[=.>?$,*Q'O\
MBGWA1=_*IEJCZ./QY1\BG8VS(+I !B5TH +H4R5*8,%Z\HR]L"2>D_XZCZ>#
MRMA'7P@MMK=R!"U0C:)9D;WW16FO-U>>^^S2_+5]O _Q4:DT4;G^UC3TSY[M
M&)0NNVDN)I-T1LV&H"_1I(,@/DI5%4&(5P+Z580Q.$4TS<E]:L-4K0U-\W@W
M?U"8VSLH5;LK$[^<T('*D-U9RX< %HNQV=FA@3S8T+<RNCHUN!<@^M9(5\<&
M_:1$=__0R;D!9W_=XPC3 C0KWRF\HE;_K'U]'ZT+G!I&I/?5)[-9>B26T$N*
M\.3OY($^5:]02O-(RL)K@+"K' DS+"]WFI0R.#35'R%+]!P*LMH=V(Z6T[3P
M4!.^@';>>A/Z&&Z7[P!N->?8D@H"@EX<NG:,G0LKHAS2_]"<T%?+H_.L^)O7
M=],+NEI>Y'W]R%AFB$M((DJ,V2#[H4 6#&P*A34/A+6IC!^V),YZ2RZ:HLW>
M=Z*?@5$G9:('D&M6$RS>6*)AT^16T18$604&I'WY=#([AA,O- $^89TJUB%P
M>,JU]=T*'>#,D1KSJ@;(H0Y@4!&3U1QVKJS0I\FX*]O>;_<LK_T2;US;%:=<
M-7;4BI<F;N0+JRZ6V>X()XI2JNA#@2Y*"%=Z:!U04BLQPU51/(=3@<64K'&6
M 2:E&35[L\&;Y<5O]X1XY995X<_:=U/SL>5O&TP6QN'36%OKA[O=;U'(Z=%J
MPLF#]BA^L6+TW?6\)'V/6,TF"%'$"FC8P7;G86I)3V\'R7X[*XQ]'&J^M])9
M(=P9).+3[A";GUV9-XO,AP+F]>Q3'F,EWX \$$\).&FMDO6&S;*B(][#)KI!
M>C"^[*>=C2?3*0<JJ]^SWJ3A'<#AZTDR&%IEJ,?828*8;031@C>!^6>8JQ)7
M->[$YY''C0"QU^Z2_V1!/GDE^D!."D^4HPJ!<(=\)PI3A4+H\SDA'*J0J/KQ
M=U;,;+U),A-Y54!Q;G!-:PAT5K,B:1'CT6)J%F#*[A"G^:5)Z4Z8M&!5HAE@
MHC5C6(5\9HU\H&BN!U0)UC5Z4(1O6LTY*>9<!^SC9OH1?<2#K#T8\T7Z9G.Y
M?#48@D\4Q= M2A-B3Y3'/)8'$*%"2!2@62TPQ!;L@_V"G3V- %9^[#JNMZ?%
M>O,BFU<_:/40[-#:G+1J[YY#;+U)-[C2)V4?Z75$P7:AXD$T;NVJY;S%^\33
MY-I-R@ KC%M@H5 2%Z5,\%3\ ANT4[9]G+W@C'YCS "=PD!JU 30J*[MZGZ
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MR?F./(<]497?=<S0$W0PF9: X(1$UI?5>F?53L(J9.>Z[62J!5D5:.5ST?A
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M5J3F4$9T0X5#PN4EC=6&,I9;YQ7/D_E92$CX \Z7<V<!O\0KB7$QFU!R<MZ
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MG0>;X59C>CIVEF<&RPIP*&N'[052D9W$_",+MMWWO?*^ \7NPAA%3^$5#IR
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M2P$"% ,4    " #NA:1(K1A9.@:U  !U* @ $0              @ $
M86QN>2TR,#$V,#,S,2YX;6Q02P$"% ,4    " #NA:1(',)2(Z$.  !+@P
M$0              @ $UM0  86QN>2TR,#$V,#,S,2YX<V102P$"% ,4
M" #NA:1(N3YTV'H.   ,RP  %0              @ $%Q   86QN>2TR,#$V
M,#,S,5]C86PN>&UL4$L! A0#%     @ [H6D2'\NH!&/*0  "_4" !4
M         ( !LM(  &%L;GDM,C Q-C S,S%?9&5F+GAM;%!+ 0(4 Q0    (
M .Z%I$B0%RGJ;%8  &A?!  5              "  73\  !A;&YY+3(P,38P
M,S,Q7VQA8BYX;6Q02P$"% ,4    " #NA:1(<L #83DK  "T60, %0
M        @ $34P$ 86QN>2TR,#$V,#,S,5]P<F4N>&UL4$L%!@     &  8
*B@$  ']^ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
